

EAU Guidelines on Renal Cell Carcinoma

A. Bex (Chair), Y. Abu-Ghanem, J. Bedke (Vice-Chair),
D.J. Breen, U. Capitanio, S. Dabestani, M. Hora, T. Klatter,
T. Kuusk, L. Lund, L. Marconi, G. Pignot, T. Powles,
C. Suárez, M. Tran, P. Zondervan
Patient Representative: S. Bonn, R. Woodward
Guidelines Associates: R. Campi, C. Palumbo
Guidelines Office: N. Schouten

TABLE OF CONTENTS

PAGE

1.	INTRODUCTION	6
	1.1 Aims and scope	6
	1.2 Panel composition	6
	1.3 Available publications	6
	1.4 Publication history and summary of changes	6
	1.4.1 Publication history	6
	1.4.2 Summary of changes	6
2.	METHODS	7
	2.1 Data identification	7
	2.2 Review	7
	2.3 Future goals	7
3.	EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY	8
	3.1 Epidemiology	8
	3.2 Aetiology	8
	3.3 Screening	9
	3.3.1 Summary of evidence and recommendations for epidemiology, aetiology and screening	9
	3.4 Histological diagnosis	9
	3.4.1 Clear-cell RCC	11
	3.4.1.a Multilocular cystic renal neoplasm of low malignant potential	11
	3.4.2 Papillary RCC	11
	3.4.3 Chromophobe RCC	11
	3.5 Other renal tumours	12
	3.5.1 Renal medullary carcinoma (SMARCB1-deficient renal medullary carcinoma)	13
	3.5.2 Carcinoma associated with end-stage renal disease; acquired cystic disease-associated RCC	14
	3.5.3 Papillary adenoma	14
	3.5.4 Renal oncocytoma	14
	3.5.5 Other oncocytic tumours of the kidney	14
	3.5.6 Classical angiomyolipoma	14
	3.5.6.a Treatment of angiomyolipoma	15
	3.5.7 Cystic renal tumours	15
	3.6 Summary of evidence and recommendations for the management of other renal tumours	16
4.	STAGING AND CLASSIFICATION SYSTEMS	16
	4.1 Staging	16
	4.2 Anatomic classification systems	17
5.	DIAGNOSTIC EVALUATION	18
	5.1 Symptoms	18
	5.1.1 Physical examination	18
	5.1.2 Laboratory findings	18
	5.2 Imaging investigations	18
	5.2.1 Computed tomography	19
	5.2.2 Magnetic resonance imaging	19
	5.2.3 Other investigations and emerging technologies	20
	5.2.4 Radiographic investigations to evaluate RCC metastases	20
	5.2.5 Bosniak classification of renal cystic masses	20
	5.3 Renal tumour biopsy	21
	5.3.1 Indications and rationale	21
	5.3.2 Technique	22
	5.3.3 Diagnostic yield and accuracy	22
	5.3.4 Morbidity	23
	5.3.5 Genetic assessment	23

5.4	Summary of evidence and recommendations for the diagnostic assessment of RCC	23
5.5	Summary of evidence and recommendations for genetic assessment of RCC	24
6.	PROGNOSTIC FACTORS	25
6.1	Definition and classification	25
6.2	Anatomical factors	25
6.3	Histological factors	25
6.4	Clinical factors	25
6.4.1	Frailty and comprehensive geriatric assessment	26
6.4.2	Nephrological assessment	28
6.5	Molecular factors	28
6.6	Prognostic models	29
6.7	Summary of evidence and recommendations for prognostic factors	29
7.	DISEASE MANAGEMENT	31
7.1	Patient involvement in kidney cancer treatment	31
7.1.1	Recommendation on patient involvement and shared decision making	32
7.1.2	Smoking cessation	32
7.1.2.a	Recommendation on smoking cessation	32
7.2	Treatment of localised RCC	32
7.2.1	Introduction	32
7.2.2	Surgical treatment	32
7.2.2.a	Nephron-sparing surgery versus radical nephrectomy in localised RCC	32
7.2.2.a.1	T1 RCC	32
7.2.2.a.2	T2 RCC	33
7.2.2.a.3	T3 RCC	33
7.2.2.b	Associated procedures	34
7.2.2.b.1	Adrenalectomy	34
7.2.2.b.2	Lymph node dissection for clinically negative lymph nodes (cN0)	34
7.2.2.b.3	Embolisation	34
7.2.2.b.4	Summary of evidence and recommendations for the treatment of localised RCC	35
7.2.3	Radical and partial nephrectomy techniques	35
7.2.3.a	Radical nephrectomy techniques	35
7.2.3.a.1	Open versus laparoscopic or robotic approach	35
7.2.3.a.2	Laparoscopic versus robotic approach	35
7.2.3.a.3	Laparoscopic single port versus laparoscopic multiport approach	35
7.2.3.b	Partial nephrectomy techniques	36
7.2.3.b.1	Open versus laparoscopic approach	36
7.2.3.b.2	Open versus robotic approach	36
7.2.3.b.3	Open versus hand-assisted approach	37
7.2.3.b.4	Open versus laparoscopic versus robotic approaches	37
7.2.3.b.5	Laparoscopic versus robotic approach	37
7.2.3.b.6	Laparoscopic transperitoneal versus retroperitoneal approach	37
7.2.3.b.7	Robotic systems	38
7.2.3.b.8	Tumour enucleation, standard partial nephrectomy and single-port approach	38
7.2.3.b.9	Off-clamp versus on-clamp PN	38
7.2.3.b.10	Use of 3D models for PN planning	38
7.2.3.c	Positive surgical margins on histopathological specimens	38
7.2.3.d	Hospital volume and outcomes of PN	39
7.2.3.e	Placement of a drain	39
7.2.3.f	Summary of evidence and recommendations for radical and partial nephrectomy techniques	39
7.2.4	Therapeutic approaches as alternatives to surgery	40
7.2.4.a	Watchful waiting	40
7.2.4.b	Active surveillance	40

7.2.4.c	Role of renal tumour biopsy before active surveillance	41
7.2.4.d	Tumour ablation	41
7.2.4.d.1	Role of renal mass biopsy	41
7.2.4.d.2	Cryoablation	42
7.2.4.d.3	Radiofrequency ablation	42
7.2.4.d.4	Microwave ablation	42
7.2.4.d.5	Tumour ablation versus surgery	42
7.2.4.d.6	Stereotactic ablative radiotherapy	43
7.2.4.d.7	Other ablative techniques	44
7.2.4.d.8	Summary of evidence and recommendations for therapeutic approaches as alternative to surgery	44
7.3	Treatment of locally advanced RCC	45
7.3.1	Introduction	45
7.3.2	Role of lymph node dissection in locally advanced RCC	45
7.3.2.a	Management of clinically negative lymph nodes (cN-) in locally advanced RCC	45
7.3.2.b	Management of clinically positive lymph nodes (cN+) in locally advanced RCC	45
7.3.3	Management of RCC with venous tumour thrombus	45
7.3.4	Management of locally advanced unresectable RCC	46
7.3.4.a	Summary of evidence and recommendations for lymph node dissection, the management of RCC with venous tumour thrombus and unresectable tumours	48
7.3.5	Neoadjuvant and adjuvant therapy	48
7.3.5.a	PD-1 Inhibition: Keynote-564	48
7.3.5.b	PD-L1 inhibition: IMmotion010	49
7.3.5.c	PD-1 and CTLA-4 inhibition: CheckMate 914	49
7.3.5.d	Perioperative PD-1 inhibition: PROSPER	49
7.3.5.e	Progression after adjuvant PD-1 therapy	50
7.3.5.f	Summary of evidence and recommendations for neoadjuvant and adjuvant therapy	52
7.4	Advanced/metastatic RCC	53
7.4.1	Local therapy of advanced/metastatic RCC	53
7.4.1.a	Cytoreductive nephrectomy	53
7.4.1.a.1	Embolisation of the primary tumour	54
7.4.1.a.2	Summary of evidence and recommendations for local therapy of advanced/metastatic renal cell carcinoma	55
7.4.2	Therapy of oligometastatic disease	55
7.4.2.a	Complete versus no/incomplete metastasectomy	55
7.4.2.b	Local therapies for RCC metastases	56
7.4.2.c	Adjuvant treatment in cM0 patients after metastasectomy	56
7.4.2.d	Summary of evidence and recommendations for local therapy of metastases in metastatic RCC	56
7.5	Systemic therapy for advanced/metastatic RCC	57
7.5.1	Chemotherapy	57
7.5.1.a	Recommendation for systemic therapy in advanced/metastatic RCC	57
7.5.2	Targeted therapies	57
7.5.2.a	Tyrosine kinase inhibitors	57
7.5.2.a.1	Sunitinib	57
7.5.2.a.2	Pazopanib	57
7.5.2.a.3	Axitinib	58
7.5.2.a.4	Cabozantinib	58
7.5.2.a.5	Lenvatinib	58
7.5.2.a.6	Tivozanib	58
7.5.2.b	Monoclonal VEGF antibody	58
7.5.2.c	mTOR inhibitors	58
7.5.2.c.1	Temsirolimus	58
7.5.2.c.2	Everolimus	58
7.5.2.d	Small molecule inhibitor.	59
7.5.2.d.1	Belzutifan	59

	7.5.2.d.2	Vascular endothelial growth factor (VEGF) targeted therapy	59
	7.5.2.e	Summary of evidence and recommendations for single-agent targeted therapy in metastatic clear-cell RCC	59
7.5.3		Immunotherapy	60
	7.5.3.a	Immune checkpoint inhibitors	60
	7.5.3.a.1	Immuno-oncology monotherapy	60
	7.5.3.b	Immunotherapy/combination therapy	60
7.5.4		Therapeutic strategies	65
	7.5.4.a	Treatment-naïve patients with clear-cell metastatic RCC	65
	7.5.4.a.1	Sequencing systemic therapy in clear-cell metastatic RCC	65
	7.5.4.a.2	Summary of evidence and recommendations for immunotherapy in cc-mRCC	65
	7.5.4.a.3	Renal tumours with sarcomatoid features	68
	7.5.4.a.4	Summary of evidence and recommendation for targeted therapy in RCC with sarcomatoid features	69
	7.5.4.b	Treatment of patients with non-clear-cell metastatic RCC (general considerations)	69
	7.5.4.b.1	Treatment of patients with papillary metastatic RCC	69
	7.5.4.b.2	Summary of evidence and recommendations for systemic therapy in papillary metastatic RCC	70
	7.5.4.b.3	Treatment of patients with metastatic non-ccRCC other than papillary RCC	70
	7.5.4.b.4	Summary of evidence and recommendation for systemic therapy in chromophobe and unclassified RCC	70
	7.5.4.c	Treatment of patients with rare tumours	71
	7.5.4.c.1	SMARCB1-deficient renal medullary carcinoma	71
	7.5.4.c.2	Other rare tumours	71
7.6		Locally recurrent RCC after treatment of localised disease	72
	7.6.1	Locally recurrent RCC after nephron-sparing approaches	72
	7.6.2	Locally recurrent RCC after radical nephrectomy	72
	7.6.3	Summary of evidence and recommendation on locally recurrent RCC after treatment of localised disease	74
8.		HEREDITARY AND SYNDROME SPECIFIC RCC	74
	8.1	Microphthalmia-associated transcription factors (MITF) associated translocation tumours	74
	8.2	Management of hereditary and syndrome-specific RCC	76
	8.2.1	Von Hippel-Lindau-disease-associated RCC	76
	8.2.2	TFE3-rearranged RCC	77
	8.2.3	TFEB-altered RCC	77
	8.2.4	Combined therapy for TFE3- and TFEB-altered RCCs	77
	8.2.5	Summary of evidence and recommendation for hereditary and syndrome-specific RCC	77
9.		FOLLOW-UP IN RCC	78
	9.1	Introduction	78
	9.2	Which imaging investigations for which patients, and when?	79
	9.3	Summary of evidence and recommendations for surveillance following RN or PN or ablative therapies in RCC	80
10.		REFERENCES	81
11.		CONFLICT OF INTEREST	124
12.		CITATION INFORMATION	125
13.		COPYRIGHT AND TERMS OF USE	125

1. INTRODUCTION

1.1 Aims and scope

The European Association of Urology (EAU) Renal Cell Cancer (RCC) Guidelines Panel has compiled these clinical guidelines to provide urologists with evidence-based information and recommendations for the management of RCC.

It must be emphasised that clinical guidelines present the best evidence available to the experts, but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients but rather help to focus decisions - also taking into account personal values and preferences/individual circumstances of patients. Guidelines are not mandates and do not purport to be a legal standard of care.

1.2 Panel composition

The EAU Guidelines Panel on RCC consists of an international multidisciplinary group of clinicians, including urological surgeons, oncologists, methodologists, a pathologist and a radiologist, with particular expertise in the field of renal cancer care. Dr. David Breen formally represents The Cardiovascular and Interventional Radiological Society of Europe. Since 2015, the Panel has included patient advocates to provide a patient-centred perspective for its Guidelines. All experts involved in the production of this document have submitted potential conflict of interest statements, which can be viewed on the EAU website Uroweb: <http://uroweb.org/guideline/renalcellcarcinoma/>.

1.3 Available publications

A quick reference document, the Pocket Guidelines, is available in print. This is an abridged version which may require consultation together with the full text version. Several scientific publications are available, and all documents are accessible through the EAU website Uroweb: <http://uroweb.org/guideline/renal-cell-carcinoma/>. An EAU Guidelines-based chatbot is available on the EAU website, offering Guideline-derived information that should not replace clinical expertise or individual judgement.

An EAU Guidelines app for iOS and Android devices is also available containing the Pocket Guidelines, interactive algorithms and calculators, clinical decision support tools, Guidelines cheat sheets and links to the extended guidelines.

1.4 Publication history and summary of changes

1.4.1 Publication history

The EAU RCC Guidelines were first published in 2000. This 2026 RCC Guidelines document presents a limited update of the 2025 publication.

1.4.2 Summary of changes

All chapters of the 2026 RCC Guidelines have been updated, based on the 2025 version of the Guidelines. References have been added throughout the document. Other key changes incorporated in this publication include:

- Update throughout Chapter 3, 'Epidemiology, aetiology and pathology,' as well as in Table 3.2.
- Update throughout Chapter 4 on anatomic classification systems.
- New subchapter on frailty and comprehensive geriatric assessment in Chapter 6, as well as a new flowchart and updated Section 6.4.2 on nephrological assessment.
- New summary of evidence (SoE) and recommendations in Section 6.7.
- Update in Section 7.1 regarding patient involvement in kidney cancer provided by the panel patient representatives.
- Inclusion of new text throughout Section 7.2.3.a on radical nephrectomy and Section 7.2.3.b on partial nephrectomy techniques, as well as inclusion of new SOE and recommendations in Section 7.2.3.d.
- New Figure 7.2.4.d.7.a on alternatives to surgery, as well as new recommendations in Figure 7.2.4.d.8 on the therapeutic approaches as alternative to surgery.
- Updated text on the therapy of oligometastatic disease in Section 7.4.2.
- Update of the text, SoE and recommendations in Chapter 9, 'Follow-up in RCC.'

2. METHODS

2.1 Data identification

For the 2025 RCC Guidelines, new and relevant evidence has been identified, collated and appraised through a structured assessment of the literature. A broad and comprehensive scoping exercise covering all areas of the RCC Guidelines was carried out. Databases searched included Medline, EMBASE, and the Cochrane Libraries, covering a time frame between 1 May 2024 and 1 May 2025. Databases covered included Medline, EMBASE and the Cochrane Library. After de-duplication, a total of 1,690 unique records were identified, retrieved and screened for relevance. A search strategy is published online: <https://uroweb.org/guidelines/renal-cell-carcinoma/publications-appendices>.

The Panels develop the recommendations within the Guidelines to prioritise clinically important care decisions. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and the nature and variability of patient values and preferences. This decision process, which can be reviewed in the strength rating forms which accompany each guideline statement, addresses a number of key elements:

1. the overall quality of the evidence which exists for the recommendation [1];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes; and
5. the impact and certainty of patient values and preferences on the intervention.

Strong recommendations typically indicate a high degree of evidence quality and/or a favourable balance of benefit to harm and patient preference. Weak recommendations typically indicate availability of lower quality evidence, and/or equivocal balance between benefit and harm, and uncertainty or variability of patient preference [2].

Additional methodology information and a list of associations endorsing the EAU Guidelines can be found online: <https://uroweb.org/eau-guidelines/methodology-policies>.

2.2 Review

All publications ensuing from systematic reviews (SR)s have been peer-reviewed. The 2025 print of the RCC Guidelines was also peer-reviewed prior to publication.

2.3 Future goals

The RCC Guideline Panel supports the focus on patient-reported outcomes, as well as the development of clinical quality indicators [3]. The Panel identified potential quality indicators that may help assessing quality of care:

- the proportion of patients undergoing thorax computed tomography (CT) for staging of pulmonary metastasis;
- proportion of patients with T1aN0M0 tumours undergoing nephron-sparing surgery (NSS) as first treatment;
- the proportion of patients with metastatic RCC (mRCC) offered systemic therapy; and
- the proportion of patients who undergo minimally invasive or operative treatment as first treatment who die within 30 days.

The Panel have set up a database to investigate current practice in follow-up of RCC patients in a number of European centres. Assessing patterns of recurrence and use of imaging techniques are primary outcomes for this project.

In addition, the panel has collected data from various European datasets on atypical recurrences following minimally invasive renal surgery to establish incidence and insight on potential causes, their management and outcome.

Additionally, a registry for Bosniak III-IV cysts has been established to investigate if diameter of the cyst or nodule is leading in clinical management. An SR as preparatory step has been published [4].

The panel plan to perform a survey investigating the decision factors and the rate of urologists performing NSS in patients with T1a N0M0.

The results of ongoing and new SRs will be included in future updates of the RCC Guidelines:

- Systematic review of the treatment modalities in Oligometastatic RCC with and without systemic therapy.

3. EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY

3.1 Epidemiology

Renal cell carcinoma ranks 14th on the list of cancers, representing approximately 2% of all cancers, with the highest incidence occurring in Western countries [5-7]. In 2022, there were an estimated 434,840 [7, 8] new cases of RCC globally with 155,953 deaths worldwide [9]. Incidence and mortality are the highest in Europe and Asia, whereas the age-standardised incidence rate per 100,000 person/years (age-standardised rate [ASR] World) is the highest in Northern America and mortality in Eastern Europe. There is predominance in men over women ASR of 13.7 and 6.4, respectively, with a higher incidence in the older population [10].

In Europe, incidence of RCC was 145,721 in 2022 with mortality of 52,347 [10], with ASR (European 2013) of 18.9 and 6.9 in 27 European Union (EU) countries [11, 12]. In 2022, Belarus, Latvia and Czechia reported the highest overall rate of RCC in Europe [12], with estimated ASR (European 2013) for Czechia and Latvia for males being 41.3 and 37.8, respectively, while being the lowest in Cyprus, Luxembourg and Bulgaria (13.9-15.4) [13].

Mortality was lowest amongst 27 EU countries in males in Luxembourg, Cyprus and Finland, with ASR (European 2013) of 4.6, 6.9 and 7.3, respectively. In contrast, the highest mortality rates were reported in the Baltics followed by Czechia and Slovakia (15.5-16.2, 14.7 and 14.4, respectively) [13].

Overall, there is an ongoing rise in incidence of RCC, however, mortality trends vary. In Europe, there has been a decrease in mortality since the 1980s in Scandinavian countries and since the early 1990s in France, Germany, Austria, the Netherlands and Italy [14].

Geographic areas and individual countries with a higher level of human development index have higher RCC incidence and age-standardised mortality rates (all $p < 0.0001$) [8].

Based on the expected population growth and ageing, the incidence of RCC is projected to increase in the coming years. Globally, 745,791 new cases and 304,861 new deaths are predicted by the year 2050. The estimated increase in both incidence and mortality is consistent across sexes and varies considerably by geographic area (from +19% in Europe to +106% in Africa for RCC incidence; from +39% in Europe to +103% in Africa for RCC mortality).

3.2 Aetiology

Established risk factors include lifestyle factors such as smoking (hazard ratio [HR]: 1.23-1.58), obesity body mass index (BMI) (>35 vs. <25), (HR: 1.71 [1.06-2.79]), hypertension (HR: 1.70 [1.30-2.22]) and metabolic syndrome (relative risk [RR] 1.62 [1.41-1.87]) [6, 11, 15-19]. A total of 50.2% of patients with RCC are current or former smokers. By histology, the proportions of current or former smokers range from 38% in patients with chromophobe renal cell carcinoma (chrCC) to 61.9% in those with collecting duct/medullary carcinoma [20]. In an SR, diabetes was also found to be detrimental [21]. Having a first-degree relative (FDR) with kidney cancer is also associated with an increased risk of RCC [22]. Having one or more FDR (parents, siblings or children) with RCC approximately doubles the risk of RCC with a higher risk increase for women than for men [23]. Moderate alcohol consumption has a protective effect, (RR: 0.85) [24] while any physical activity level also appears to have some protective effect [6, 8, 11, 21, 25, 26]. A number of other factors have been suggested to be associated with lower risk of RCC, including specific dietary habits such as vegetables (HR: 0.68), coffee (HR: 0.85), tea (HR: 0.85) and limited intake of red meat (RR: 1.46) for higher versus lower intake [27]. In contrast, a higher risk of RCC has been associated with ultra-processed (industrially produced) food (HR: 1.42) [28] and a higher risk and occupational exposure to specific carcinogens, but no high-quality evidence level exists [15, 29]. The most effective prophylaxis is to avoid cigarette smoking and reduce obesity [6, 11, 15, 16]. Genetic risk factors are known to play a role in the development of RCC (see Section 8, 'Hereditary and syndrome specific RCC').

3.3 Screening

Despite a growing interest among both patients and clinicians in RCC screening programmes, there is a relative lack of studies reporting the efficacy, cost-effectiveness and optimal modality for RCC screening. Urinary dipstick is an inadequate screening tool due to low sensitivity and specificity. In addition, incidence of RCC with non-visible haematuria is low: 0.58% [30]. No clinically validated urinary or serum biomarkers have as yet been identified. Computed tomography cannot be recommended due to cost, radiation dose and the increased potential for other incidental findings. A non-contrast CT in the Yorkshire Kidney Screening Trial (performed in a prespecified risk group of smokers) ultimately yielded solid renal masses or Bosniak 3/4 cysts in 0.62%. 0.25% participants were subsequently histologically proven to be RCCs, 0.12% oncocytomas [31]. Based on this study, the evidence for screening in the general population remains uncertain [31]. Ultrasound (US) could be used and has acceptable sensitivity and specificity, although it is tumour size and operator-dependant. Major barriers to population screening include the relatively low prevalence of the disease, the potential for false positives and overdiagnosis of slow-growing kidney tumours. Targeting high-risk individuals and/or combining detection of RCC with other routine health screenings may represent pragmatic options to improve the cost-effectiveness and reduce the potential harms of RCC screening [32-35]. Targeting of high-risk patient groups, e.g. those with end-stage renal disease (ESRD) which is associated with a tenfold increased risk of developing RCC, may also be a valid approach (see Section 3.5.2) [36]. People with two FDRs with RCC constitute a small high-risk group that may benefit from screening [23]. There is currently no evidence to support primary screening in the general population.

3.3.1 Summary of evidence and recommendations for epidemiology, aetiology and screening

Summary of evidence	LE
Several verified risk factors have been identified, including smoking, obesity and hypertension. These are considered definite risk factors for RCC.	2a
There is no evidence to support primary screening for RCC.	4

Recommendations	Strength rating
Increase physical activity, eliminate smoking and in patients with obesity reduce weight are the primary preventative measures to decrease the risk of RCC.	Strong
Do not routinely screen people for primary RCC.	Weak

3.4 Histological diagnosis

Renal cell carcinomas and other renal tumours comprise a broad spectrum of histopathological entities described in the 5th edition of the World Health Organization (WHO) classification of urogenital tumours published in 2022 [37-39]. The 5th edition presents standard morphologic diagnostic criteria, combined with immunohistochemistry, and relevant molecular tests, and was significantly revised as compared to the 2016 classification [40]. The global application of next-generation sequencing (NGS) will result in a diagnostic shift from morphology to molecular analyses. Therefore, a molecular-driven renal tumour classification has been introduced in addition to morphology-based renal tumours (Table 3.1). Examples of molecularly defined epithelial renal tumours include *SMARCB1*-deficient renal medullary carcinoma, *TFE3*- and *TFEB*-rearranged RCC, *ALK*-rearranged RCC and *eloin C (ELOC)*-mutated RCC. The most profound changes in the 2022 WHO classification mainly relate to rare kidney tumours.

There are three main RCC types: clear cell (ccRCC), papillary (pRCC, no longer divided into type I and II) and chRCC. The RCC type classification has been confirmed by cytogenetic and genetic analyses [40, 41] (LE: 2b). The five-year overall survival (OS) for nonmetastatic (including N0-N1) chromophobe, papillary, clear-cell and collecting duct RCC is 91%, 82%, 81% and 44%, respectively [42]. Sarcomatoid RCC is not a specific subtype but essentially represents a pattern of dedifferentiation associated with adverse outcome and poor cancer-specific survival (CSS), irrespective of the underlying RCC subtype. Sarcomatoid RCC should be graded as grade IV on the WHO/International Society of Urological Pathology (ISUP) scale. At the time of diagnosis of sarcomatoid RCC, only 15.3% are localised, 28.9% locally advanced and 55.8% metastatic. The five-year OS was 18.1% for all patients and 27.1% in patients who underwent surgery [43]. Multilocular cystic renal neoplasm of low malignant potential is a new subtype of ccRCC in the 2022 classification. A new group, 'oncocytic and chromophobe tumours', encompass oncocytoma, together with chRCC and other oncocytic tumours. Other oncocytic tumours include tumours that do not strictly fit into either the oncocytoma or chRCC subtypes [37, 44].

In addition to RCC type, histological diagnosis includes evaluation of ISUP nuclear grade, sarcomatoid features, vascular invasion, tumour necrosis, and invasion of the collecting system and peri-renal fat, pT, or even pN categories. The four-tiered WHO/ISUP grading system has replaced the Fuhrman grading system [37, 40].

Table 3.1 World Health Organization classification of renal tumours 2022 [37, 38]

WHO classification of renal tumours 2022	
1. Renal Cell Tumours	
01.I	Clear cell renal tumours
	Clear cell RCC
	Multilocular cystic renal neoplasm of low malignant potential
01.II	Papillary renal tumours
	Papillary adenoma
	Papillary RCC
01.III	Oncocytic and chromophobe renal tumours
	Oncocytoma of the kidney
	Chromophobe RCC
	Other oncocytic tumours of the kidney
01.IV	Collecting duct tumours
	Collecting duct carcinoma
01.V	Other renal tumours
	Clear cell papillary renal cell tumour
	Mucinous tubular and spindle cell carcinoma
	Tubulocystic RCC
	Acquired cystic disease-associated RCC
	Eosinophilic solid and cystic (ESC) RCC
	RCC Not Otherwise Specified (NOS)
01.VI	Molecularly defined renal tumours
	<i>TFE3</i> -rearranged RCCs
	<i>TFEB</i> -altered RCC (<i>TFEB</i> -rearranged RCC and <i>TFEB</i> amplified RCC)
	<i>ELOC</i> (formerly <i>TCEB1</i>)-mutated RCC
	Fumarate hydratase-deficient RCC
	Succinate dehydrogenase-deficient RCC
	<i>ALK</i> -rearranged RCCs
	<i>SMARCB1</i> -deficient renal medullary carcinoma
2. Metanephric tumours	
	Metanephric adenoma
	Metanephric adenofibroma
	Metanephric stromal tumour
3. Mixed epithelial and stromal tumour family	
	Mixed epithelial and stromal tumour
	Adult cystic nephroma
4. Renal mesenchymal tumours	
04.I	Adult renal mesenchymal tumours
	Classic angiomyolipoma/PEComa of the kidney
	Epithelioid angiomyolipoma/epithelioid PEComa of the kidney
	Renal haemangioblastoma
	Juxtaglomerular cell tumour
	Renomedullary interstitial cell tumour
04.II	Paediatric renal mesenchymal tumours

	Ossifying renal tumour of infancy
	Congenital mesoblastic nephroma
	Rhabdoid tumour of kidney
	Clear cell sarcoma of kidney
5. Embryonal neoplasms of the kidney	
Nephroblastic tumours	
	Nephrogenic rests
	Paediatric cystic nephroma
	Cystic partially differentiated nephroblastoma
	Nephroblastoma
6. Miscellaneous tumours	
Germ cell tumours of the kidney	

3.4.1 **Clear-cell RCC**

Overall, ccRCC, representing approximately 70% of RCC [38], is well circumscribed with a pseudocapsule. The cut surface is golden-yellow, often with haemorrhage and necrosis. Loss of chromosome 3p and mutation of the Von Hippel-Lindau (VHL) gene at chromosome 3p25 are frequently found. The loss of VHL protein function contributes to tumour initiation, progression and metastases. The 3p locus harbours additional ccRCC tumour suppressor genes (*UTX*, *JARID1C*, *SETD2*, *PBRM1*, *BAP1*) [37]. For details regarding prognosis, see Section 6.3.

3.4.1.a **Multilocular cystic renal neoplasm of low malignant potential**

Indolent, exclusively cystic, multiloculated renal tumour devoid of any expansile solid growth, with clear cells lining and low-grade nuclei. Detection of small solid expansive nodules and tumour necrosis are incompatible with multilocular cystic renal neoplasm of low malignant potential (MCNLMP). It represents 0.5-2.5% of all renal tumours and is a benign lesion. Long-term follow-up has shown no reports of progression, metastases or cancer-related death [37, 38].

3.4.2 **Papillary RCC**

Papillary RCC is the second-most encountered morphotype of RCC accounting for 13-20% of renal epithelial tumours. This type of RCC is usually circumscribed and characterised by papillary or tubulopapillary architecture, without specific features of other RCCs with papillary architecture [37, 38]. Papillary RCC has traditionally been subdivided into two types: Type I and II pRCC [40]. However, in the new 2022 WHO classification, the former pRCC type I is now referred to as 'pRCC of classic pattern.' Three additional morphologic patterns of pRCC have been introduced including: a) biphasic (alveolo-squamoid) pattern exhibiting mostly solid growth, b) papillary neoplasm with reverse nuclear polarity, previously described as 'oncocytic low-grade pRCC', and c) Warthin-like pRCC that exhibits brisk inflammation mimicking Warthin tumour of the salivary gland.

Genetic changes of pRCC include trisomy and tetrasomy of chromosomes 7 and 17 and loss of Y-chromosome. Mesenchymal-epithelial Transition (MET) gene mutations are more frequent in low-grade pRCC.

The typical histology of classical pattern pRCC, formerly type I pRCC (narrow papillae without any binding, and only microcapillaries in papillae), explains its typical clinical signs. Narrow papillae without any binding and a tough pseudocapsule explain the ideal rounded shape (Pascal's law) and fragility (specimens have a 'minced meat' structure). Tumour growth causes narcotisation of papillae, which is a source of hyperosmotic proteins that cause subsequent 'growth' of the tumour, fluid inside the tumour and only a serpiginous, contrast-enhancing margin. Stagnation in the microcapillaries explains the minimal post-contrast attenuation on CT. Classical pattern pRCC can imitate a pathologically changed cyst (Bosniak IIF or III). The typical signs of classical pattern pRCC are an ochre colour, frequently exophytic, extrarenal growth and low grade. A risk of renal tumour biopsy tract seeding exists, probably due to the fragility of the tumour papillae [45, 46].

3.4.3 **Chromophobe RCC**

Chromophobe RCC is now grouped in 'Oncocytic and chromophobe tumours.' Most chRCC are discovered incidentally in asymptomatic patients [37, 38]. Overall, chRCC presents as a pale tan, relatively homogenous and tough, well-demarcated mass without a capsule. Most tumours are sporadic. Rare hereditary forms include Birt-Hogg-Dubé (BHD) syndrome with mutations in folliculin and Cowden syndrome with mutations in phosphatase and tensin homolog (PTEN) (see Chapter 8 for further information) [37, 38]. Due to its innate

nuclear atypia, chromophobe RCC cannot be graded using the WHO/ISUP (formerly Fuhrman) grading system. An alternative grading system has been proposed but has yet to be validated and broadly accepted [37, 38, 47]. Loss of chromosomes Y, 1, 2, 6, 10, 13, 17 and 21 are typical genetic changes [37, 38]. The prognosis is relatively good, with high five-year recurrence-free survival (RFS), and ten-year CSS. The five- and ten-year RFS rates were 94.3% and 89.2%, respectively. Recurrent disease developed in 5.7% of patients, and 76.5% presented with distant metastases with 54% of metastatic disease diagnoses involving a single organ, most commonly bone. Recurrence and death after surgically resected chRCC are rare. For completely excised lesions < pT2a without coagulative necrosis or sarcomatoid features, the prognosis is excellent [48].

3.5 Other renal tumours

Other renal tumours constitute the remaining renal cortical tumours. These include a variety of uncommon, sporadic and familial carcinomas/tumours - some only recently described - as well as a group of unclassified carcinomas. A summary of these tumours is provided in Table 3.1, but some clinically relevant tumours and extremely rare entities are mentioned in Table 3.2, including a summary on their management. Approximately 15% of excised renal masses are benign [49]. For hereditary and syndrome-specific RCC, see Chapter 8.

Table 3.2: Other renal cortical tumours and recommendations for treatment (strength rating: weak)

Entity	Clinical relevant notes	Malignant potential	Treatment
Collecting duct carcinoma	Formerly Bellini duct carcinoma. No hemoglobinopathy or <i>SMARCB1</i> abnormality. Rare, often presenting at an advanced stage (N+ 44% and M1 33% at diagnosis). The HR CSS in comparison with ccRCC is 4.49 [37, 38, 50].	High, very aggressive. Median survival 30 months [51].	Surgery. Systemic therapy and surgery in metastatic disease [52].
Clear-cell papillary renal cell tumour	Patient with ACKD, 100 times greater risk compared with general population [38].	Indolent.	Surgery, NSS, discuss active surveillance.
Mucinous tubular and spindle cell carcinoma	Tumour is associated with the loop of Henle. < 1% of renal neoplasm. Female predilection (3-4:1) [38].	Intermediate.	Surgery, NSS.
Tubulocystic RCC	Rare (< 1%). Mainly men, imaging can be Bosniak III or IV.	Low (90% indolent).	Surgery, NSS.
Eosinophilic solid and cystic RCC (ESC RCC)	Usually, alteration of <i>TCS</i> genes. Predominantly in adult women. Some with TSC (tuberous sclerosis complex) syndrome.	Rarely metastatic.	NSS.
<i>TFE3</i> re-arranged RCC	Gene fusions involving <i>TFE3</i> with one of many different partner genes. Formerly translocation RCC (<i>TRCC</i>) Xp11.2. Appr. 40% of paediatric RCC and 1.6-4% of adult RCC [24].	Survival similar to clear cell RCC.	Surgery. Systemic therapy in metastatic disease, TKI and immunotherapy [53].
<i>TFEB</i> altered (rearranged and amplified) RCC	Gene fusions involving the <i>TFEB</i> transcription factor, typically via a t(6;11)(p21;q12) translocation resulting in a <i>MALAT1-TFEB</i> gene fusion. Formerly translocation RCC t(6;11). Less common than <i>TFE3</i> -rearranged RCC. Appr. 100 cases in the literature [38]. <i>TFEB</i> -amplified in older patient and has a worse prognosis.	More indolent than the <i>TFE3</i> -rearranged RCC, with fewer than 10% of cases resulting in patient death.	Surgery. Systemic therapy in metastatic - PD-L1 inhibitor therapy [53].

<i>ELOC</i> (formerly <i>TCBE1</i>)-mutated RCC	Twenty cases described in literature [37, 38]. Typically, T1.	Indolent. Only two metastatic cases described.	NSS.
Fumarate hydratase-deficient RCC [For more information, please review Chapter 8 on hereditary kidney tumours]	Formerly hereditary leiomyomatosis and RCC-associated RCC. Alterations in the <i>FH</i> gene. Autosomal dominant. 21-30% lifetime risk of RCC [54]. Cutaneous leiomyomas, female uterine leiomyoma or leiomyosarcoma. More common in males. Median age 44 years [37, 44, 55].	Often aggressive. »75% of cases staged as pT3-4 at nephrectomy.	Immediate surgery. In metastatic disease, bevacizumab, erlotinib, immunotherapy [53]. Genetic counselling in the family. Imaging screening in relatives [54].
Succinate dehydrogenase-deficient RCC (SDH-deficient RCC) [For more information, please review Chapter 8 on hereditary kidney tumours]	Rare. 0.05-0.2 % of all RCCs.	A metastatic rate of 11%.	Surgery, NSS. Long-term follow-up and surveillance for other SDH-deficient neoplasms (i.e. paraganglioma, SDH-deficient gastrointestinal stromal tumour, and pituitary adenoma) is indicated for cases associated with germline mutation [23].
<i>ALK</i> -rearranged RCC	Gene fusions involving anaplastic lymphoma kinase gene (<i>ALK</i>) at chromosome 2p23. Fewer than 100 cases described. [37, 38].	Low (90% indolent).	Surgery, NSS. In systemic disease, <i>ALK</i> kinase inhibitors such as sunitinib [53].
Metanephric tumours	Divided into metanephric adenoma, adenofibroma and metanephric stromal tumours.	Benign.	NSS.
Mixed epithelial and stromal renal tumour	Encompasses two benign lesions - mixed epithelial and stromal tumour (MEST) of the kidney (MEST) and adult cystic nephroma. Imaging - Bosniak type III or IIF/IV. Overwhelmingly in women (7:1).	Benign.	Active surveillance. NSS.
Renal cysts/cystic lesions	Simple cysts are frequently occurring, while occurring septa, calcifications and solid components require follow-up and/or management.	Mostly benign.	Treatment or follow-up recommendation based on Bosniak classification.

ACKD: Acquired Cystic Kidney Disease; *ALK*: Anaplastic Lymphoma Kinase; NSS: Nephron-Sparing Surgery; *SMARCB1*: *SWI/SNF*-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily B, Member 1; *TCS*: Tuberous Sclerosis Complex; *TFEB*: Transcription Factor EB.

3.5.1 Renal medullary carcinoma (*SMARCB1*-deficient renal medullary carcinoma)

Renal medullary carcinoma (RMC) (referred to as *SMARCB1*-deficient RMC in the 2022 WHO Classification) is a very rare tumour, comprising < 0.5% of all RCCs [56], predominantly diagnosed in young adults of African ancestry (median age 28 years) with sickle haemoglobinopathies (including sickle cell trait). Renal medullary carcinoma has a male predominance of 2:1 and is mainly centrally located with ill-defined borders. Renal medullary carcinoma is one of the most aggressive RCCs [57, 58] and most patients (±67%) will present with metastatic disease [57, 59]. Even patients who present with seemingly localised disease may develop unequivocal metastases shortly (within weeks) after diagnosis (for treatment, see Chapter 7). Apart from the RMC described above, some patients present with identical tumours without haemoglobinopathy. Such tumours have been described as 'unclassified RCC with medullary phenotype' [37].

3.5.2 ***Carcinoma associated with end-stage renal disease; acquired cystic disease-associated RCC***

Cystic degenerative changes (acquired cystic kidney disease [ACKD]) and a higher incidence of RCC, are typical features of ESRD. Renal cell carcinomas of native end-stage kidneys are found in approximately 4% of patients with ESRD. Their lifetime risk of developing RCCs is at least ten times higher than in the general population. Compared with sporadic RCCs, RCCs associated with ESRD are generally multicentric and bilateral, found in younger patients (mostly male), and are less aggressive. Whether the relatively indolent outcome of tumours in ESRD is due to the mode of diagnosis or a specific ACKD-related molecular pathway still has to be determined. Although the histological spectrum of ESRD tumours is like that of sporadic RCC; pRCC occur relatively more frequently [44, 60]. A specific subtype of RCC occurring only in end-stage kidneys has been described as 'acquired cystic disease-associated RCC' (ACD-RCC). Tumours present exclusively in patients with ACKD, usually after long-term dialysis. The vast majority occur in men. Tumours are often multiple and bilateral and, in most cases, have an indolent clinical behaviour, although aggressive courses have been documented [37].

3.5.3 ***Papillary adenoma***

These tumours have a papillary or tubular architecture of low nuclear grade and may be up to 15mm in diameter or smaller, according to the 2022 WHO classification [37].

3.5.4 ***Renal oncocytoma***

Oncocytoma is a benign tumour representing 4-7% of all solid renal tumours and 30% of benign surgically removed kidney masses are contributed to oncocytomas [40, 61, 62]. The diagnostic accuracy of imaging modalities (CT, magnetic resonance imaging [MRI]) in renal oncocytoma is limited and histopathology remains the only reliable diagnostic modality [40, 61]. However, ^{99m}Tc-sestamibi (SestaMIBI, MIBI) SPECT/CT has shown promising initial results for the differentiation between benign and low-grade RCC [63-66]. Standard treatment for renal oncocytoma is similar to that of other renal tumours: surgical excision by partial or radical nephrectomy (RN) with subsequent histopathological verification. However, due to the inability of modern imaging techniques to differentiate benign from malignant renal masses, there is a renewed interest in renal mass biopsy (RMB) prior to surgical intervention. Oncocytic renal neoplasms diagnosed by RMB were found to be oncocytoma in 64% of cases, the remainder of the tumours were mainly chRCC (18.7% including 6.3% hybrid oncocytic/chromophobe tumours, which have now been grouped histologically with chRCC) [37, 38], other RCCs (12.5%), and other benign lesions (4.2%) [67, 68]. The 2022 WHO classification strictly excludes that a definitive diagnosis of oncocytoma be performed on a needle-core biopsy (see Section 5.3). The majority of oncocytomas slowly progress in size with an annual growth rate of approximately 2mm [61]. Preliminary data show that active surveillance (AS) may be a safe option to manage oncocytoma in appropriately selected patients. There are no reports of distant metastases or disease-related death for oncocytoma on AS [69]. Potential triggers to change management of patients on AS are not well defined [70, 71].

3.5.5 ***Other oncocytic tumours of the kidney***

Other oncocytic tumours of the kidney are a heterogeneous group of oncocytic tumours not classifiable as oncocytoma, chRCC or other tumour types with eosinophilic features. These tumours are typically indolent, therefore, it is important to distinguish such low-grade tumours from the high-grade unclassified RCCs that typically behave aggressively. In the setting of BHD syndrome (see Chapter 8), tumours with such intermediate features (hybrid oncocytic tumours) also exist, typically being multifocal and bilateral. As this is a heterogeneous tumour group, it is likely that new subtypes of renal neoplasia will emerge. There are already two emerging entities: eosinophilic vacuolated tumour (EVT) and low-grade oncocytic tumour (LOT) [37].

3.5.6 ***Classical angiomyolipoma***

Classical angiomyolipoma (AML)/perivascular epithelioid cell tumours (PEComas) of the kidney is a benign mesenchymal tumour, which can occur sporadically or as part of tuberous sclerosis complex [72]. Overall prevalence is 0.44%, with 0.6% in female and 0.3% in male populations. Only 5% of these patients present with multiple AMLs [73]. Angiomyolipoma belongs to a family of so-called PEComas, characterised by the proliferation of perivascular epithelioid cells. Some PEComas can behave aggressively and even metastasise, while classic AMLs are completely benign [40, 74, 75]. Ultrasound, CT and MRI often lead to the diagnosis of AMLs due to the presence of adipose tissue. However, in fat-poor AML, diagnostic imaging cannot reliably identify these lesions. Percutaneous biopsy is rarely useful. Renal tumours that cannot be clearly identified as benign during the initial diagnostic workup should be treated according to the recommendations provided for the treatment of RCC. In tuberous sclerosis, AML can be found in enlarged lymph nodes (LNs), which does not represent metastatic spread but a multicentric spread of AMLs. In rare cases, an extension of a non-malignant thrombus into the renal vein or inferior vena cava (IVC) can be found, associated with an angiotrophic-type growth of AML. Epithelioid AML, a very rare variant of AML, consists of at least 80% epithelioid cells and with mean age of onset of 50 years (range 30-80 years) without gender predilection [74, 75]. Epithelioid AMLs are

potentially malignant, with a variable proportion of cases with aggressive behaviour [76]. Criteria to predict the biological behaviour in epithelioid AML were proposed by the WHO 2022 [37, 38]. Angiomyolipoma, in general, has a slow and consistent growth rate and minimal morbidity [77]. Subtypes of AML are oncocytic AML and AML with epithelial cysts [37].

In some cases, larger AMLs can cause local pain. The main complication of AMLs is spontaneous bleeding in the retroperitoneum or into the collecting system, which can be life threatening. Bleeding is caused by spontaneous rupture of the tumour. Little is known about the risk factors for bleeding, but it is believed to increase with tumour size and may be related to the angiogenic component of the tumour that includes irregular blood vessels [77]. The major risk factors for bleeding are tumour size, grade of the angiogenic component, and the presence of tuberous sclerosis.

3.5.6.a Treatment of angiomyolipoma

Active surveillance is the most appropriate option for most AMLs (48%). In a group of patients on AS, only 11% of AMLs showed growth, and spontaneous bleeding was reported in 2%, resulting in active treatment in 5% of patients [77] (LE: 3). The association between AML size and the risk of bleeding remains unclear, and the traditionally used 4cm cut-off should not per se trigger active treatment [77]. When surgery is indicated, if technically feasible, NSS is the preferred option. Main disadvantages of less invasive selective arterial embolisation (SAE) are more recurrences and a need for secondary treatment (0.85% for surgery vs. 31% for SAE). For thermal ablation, only limited data are available, and this option is used less frequently [77].

Active treatment (SAE, surgery or ablation) should be instigated in case of persistent pain, ruptured AML (acute or repeated bleeding) or in case of a very large AML. Specific patient circumstances may influence the choice to offer active treatment, such as patients at high risk of abdominal trauma, females of childbearing age, or patients in whom follow-up or access to emergency care may be inadequate. Selective arterial embolisation is an option in case of life-threatening AML bleeding.

In patients diagnosed with tuberous sclerosis, size reduction of often-bilateral AMLs can be induced by inhibiting the mTOR pathway using everolimus, as demonstrated in randomised controlled trials (RCTs) [78, 79]. In a small phase II trial (n = 20), efficacy of everolimus was demonstrated in sporadic AML as well. A 25% or greater reduction in tumour volume at four and six months was demonstrated in 55.6% and 71.4% of patients, respectively. However, 20% of patients were withdrawn due to toxicities and 40% self-withdrew from the study due to side effects [80].

3.5.7 Cystic renal tumours

Cystic renal lesions are classified according to the Bosniak classification (see Section 5.2.5). Bosniak I and II cysts are benign lesions which do not require follow-up [81]. Bosniak IV cysts are mostly (83%) malignant tumours with pseudo-cystic changes only [82]. Bosniak IIF and III cysts remain challenging for clinicians. The differentiation of benign and malignant tumour into categories IIF/III is based on imaging - mostly CT - with an increasing role of MRI and contrast-enhanced US (CEUS). Computed tomography shows poor sensitivity (36%) and specificity (76%; κ [kappa coefficient] = 0.11) compared with 71% sensitivity and 91% specificity (κ = 0.64) for MRI and 100% sensitivity and 97% specificity for CEUS (κ = 0.95) [83]. Surgical and radiological cohorts pooled estimates show a prevalence of malignancy of 0.51 (0.44-0.58) in Bosniak III and 0.89 (0.83-0.92) in Bosniak IV cysts, respectively. In an SR, less than 1% of stable Bosniak IIF cysts showed malignancy during follow-up. Twelve percent of Bosniak IIF cysts had to be reclassified to Bosniak III/IV during radiological follow-up, with 85% of these showing malignancy, which is comparable to the malignancy rates of Bosniak IV cysts [81]. The updated Bosniak classification strengthens the classification and includes also MRI [84] and even CEUS diagnostic criteria [85].

The most common histological types for Bosniak III cysts are ccRCC, with pseudo-cystic changes and low malignant potential [86, 87]; multilocular cystic renal neoplasm of low malignant potential (see Section 3.4.1.a); classical pattern pRCC (very low malignant potential); benign multilocular cyst; benign group of mixed epithelial and stromal renal tumour (mixed epithelial and stromal tumour of the kidney and adult cystic nephroma); and other rare entities. Surgery in Bosniak III cysts will result in overtreatment in 49% of the tumours, which are lesions with a low malignant potential. In view of the excellent outcome of these patients in general, a surveillance approach is an alternative to surgical treatment [81, 84, 88, 89]. A SR described AS as a safe initial strategy for selected patients with cystic renal masses, particularly Bosniak IIF [4].

3.6 Summary of evidence and recommendations for the management of other renal tumours

Summary of evidence	LE
A variety of renal tumours exist, approximately 15% of which are benign.	3
The most common renal tumours are three malignant types of RCC (clear cell, papillary and chromophobe) and two benign renal tumours (oncocytoma and angiomyolipoma).	3
A definitive histopathological diagnosis of oncocytoma cannot be made on a needle-core biopsy, because chRCC can show intratumoural heterogeneity with areas very similar to oncocytoma.	3
Histological workup and results of AS of Bosniak III cysts shows low risk of malignant potential/course.	2

Recommendations	Strength rating
Manage Bosniak type III cysts the same as localised RCC, or offer active surveillance (AS).	Weak
Manage Bosniak type IV cysts the same as localised RCC.	Strong
Offer AS to patients with biopsy-proven oncocytoma or other oncocytic renal tumours as an acceptable alternative to surgery or ablation.	Weak
Treat angiomyolipoma (AML) with selective arterial embolisation or nephron-sparing surgery in: <ul style="list-style-type: none"> • large tumours (a recommended threshold of intervention does not exist); • females of childbearing age; • patients in whom follow-up or access to emergency care may be inadequate; • persistent pain or acute or repeated bleeding episodes. 	Weak
Offer systemic therapy (everolimus) to patients with surgically unresectable AMLs which are not amenable to embolisation and require therapy.	Weak

4. STAGING AND CLASSIFICATION SYSTEMS

4.1 Staging

The Tumour Node Metastasis (TNM) classification system is recommended for clinical and scientific use [90]. Tumour size, venous invasion, renal capsular invasion, adrenal involvement, LN and distant metastasis are included in the TNM classification system (Table 4.1). However, some uncertainties remain:

- The sub-classification of T1a versus T1b tumours using a cut-off of 4cm might not be optimal in NSS for localised cancer [91]. A cut-off of 3cm has been proposed, particularly for its implications for decision-making [91].
- The value of size stratification of T2 tumours has been questioned [92], as well.
- Renal sinus fat invasion might carry a worse prognosis than perinephric fat invasion but is nevertheless included in the same pT3a stage group [93-96] (LE: 3).
- Sub T-stages (pT2b, pT3a, pT3c and pT4) may overlap [97]:
 - N status should be better stratified to discriminate by burden of lymph node involvement (size, number and morphology) with a view to considering extensive local regional lymph node disease as an M status.
 - M status would require sub stratification according to the metastatic burden. For adequate M staging, accurate preoperative imaging (chest and abdominal CT) should be performed [98, 99] (LE: 4).

The TNM classification should not be considered the only criterion for clinical decision-making, but patient's condition, comorbidities and wishes are of fundamental importance to select the most optimal treatment. The EAU panel proposed a clinically guided RCC staging classification in 2022, based on changes observed in the management of small renal masses (SRM) and locally advanced and metastatic disease [91]. A proposed imaging analysis of Tumour Contour Irregularity might be a valuable tool to enhance the preoperative staging between T1 and T3a RCCs for treatment decisions [100], as well.

Table 4.1: 2017 TNM classification system [101]

T - Primary tumour			
TX	Primary tumour cannot be assessed		
T0	No evidence of primary tumour		
T1	Tumour ≤ 7 cm or less in greatest dimension, limited to the kidney		
	T1a	Tumour ≤ 4 cm or less	
	T1b	Tumour > 4 cm but ≤ 7 cm	
T2	Tumour > 7 cm in greatest dimension, limited to the kidney		
	T2a	Tumour > 7 cm but ≤ 10 cm	
	T2b	Tumours > 10 cm, limited to the kidney	
T3	Tumour extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond Gerota fascia		
	T3a	Tumour extends into the renal vein or its segmental branches, or invades the pelvicalyceal system or invades perirenal and/or renal sinus fat*, but not beyond Gerota fascia*	
	T3b	Tumour grossly extends into the vena cava below diaphragm	
	T3c	Tumour grossly extends into vena cava above the diaphragm or invades the wall of the vena cava	
T4	Tumour invades beyond Gerota fascia (including contiguous extension into the ipsilateral adrenal gland)		
N - Regional lymph nodes			
NX	Regional lymph nodes cannot be assessed		
N0	No regional lymph node metastasis		
N1	Metastasis in regional lymph node(s)		
M - Distant metastasis			
M0	No distant metastasis		
M1	Distant metastasis		
pTNM stage grouping			
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T3	N0	M0
	T1, T2, T3	N1	M0
Stage IV	T4	Any N	M0
	Any T	Any N	M1

A help desk for specific questions about TNM classification is available at <http://www.uicc.org/tnm>.

*Adapted based on the American Joint Committee on Cancer (AJCC), 8th Edn. 2017 [94].

4.2 Anatomic classification systems

Objective anatomic classification systems, such as the Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) classification system, the SPARE score [103] the R.E.N.A.L. nephrometry score, the C-index, the Arterial Based Complexity (ABC) Scoring System, DAP score [104], and the Zonal NePhRO scoring system, have been proposed to standardise the description of renal tumours [105-107], while other tools such as the MAP score [108] assess adherent perinephric fat and predict the risk of intra- and postoperative complications during partial nephrectomy. These systems include assessment of tumour size, exophytic/endophytic properties, proximity to the collecting system and renal sinus, and anterior/posterior or lower/upper pole location. Increasing tumour shape irregularity on imaging is associated with an increased risk of pT3a upgrading and grade 3-4 disease, but the positive margin rate was similar [109]. In a head-to-head comparison of all the available anatomical classification systems [110], a dedicated urologist prospectively reviewed preoperative CT scan to assign points to variables of interest included in RENAL, PADUA, SPARE, C-Index, DAP and MAP score in 202 RCC surgical candidates. The primary outcome was surgical success, defined as PN completion, absence of grade >II Clavien-Dindo complications, ischemia time ≤ 20min., and negative surgical margins. The secondary outcome was PN completion relative to RN. At multivariable analyses, all the scores,

scores independently predicted both outcomes ($p < 0.001$). However, the highest predictive accuracy for surgical success and PN completion was recorded for SPARE (AUC: 0.79 and 0.89) [110].

The use of those anatomic classification systems is helpful. The systems allow a standardised preoperative assessment, surgical decision support, perioperative risk prediction, patient counselling and outcome comparison across centres, as well as objective prediction of potential morbidity of NSS and tumour ablation techniques. However, when selecting the most optimal treatment option, anatomic scores must be considered together with patient features and surgeon experience.

5. DIAGNOSTIC EVALUATION

5.1 Symptoms

Many renal masses remain asymptomatic until the late disease stages. The majority of RCCs are detected incidentally by means of non-invasive imaging investigating various non-specific symptoms and other abdominal diseases [111, 112] (LE: 3). In a retrospective observational cohort study, 60% of patients overall, 87% of patients with stage T1a renal tumours and 39% of patients with stage III or IV disease presented incidentally [113]. The classic triad of flank pain, visible haematuria and palpable abdominal mass is rare (0.6%) [113]. Patients who have tumours with local symptoms or systemic symptoms correlate with aggressive histology, advanced disease and poorer outcomes [114, 115] (LE: 3). The increasing detection of incidental tumours is found in females and older patients with a better prognosis and lower stage [115]. Paraneoplastic syndromes (PNS) are found in approximately 33% of patients with symptomatic RCCs, but resolution of PNS occurred in 52% of patients after nephrectomy [116, 117] (LE: 4). Some symptomatic patients present with symptoms caused by metastatic disease, such as bone pain or persistent cough [118] (LE: 3).

5.1.1 Physical examination

Physical examination has a limited role in RCC diagnosis. However, the following findings should prompt radiological examinations:

- palpable abdominal mass;
- palpable cervical lymphadenopathy;
- non-reducing varicocele and bilateral lower extremity oedema, which suggests venous involvement.

5.1.2 Laboratory findings

Commonly assessed laboratory parameters are serum creatinine, estimated glomerular filtration rate (e-GFR), complete cell blood count, C-reactive protein (CRP) or erythrocyte sedimentation rate, liver function study, alkaline phosphatase, lactate dehydrogenase (LDH) [119], coagulation study, and urinalysis (LE: 4). For central renal masses abutting or invading the collecting system, urinary cytology and possibly endoscopic assessment should be considered to exclude urothelial cancer (LE: 4).

Split renal function should be estimated using renal scintigraphy in the following situations [120, 121] (LE: 2b):

- when renal function is compromised, as indicated by increased serum creatinine or significantly decreased e-GFR;
- when renal function is clinically important, e.g. in patients with a solitary kidney or multiple or bilateral tumours.

Renal scintigraphy is an additional diagnostic option in patients at risk of future renal impairment due to comorbid disorders.

5.2 Imaging investigations

Most renal tumours are diagnosed by abdominal US or CT performed for other medical reasons [113] (LE: 3). Renal masses are classified as solid or cystic based on imaging findings.

With solid renal masses, the most important criterion for differentiating malignant lesions is the presence of enhancement [122] (LE: 3). Traditionally, US, CT and MRI are used for detecting and characterising renal masses. Most renal masses are diagnosed accurately by imaging alone.

5.2.1 **Computed tomography**

Imaging must be performed unenhanced, in an early arterial phase, and in a parenchymal phase with intravenous contrast material to demonstrate enhancement. In CT imaging, enhancement in renal masses is determined by comparing Hounsfield units (HU) before and after contrast administration. A change of fifteen HU or more in the solid tumour parts demonstrates enhancement and thus vital tumour parts [123] (LE: 3). Abdominal CT with contrast provides information on [124]:

- function and morphology of the contralateral kidney [125] (LE: 3);
- primary tumour extension;
- venous involvement;
- enlargement of locoregional LNs;
- condition of the adrenal glands and other solid organs (LE: 3).

Abdominal contrast-enhanced CT (CECT) angiography is useful in selected cases when detailed information on the renal vascular supply is needed [126, 127]. If the results of CT are indeterminate, CEUS is a valuable alternative to further characterise renal lesions [128-131] (LE: 1b).

5.2.2 **Magnetic resonance imaging**

Magnetic resonance imaging may provide additional information on venous involvement if the extent of an IVC tumour thrombus is poorly defined on CT [132, 133] (LE: 3). In MRI, especially high-resolution, T2-weighted images provide a superior delineation of the uppermost tumour thrombus, as the inflow of the enhanced blood may be reduced due to extensive occlusive tumour thrombus growth in the IVC. The T2-weighted image with its intrinsic contrast allows a good delineation [133].

Magnetic resonance imaging is indicated in patients who are allergic to intravenous CT contrast medium and in pregnancy without renal failure [133, 134] (LE: 3). Magnetic resonance imaging allows the evaluation of a dynamic enhancement without radiation exposure. Advanced MRI techniques such as diffusion-weighted imaging (DWI) and perfusion-weighted imaging are being explored for renal mass assessment [135]. The use of multiparametric MRI (mpMRI) to diagnose ccRCC by means of a clear cell likelihood score (ccLS) in SRMs was reported [136]. The ccLS is a five-tier classification that denotes the likelihood of a mass representing ccRCC, ranging from 'very unlikely' to 'very likely.' The authors prospectively validated the diagnostic performance of ccLS in 57 patients with cT1a tumours and found a high diagnostic accuracy. The diagnostic performance of mpMRI-based ccLS was further validated in a larger retrospective cohort (n = 434) across all tumour sizes and stages [137], and ccLS was found to be an independent prognostic factor for identifying ccRCC.

For the diagnosis of complex renal cysts (Bosniak IIF-III) MRI may be preferable. The accuracy of CT is limited in these cases, with poor sensitivity (36%) and specificity (76%; $\kappa = 0.11$). Due to a higher sensitivity for enhancement, MRI showed a 71% sensitivity and 91% specificity ($\kappa = 0.64$). Contrast-enhanced US showed high sensitivity (100%) and specificity (97%), with a negative predictive value of 100% ($\kappa = 0.95$) [83].

In younger patients and females who are worried about the radiation exposure of frequent CT scans, MRI can be offered as alternative, although only limited data exist correlating diagnostic radiation exposure to the development of secondary cancers [138].

An SR and meta-analysis [139] compared the diagnostic performance of CEUS versus CECT and contrast-enhanced MRI (CEMRI) in the assessment of benign and malignant cystic and solid renal masses. Sixteen studies were included in the pooled analysis. The results suggested comparable diagnostic performance of CEUS compared with CECT (pooled sensitivity 0.96 [95% CI: 0.94-0.98], vs. 0.90 [95% CI: 0.86-0.93], for studies with a final diagnosis of benign or malignant renal masses by pathology), and CEUS versus CEMRI (pooled sensitivity 0.98 [95% CI: 0.94-1.0], vs. 0.78 [95% CI: 0.66-0.91] for studies with final diagnosis by pathology report or reaffirmed diagnosis by follow-up imaging without pathology report). However, there were significant limitations in the data, including very few studies for CEMRI, clinical and statistical heterogeneity and inconsistency, and high risks of confounding.

Computed tomography or MRI allows accurate diagnosis of RCC but cannot reliably distinguish oncocytoma and fat-free AML from malignant renal neoplasms [140-143] (LE: 3).

5.2.3 **Other investigations and emerging technologies**

Renal arteriography and inferior venacavography have a limited role in the workup of selected RCC patients (LE: 3). In patients with any sign of impaired renal function, an isotope renogram and total renal function evaluation should be considered to optimise treatment decision-making [120, 121] (LE: 2a). ¹⁸F-DG positron-emission tomography (PET) is not recommended in primary staging. [128, 144] (LE: 1b).

Emerging technologies have a growing body of evidence with regard to prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-CT [145-148], ⁹⁹Tc sestamibi SPECT/CT [63-66, 149] and ⁸⁹Zr-DFO-Girentuximab PET-CT [150] for differentiation of RCC subtypes, differentiation between benign tumours and RCC, and differentiation between high-grade from low-grade tumours. Additionally, some of these modalities are being evaluated for staging purposes [65, 147]. Currently, the level of published evidence is not sufficient in terms of external validation to allow any guideline recommendation to be made.

In an SR and meta-analysis from 64 studies, mainly based on CT scan imaging, AI algorithms showed acceptable performance compared to clinicians in the detection and classification of RCC [151]. However, heterogeneity and inconsistency between studies underscore the necessity for cautious interpretation and the need for further prospective studies. A retrospective observational study showed that deep learning models can predict the likelihood of malignant and aggressive pathology of a renal mass based on preoperative multiphase CT images [152].

These novel imaging tools may aid in patient management by providing a comprehensive virtual biopsy with information on tumour histology and thereby disease prognosis [152].

5.2.4 **Radiographic investigations to evaluate RCC metastases**

Chest CT is accurate for chest staging [98, 99, 153-155] (LE: 3). The use of nomograms to calculate risk of lung metastases has been proposed based on tumour size, clinical stage and presence of systemic symptoms [156, 157]. These are based on large, retrospective datasets, and suggest that chest CT may be omitted in patients with cT1a and cN0, and without systemic symptoms, anaemia or thrombocytopenia, due to the low incidence of lung metastases (<1%) in this group of patients [158]. There is a consensus that most bone metastases are symptomatic at diagnosis. Therefore, routine bone imaging is not generally indicated [153, 159, 160] (LE: 3). However, bone scan, brain CT or MRI can be used in the presence of specific clinical or laboratory signs and symptoms [159, 161, 162] (LE: 3). A prospective comparative blinded study involving 92 consecutive mRCC patients treated with first-line vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI) (median follow-up 35 months) found that whole-body DWI/MRI detected a statistically significant higher number of bony metastases compared with conventional thoraco-abdominopelvic contrast-enhanced CT, with higher number of metastases being an independent prognostic factor for progression-free survival (PFS) and OS [163].

The incidence of brain metastasis without neurological symptoms was retrospectively evaluated in 1,689 mRCC patients selected to be included in 68 clinical trials between 2001-2013 [164]. All patients had a mandatory brain screening by CT/MRI. Seventy-two patients (4.3%) were diagnosed with occult brain metastases, of whom 39% multifocal. Most patients (61%) were International Metastatic Renal Cancer Database Consortium (IMDC) intermediate risk and 26% were favourable risk. A majority (86%) of the patients had >2 extracranial metastatic sites, including lung metastases in 92%. After predominantly radiotherapy, performed in 93% of patients, a median OS of 10.3 months (range 7.0-17.9 months) was observed.

5.2.5 **Bosniak classification of renal cystic masses**

This system classifies renal cysts into five categories, based on CT imaging appearance, to predict malignancy risk [165, 166] (LE: 3), and also advocates treatment for each category (Table 5.1). An updated Bosniak classification (2019) strengthened the classification and included MRI diagnostic criteria [84], however, it requires further validation. According to two meta-analyses, the risk of malignancy of Bosniak IIF-III may be higher than with the old classification [167, 168]. The latest meta-analysis, which includes 12 studies reporting 975 cystic renal masses assessed by Bosniak 2019 with histopathology as reference with at least five years of imaging follow-up, showed malignancy BII 9%, BIIF 26%, B III 80% and B IV 88% [168]. The imaging report should therefore identify which classification has been used. Lastly, the management of cystic renal tumours is also discussed in Section 3.5.7.

Table 5.1: Bosniak classification of renal cysts updated 2019 [75]

Bosniak classification / Imaging modality	CT	MRI
1 (Benign)	Well-defined, thin ($\leq 2\text{mm}$) smooth wall; homogeneous simple fluid (-9 to 20 HU); no septa or calcifications; the wall may enhance	Well-defined, thin ($\leq 2\text{mm}$) smooth wall; homogeneous simple fluid (signal intensity similar to CSF); no septa or calcifications; the wall may enhance
2 (Benign)	<ol style="list-style-type: none"> 1. Cystic masses with thin ($\leq 2\text{mm}$) and few (1-3) septa; septa and wall may enhance; may have calcification of any type 2. Homogeneous hyperattenuating (≥ 70 HU) masses at non-contrast CT 3. Homogeneous non-enhancing masses. 20 HU at renal mass protocol CT, may have calcification of any type† 4. Homogeneous masses -9 to 20 HU at non-contrast CT 5. Homogeneous masses 21 to 30 HU at portal venous phase CT 6. Homogeneous low-attenuation masses that are too small to characterise 	<ol style="list-style-type: none"> 1. Cystic masses with thin ($\leq 2\text{mm}$) and few (1-3) enhancing septa; any non-enhancing septa; may have calcification of any type 2. Homogeneous masses markedly hyperintense at T2-weighted imaging (similar to CSF) at non-contrast MRI 3. Homogeneous masses markedly hyperintense at T1-weighted imaging (approximately 32.5 normal parenchymal signal intensity) at non-contrast MRI
2F (Follow-up, up to five years. Some are malignant.)	Cystic masses with a smooth minimally thickened (3mm) enhancing wall, or smooth minimal thickening (3mm) of one or more enhancing septa, or many (≥ 4 mm) smooth thin ($\leq 2\text{mm}$) enhancing septa	<ol style="list-style-type: none"> 1. Cystic masses with a smooth minimally thickened (3mm) enhancing wall, or smooth minimal thickening (3mm) of one or more enhancing septa, or many ($\geq 4\text{mm}$) smooth thin ($\leq 2\text{mm}$) enhancing septa 2. Cystic masses that are heterogeneously hyperintense at unenhanced fat-saturated T1-weighted imaging
3 (Surgery or AS - see Chapter 7. Over 50% are malignant.)	One or more enhancing thick ($\geq 4\text{mm}$ width) or enhancing irregular (displaying $\leq 3\text{mm}$ obtusely margined convex protrusion[s]) walls or septa	One or more enhancing thick ($\geq 4\text{mm}$ width) or enhancing irregular (displaying $\leq 3\text{mm}$ obtusely margined convex protrusion[s]) walls or septa
4 (Surgery. Most are malignant.)	One or more enhancing nodule(s) ($\geq 4\text{mm}$ convex protrusion with obtuse margins, or a convex protrusion of any size that has acute margins	One or more enhancing nodule(s) ($\geq 4\text{mm}$ convex protrusion with obtuse margins, or a convex protrusion of any size that has acute margins)

AS: Active Surveillance; CSF: Cerebrospinal Fluid; CT: Computed Tomography; HU: Hounsfield Units; MRI: Magnetic Resonance Imaging

5.3 Renal tumour biopsy

5.3.1 Indications and rationale

Percutaneous biopsy can reveal histology of radiologically indeterminate renal masses and can be considered in patients who are candidates for AS of small masses, to obtain histology before ablative treatments, and to select the most suitable medical and surgical treatment strategy in the setting of metastatic disease [169-174] (LE: 3).

A multicentre study assessing 542 surgically removed SRMs showed that the likelihood of benign findings at pathology is significantly lower in centres where biopsies are performed (5% vs. 16%), suggesting that biopsies can reduce surgery for benign tumours and the potential for short-term and long-term morbidity associated with these procedures [175]. In a series of patients who underwent a percutaneous biopsy for an SRM, active treatment (surgery or cryotherapy) was avoided in 50/182 patients (27.5%) because of a benign diagnosis at biopsy [176].

However, the 2022 WHO classification categorically precludes establishing a definitive diagnosis of oncocytoma on needle-core biopsy, which will impact on the utility of percutaneous biopsy in the diagnostic pathway for mitigating overtreatment of benign renal lesions. Consequently, the urological community must remain cognisant of the substantial proportion of benign lesions identified following partial or radical nephrectomy (see also Section 3.5.4).

Renal biopsy is not indicated in comorbid and frail patients, who can be considered only for conservative management (watchful waiting [WW]), nor is it necessary in patients for whom surgery is planned, regardless of biopsy results (LE: 4).

Core biopsies of cystic renal masses have a lower diagnostic yield and accuracy and are not recommended, unless areas with a solid pattern are present (Bosniak IV cysts) [169, 172, 177] (LE: 2b/3). Histological characterisation by percutaneous biopsy of undefined retroperitoneal masses at imaging may be useful for decision-making, especially in the younger patient population.

The use of biopsy in the diagnostic pathway of renal tumours is approximately 20% and remains contentious, with barriers such as clinician bias and concerns regarding seeding persist in limiting adoption into routine practice [178]. A modified Delphi consensus statement, coproduced by patients and clinicians, on the current role of biopsy in SRM identified the need for more evidence that a biopsy changes a patient's treatment choice and reduces the number of benign nephrectomies to improve utility [179].

5.3.2 **Technique**

Percutaneous sampling can be performed under local anaesthesia with needle core biopsy and/or fine needle aspiration (FNA). Biopsies can be performed under US or CT guidance, with a similar diagnostic yield [172, 180] (LE: 2b). Eighteen-gauge needles are ideal for core biopsies, as they result in low morbidity and provide sufficient tissue for diagnosis [169, 173, 181] (LE: 2b). A coaxial technique allowing multiple biopsies through a coaxial cannula should always be used to avoid potential tumour seeding [169, 173] (LE: 3).

Core biopsies are preferred for the characterisation of solid renal masses, while a combination with FNA can provide complimentary results and improve accuracy for complex cystic lesions [177, 182, 183] (LE: 2a). An SR and meta-analysis of the diagnostic performance and complications of renal tumour biopsy was performed by the Panel, including 57 publications and a total of 5,228 patients. Needle core biopsies were found to have better accuracy for the diagnosis of malignancy compared with FNA [177]. Other studies showed that solid pattern, larger tumour size and exophytic location are predictors of a diagnostic core biopsy [169, 172, 180] (LE: 2b).

5.3.3 **Diagnostic yield and accuracy**

In experienced centres, core biopsies have a high diagnostic yield, specificity and sensitivity for the diagnosis of malignancy. The above-mentioned meta-analysis showed that sensitivity and specificity of diagnostic core biopsies for the diagnosis of malignancy are 99.1% and 99.7%, respectively [177] (LE: 2b). However, 0-22.6% of core biopsies are nondiagnostic (8% in the meta-analysis) [170-174, 180, 181, 184] (LE: 2a). If a biopsy is nondiagnostic and radiologic findings are suspicious for malignancy, a further biopsy or surgical exploration should be considered (LE: 4). Repeat biopsies have been reported to be diagnostic in a high proportion of cases (83-100%) [169, 185-187].

Accuracy of renal tumour biopsies for the diagnosis of tumour histotype is good. The median concordance rate between tumour histotype on renal tumour biopsy and on surgical specimen following PN or RN was 90.3% in the pooled analysis [177]. A retrospective observational study assessing the diagnostic performance of 151 renal tumour biopsies performed before robotic PN or RN confirmed that pathology on RTBs is highly concordant with the presence/absence of malignancy (147/151 = 97%) and the histotype on surgical specimens (141/151=93%) [188].

Assessment of tumour grade on core biopsies is challenging. In the pooled analysis, the overall accuracy for nuclear grading was poor (62.5%) but significantly improved (87%) using a simplified two-tier system (high vs. low grade) [177] (LE: 2a).

The ideal number and location of core biopsies are not defined. However, at least two good quality cores should be obtained, and necrotic areas should be avoided to maximise diagnostic yield [169, 172, 189, 190] (LE: 2b). Peripheral biopsies are preferable for larger tumours to avoid areas of central necrosis [191] (LE: 2b). In cT2 or greater renal masses, multiple core biopsies taken from at least four separate solid enhancing areas in the tumour were shown to achieve a higher diagnostic yield and a higher accuracy to identify sarcomatoid features, without increasing the complication rate [192].

5.3.4 **Morbidity**

Overall, percutaneous biopsies have a low morbidity [177]. Tumour seeding along the needle tract has been regarded as anecdotal in large series and pooled analyses on renal tumour biopsies. The coaxial technique in particular has been regarded as a safe method to avoid any seeding of tumour cells. However, authors recently reported on seven patients in whom tumour seeding was identified on histological examination of the resection specimen after surgical resection of RCC following diagnostic percutaneous biopsy [193]. Six of the seven cases were of the pRCC type. The clinical significance of these findings is still uncertain, as the only patient to develop local tumour recurrence at the site of the previous biopsy was a case treated with an open partial nephrectomy with positive surgical margins [193].

Spontaneously resolving subcapsular/perinephric haematomas are reported in 4.3% of cases in a pooled analysis, but clinically significant bleeding is unusual (0-1.4%; 0.7% in the pooled analysis) and generally self-limiting [177].

Percutaneous biopsy of renal hilar masses is technically feasible with a diagnostic yield similar to that of cortical masses, but with significantly higher post-procedural bleeding compared with cortical masses [194].

5.3.5 **Genetic assessment**

Renal cancer can be related to an inherited or *de novo* monogenic germline alteration and this recognition has significant implications [195]. Hereditary kidney cancer is thought to account for 5-8% of all kidney cancer cases, although this number is likely an underestimation since a more recent study found germline mutations in up to 38% of all metastatic kidney cancer patients [196] (see Chapter 8 on hereditary kidney tumours). Patients with a germline predisposition to kidney cancer often require multidisciplinary approaches. It is therefore critical for clinicians to be familiar with how and when referral for counselling is warranted, methods of genetic testing, implications of the findings, screening of at-risk (non-renal) organs, and the screening protocol for family members. Well-defined RCC management strategies exist, and specific therapeutic strategies are available or in development (see Chapter 8). Lack of a syndromic manifestation does not exclude a genetic contribution to cancer development. Moreover, other genetic components or polymorphisms are heritable and may confer a mildly increased risk. When several risk alleles are present, they can significantly increase cancer risk.

Many factors are associated with an increased risk of hereditary RCC syndromes. For instance, even in the absence of clinical manifestations and personal/family history, an age of onset of 46 years or younger should trigger consideration for genetic counselling/germline mutation testing [197]. Moreover, presence of bilateral or multifocal tumours/cysts and/or a first- or second-degree relative with RCC and/or a close blood relative with a known pathogenic variant significantly increases the risk to detect hereditary cancer. The presence of renal cysts can be associated with BHD and VHL and form part of the clinical diagnostic spectrum. Moreover, specific histologic characteristics can support differential diagnosis of a particular RCC syndrome (e.g. multifocal papillary histology, hereditary fumarate hydratase-deficient RCC, RCC with fumarate hydratase deficiency, multiple chromophobe, oncocytoma or oncocytic hybrid, succinate dehydrogenase-deficient RCC histology). Finally, additional tuberous sclerosis complex criteria should be assessed in individuals with AML [197-206].

If additional risk factors are established in a patient, referral to a comprehensive clinical care centre, or a hospital with demonstrated expertise in managing hereditary cancer syndromes, will provide a dedicated working team, tailored clinical decisions, research translational programme, appropriate patient psychosocial support and prospective collection of clinical data and biological samples. This can contribute to a better patient's care and further improvements in cancer care.

5.4 **Summary of evidence and recommendations for the diagnostic assessment of RCC**

Summary of evidence	LE
Contrast enhanced multiphasic CT has a high sensitivity and specificity for characterisation and detection of RCC, invasion, tumour thrombus and mRCC.	2a
The incidence of lung metastases in cT1a, cN0, without systemic symptoms and normal haemoglobin and thrombocytes is negligible.	3
Magnetic resonance imaging has a slightly higher sensitivity and specificity for small cystic renal masses and tumour thrombi as compared to CT.	2a
Contrast-enhanced US has a high sensitivity and specificity for characterisation of renal masses.	2a

Renal mass biopsies are associated with reduced overtreatment of benign masses and offers patients additional information (i.e. grade, subtype) for an informed decision regarding optimal management.	3
Ultrasound, Power Doppler US and PET CT have a low sensitivity and specificity for detection and characterisation of RCC.	2a

Recommendations	Strength rating
Use multiphase contrast-enhanced computed tomography (CT) of abdomen and chest for the diagnosis and staging of renal tumours.	Strong
Omit chest CT in patients with incidentally noted cT1a disease due to the low risk of lung metastases in this cohort.	Weak
Use magnetic resonance imaging (MRI) to better evaluate venous involvement, reduce radiation or avoid intravenous CT contrast medium.	Weak
Use non-ionising modalities, including MRI and contrast-enhanced ultrasound, for further characterisation of small renal masses, tumour thrombus and differentiation of unclear renal masses if the results of contrast-enhanced CT are indeterminate.	Strong
Offer brain CT/MRI in metastatic patients when systemic therapy or cytoreductive nephrectomy is considered.	Weak
Do not use bone scan and/or fluorodeoxyglucose positron emission tomography (FDG-PET) CT for primary staging of renal cell carcinoma.	Weak
Perform a renal tumour biopsy before ablative therapy and systemic therapy without previous pathology.	Strong
Perform a percutaneous biopsy in select patients who are considering active surveillance.	Weak
Use a coaxial technique when performing a renal tumour biopsy.	Strong
Do not perform a renal tumour biopsy of cystic renal masses unless a significant solid component is visible at imaging.	Strong
Use a core biopsy technique rather than fine needle aspiration for histological characterisation of solid renal tumours.	Strong

5.5 Summary of evidence and recommendations for genetic assessment of RCC

Summary of evidence	LE
Hereditary kidney cancer is thought to account for 5-8% of all kidney cancer cases, though that number is likely an underestimate.	3
In case of renal cancer, if a patient's age is 46 years, or younger and/or with bilateral or multifocal tumours and/or with a first- or second-degree relative with RCC and/or with a close blood relative with a known pathogenic variant and/or with specific histologic characteristics (see text), the risk of hereditary cancer is significantly higher.	3
Hereditary RCC detection has unique implications for decision-making and follow-up.	3

Recommendations	Strength rating
Perform a genetic evaluation in patients aged ≤ 46 years, with bilateral or multifocal tumours and/or a first- or second-degree relative with RCC and/or a close blood relative with a known pathogenic variant and/or specific histologic characteristics which suggest the presence of a hereditary form of RCC.	Strong
Refer patients to a cancer geneticist or to a comprehensive clinical care centre in case of suspected hereditary RCC.	Strong

6. PROGNOSTIC FACTORS

6.1 Definition and classification

Prognostic factors are defined as variables associated with clinical endpoints (i.e. recurrence, progression and survival) independent of a treatment, thereby reflecting the natural course of the disease. Predictive factors, in contrast, provide information on the effectiveness (i.e. response, progression, survival) of a specific treatment. Notably, there is substantial overlap between the two categories, because prognostic factors may also serve as predictive factors and vice versa. Both can be classified into anatomical, histological, clinical and molecular factors.

6.2 Anatomical factors

Tumour size, venous invasion and extension, collecting system invasion, perinephric- and sinus fat invasion, adrenal involvement and LN and distant metastasis are included in the TNM classification system [90, 102] (see Table 4.1).

6.3 Histological factors

Histological factors include tumour grade, RCC subtype, lymphovascular invasion, tumour necrosis and invasion of the collecting system [207, 208]. Tumour grade is considered one of the most important histological prognostic factors. The Fuhrman nuclear grade [209] has now been replaced by the WHO/ISUP grading classification [210]. This relies solely on nucleolar prominence for grade 1-3 tumours, allowing for less interobserver variation [211]. It has been shown that the WHO/ISUP grading provides superior prognostic information compared to Fuhrman grading, particularly for grade 2 and grade 3 tumours [212]. Rhabdoid and sarcomatoid changes can be found in all RCC types and are equivalent to grade 4 tumours. Sarcomatoid changes are more often found in chRCC than other subtypes [213]. The percentage of the sarcomatoid component appears to be prognostic as well, with a larger percentage of involvement being associated with worse survival. There is no agreement on the optimal prognostic cut-off for subclassifying sarcomatoid changes [214, 215], although 20% has been suggested to distinguish focal and extensive amount of sarcomatoid features [216]. The WHO/ISUP grading system is applicable to both ccRCC and pRCC. Grading chRCC is currently not recommended. However, a study suggested a two-tiered chRCC grading system (low vs. high grade) based on the presence of sarcomatoid differentiation and/or tumour necrosis, which was statistically significant on multivariable analysis [217]. Both the WHO/ISUP and chRCC grading systems must be validated for prognostic systems and nomograms [210].

Renal cell carcinoma subtype is regarded as another important prognostic factor. On univariable analysis, patients with chRCC vs. pRCC vs. ccRCC had a better prognosis [218, 219] (Table 6.1). However, prognostic information provided by the RCC type is lost when stratified according to tumour stage [219, 220] (LE: 3).

Table 6.1: Cancer-specific survival by stage [218]

Grade	HR (95% CI)
T1N0M0	Referent
T2N0M0	2.71 (2.17-3.39)
T3N0M0	5.20 (4.36-6.21)
T4N0M0	16.88 (12.40-22.98)
N+M0	16.33 (12.89-20.73)
M+	33.23 (28.18-39.18)

CI = confidence interval; HR = hazard ratio.

6.4 Clinical factors

Clinical factors include performance status (PS), local symptoms, early versus late recurrence, cachexia, anaemia, platelet count, neutrophil count, lymphocyte count, CRP [229], albumin and various indices deriving from these factors, such as the neutrophil-to-lymphocyte ratio (NLR) [118, 230-236] (LE: 3). As a marker of systemic inflammatory response, a high preoperative NLR has been associated with poor prognosis [237], but there is significant heterogeneity in the data and no agreement on the optimal prognostic cut-off. Even though obesity is an aetiological factor for RCC, it has also been observed to provide prognostic information. A high body mass index (BMI) appears to be associated with improved survival outcomes in both non-metastatic and metastatic RCC [238-240]. This association is linear with regards to cancer-specific mortality (CSM), while RCC patients with obesity show increasing all-cause mortality with increasing BMI [241]. Evidence is also available

on the prognostic value of body composition indices measured on cross-sectional imaging, such as sarcopenia and fat accumulation [235, 242, 243]. Health-related quality of life (HRQoL) at baseline and during treatment of mRCC may also be prognostic. In CheckMate 214, HRQoL measured by the Functional Assessment of Cancer Therapy Kidney Symptom Index 19 at baseline and during follow-up was associated with improved OS in both the ipilimumab+nivolumab and the sunitinib arm [244]. Perioperative blood transfusion is linked to worse cancer-specific and overall mortality, as well as a higher risk of recurrence. However, receiving one to two units of packed red blood cells does not significantly impact outcomes compared to receiving three or more units. Notably, intraoperative transfusion is associated with higher cancer-specific mortality and recurrence, while postoperative transfusion is not [245].

6.4.1 **Frailty and comprehensive geriatric assessment**

Frailty is a geriatric syndrome characterised by a decline in individuals' resilience and physiological functional reserve across multiple body systems, resulting in increased vulnerability to external stressors [246, 247]. Frailty is an adverse prognostic factor in older patients with localized RCC, being associated with worse perioperative outcomes as well as poorer oncological outcomes across different stages [246].

Several instruments have been developed and implemented in clinical practice for the diagnosis and measurement of frailty [247].


Among these, the G8 (Geriatric 8) health status screening tool, which assesses several patient variables (age, perceived health status, food intake, weight loss, BMI, mobility, neuropsychology, and polypharmacy), is widely used in oncogeriatrics to identify older cancer patients who could benefit from geriatric assessment, and has been validated to predict health outcomes in older cancer patients [247].

The EAU Guidelines Office has endorsed the G8 score as a screening tool for frailty [248-250].

Referral to comprehensive geriatric assessment (CGA), performed by dedicated geriatricians, is advised in patients with a G8 score $\leq 14/17$ [247].

The CGA explores several domains: functional capacity, polypharmacy, performance status, cognition, social support, psychological status and nutritional status. The CGA can identify frailty and risk of geriatric syndromes, as well as support clinical decision-making in both localised and metastatic RCC [247, 251]. Multidisciplinary management of patients characterised as frail after CGA is essential.

Table 6.2 Frailty and geriatric assessment factors



6.4.2 **Nephrological assessment**

Renal function considerations are key for shared decision-making in patients with localised RCC, considering the bidirectional relationship between RCC and chronic kidney disease (CKD) [252].

Selected patients who are candidate for treatment for RCC may benefit from nephrological consultation, including patients with pre-existing stage 3-5 CKD or proteinuria; patients with a solitary kidney, especially those with borderline/known CKD. Patients with known medical comorbidities that may potentially affect renal function; and patients whose expected new baseline renal function after surgery is below 45ml/min./1.73m².

To date, while several models have been proposed for predicting postoperative renal function after RCC surgery, most relied on retrospective cohorts, had a high risk of bias and high concern regarding the applicability of the proposed model. As such, most of these models are not ready for routine clinical practice, while a few have been externally validated [253].

In such patients, nephrological consultation before treatment can recommend further diagnostic tests for CKD, optimise CKD risk factors (e.g. hypertension, hyperglycaemia, obesity, etc.), recommend specific lifestyle and/or medical interventions to decrease the risk of acute kidney injury or renal function deterioration after treatment and improve shared decision-making [254].

6.5 **Molecular factors**

Numerous molecular markers such as carbonic anhydrase IX (CaIX), VEGF, HIF, Ki67 (proliferation), p53, p21 [255], PTEN (phosphatase and tensin homolog) cell cycle [256], E-cadherin, osteopontin [257] CD44 (cell adhesion) [258, 259], CXCR4 [260], PD-L1 [261], miRNA, SNPs, gene mutations, and gene methylations have been investigated (LE: 3) [262]. While the majority of these markers are associated with prognosis and many improve the discrimination of current prognostic models, very little emphasis has been placed on external validation studies. Moreover, there is no conclusive evidence on the value of molecular markers for treatment selection in mRCC [229, 261, 263]. The routine use of molecular markers in clinical practice is therefore not recommended.

Several prognostic and predictive marker signatures have been described for specific systemic treatments in mRCC. In the JAVELIN Renal 101 trial (NCT02684006), a 26-gene immunomodulatory gene signature predicted PFS in those treated with avelumab plus axitinib, while an angiogenesis gene signature was associated with PFS for sunitinib. Mutational profiles and histocompatibility leukocyte antigen types were also associated with PFS, while programmed death-ligand 1 (PD-L1) expression and tumour mutational burden were not [264]. In IMmotion151 (NCT02420821), a T effector/IFN- γ -high or angiogenesis-low gene expression signature predicted improved PFS for atezolizumab plus bevacizumab compared to sunitinib. The angiogenesis-high gene expression signature correlated with longer PFS in patients treated with sunitinib [265]. In CheckMate214 (NCT02231749), a higher angiogenesis gene signature score was associated with better overall response rates and PFS for sunitinib, while a lower angiogenesis score was associated with higher overall relative risk in those treated with nivolumab plus ipilimumab. Progression-free survival > 18 months was more often seen in patients with higher expression of Hallmark inflammatory response and Hallmark epithelial mesenchymal transition gene sets [235].

Urinary and plasma Kidney-Injury Molecule-1 (KIM-1) has been identified as a potential diagnostic and prognostic marker. With KIM-1 concentrations are elevated in RCC patients at least up to five years before diagnosis and were associated with a shorter survival time [266]. Kidney-Injury Molecule-1 is a glycoprotein marker of acute proximal tubular injury and therefore mainly expressed in RCC derived from the proximal tubules such as ccRCC and pRCC [267].

In the CheckMate214 trial comparing ipilimumab plus nivolumab with sunitinib, higher baseline serum KIM-1 levels were associated with shorter OS. A decline in KIM-1 levels correlated with improved PFS and OS in patients treated with ipilimumab and nivolumab [268]. In a *post hoc* analysis of the IMmotion010 trial in patients with high-risk resected RCC, elevated baseline plasma KIM-1 levels were linked to worse disease-free survival (DFS), but also to improved DFS in those receiving adjuvant atezolizumab versus placebo [269]. These findings suggest that KIM-1 is a promising biomarker and warrants further investigation.

Another promising marker is the urinary glycosaminoglycan score (GAGome) for detecting recurrence after curative surgery for ccRCC. In a prospective study (AURORAX-0087A), the score demonstrated 90% sensitivity and 51% specificity for radiologically confirmed recurrence [270]. A validation study is currently underway.

Several retrospective studies and large molecular screening programmes have identified mutated genes and chromosomal changes in ccRCC with distinct clinical outcomes. The expression of the BAP1 and PBRM1 genes, situated on chromosome 3p in a region that is deleted in more than 90% of ccRCCs, have shown to be independent prognostic factors for tumour recurrence [271-274]. These published reports suggest that patients with BAP1 mutant tumours have worse outcomes compared with patients with PBRM1 mutant tumours [272]. Loss of chromosome 9p and 14q have been consistently shown to be associated with poorer survival [275-277]. The TRACERx renal consortium has proposed a genetic classification based on RCC evolution (punctuated vs. branched vs. linear), which correlates with tumour aggressiveness and survival [276]. Additionally, a 16-gene signature was shown to predict DFS in patients with non-metastatic RCC [278]. However, these signatures have not been validated by independent researchers yet.

6.6 Prognostic models

Prognostic models combining independent prognostic factors have been developed and externally validated [279-286]. These models are more accurate than TNM stage or grade alone for predicting clinically relevant oncological outcomes [287] (LE: 3). Before being adopted, new prognostic models should be evaluated and compared to current prognostic models with regards to discrimination, calibration and net benefit. Pathological prognostic factors are used in the Leibovich 2003 score/groups for ccRCC [282]. Prognostic models for non-ccRCC are available, such as the VENUSS score for pRCC [288]. Although both were validated in several studies and showed superior discrimination to other prognostic models, molecular markers are needed [289-292]. In metastatic disease, risk groups assigned by the Memorial Sloan Kettering Cancer Centre (MSKCC) (primarily created in the pre-targeted therapy era and validated in patients receiving targeted therapy) and the IMDC (initially created in the targeted therapy era) differ in 23% of cases [293]. The IMDC model has been used in most of the recent RCTs, including those with immune checkpoint inhibitors (ICIs), and may therefore be the preferred model for clinical practice. The IMDC model has been shown to be of continued use for risk stratifying patients with mRCC treated with contemporary first-line IO combination therapies [294].

The discrimination of the IMDC models improves by additional variables, such as presence of brain metastasis, bone metastasis, liver metastasis, NLR and platelet count [295-298]. Tables 6.3 and 6.4 summarise the current, most-relevant prognostic models.

6.7 Summary of evidence and recommendations for prognostic factors

Summary of evidence	LE
In RCC patients, TNM stage, tumour size, grade and RCC subtype provide important prognostic information.	2a
The 2003 Leibovich score is a validated prognostic model to predict the short- and long-term risk of metastasis in individual patients with sporadic, unilateral pT1-4 N0/+ M0 ccRCC.	2b
The VENUSS score is a validated prognostic model to predict the short- and long-term risk of disease recurrence in individual patients with sporadic, unilateral pT1-4 N0/+ M0 pRCC.	2b
Frailty is associated with adverse clinical outcomes in patients undergoing treatment for non-metastatic RCC.	3
There is a bidirectional relationship between RCC and CKD.	3

Recommendations	Strength rating
Use the current Tumour, Node, Metastasis classification system.	Strong
Use the WHO/ISUP grading system and classify RCC type.	Strong
Use prognostic models in localised and metastatic disease.	Strong
Use the 2003 Leibovich scoring model for risk stratification of localised and locally advanced clear cell RCC.	Weak
Use the VENUSS scoring model for risk stratification of localised and locally advanced papillary RCC.	Weak
Do not routinely use molecular markers to assess prognosis.	Strong
Screen elderly patients with a renal mass/RCC with a validated geriatric frailty score to identify patients at risk for frailty.	Weak

Offer comprehensive geriatric assessment in elderly patients whose screening revealed a risk for frailty.	Weak
Offer pre-treatment nephrological consultation in selected patients with or at risk for impaired renal function (e.g. pre-existing chronic kidney disease or proteinuria; solitary kidney, known medical comorbidities affecting renal function; new baseline eGFR below 45ml/min./1.73m ²)	Weak

eGFR = estimated glomerular filtration rate; ISUP = International Society of Urological Pathology; WHO = World health organisation; VENUSS = venous involvement, necrosis, size, stage and sarcomatoid differentiation.

Table 6.3: Prognostic models for localised RCC

Prognostic model	Subtype*	Risk factors/prognostic factors
UISS** [299]	All	<ol style="list-style-type: none"> 1. ECOG PS 2. T classification 3. N classification (N+ classified as metastatic) 4. Grade <p>T1N0M0G1-2, ECOG PS 0: low-risk disease T3N0M0G2-4, ECOG PS ≥ 1 OR T4N0M0: high-risk disease Any other N0M0: intermediate-risk disease</p>
Leibovich score/ model 2003 [282]	CC	<ol style="list-style-type: none"> 1. T classification (pT1a: 0, pT1b: 2, pT2:3, pT3-4: 4 points) 2. N classification (pNx/N0: 0, pN+: 2 points) 3. Tumour size (< 10 cm: 0, ≥ 10 cm: 1 point) 4. Grade (G1-2: 0, G3: 1, G4: 3 points) 5. Tumour necrosis (absent: 0, present: 1 point) <p>0-2 points: low-risk disease 3-5 points: intermediate-risk disease 6 or more points: high-risk disease</p>
Leibovich score/ model 2018 [300]	CC, P, CH	<p><u>ccRCC</u></p> <ul style="list-style-type: none"> • Progression (nine factors): constitutional symptoms, grade, tumour necrosis, sarcomatoid features, tumour size, perinephric or sinus fat invasion, tumour thrombus level, extension beyond kidney, nodal involvement. • Cancer-specific survival (12 factors): age, ECOG PS, constitutional symptoms, adrenalectomy, surgical margins, grade, tumour necrosis, sarcomatoid features, tumour size, perinephric or sinus fat invasion, tumour thrombus, nodal involvement. • No risk groups /prognostic groups. <p><u>pRCC</u></p> <ul style="list-style-type: none"> • Low risk (group 1): grade 1-2, no fat invasion, no tumour thrombus. • Intermediate risk (group 2): grade 3, no fat invasion, no tumour thrombus. • High risk (group 3): grade 4 or fat invasion or any level tumour thrombus. <p><u>chRCC</u></p> <ul style="list-style-type: none"> • Low risk (group 1): no fat invasion, no sarcomatoid differentiation, no nodal involvement. • Intermediate risk (group 2): fat invasion and no sarcomatoid differentiation and no nodal involvement. • High risk (group 3): sarcomatoid differentiation or nodal involvement.
VENUSS score/ model*** [288, 289]	P	<ol style="list-style-type: none"> 1. T classification (pT1: 0, pT2: 1, pT3-4: 2 points) 2. N classification (pNx/pN0: 0, pN1: 3 points) 3. Tumour size (≤ 4 cm: 0, > 4 cm: 2 points) 4. Grade (G1/2: 0, G3/4: 2 points) 5. Tumour thrombus (absent: 0, present: 2 points) <p>0-2 points: low-risk disease 3-5 points: intermediate-risk disease 6 or more points: high-risk disease</p>

GRANT score/ model**** [301]	All	<ol style="list-style-type: none"> Age > 60 years T classification = T3b, pT3c or pT4 N classification = pN1 (Fuhrman) grade = G3 or G4 <p>0-1 factors: favourable-risk disease 2 or more factors: unfavourable-risk disease</p>
---------------------------------	-----	---

* ccRCC = clear-cell RCC; ECOG = Eastern Cooperative Oncology Group; pRCC = papillary RCC; chRCC = chromophobe RCC; PS = performance status.

** UUniversity of California Integrated Staging system. Available at

<https://www.mdcalc.com/ucla-integratedstaging-system-uiss-renal-cell-carcinoma-rcc>.

*** Venous extension, Nuclear grade, Size, Stage. Available at <https://www.evidencio.com/models/show/2369>.

**** Grade, Age, Nodes and Tumour.

Table 6.4: Prognostic models for metastatic RCC

Prognostic model	Subtype	Risk factors/prognostic factors
MSKCC [302]**	All	<ol style="list-style-type: none"> Karnofsky PS [303]* < 80% Interval from diagnosis to systemic treatment < 1 year Haemoglobin < Lower Limit of Normal Corrected calcium > 10mg/dL/> 2.5mmol/L LDH > 1.5x Upper Limit of Normal <p>0 factors: favourable-risk disease 1-2 factors: intermediate-risk disease 3-5 factors: poor-risk disease</p>
IMDC [304]***	All	<ol style="list-style-type: none"> Karnofsky PS [303]* < 80% Interval from diagnosis to treatment < 1 year Haemoglobin < lower limit of normal Corrected calcium > upper limit of normal (i.e. > 10.2mg/dL) Neutrophil count > upper limit of normal (i.e. > 7.0×10⁹/L) Platelet count > upper limit of normal (i.e. > 400,000) <p>0 factors: favourable-risk disease 1-2 factors: intermediate-risk disease 3-6 factors: poor-risk disease</p>

IMDC = International Metastatic Renal Cancer Database Consortium; LDH = lactate dehydrogenase;

MSKCC = Memorial Sloan Kettering Cancer Center; PS = performance status.

* Karnofsky performance status calculator: <https://www.thecalculator.co/health/Karnofsky-Score-for-Performance-Status-Calculator-961.html>.

** MSKCC: <https://www.mdcalc.com/memorial-sloan-kettering-cancer-center-mskcc-motzer-coreetastaticrenal-cell-carcinoma-rcc>.

*** IMDC: <https://www.mdcalc.com/imdc-international-metastatic-rcc-database-consortium-risk-score-rcc>.

7. DISEASE MANAGEMENT

7.1 Patient involvement in kidney cancer treatment

A large-scale global survey of patients with RCC performed by the International Kidney Cancer Coalition (IKCC) identified geographic variations in patient education, experience, awareness, access to care, best practices, quality of life and unmet psychosocial needs [305]. A total of 1,400 patients from 43 countries revealed that, at diagnosis, 43% of all respondents had no understanding of their RCC subtype, 29% reported no involvement in their treatment decision and 96% reported psychosocial impacts, with only 50% disclosing it to their health care team. Moreover, 90% of patients indicated that they would be interested in participating in clinical trials if asked. Furthermore, an effort should be made to increase diversity in clinical trial participants, ensuring representation of the target population.

Shared decision-making ensures that patients are supported in making decisions about their care and treatment given their own individual needs, personal circumstances, goals, values and beliefs. It is a collaborative process between patients and healthcare professionals that involves information sharing, collaboration and problem solving given each patient's prerequisites [306]. Shared decision-making brings together the healthcare providers expertise on treatment options, evidence, risks and benefits, and the patient's individual preferences. However, to ensure patient participation and build the patient-health care professional relationship, adequate time is needed [307]. Nurse-led patient engagement interventions have shown positive effects on cancer patients' participation in the decision-making process, health literacy, self-efficacy and quality of life (QoL) [308]. More evidence, specifically regarding patients with RCC, has been called for [309]. One RCT has indicated that patient involvement in reporting their symptoms during management of a variety of metastatic solid tumours can improve clinical outcomes, including OS [310].

7.1.1 Recommendation on patient involvement and shared decision making

Recommendation	Strength rating
Employ a shared decision-making approach when deciding on appropriate treatment for RCC.	Strong

7.1.2 Smoking cessation

A prospective study on 212 patients with RCC investigated the impact of smoking cessation on the risk of tumour recurrence/progression, RCC-specific and all-cause mortality. Quitting smoking was associated with lower all-cause mortality, lower cancer-specific mortality and a lower risk of recurrence/progression.

The beneficial effect of quitting smoking was evident across all RCC stages and all levels of smoking [311] and avoidance of smoking (any form of tobacco or vaping products) and quitting smoking were included in the WHO European Code against Cancer [312].

7.1.2.a Recommendation on smoking cessation

Recommendation	Strength rating
Counsel RCC patients to stop smoking.	Strong

7.2 Treatment of localised RCC

7.2.1 Introduction

Section 7.2.2 is underpinned by an SR that includes all relevant published literature comparing surgical management of localised RCC (T1-2N0M0). Randomised or quasi-RCTs were included. However, due to the very limited number of RCTs, non-randomised studies, prospective observational studies with controls, retrospective matched-pair studies and comparative studies from the databases of well-defined registries were also included. A SR highlights the heterogeneity of outcome reporting and definitions in studies in localised RCC, supporting the development of a core outcome set to enable robust evaluation of evidence [313]. Surgery has historically been the benchmark for the treatment of localised RCC.

7.2.2 Surgical treatment

7.2.2.a Nephron-sparing surgery versus radical nephrectomy in localised RCC

7.2.2.a.1 T1 RCC

Outcome 1: Cancer-specific survival

Most studies comparing the oncological outcomes of PN and RN are retrospective and include cohorts of varied and, overall, limited size [314, 315]. Only one (prematurely closed) prospective RCT including patients with organ-confined RCCs of limited size (< 5cm) has been published, showing comparable noninferiority of CSS for PN versus RN (HR: 2.06 [95% CI: 0.62-6.84]) [316].

Outcomes 2 & 3: Overall mortality and renal function

Partial nephrectomy preserved kidney function better after surgery, thereby potentially lowering the risk of development of cardiovascular disorders [314, 317] and cardiovascular-specific mortality.

In the only prospectively randomised (prematurely closed and heavily underpowered) trial, PN appears to be less effective than RN in terms of OS in the intention to treat (ITT) population (HR: 1.50 [95% CI: 1.03-2.16]). However, in the targeted RCC population of the only RCT, the trend in favour of RN was no longer significant [316]. Considering the limitations of the available evidence (most studies are retrospective with a high risk of bias and unmeasured confounding), the OS advantage suggested for PN versus RN remains an unresolved issue.

Patients with a normal preoperative renal function and a decreased GFR due to surgical treatment (either RN or PN), generally present with stable long-term renal function [318]. Adverse OS in patients with a pre-existing glomerular filtration rate (GFR) reduction does not appear to result from further renal function impairment following surgery, but rather from other medical comorbidities causing presurgical CKD [319]. However, in particular in patients with pre-existing CKD, PN is the treatment of choice to limit the risk of development of ESRD, which requires haemodialysis. A retrospective cohort study found that 26% of patients with newly diagnosed RCC had an $\text{GFR} \leq 60\text{mL/min.}$, even though their baseline serum creatinine levels were in the normal range [121].

Outcomes 4 & 5: Perioperative outcomes and quality of life

In terms of the intra- and perioperative morbidity/complications associated with PN versus RN, the European Organisation for Research and Treatment of Cancer (EORTC) randomised trial showed that PN for small, easily resectable, incidentally discovered RCC, in the presence of a normal contralateral kidney, can be performed safely with slightly higher complication rates than after RN [320].

Only a limited number of studies are available addressing QoL following PN vs. RN, irrespective of the surgical approach used (open vs. minimally invasive). Quality of life was ranked higher following PN as compared to RN, but generally speaking patients' health status deteriorated following both approaches [320, 321].

In view of the above, and since the oncological outcomes (CSS and RFS) of PN are comparable to those of RN, PN is the treatment of choice for T1 RCC, because it better preserves kidney function and potentially limits the long-term incidence of cardiovascular disorders and ESRD. In frail patients, treatment decisions should be individualised, weighing the risks and benefits of PN versus RN, the increased risk of perioperative complications with PN and the increased risk of developing or worsening CKD with RN.

7.2.2.a.2 T2 RCC

Very limited evidence is available on the comparative effectiveness of PN and RN for patients with radiologically defined cT2 renal masses.

Some retrospective comparative studies of PN versus RN for T2 RCC have been published [322]. A trend for lower tumour recurrence and CSM is reported in PN groups. The estimated blood loss is reported to be higher for PN groups, as is the likelihood of postoperative complications [322]. A multicentre study compared the survival outcomes in patients with larger ($> 7\text{cm}$) ccRCC treated with PN versus RN with long-term follow-up (median 102 months). Compared to the RN group, the PN group had a significantly longer median OS ($p = 0.014$) and median CSS ($p = 0.04$) [323]. Retrospective comparative studies of cT1 and cT2 RCC patients upstaged to pT3a RCC show contradictory results: some reports suggest similar oncologic outcomes between PN and RN [324], whilst another report suggests that PN of clinical T1 in pathologically upstaged pT3a of cT1 RCC is associated with a significantly shorter RFS than RN [325]. Overall, the level of the evidence is low. These studies including T2 masses all have a high risk of selection bias due to imbalance between the PN and RN groups regarding patient's age, comorbidities, tumour size, stage and tumour position. These imbalances in covariation factors may have a greater impact on patient outcome than the choice of PN or RN. The Panel's confidence in the results is limited, and the true effects may be substantially different.

In view of the above, the risks and benefits of PN should be discussed with patients with T2 tumours. In this setting, PN should be considered, if technically feasible, in patients with a solitary kidney, bilateral renal tumours or CKD with sufficient parenchymal volume preserved to allow sufficient postoperative renal function.

7.2.2.a.3 T3 RCC

The prevalence of cT1 to pT3a is reported in up to 5.7% of the patients, risk factors include age (OR: 1.03), tumour size (OR: 1.51) and RENAL score (OR: 2.80) [326].

A meta-analysis of nine articles including 1,278 patients with PN and 2,113 patients with RN for pT3a RCC showed no difference in CSS, OS, CSM and RFS, indicating that PN techniques can be used for functional benefits and if technically feasible [327].

Overall, there is lack of high-quality evidence on the comparative effectiveness and safety of PN versus RN for radiologically cT3 tumours and/or pathologically upstaged cT1-2-pT3 RCC. For this reason, the decision to perform PN in these patients should carefully balance the potential benefits of PN for renal function preservation against its potential oncologic risks.

7.2.2.b Associated procedures

7.2.2.b.1 Adrenalectomy

One prospective non-randomised study compared the outcomes of RN with, or without, ipsilateral adrenalectomy [328]. Multivariable analysis showed that upper pole location was not predictive of adrenal involvement, but tumour size was. No difference in OS at five or ten years was seen with, or without, adrenalectomy. Adrenalectomy was justified using criteria based on radiographic and intraoperative findings. Only 48 of 2,065 patients underwent concurrent ipsilateral adrenalectomy, of which 42 of the 48 interventions were for benign lesions [328].

7.2.2.b.2 Lymph node dissection for clinically negative lymph nodes (cN0)

The indication for LN dissection (LND) together with PN or RN is still controversial [329]. The clinical assessment of LN status is based on the detection of an enlargement of LNs either by CT/MRI or intraoperative palpability of enlarged nodes. Fewer than 20% of suspected metastatic nodes (cN+) are positive for metastatic disease at histopathological examination (pN+) [330]. Both CT and MRI are unsuitable for detecting malignant disease in nodes of normal shape and size [331]. For clinically positive LNs (cN+), see Section 7.2.2.

Only one prospective RCT evaluating the clinical value of LND combined with surgical treatment of primary RCC has been published so far. With an incidence of LN involvement of only 4%, the risk of lymphatic spread appears to be very low. Recognising the latter, only a staging effect was attributed to LND [330]. This trial included a very high percentage of patients with pT2 tumours, which are not at increased risk for LN metastases. Only 25% of patients with pT3 tumours underwent a complete LND and the LN template used by the authors was not clearly stated.

Contemporary pooled retrospective analyses have confirmed a lack of benefit for LND in low-stage RCC [332].

Smaller retrospective studies have suggested a clinical benefit associated with a more or less extensive LND, preferably in patients at high risk for lymphogenic spread. In a large retrospective study, the outcomes of RN with or without LND in patients with high-risk non-mRCC were compared using a propensity score analysis. In this study, LND was not significantly associated with a reduced risk of distant metastases, cancer-specific or all-cause mortality. The extent of the LND was not associated with improved oncologic outcomes [333]. The number of LN metastases (< / > 4), as well as the intra- and extra-capsular extension of intra-nodal metastasis, correlated with the patients clinical prognosis in some studies [331, 334-336]. Better survival outcomes were seen in patients with a low number of positive LNs (< 4) and no extranodal extension. Based on a retrospective Surveillance, Epidemiology and End Results (SEER) database analysis of > 9,000 patients, no effects of an extended LND (eLND) on the disease-specific survival (DSS) of patients with pathologically confined negative nodes was demonstrated [337]. However, in patients with pathologically proven lymphogenic spread (pN+), an increase of 10 for the number of nodes dissected resulted in a 10% absolute increase in DSS.

In addition, a larger cohort of 1,983 patients demonstrated that eLND results in a significant prolongation of CSS in patients with unfavourable prognostic features (e.g. sarcomatoid differentiation, large tumour size) [338]. With regard to morbidity related to eLND, a retrospective propensity score analysis from a large single-centre database showed that eLND is not associated with an increased risk of Clavien grade > 3 complications. Moreover, LND was not associated with length of hospital stay or estimated blood loss [339].

The optimal extent of LND remains controversial. Retrospective studies suggest that an eLND should involve the LNs surrounding the ipsilateral great vessel and the inter-aortocaval region from the crus of the diaphragm to the common iliac artery. Involvement of inter-aortocaval LNs without regional hilar involvement is reported in up to 35-45% of cases [331, 340, 341]. At least fifteen LNs should be removed [338, 342]. Sentinel LND is an investigational technique [343, 344].

7.2.2.b.3 Embolisation

Before routine nephrectomy, tumour embolisation has no benefit [345, 346]. In patients unfit for surgery, or with non-resectable disease, embolisation can control symptoms, including visible haematuria or flank pain [347]. These indications will be revisited in Sections 7.2 and 7.3, with cross-reference to the summary of evidence and recommendations below.

7.2.2.b.4 Summary of evidence and recommendations for the treatment of localised RCC

Summary of evidence	LE
The oncological outcome in terms of OS following PN equals that of RN in patients with c/p T1 RCC.	1b
Retrospective studies suggest that oncological outcomes are similar following PN versus RN in patients with larger (≥ 7 cm) RCC. Postoperative complication rates are higher in PN patients.	3b
Ipsilateral adrenalectomy during RN or PN has no survival advantage in the absence of clinically evident adrenal involvement.	3
In patients with localised disease without radiographic evidence of LN metastases, a survival advantage of LND in conjunction with RN is not demonstrated in RCTs.	1b
Retrospective studies suggest a clinical benefit associated with LND in high-risk patients.	2b
In patients unfit for surgery with massive haematuria or flank pain, embolisation can be a beneficial palliative approach.	3

Recommendations	Strength rating
Offer surgery to achieve cure in localised RCC.	Strong
Offer partial nephrectomy (PN) to patients with T1 tumours.	Strong
Offer PN to patients with T2 tumours and a solitary kidney or chronic kidney disease, if technically feasible.	Weak
Do not perform ipsilateral adrenalectomy if there is no clinical evidence of invasion of the adrenal gland.	Strong
Do not routinely perform a lymph node dissection to patients with organ-confined disease.	Weak
Offer embolisation to patients unfit for surgery presenting with massive haematuria or flank pain.	Weak

7.2.3 Radical and partial nephrectomy techniques

7.2.3.a Radical nephrectomy techniques

7.2.3.a.1 Open versus laparoscopic or robotic approach

No RCTs have assessed the oncological outcomes of laparoscopic versus open RN. An SR did not demonstrate any survival difference in laparoscopic RN and open RN [348].

Data from one SR [348] and two non-randomised studies [349, 350] showed a significantly shorter hospital stay and lower analgesic requirement for the laparoscopic RN group as compared with the open group. Convalescence time was also significantly shorter [350]. Surgical complication rates were low with very wide confidence intervals. There was no difference in complications, but operation time was significantly shorter in the open nephrectomy arm. The QoL and perioperative outcomes were inconsistently defined, measured or reported [314, 348] (LE: 2b, based on one low quality SR).

7.2.3.a.2 Laparoscopic versus robotic approach

Data from a large retrospective cohort study on robot-assisted laparoscopic versus laparoscopic RN showed that robot-assisted laparoscopic RN was not associated with increased risk of any or major complications but had a longer operating time and higher hospital costs compared with laparoscopic RN [351].

A SR comparing the outcomes of robotic surgery to those of laparoscopic and open surgery in patients undergoing RN for RCC (n=12 studies involving 64,221 patients) found that, compared to laparoscopic RN, robotic RN was associated with longer operative time (weighted mean difference (WMD) 37.44 min.), shorter length of stay (WMD -0.84 days) and higher total costs [352]. Compared to open RN, robotic RN was associated with shorter length of stay, fewer overall complications, lower estimated blood loss and higher total hospital costs. High heterogeneity was observed across all analyses.

7.2.3.a.3 Laparoscopic single port versus laparoscopic multiport approach

Similar results were seen in observational cohort studies comparing 'portless' and three-port laparoscopic RN, with similar perioperative outcomes [353, 354].

Transperitoneal versus retroperitoneal RN

A SR and pooled analysis compared the safety and efficacy of transperitoneal (TLRN) versus retroperitoneal laparoscopic RN (RLRN) for the treatment of large-volume (> 7cm) renal masses (including 14 studies, of which five RCTs and nine retrospective studies) [355]. Most studies were limited by the small number of patients included, limited/unreported follow-up and moderate-to-high risk of bias.

The merged data showed shorter operating time for RLRN operating time (OT) (MD [mean difference]: -26.57); less estimated blood loss (EBL) (MD: -20.55); and faster postoperative intestinal exhaust (MD: -0.65). The two approaches were comparable regarding LOS, blood transfusion, conversion rate, intra- and postoperative complications, local recurrence rate, positive surgical margins, and distant recurrence rate.

7.2.3.b Partial nephrectomy techniques

7.2.3.b.1 Open versus laparoscopic approach

Two small RCTs have compared the outcomes of open versus laparoscopic PN [356]. Studies comparing laparoscopic and open PN found no difference in PFS [357-360] and OS [359, 360] in centres with laparoscopic expertise.

The results for GFR decline are debatable. An RCT reported greater three- to 12-month kidney function reduction in the open group [356], whilst in a matched-pair comparison, GFR decline was greater in the laparoscopic PN group in the immediate postoperative period [360], but not after 3.6-years follow-up. In another comparative study, the surgical approach was not an independent predictor for postoperative CKD [361].

Retroperitoneal and transperitoneal laparoscopic PN have similar perioperative outcomes [362].

The feasibility of laparoendoscopic single-site PN has been shown in selected patients, but larger studies are needed to confirm its safety and clinical role [363].

7.2.3.b.2 Open versus robotic approach

The prospective, randomised, open-label, multicentre OpeRa trial (NCT03849820) aimed to determine whether robotic-assisted partial nephrectomy (RAPN) is superior to open partial nephrectomy (OPN) in reducing 30-day postoperative complications during the treatment of intermediate/high-complexity renal tumours (RENAL score ≥ 7) [364]. The primary endpoint of the 30-day complication rate did not differ between groups (RAPN 37% vs. OPN 46%), but a limitation was that the trial failed to fully accrue (240 of 606) and closed prematurely. The most frequent high-grade complications (CD III-IV) to postoperative day 30 (POD30) were urine leakage [RAPN 4/112 (4%) vs. OPN 2/89 (2%)] and postoperative bleeding [2/117 (2%) versus 1/89 (1%)] [364]. Compared with OPN, RAPN patients had longer operative and warm ischaemia times, shorter hospital stays and reported better recovery, less opioid use, less pain and improved QoL up to POD30 [364].

The single-centre, open-label ROBOCOP II RCT assessed the feasibility of recruitment as a primary endpoint and demonstrated as secondary outcomes that included perioperative and postoperative data. In comparison to open PN, robot-assisted PN had lower blood loss, less need for opioids and fewer complications according to the mean Comprehensive Complication Index [365]. Open PN has a shorter operative time and warm ischemia time. There were no differences between robot-assisted PN and open PN regarding postoperative functional outcomes [365].

The IRON-1 study collected real world data of RAPN versus Open in single cT1-2N0M0 renal masses [366]. RAPN was associated with lower intraoperative (OR: 0.39, 95% CI: 0.22, 0.68) and Clavien-Dindo 2 postoperative (OR: 0.29, 95% CI: 0.16, 0.50) complications (both $p < 0.05$). On multivariable analyses, no differences were found between the two techniques with respect to functional and oncologic outcomes [366].

In a SR and network meta-analysis [367], the EBL, postoperative complications and length of stay were all significantly reduced in RAPN when compared with OPN.

One study prospectively compared the perioperative outcomes of a series of robot-assisted and open PN performed by the same experienced surgeon. Robot-assisted PN was superior to open PN in terms of lower EBL and shorter hospital stay. Warm ischaemia time, operative time, immediate- early- and short-term complications, variation in creatinine levels and pathologic margins were similar between groups [368].

A multicentre French prospective database compared the outcomes of 1,800 patients who underwent open PN and robot-assisted PN. Although the follow-up was shorter, there was a decreased morbidity in the robot-assisted PN group with fewer overall complications, fewer major complications, fewer transfusions and a much shorter hospital stay [369].

An SR and meta-analysis comparing RAPN and OPN demonstrated similar short-term functional outcomes, however, results are inconsistent [370].

7.2.3.b.3 Open versus hand-assisted approach

Hand-assisted laparoscopic PN (HALPN) is rarely performed. A comparative study of open versus HALPN showed no difference in OS or RFS at intermediate-term follow-up. The authors observed a lower rate of intraoperative and all-grade postoperative 30-day complications in HALPN versus open PN patients, but no significant difference in high Clavien grade complications was observed. Three months after the operation, GFR was lower in the HALPN than in the open PN group [371].

7.2.3.b.4 Open versus laparoscopic versus robotic approaches

In a retrospective propensity-score-matched study, comparing open-, laparoscopic- and robot-assisted PN, after five years of median follow-up, similar rates of local recurrence, distant metastasis and cancer-related death rates were found [372].

An SR comparing the three approaches included 31 studies with a combined 7,869 patients (33.7% OPN, 20.8% LPN, 45.5% RAPN). There was no difference in ischaemia time, intraoperative complications, positive surgical margins, operative time or trifecta rate. The estimated blood loss, postoperative complications and length of stay were all significantly reduced with robot-assisted PN and laparoscopic PN compared to open surgery, with robot-assisted PN superior to laparoscopic PN in terms of reduced EBL [367]. In PADUA score < 10 lesions, robotic surgery had higher probability of achieving a modified trifecta than open PN (OR: 1.66; 95% CI: 1.09-2.53; $p = 0.018$) and laparoscopy (OR: 1.34; 95% CI: 0.94-1.90; $p = 0.11$) [367].

7.2.3.b.5 Laparoscopic versus robotic approach

A meta-analysis, including a series of NSS with variable methodological quality compared the perioperative outcomes of robot-assisted and laparoscopic PN. The robotic group had a significantly lower rate of conversion to open surgery and to radical surgery, shorter warm ischaemia time, smaller change in estimated GFR after surgery and shorter length of hospital stay. No significant differences were observed between the two groups regarding complications, change of serum creatinine after surgery, operative time, estimated blood loss and PSMs [373].

In another SR and network meta-analysis [367], the outcomes of RAPN and LPN were largely similar except the significantly reduced EBL in RAPN.

Single-site laparoscopic and single-port robotic approaches for PN

The feasibility of laparoendoscopic, single-site PN has been shown in selected patients [363]. Several studies have reported on the outcomes of single-port RAPN [374-378] and the current evidence is limited by lack of prospective RCTs comparing the outcomes of single-port versus multiport RAPN, as well as the high risk of selection bias and confounding of available retrospective studies.

An SR and meta-analysis assessed the perioperative, functional and oncological outcomes of single-port (SP) versus multiport (MP) RAPN [379]. Ten studies were included (no RCTs were identified). Most of these studies were limited by a retrospective design, selection bias, small sample size and moderate-to-high risk of bias. The meta-analysis did not find significant differences between SP- and MP-RAPN regarding intra- and perioperative outcomes, with the exception of a significantly longer length of hospitalisation and higher pain score on postoperative day 1 for MP-RAPN, and a significantly longer warm ischaemia time for SP-RAPN.

7.2.3.b.6 Laparoscopic transperitoneal versus retroperitoneal approach

An SR assessed the outcomes of retroperitoneal versus transperitoneal robotic-assisted PN. Seventeen studies, published between 2013 and 2021, were retrieved, none of which was an RCT. Among the 6,266 patients included, 2,261 (36.1%) and 4,005 (63.9%) underwent retroperitoneal versus transperitoneal robotic-assisted PN, respectively. Both retroperitoneal and transperitoneal robotic-assisted PN offered similar surgical outcomes, while retroperitoneal robotic-assisted PN was associated with shorter surgical time and length of hospital stay [380]. The feasibility of a future RCT comparing RRPN versus TRPN has been shown [381].

7.2.3.b.7 **Robotic systems**

Several novel multiport robotic systems have been developed and introduced into clinical practice for urological surgery following regulatory approval [382]. The existing literature mostly includes single-arm explorative studies.

7.2.3.b.8 **Tumour enucleation, standard partial nephrectomy and single-port approach**

Simple tumour enucleation also had similar PFS and CSS rates compared to standard PN and RN in a large study [383]. The feasibility of laparoendoscopic single-site PN has been shown in selected patients, but larger studies are needed to confirm its safety and clinical role [363].

The only prospective multicentre study available to date assessing the impact of resection technique (enucleation vs. enucleoresection vs. resection) during PN using a standardised reporting score to classify the resection technique after surgery found that the resection technique significantly impacts surgical complications, early functional outcomes and positive surgical margins after PN of localised renal masses [384].

An SR and pooled analysis found heterogeneity in the reporting of resection techniques across robotic PN series [385]. Out of twenty studies retrieved, nine compared 'standard' resection versus enucleation. A pooled analysis did not reveal significant differences in terms of operative time, ischemia time, blood loss, transfusions or positive margins. Significant differences favouring enucleation were found for clamping management (odds ratio [OR] for renal artery clamping 3.51, 95% confidence interval [CI] 1.13-10.88; $p = 0.03$), overall complications (OR: for occurrence 0.55, 95% CI: 0.34-0.87; $p = 0.01$) major complications (OR: for occurrence 0.39, 95% CI: 0.19-0.79; $p = 0.009$), length of stay (WMD -0.72 d, 95% CI: -0.99 to -0.45; $p < 0.001$), and decrease in eGFR (WMD -2.64 ml/min., 95% CI: -5.15 to -0.12; $p = 0.04$). Data from a single-centre prospective randomised noninferiority trial, supports these findings in the low to intermediate complexity setting [386].

7.2.3.b.9 **Off-clamp versus on-clamp PN**

The use of an off-clamp and selective-clamping approaches for PN has increased in recent years with the aim to minimise/avoid warm ischemia time and improve functional outcomes. One RCT (CLOCK study) showed a comparable safety profile of off-clamp versus on-clamp PN in terms of intra- and perioperative complications, as well as comparable absolute eGFR variation and split renal function at six months from surgery in patients with regular baseline function and two kidneys. However, 40% of the patients randomised in the off-clamp group were intraoperatively shifted to on-clamp (median ischemia time of fifteen minutes) [387, 388]. Due to the selective inclusion criteria of the RCT, off-clamp techniques may still be indicated in patients with CKD single kidney or multifocal disease [389, 390].

In a contemporary cohort of 1,359 patients from the prospectively maintained database of the French national network of research on kidney cancer (UROCCR), PSM rate was not statistically different between the off-clamp group (5.6%) and the on-clamp group (11%) ($p = 0.1$). With short median follow-up, no statistical differences between the two groups were seen in OS, local RFS and metastasis-free survival [391].

7.2.3.b.10 **Use of 3D models for PN planning**

3D models based on cross-sectional imaging are evolving to facilitate pre- and intra-operative planning of PN. An SR and meta-analysis found that the use of 3D technology led to a significant reduction in the global ischemia rate and was associated with less blood loss and transfusion rate. However, 3D guidance did not impact the risk of conversion to radical nephrectomy, the rate of minor and major complications, the change in glomerular filtration rate or risk of positive surgical margins [392]. There is lack of evidence regarding oncological outcomes with use of 3D models.

Several prospective, RCTs evaluating the impact of 3D models on robot-assisted partial nephrectomy (RAPN) outcomes and patient experience are ongoing [393-395].

7.2.3.c **Positive surgical margins on histopathological specimens**

A PSM is encountered in approximately 2-8% of T1 PNs [396]. Studies comparing surgical margins with various surgical approaches (open, laparoscopic, robotic) are inconclusive [397-399]. Most trials showed that intraoperative frozen section analysis had no influence on the risk of definite PSMs [400]. A PSM status occurs more frequently in cases in which surgery is imperative (solitary kidneys and bilateral tumours) and in patients with adverse pathological features (pT2a, pT3a, grade III-IV) [401-404].

The majority of retrospective analyses reported so far indicated that PSMs do not translate into a higher risk of metastases or a decreased CSS [402, 403]. On the other hand, another retrospective study of a large single-institutional series showed that PSMs are an independent predictor of PFS due to a higher incidence of distant and local relapses [405]. Another retrospective study of 42,114 PN patients with 2,823 PSM patients (6.7%) showed an increased presence of PSM in upstaged pT3a tumours (14.1%), increased all-cause mortality in PSM patients and a decreased five-year OS rate in pT3a tumours (PSM: 69% vs. NSM: 90.9%) [406].

However, only a proportion of patients with an uncertain margin status actually harbour residual malignancy. Local tumour bed recurrences were found in 16% in patients with PSMs compared with 3% in those with negative margins [401], therefore, RN or re-resection of margins can result in overtreatment in many cases. Patients with PSMs should be informed that they will need a more intense surveillance (imaging) follow-up and that they are at increased risk of secondary local therapies [402, 407]. On the other hand, protection from recurrence is not ensured by negative surgical margins [408], because it is reported in up to 1.5% of cases in this category of patients [396].

7.2.3.d Hospital volume and outcomes of PN

The EAU RCC Guideline Panel performed a protocol-driven SR of the association between hospital volume (HV) and oncological, functional and complication outcomes following PN for RCC [409]. Higher HV was associated with lower complication rates, shorter length of stay, lower PSM rates and lower transfusion rates. Most studies were judged to have high risk of bias. Apart from better PN outcomes, treatment in higher-volume centres appears to be associated with closer adherence to Guidelines regarding the management of T1 RCC, with more frequent use of PN instead of RN [410-413].

7.2.3.e Placement of a drain

Routine drain placement after PN or RN is increasingly being questioned.

A number of SRs and cohort studies have been reported on the clinical impact of using versus omitting surgical drains after nephrectomy [414-417].

In one review, no differences were found for overall complications (OR: 0.99) or reintervention (OR: 1.16) in patients undergoing PN [416]. In another review, in RAPN, patients without postoperative drainage had shorter length of hospital stay (mean difference: -0.84 days) and similar low-grade (P = 0.94) and high-grade (P = 0.31) complications, urinary leakage (P = 0.49), haemorrhage (P = 0.39), reintervention (P = 0.69) and readmission (P = 0.20) compared with routinely drained patients [415].

Overall, the available evidence suggests that omitting drain placement after standard PN or RN is not associated with increased surgical complication rates and may lead to shorter length of hospitalisation. However, the evidence is limited by lack of randomised trials (in the RAPN era).

7.2.3.f Summary of evidence and recommendations for radical and partial nephrectomy techniques

Summary of evidence	LE
Laparoscopic RN has lower morbidity than open RN.	1b
Short-term oncological outcomes for T1-T2a tumours are equivalent for laparoscopic and open RN.	2a
Partial nephrectomy can be performed, either by open, pure laparoscopic or robot-assisted approach, based on surgeon's expertise and skills.	2b
Robot-assisted and laparoscopic PN are associated with shorter length of hospital stay and lower blood loss compared to open PN.	2b
Transperitoneal and retroperitoneal laparoscopic PN do not differ in postoperative surgical and medical complications, PSMs and kidney function.	2a
Hospital volume for PN might impact on surgical complications, warm ischaemia time and surgical margins.	3
Immediate completion nephrectomy for PSMs can result in overtreatment in many cases.	3
Off-clamp partial nephrectomy does not improve renal function outcomes in patients with baseline normal renal function.	1b
The evidence on the impact of resection technique on PN outcomes is limited by lack of standardised reporting and by the retrospective design of most available studies.	3
The placement or omittance of a drain does not alter the post-surgical course of PN.	3

Recommendations	Strength rating
Offer laparoscopic or robotic radical nephrectomy (RN) to patients with T2 tumours and localised masses not treatable by partial nephrectomy (PN).	Strong
Do not perform minimally invasive RN in patients with T1 tumours for whom a PN is feasible by any approach, including open.	Strong
Do not perform minimally invasive surgery if this approach may compromise oncological-functional- and peri-operative outcomes.	Strong
Do not perform re-resection or RN in patients with a microscopic positive surgical margins.	Weak
Intensify follow-up in patients with a positive surgical margin, especially in upstaged pT3a patients.	Weak
Do not attempt off-clamp PN unless indicated.	Weak

7.2.4 Therapeutic approaches as alternatives to surgery

7.2.4.a Watchful waiting

Elderly and comorbid patients with incidental SRMs have a low RCC-specific mortality and significant competing-cause mortality [418, 419].

Watchful waiting is employed in cases where RCC is not expected to significantly impact the patient's remaining life expectancy, and when the focus is on managing symptoms rather than attempting a cure.

7.2.4.b Active surveillance

Active surveillance is defined as the initial monitoring of tumour size by serial abdominal imaging (US, CT, or MRI) with delayed intervention reserved for tumours showing clinical progression during follow-up [420]. The concept of AS differs from the concept of WW. Unless clinically indicated, WW is reserved for patients whose comorbidities contraindicate any subsequent active treatment and who do not require follow-up imaging.

Population-based studies compared the oncological outcomes of surgery (RN or PN) and non-surgical management for tumours <4cm. The analyses showed a significantly lower CSM in patients treated with surgery [421-423]. However, the patients assigned to the surveillance arm were older and likely to be frailer and less suitable for surgery. Other-cause mortality rates in the non-surgical group significantly exceeded that of the surgical group [422]. Analyses of older patients (> 75 years) failed to show the same benefit in CSM for surgical treatment [424-426].

Growth rate and metastasis

In the largest reported series of AS, the growth of renal tumours was low and progression to metastatic disease was reported in only a limited number of patients [427, 428]. An SR of eighteen AS cohorts comprising 2,066 patients (cT1-2 N0M0) with a pooled mean follow-up of 53 months showed that 2.1% (95% CI: 1.0-3.6) of patients developed metastatic disease during follow-up [429]. For patients with SRMs (nine studies, n = 987), the pooled metastasis rate was 1.8% (95% CI: 0.5-3.7).

In 136 biopsy-proven SRMs managed by AS, median follow-up of patients who remained on AS was 5.8 years (interquartile range 3.4-7.5 years). Clear-cell RCC grew faster than papillary type 1 SRMs (0.25 and 0.02 cm/year on average, respectively, p = 0.0003). Overall, 60 (44.1 %) of the malignant SRMs progressed; 49 (82%) by rapid growth (volume doubling), seven (12%) increasing to ≥ 4cm, and four (6.7%) by both criteria. Six patients developed metastases, and all were of ccRCC histology [430].

Overall and cancer-specific survival

A single-institutional comparative study evaluating patients aged > 75 years showed decreased OS for those who underwent surveillance and nephrectomy relative to NSS for clinically T1 renal tumours. However, at multivariate analysis, management type was not associated with OS after adjusting for age, comorbidities and other variables [418]. No statistically significant differences in OS and CSS were observed in another study of RN versus PN versus AS for T1a renal masses with a follow-up of 34 months [431].

The prospective non-randomised multi-institutional Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) study enrolled 497 patients with solid renal masses < 4cm who selected either AS or primary active intervention. Patients who selected AS were older, had worse ECOG scores, more comorbidities, smaller tumours and more often had multiple and bilateral lesions. In patients who elected AS in this study, the overall

median SRM growth rate was 0.09cm/year with a median follow-up of 1.83 years. The growth rate and variability decreased with longer follow-up. No patients developed metastatic disease or died of RCC [432, 433].

Overall survival for primary intervention and AS was 98% and 96% at two years and 92% and 75% at five years ($p = 0.06$). At five years, CSS was 99% and 100%, respectively ($p = 0.3$). Active surveillance was not predictive of OS or CSS in regression modelling with relatively short follow-up [432]. In the above-mentioned large SR of 18 AS cohorts, 1.0% (95% CI: 0.3-2.1) died from RCC and 22.6% (95% CI: 15.8-30.2) died from any cause. For patients with SRMs, RCC-specific mortality was 0.6% (95% CI: 0-2.1) and all-cause mortality was 28.5% (95% CI: 17.4-41.4) [429].

A study using data from the DISSRM Registry investigated the outcomes of AS in a cohort of patients aged 60 or younger at diagnosis [434]. Of 224 patients with median follow-up of 4.9 years, 30.4% chose surveillance. There were 20 (29.4%) surveillance progression events, including four elective crossovers, and 13 (19.1%) patients underwent delayed intervention. Among patients with initial tumour size ≤ 2 cm, 15.1% crossed over, as compared to 33.3% with initial tumour size 2-4cm. Overall survival was similar in primary intervention and surveillance at seven years (94.0% vs. 90.8%, logrank $p = 0.2$). The CSS remained at 100% for both groups and RFS at five years was 96.0% and 100% for primary and delayed intervention, respectively (logrank $p = 0.6$).

Overall, both short- and intermediate-term oncological outcomes indicate that, in selected patients with advanced age and/or comorbidities, AS is appropriate for initial monitoring of SRMs, followed, if required, by treatment for progression [420, 427, 428, 435-438].

Quality of life

A multicentre study assessed QoL of patients undergoing immediate intervention versus AS. Patients undergoing immediate intervention had higher QoL scores at baseline, specifically for physical health. The perceived benefit in physical health persisted for at least one year following intervention. Mental health, which includes domains of depression and anxiety, was not adversely affected while on AS [439].

7.2.4.c Role of renal tumour biopsy before active surveillance

Histological characterisation of SRMs by renal tumour biopsy is useful to select tumours at lower risk of progression based on grade and histotype, which can be safely managed with AS. Pathology can also help to tailor surveillance imaging schedules. In the largest cohort of biopsy-proven, small, sporadic RCCs followed with AS, a significant difference in growth and progression among various RCC subtypes was observed. Clear-cell RCC SRMs grew faster than papillary type 1 SRMs (0.25 and 0.02cm/year on average, respectively, $p = 0.0003$) [430].

7.2.4.d Tumour ablation

7.2.4.d.1 Role of renal mass biopsy

An RMB is required prior to tumour ablation (see Sections 5.3, 'Renal tumour biopsy', and 5.4, 'Summary of evidence and recommendations for the diagnostic assessment of RCC'). Historically, up to 45% of patients underwent tumour ablation of a benign or non-diagnostic mass [440, 441]. An analysis of the European multi-national prospective EuRECA registry (871 patients undergoing cryoablation) showed that the use of pre-cryoablation biopsy has significantly increased from 42% (65/156) in 2015 to 72% (88/122) in 2019 ($p < 0.001$), making treatment for a benign or an unknown histology significantly less likely (OR: 0.64, $p < 0.001$ and OR: 0.31, $p = 0.044$, respectively) [442]. An RMB in a separate session reduces overtreatment significantly, with 80% of patients with benign lesions opting not to proceed with TA [441]. Additionally, there is some evidence that the oncological outcome following TA differs according to RCC subtype, which should therefore be factored into the decision-making process. In a series of 229 patients with cT1a tumours (mean size 2.5cm) treated with radiofrequency ablation (RFA), the five-year DFS rate was 90% for ccRCC and 100% for pRCC (80 months: 100% vs. 87%, $p = 0.04$) [443]. In another series, the total tumour ablation effectiveness rate was 90.9% for ccRCC and 100% for pRCC [444]. A study comparing RFA with surgery suggested worse outcomes of RFA versus PN in cT1b ccRCC, while no difference was observed in those with non-ccRCC [445]. Moreover, patients with high-grade RCC or metastasis may choose different treatments over tumour ablation. Finally, patients without biopsy or a nondiagnostic biopsy are often assumed to have RCC and will undergo potentially unnecessary radiological follow-up or further treatment.

7.2.4.d.2 **Cryoablation**

Cryoablation is performed using either a percutaneous- or a laparoscopic-assisted approach, with technical success rates of >95% [446]. In comparative studies, there was no significant difference in the overall complication rates between laparoscopic- and percutaneous cryoablation [447-449]. One comparative study reported similar OS, CSS and RFS in 145 laparoscopic patients with a longer follow-up versus 118 patients treated percutaneously with a shorter follow-up [448]. A shorter average length of hospital stay was found with the percutaneous technique [448-450]. An SR including 82 articles reported complication rates ranging between 8 and 20% with most complications being minor [451]. Although a precise definition of tumour recurrence is lacking, the authors reported a lower RFS as compared to that of PN.

Oncological outcomes after cryoablation have generally been favourable for cT1a tumours. In a series of 308 patients with cT1a and cT1b tumours undergoing percutaneous cryoablation, local recurrence was seen in 7.7% of cT1a tumours versus 34.5% of cT1b tumours. On multivariable regression, the risk of disease progression increased by 32%, with each 1cm increase in tumour size (HR: 1.32, $p < 0.001$). Mean decline in eGFR was 11.7mL/min./1.73m² [452]. In another large series of 220 patients with biopsy-proven cT1 RCC, five-year local RFS was 93.9%, while metastasis-free survival approached 94.4% [446]. A series of 134 patients with T1 RCC (median tumour size 2.8cm) submitted to percutaneous cryoablation yielded a ten-year DSF of 94% [453].

For cT1b tumours, local tumour control rates drop significantly. One study showed local tumour control in only 60.3% at three years [454]. In another series, the PFS rate was 66.7% at twelve months [455]. Moreover, analyses demonstrated five-year cancer-specific mortality rates of 7.6-9% [456, 457]. On multivariable analysis, cryoablation of cT1b tumours was associated a 2.5-fold increased risk of death from RCC compared with PN [456].

Recurrence after initial cryoablation is often managed with recryoablation, but only 45% of patients remain disease-free at two years [458].

7.2.4.d.3 **Radiofrequency ablation**

Radiofrequency ablation is performed laparoscopically or percutaneously. Several studies compared patients with cT1a tumours treated by laparoscopic or percutaneous RFA [459-462]. Complications occurred in up to 29% of patients but were mostly minor. Complication rates, recurrence rates and CSS were similar in patients treated laparoscopically and percutaneously.

The initial technical success rate on early (i.e. one month) imaging after one session of RFA is 94% for cT1a and 81% for cT1b tumours [463]. This is generally managed by re-RFA, approaching overall total technical success rates > 95% with one or more sessions [464].

Long-term outcomes with over five years of follow-up following RFA have been reported. Some studies reported five-year OS rates of 73-79% [463, 464] due to patient selection. While oncological outcomes have been favourable for cT1a tumours, important to note is that, within the T1a 3-4cm subpopulation, these outcomes are less encouraging [465]. A study involving 106 patients treated with radiofrequency ablation, and with a median follow-up of 79 months, the ten-year DFS rate was 82%, but a notable decline was observed to 68% for tumours larger than 3cm [464]. In series focusing on clinical T1b tumours (4.1-7.0cm), the five-year DFS rate was 74.5% to 81% [463, 466]. Oncological outcomes appear to be worse than after surgery, but comparative data are severely biased (see Section 7.2.4.d.4). In general, most disease recurrences occur locally and recurrences beyond five years are rare [464, 466].

7.2.4.d.4 **Microwave ablation**

The best evidence base for these techniques exists for percutaneous microwave ablation. In a study of 185 patients with a median follow-up of 40 months, the five-year local progression rate was 3.2%, while 4.3% developed distant metastases [467]. Results appear to be favourable for cT1b tumours, as well [468]. Overall, current data on cryoablation, RFA and microwave ablation of cT1a renal tumours indicate short-term equivalence with regards to complications, oncological and renal functional outcomes [469, 470].

7.2.4.d.5 **Tumour ablation versus surgery**

The Guideline Panel performed a protocol-driven SR of comparative studies (including > 50 patients) of tumour ablation (TA) with PN for T1N0M0 renal masses [471]. Twenty-six non-randomised comparative studies published between 2000 and 2019 were included, recruiting a total of 16,780 patients. Four studies compared laparoscopic TA versus laparoscopic/robotic PN; sixteen studies compared laparoscopic or percutaneous TA versus open, laparoscopic or robotic PN; two studies compared various TA techniques; and four studies

compared TA versus PN versus RN. In this SR, TA as treatment for T1 renal masses was found to be safe in terms of complications and adverse events, but its long-term oncological effectiveness compared with PN remained unclear. The primary reason for the persisting uncertainty was related to the nature of the available data - most studies were retrospective observational studies with poorly matched controls or single-arm case series with short follow-up. Many studies were poorly described and lacked a clear comparator.

There was also considerable methodological heterogeneity. Another major limitation was the absence of clearly defined primary outcome measures. Even when a clear endpoint such as OS was reported, data were difficult to interpret because of the varying length and type of follow-up amongst studies. The Panel also appraised the published SRs based on the AMSTAR 2 tool, which showed 'Critically Low' or 'Low' ratings [471].

A SR and meta-analysis encompassing 133 studies of ablative therapies for localised RCC was published [472]. Of note, 80% of the included studies were retrospective, while only 8% were comparative. The interventions evaluated consisted of SBRT, RFA, mWA and cryotherapy, represented in 21, 48, 32 and 43 studies, respectively. The primary endpoint was local control at one, two and five years, defined as the proportion of patients without evidence of tumour progression - growth or recurrence - on imaging or biopsy. The review reported high local-control rates across all ablative modalities. Despite these findings, several methodological limitations warrant consideration. These include heterogeneity in the definition of local control, the potential for double counting of patients across studies and the application of the ROBINS-I tool to predominantly single-arm designs, its suitability for which is uncertain [473]. Moreover, the meta-analytic pooling of heterogeneous, largely noncomparative datasets may convey an unwarranted impression of statistical precision and evidentiary robustness that is not supported by the underlying data.

Tumour ablation has been demonstrated to be associated with good long-term survival in several single-arm non-comparative studies [474, 475]. Due to the lack of controls, this apparent benefit is subject to significant uncertainties. Whether such benefit is due to the favourable natural history of such tumours or due to the therapeutic efficacy of TA, as compared to PN, remains unknown. In addition, data is available from comparative studies suggesting that TA may be associated with worse oncological outcomes in terms of local recurrence and metastatic progression and CSM [456, 457, 476-480]. However, there appears to be no clinically significant difference in five-year CSM between TA and AS [423]. A retrospective multicentre study, including 86 partial nephrectomies and 104 TA, matched for complexities, has shown that PN and cryoablation are comparable regarding complications within 90 days after treatment [481].

The Panel concluded that the current data are inadequate to reach conclusions regarding the clinical effectiveness of TA as compared with PN. A cohort-embedded randomised feasibility study suggests that a larger RCT could be conducted to compare cryoablation to PN [482].

Given these uncertainties in the presence of only low-quality evidence, the panel feels that an RCT is needed.


7.2.4.d.6 Stereotactic ablative radiotherapy

Stereotactic ablative radiotherapy (SABR) has been emerging as a treatment option for medically inoperable patients with localised cT1a and cT1b tumours [483-486]. A variety of dose-fractionation schedules have been reported (26-60Gy; single, three and five fractions) [484]. The international society of stereotactic radiosurgery guidelines suggest the optimal dose fractionation is 25-26 Gy in one fraction for tumours < 4-5cm, or 42-48Gy in three fractions for larger tumours [487]. Published single-arm studies, mainly including cT1 RCC, with a median follow-up range of 16.4-34.3 months, reported local control rates of 90-97.2% [484, 488-495]. However, viable tumour cells are often seen in post-SABR biopsies, although their clinical significance remains unclear [490]. In the multicentre FASTRACK II phase II clinical trial, 70 patients with a biopsy confirmed primary RCC (medically inoperable, technically at high risk of complications or declined surgery), received either a single fraction SABR 26Gy or 42Gy in three fractions, according to tumour size. Median tumour size was 4.6cm (IQR 3.7-5.5). Primary endpoint was local control rate at 12 months, defined by RECIST criteria meaning a 30% increase of tumour diameter (progressive disease) compared to base line as local failure. Based on this definition, local control was 100% after 12 months and freedom from distant failure at 12 and 36 months was 97% [496]. Grade 3 or 4 toxicities were reported in 0-9.1% of the patients across studies [484]. In FASTRACK II, the ipsilateral kidney GFR (determined by SPECT/CT) decreased from baseline by 42% and 39% in the 26Gy/single fraction cohort and by 45% and 62% in the 42 Gy/3 fractions cohort, at 12 and 24 months, respectively [497]. Although early reported results of SABR look encouraging, more evidence from well-conducted prospective studies with longer follow-up is needed [487].

7.2.4.d.7 Other ablative techniques

Some studies have shown the feasibility of other ablative techniques, such as high-intensity focused US ablation and nonthermal irreversible electroporation. However, these techniques are still considered experimental.

Figure 7.2.4.d.7.1: Alternatives to surgery



CKD = Chronic Kidney Disease; Cryo = Cryoablation; MWA = Microwave Ablation; RCC = Renal Cell Carcinoma; RFA = Radiofrequency Ablation; SABR = Stereotactic Ablative Body Radiotherapy.

7.2.4.d.8 Summary of evidence and recommendations for therapeutic approaches as alternative to surgery

Summary of evidence	LE
Most population-based analyses show a significantly lower cancer-specific mortality for patients treated with surgery compared to no intervention.	3
In AS cohorts, the growth of SRMs is low in most cases and progression to metastatic disease is rare (1-2%).	3
Low-quality studies suggest higher disease recurrence rates after RFA of tumours > 3cm and after cryoablation of tumours > 4cm.	3
Low quality studies suggest a higher local recurrence rate for TA therapies compared to PN, but quality of data does not allow definitive conclusions.	3
Stereotactic ablative radiotherapy in patients with non-metastatic RCC who were unfit for or declined surgery, demonstrated short-term safety and efficacy but long-term and comparative data are lacking.	3

Recommendations	Strength rating
Offer watchful waiting to highly frail and comorbid patients with reduced life expectancy.	Weak
Offer active surveillance (AS) to cT1a patients with no indication for immediate treatment and where delayed intervention may be appropriate.	Weak
Offer tumour ablation (TA) or stereotactic ablative radiotherapy (SABR) in patients with cT1 lesions who have an indication for treatment but are unfit for surgery.	Weak
Perform a percutaneous renal mass biopsy prior to, and not concomitantly with, TA.	Strong
Discuss the limitations in the clinical evidence, with regards to oncological outcomes and complications when TA or AS is offered.	Strong
Do not routinely offer radiofrequency ablation for tumours > 3cm and cryoablation for tumours > 4cm.	Weak

7.3 Treatment of locally advanced RCC

7.3.1 Introduction

In addition to the summary of evidence and recommendations outlined in Section 7.2 for localised RCC, certain therapeutic strategies arise in specific situations for locally advanced disease.

7.3.2 Role of lymph node dissection in locally advanced RCC

In locally advanced RCC, the role of LND is still controversial. The only available RCT demonstrated no survival benefit for patients undergoing LND, but this trial mainly included organ-confined disease cases [330]. In the setting of locally advanced disease, several retrospective papers and SRs addressed the topic with contradictory results. An SR and meta-analyses could not confirm any survival benefit in patients at high risk of progression treated with LND [498]. Another SR and meta-analyses showed a survival benefit in patients with locally advanced disease treated with LND [499]. Thirteen studies on patients with LND and non-LND were identified and included in the analyses. In the subgroup of locally advanced RCC (cT3-T4NxM0), LND showed a significantly better OS rate in patients who had undergone LND compared to those without LND (HR: 0.73, 95% CI: 0.60-0.90, $p = 0.003$), although potential unknown biases could have had an impact on the findings.

7.3.2.a Management of clinically negative lymph nodes (cN-) in locally advanced RCC

In case of cN-, the probability of finding pathologically confirmed LN metastases ranges between 0 and 25%, depending mainly on primary tumour size and the presence of distant metastases [500]. In case of clinically negative LNs (cN-) at imaging, removal of LNs is justified only if visible or palpable during surgery [501], at least for staging, prognosis, adjuvant therapy and follow-up implications, although a benefit in terms of cancer control has not yet been demonstrated [333, 498].

7.3.2.b Management of clinically positive lymph nodes (cN+) in locally advanced RCC

In case of cN+, the probability to identify pathologically confirmed LN metastases ranges between 10.3% (cT1 tumours) and up to 54.5% in case of locally advanced disease. In cN+, removal of visible and palpable nodes during LND is justified [501], at least for staging, prognosis, adjuvant therapy and follow-up implications, although a benefit in terms of cancer control has not yet been demonstrated [333, 498]. Whether to extend the LND in case of lymphadenopathy (cN1) remains controversial. Retrospective data showed for resected isolated macroscopical lymph node metastasis (pN1) that the time to systemic progression was a median of 4.2 months [502], suggesting that systemic therapy should always be discussed in the presence of lymph node invasion.

7.3.3 Management of RCC with venous tumour thrombus

Tumour thrombus formation in RCC patients accounts for 4-10% of RCC and may involve renal vein (pT3a, 78.3%), subdiaphragmatic inferior vena cava (pT3b, 16.4%) or supradiaphragmatic inferior vena cava (pT3c, 5.3%) [503]. This is a significant adverse prognostic factor with a five-year survival rate of 36% to 57% for patients without metastatic disease to other organs [504-507]. The majority are ccRCC and sarcomatoid differentiation are frequent (58%) [508].

Magnetic resonance imaging has been established as the imaging method of choice to determine the upper extent of the tumour thrombus, the degree of IVC occlusion and to predict IVC wall invasion [133]. However, with the advent of the multidetector CT (MDCT), MRI may one day be replaced.

Several classifications have been described to distinguish the level of thrombus, the best known being the Mayo classification (Level 0: Tumour thrombus is limited to the renal vein, Level 1: Tumour thrombus extends into the IVC, < 2cm above the renal vein, Level 2: > 2cm above the renal vein but below the hepatic veins, Level 3: above the hepatic veins but below the diaphragm Level 4: above the diaphragm, including atrial thrombus) [509].

Traditionally, patients with venous tumour thrombus undergo surgery to remove the kidney and tumour thrombus. Aggressive surgical resection is widely accepted as the default management option for patients with venous tumour thrombus, although the associated surgical mortality is 2-10% [503, 504, 506, 507, 510-512]. Close collaboration with the anaesthesia team is mandatory, as well as a preoperative multidisciplinary team (MDT) for optimal surgical planning, including, for T3c, thoracic or vascular surgeon to consider the possibility of cardiopulmonary bypass and cardioplegia (requiring preoperative cardiac catheterisation) [513-515, 465].

A preoperative imaging within one to two weeks of surgery is recommended given the propensity for tumour thrombus to progress rapidly [513]. Further intraoperative real-time evaluation of the thrombus level using transoesophageal echocardiography may be helpful [515].

Complete surgical excision should always be attempted because positive vascular wall margins increase local recurrence rates [516].

The role of neoadjuvant treatment with targeted agents has also been investigated in downstaging of tumour thrombus within the IVC with limited and controversial results [505, 517, 518]. Further investigations are needed to better identify which patients with RCC and tumour venous might benefit from neoadjuvant therapy (See also Section 7.3.5).

Several scores and tools have been proposed to estimate surgical complexity and the risk of complications, although an external validation is needed [519, 520].

In the largest published study, OS was higher in patients with a level of thrombus in the renal vein compared to inferior caval vein [521]. Survival was also associated with tumour size, grade, perinephric fat extension, sarcomatoid features, Eastern Cooperative Oncology Group PS and regional and distant metastases in multivariate analysis [505, 521]. Therefore, all patients with nonmetastatic disease and venous tumour thrombus, and an acceptable PS, should be considered for surgical intervention, irrespective of the extent of tumour thrombus at presentation.

The presence of tumor thrombus in RCC patients represents a key risk factor for worse perioperative, as well as long-term renal function. Specifically, patients with tumor thrombus harbour a significant and early estimated GFR decrease. However, despite tumor thrombus, patients show a greater estimated GFR decline after surgery - they retain acceptable renal function, which remains stable over time [522].

The surgical technique and approach (open versus laparoscopic versus robotic) for each case should be selected based on patients' characteristics, surgeon and hospital volumes and the extent of tumour thrombus and the grade of occlusion of the IVC [517, 523-525].

An SR and meta-analysis regarding surgical approach included 1,375 patients, of which 329 patients were in single-arm studies and 1,046 patients were in comparative studies [526]. Of the 329 patients who underwent robotic, 14.7% were level I, 60.9% level II, 20.4% level III and 2.5% level IV thrombus. Compared with open thrombectomy, robotic approach was associated with a lower blood transfusion rate and fewer overall complications. Major complication and 30-day mortality rates were similar in both groups.


In a propensity-matched retrospective cohort including 324 patients with renal tumour and venous thrombus, robotic approach was associated with a shorter operative time, a lower blood loss and transfusion rate, and a lower complication rate and postoperative hospital stay after matching, while there was no significant difference in survival [527]. In experienced hands with carefully selected patients, robotic thrombectomy can be considered. However, an emphasised selection bias limits definitive inference of these results, and optimal patient selection criteria are necessary: robotic approach is possible for stage 1 and selected stage 2 cases.

In case of venous thrombus, referral to a tertiary care centre/specialised centre is recommended to guarantee a multidisciplinary evaluation and treatment, especially in case of caval thrombus.

7.3.4 Management of locally advanced unresectable RCC

The management of locally advanced unresectable RCC should be based around systemic therapy [528]. A multidisciplinary evaluation, including urologists, medical oncologists and radiation therapists is suggested to maximise cancer control, pain control and the best supportive care. In patients with unresectable disease, embolisation can control symptoms, including visible haematuria or flank pain [347, 529-531].

Figure 7.1: Treatment of locally advanced RCC



CECT = contrast-enhanced computed tomography; IVC = inferior vena cava; LND = lymph node dissection; MDT = multidisciplinary team; MRI = magnetic resonance imaging; TEE = transoesophageal echocardiogram.

7.3.4.a Summary of evidence and recommendations for lymph node dissection, the management of RCC with venous tumour thrombus and unresectable tumours

Summary of evidence	LE
In patients with locally advanced disease, the survival benefit of LN dissection is unproven, but LN dissection has significant staging, prognosis, adjuvant therapy and follow-up implications.	3
Low-quality data suggest that tumour thrombus excision in nonmetastatic disease may be beneficial.	3

Recommendations	Strength rating
During nephrectomy, remove clinically enlarged lymph nodes for staging, prognosis and follow-up implications.	Weak
Remove the renal tumour and thrombus in case of venous involvement in nonmetastatic disease.	Strong
Discuss treatment options in patients with locally advanced unresectable RCC (biopsy and/or systemic therapy/deferred resection or palliative management) within a multidisciplinary team to determine treatment goal.	Strong

7.3.5 Neoadjuvant and adjuvant therapy

Neoadjuvant therapy is currently under investigation and available in clinical trials. In the presurgical setting, neoadjuvant TKI and immune checkpoint therapy demonstrated varying response rates between 7 and 59% in retrospective series and some phase II trials [517, 532, 533].

In a presurgical phase II trial in patients with vascular thrombus, treatment with axitinib demonstrated a reduction in the level of tumour thrombus in 35% of patients (7/20) [532]. Another presurgical phase II trial with axitinib showed a median shrinkage of tumour diameter of 1.3cm in complex renal tumours (RENAL Score 10-12) [534] and presurgical nivolumab did not show any primary tumour response in a prospective single arm trial [535]. There is currently no evidence of a prolonged OS by neoadjuvant treatment and at present, the data do not support its use outside clinical trials.

There is currently no evidence from an SR (including ten retrospective studies and two RCTs) that adjuvant radiation therapy increases survival [536]. The impact on OS of adjuvant tumour vaccination in selected patients undergoing nephrectomy for T3 renal carcinomas remains unconfirmed [537-541] (LE: 1b). A similar observation was made in an adjuvant trial of girentuximab, a monoclonal antibody against carbonic anhydrase IX (CAIX) (ARISER Study) [542].

At present, no OS data is available supporting the use of adjuvant VEGFR or mTOR inhibitors. Thus far, several RCTs comparing VEGFR-TKI or mTOR versus placebo have been published [543-550]. A sub analysis of EVEREST trial exploring adjuvant everolimus (mTOR) in non-clear cell RCC population did not show oncological benefit [551]. Only S-TRAC, a trial of adjuvant sunitinib versus placebo demonstrated a DFS benefit that was not reproduced in ASSURE, a trial of sunitinib and sorafenib versus placebo. Due to an unfavourable AE profile and no survival advantage, none of these drugs are recommended [550].

7.3.5.a PD-1 Inhibition: Keynote-564

The Keynote-564 trial is the first trial to report positive primary endpoint data on DFS [552, 553] and OS [554]. Keynote-564 evaluated pembrolizumab (17 cycles of three-weekly therapy) versus placebo as adjuvant therapy in 994 patients with intermediate (pT2, grade 4 or sarcomatoid, N0, M0; or pT3, any grade, N0, M0) or high risk (pT4, any grade, N0, M0; or pT any stage, and grade, or N+, M0), or M1 (no evidence of disease [NED] after primary tumour plus soft tissue metastases completely resected < one year from nephrectomy) disease. The median follow-up, defined as time from randomisation to data cut-off, was 24.1 months. The primary endpoint of DFS per investigator assessment was significantly improved in the pembrolizumab group vs. (at the primary analysis HR: 0.68, 95% CI: 0.53-0.87, p = 0.001). The estimated 48-month DFS rate was 64.9% versus 56.6% for pembrolizumab and placebo, respectively. Benefit occurred across broad subgroups of patients including those with M1/NED disease post-surgery (n = 58 [6%]). Investigator-assessed DFS was considered preferable to DFS by central review, due to its clinical applicability. Overall survival was statistically significant with a benefit in the pembrolizumab arm (HR: 0.62, 95% CI: 0.44-0.87, p = 0.005) and a consistent DFS advantage (HR: 0.72) after median follow-up of 57.2 months [554]. The estimated overall survival 91.2% in the pembrolizumab group versus 86.0% in the placebo group at 48 months. The five-year update (median follow-up 69.5 months) showed

consistency in DFS and OS results [555]. Grade III-V all-cause adverse events occurred in 32% versus 18% of patients for pembrolizumab and placebo, respectively. Quality of life assessment by FKSI-DRS and QLQ30 did not show a statistically significant or clinically meaningful deterioration in health-related QoL or symptom scores for either adjuvant pembrolizumab or placebo.

7.3.5.b PD-L1 inhibition: IMmotion010

The IMmotion010 phase III trial was the first adjuvant ICI trial to be developed in RCC to investigate the effect of a PD-L1 inhibitor on DFS [556]. IMmotion010 evaluated atezolizumab 1200 mg (once every three weeks for sixteen cycles or one year) versus placebo as adjuvant therapy in 778 patients with increased risk of recurrence defined as: pT2, grade 4 or sarcomatoid, N0, M0; pT3, grade 3-4, N0, M0; pT3b/c/T4, any grade, N0, M0; pT any stage and grade, pN1, M0; or M1 no NED after primary tumour plus soft tissue metastases completely resected either synchronous or if metachronous, > 12 months from nephrectomy.

The minimum follow-up, defined as time from randomisation to data cut-off, was 38.6 months. The primary endpoint of DFS per investigator assessment was not met in the atezolizumab group versus placebo (HR: 0.93, 95% CI: 0.75-1.15, $p = 0.4950$) with a median DFS of 57.2 months (95% CI: 44.6, NE) for atezolizumab vs. 49.5 months for placebo (47.4, NE). None of the exploratory subgroups suggested a DFS benefit with atezolizumab, most notably the M1 NED subgroup ($n = 108/13.9\%$) which was larger than in Keynote-564 (5.8%), the sarcomatoid subgroup and the subgroup expressing > 1% PD-L1 had a HR of 0.93 (0.58-1.49), 0.77 (0.44-1.36) and 0.83 (0.63-1.10), respectively.

There were no OS differences. Grade 3-4 all-cause and treatment-related adverse events occurred in 27.2% and 14.1% versus 21.1% and 4.7% of patients for atezolizumab and placebo, respectively. There was no treatment-related grade 5 adverse events.

7.3.5.c PD-1 and CTLA-4 inhibition: CheckMate 914

CheckMate 914 was the first phase III trial to investigate a combination of nivolumab plus ipilimumab versus placebo as adjuvant treatment in RCC (part A) [557]. Subsequently, a nivolumab monotherapy arm was also added to the trial (part B). The following results relate to part A, which evaluated nivolumab 240mg every two weeks (Q2W) for twelve cycles or six months plus ipilimumab 1mg/kg Q6W for four cycles versus placebo in 816 patients with recurrence risk defined as pT2a, grade 3 or 4, N0, M0; pT2b/T3/T4, any grade, N0, M0; or pT any stage, any grade, pN1, M0. The median time of follow-up, defined as time from randomisation to data cut-off, was 37 months. The primary endpoint of DFS per investigator assessment was not met in the nivolumab plus ipilimumab group versus placebo (HR: 0.92 [0.71-1.19], $p = 0.5347$). Of the exploratory subgroups, patients with sarcomatoid tumours ($n = 40$) and those with > 1% PD-L1 expression ($n = 107$) had a HR of 0.29 (0.09-0.91) and 0.46 (0.23-0.94) in favour of the ICI combination, respectively.

All-cause treatment discontinuation due to study drug occurred in 43% and 33% in the nivolumab plus ipilimumab group versus 11% and 1% in the placebo group. Treatment-related adverse events grade > III were 29% in the nivolumab plus ipilimumab group and 2% in the placebo group with four deaths (1%) considered related to combination therapy. The high adverse event profile may have contributed to the lack of efficacy and patient retention. The results of the nivolumab arm are awaited.

The results from Part B, (efficacy and safety of adjuvant NIVO monotherapy versus placebo) did not meet the primary endpoint, DFS of NIVO versus placebo per blinded independent central review (BICR), was not met (HR: (95% CI), 0.87 (0.62-1.21) $p = 0.3962$ with median DFS not reached in both arms) [558, 559].

7.3.5.d Perioperative PD-1 inhibition: PROSPER

PROSPER is a perioperative trial of neoadjuvant nivolumab (one cycle) followed by RN or PN and adjuvant nivolumab (480mg IV q4 weeks) for nine doses compared to surgery followed by surveillance without a placebo [560]. Patients with clinical stage > T2 or T any N+ RCC or patients with selected oligometastatic disease were included if they had no evidence of disease within twelve-weeks post-surgery. A total of 819 patients with clear cell (87%) and non-ccRCC were included, a biopsy in the nivolumab arm was mandatory. The primary endpoint of RFS was similar between the arms (HR: 0.97; 95% CI: 0.74-1.28; $p = 0.43$) and the trial was stopped by the data and safety monitoring committee. The OS was not statistically different (HR: 1.48; 95% CI: 0.89-2.48; $p = 0.93$), although not mature. Grade III-IV adverse events occurred in 20% (nivolumab arm) and 6% (control arm) of patients, respectively. Fifteen (4%) patients died in the nivolumab arm and eighteen (4%) in the surgery-alone arm.

The panel reached consensus and issued a strong recommendation for adjuvant pembrolizumab for patients with high-risk (defined as per study) operable ccRCC as final OS data is now available [554, 561]. This decision was taken as ICI therapy has a different mode of action than VEGFR-TKI, resulting in complete responses in up to 16% of patients in PD-1 unselected populations in metastatic disease [562]. Despite immature OS data with the early OS signal potentially driven by the M1 population, the Panel cannot exclude that a survival benefit will emerge. This was not the case in the adjuvant sunitinib trial (S-TRAC) [557, 563]. The Panel recommends for adjuvant pembrolizumab, but the following topics should be considered:

- A high proportion of patients, cured by surgery, are receiving unnecessary treatment.
- The tolerability profile is acceptable, but treatment related grade III-V adverse events were higher, with 18.6% in the pembrolizumab arm versus 1.2% in the placebo arm (occurring in approximately one-third of patients, all cause). Approximately 21% of patients required treatment discontinuation for adverse events.
- There is a risk of life-changing toxicity.
- Other ICI trials have not shown consistent results.
- Biomarker analysis to predict outcome and adverse events is not available.

The results of IMmotion010, CheckMate 914 and PROSPER need to be discussed with patients [556, 557, 560]. Meta-analysis with these data sets is not recommended due to heterogeneity across the ICI studies. It is likely that there are several reasons behind these inconsistent results, including study population with potential heterogeneity independent of TNM risk groups, selection criteria and trial design. To date, pembrolizumab is the only positive trial [563].

While the results of IMmotion010 may reflect the nonsignificant OS results seen in the metastatic setting with PD-L1 inhibitors (IMmotion151, Javelin 101), the results of CheckMate 914 and PROSPER are more difficult to interpret. Nivolumab and ipilimumab leads to durable remission and long-term OS in metastatic disease and nivolumab has a similar mode of action as pembrolizumab (anti PD-1).

The high treatment discontinuation rate of 33% in CheckMate 914 is of concern and may have had an impact on the trial effectivity (20% in Keynote-564). The Panel strongly feels that biomarker work on all of these trials should be carried out to identify patients that do respond to therapy and to give a better explanation for the inconsistent results with KIM-1 as a potential prognostic factor as shown in IMmotion010 [269]. Treatment of unselected patients in the adjuvant setting based on the Keynote-564 criteria will result in a large proportion of patients receiving unnecessary therapy. In the absence of OS data or appropriate biomarkers, the patient preference should be leading in a shared decision-making process. Patients considering adjuvant therapy should be aware of all trials and not be presented with only one data set.

7.3.5.e Progression after adjuvant PD-1 therapy

Currently, uncertainty exists regarding further treatment of patients who receive adjuvant therapy with pembrolizumab and develop a recurrence. Due to the relatively recent approval and recommendation, no phase III prospective trial data exist in this setting. The Guideline panel believes that there are different patient categories for patient progressing on or after pembrolizumab:

1. IO-Refractory patients: Progressing within the first three months of adjuvant pembrolizumab.
2. Early progressors: Patient progressing during pembrolizumab therapy.
3. Intermediate progressors: Patient progressing within the first six months after finishing adjuvant pembrolizumab treatment.
4. Late progressors: Patient progressing more than twelve months after finishing adjuvant pembrolizumab treatment.

The CONTACT-03 [564] and TiNivo [565] trial in mRCC patients showed no additional benefit of TKI+IO combinations over single agent TKI in IO pretreated patients. Therefore, it is likely that the first two groups of IO-refractory patients and early progressors after adjuvant pembrolizumab will not benefit from a subsequent TKI+IO combination and should be treated with TKI monotherapy. For late progressors and potentially intermediate progressing patients, the benefit of an IO combination cannot be excluded, but neither can it be confirmed.

Table 7.1: Overview phase III trials of PD-1 immune checkpoint inhibitors in adjuvant RCC

Phase III trial of PD-1 immune checkpoint inhibitors in adjuvant RCC						
Study	N	Experimental arm	Primary endpoint	Risk groups	DFS (mo) Median (95% CI) HR	OS (mo.) Median (95% CI) HR
Keynote-564 NCT03142334 Median follow-up of 69.5 mos. [552, 554, 555]	994	PEMBRO 200mg IV Q3W (17 cycles) vs. placebo	DFS in the ITT by IR	Intermediate-high: pT2 grade 4 or sarcomatoid; pT3 any grade High: pT4 any grade, pN1 M1 NED: cM0 after resection of oligometastatic disease < 12 mo.	(ITT) PEMBRO: NR (NE) PLACEBO: 68.3 (51.7 - NR) HR: 0.71 (95% CI: 0.59-0.86)) P < 0.002 DFS at 72 mos.: PEMBRO: 58.5% PLACEBO: 48.7%	(ITT) PEMBRO: NR (NE) PLACEBO: NR (NE) HR: 0.66 (95% CI: 0.48-0.90) p < 0.005 alive at 60 mos.: PEMBRO: 87.7% PLACEBO: 82.3%
IMmotion010 NCT03024996 Median follow-up of 44.7 mos. [556]	778	ATEZO 1200mg IV Q3W (16 cycles or 1 yr.) vs. placebo	DFS in the ITT by IR	By TNM: pT2 grade 4 or sarcomatoid; pT3 a grade 3-4; pT3b/c/T4 any grade, pN1 M1 NED: cM0 after resection of oligometastatic disease (synchronous or >= 12 mos.)	(ITT) ATEZO: 57.2 (44.6-NE) PLACEBO: 49.5 (47.4-NE) HR: 0.93 (95% CI: 0.75-1.15) p = 0.4950 DFS at 24 mos.: NR	(ITT) ATEZO : NE (59.8-NE) PLACEBO : NE (NE-NE) HR: 0.97 (95% CI: 0.67-1.42) alive at 24 mo.: NR
CheckMate 914 NCT03138512 Median follow-up of 37.0 mos.[557]	816	NIVO 240 mg IV Q2W (x 12 cycles) + ipilimumab 1 mg/kg IV Q6W (x 4 cycles vs. placebo)	DFS in the ITT by BICR	By TNM: pT2a grade 3-4; pT2b/T3/T4 any grade, pN1	(ITT) NIVO + IPI: NR (NE) PLACEBO: 50.7 (48.1-NE) HR: 0.92 (95% CI: 0.71-1.19) p = 0.5347 DFS at 24 mos.: NIVO + IPI: 76.4% PLACEBO: 74.0%	NR

Arm B median follow-up of 27 months [558, 559]	825 Arm B	Nivolumab 240 mg IV Q2W (x 12 cycles) + placebo Q6W (x 4 doses) vs. placebo IV Q2W (x 12) + placebo IV Q6W (x 4) vs. Nivolumab 240 mg IV Q2W (x 12) + ipilimumab 1 mg/kg IV Q6W (x 4) 2:1:1	DFS in the ITT by BICR	By TNM: pT2a grade 3-4; pT2b/T3/T4 any grade, pN1	(ITT) NIVO: NR (NE) PLACEBO: NR (NE) HR: 0.87 (95% CI:0.62-1.21) p = 0.3962 DFS at 18 months NIVO: 78.4% PLACEBO: 75.4% Secondary endpoint: NIVO: NR (NE) NIVO+IPI: (NR (NE)) HR: 1.27 (95% CI: 0.92-1.76) DFS at 18 months NIVO: 78.4% NIVO+IPI: 72.3%	NR
PROSPER NCT03055013 Median follow-up: NR [560]	779	Neoadjuvant NIVO 240mg IV Q2W (x 2 cycles) followed by adjuvant nivolumab 240mg Q2W for 3 mos. and Q4W for 6 mos. vs. observation	RFS in the ITT by IR	By TNM: >/= cT2 (7 cm) or cT any cN1	(ITT), RFS: NIVO: NR (NE) Observation: NR (NE) HR: 0.94 (95% CI: 0.74-1.21) p = 0.32	(ITT) NIVO: NR (NE) Observation : NR (NE) HR: 1.28 (95% CI: 0.84-1.95) p = 0.26

ATEZO = atezolizumab; BICR = blinded independent central review; CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; IPI = ipilimumab; IR = investigator review; ITT = intention-to-treat; IV = intravenous; mos. = months; NE = non-estimable; NED = no evidence of disease; NIVO = nivolumab; NR = not reached; OS = overall survival; PD-1 = programmed death-receptor 1; PEMBRO = pembrolizumab; PFS = progression free survival; Q2W = every 2 weeks; Q3W = every 3 weeks.

7.3.5.f Summary of evidence and recommendations for neoadjuvant and adjuvant therapy

Summary of evidence	LE
Neoadjuvant systemic therapy can reduce vascular thrombus and tumour size in the presurgical setting.	2a
Adjuvant sunitinib, sorafenib, pazopanib, everolimus, girentuximab or axitinib does not improve OS after nephrectomy.	1b
Adjuvant PD1 inhibition with pembrolizumab defined by the inclusion criteria of the trial* after nephrectomy improves DFS and OS.	1b
Adjuvant PD-L1 inhibition with atezolizumab and PD1 inhibition with nivolumab did not improve DFS or OS.	1b
Adjuvant dual PD-1 and CTLA-4 inhibition with nivolumab and ipilimumab did not improve DFS.	1b
Perioperative treatment with nivolumab did not improve RFS.	1b
There is uncertainty regarding further systemic therapy in patients who receive adjuvant pembrolizumab and develop a recurrence.	4
The lack of biomarker data is hindering progress in this field.	4

* pT2 G4 or pT3 any G; pT4 any G; pN+ any G; M1, NED after resection of metastases.

Recommendations	Strength rating
Do not use neoadjuvant therapy outside a clinical trial setting.	Weak
Offer adjuvant pembrolizumab to ccRCC patients, preferably within 12-16 weeks post-nephrectomy, following restaging, with a recurrence risk as defined in the Keynote-564 trial: Intermediate-high risk: <ul style="list-style-type: none"> pT2, grade 4 or sarcomatoid, N0 M0 pT3, any grade, N0, M0 High risk: <ul style="list-style-type: none"> pT4, any grade, N0, M0 any pT, any grade, N+, M0 M1 no evidence of disease (NED): <ul style="list-style-type: none"> NED after resection of oligometastatic sites within one year from nephrectomy. 	Strong
If adjuvant therapy is planned: <ul style="list-style-type: none"> Discuss the contradictory results of the available adjuvant immune checkpoint inhibitor (ICI) trials with the patient to facilitate shared decision making. Inform the patient about the potential risk of overtreatment and immune related side effects if adjuvant therapy is considered. 	Strong
Do not offer adjuvant sunitinib following surgically resected high-risk clear-cell renal cell carcinoma (ccRCC).	Weak
Offer vascular endothelial growth factor receptor - tyrosine kinase inhibitor (VEGFR-TKI) to patients developing a recurrence while receiving pembrolizumab or within the first six months after stopping pembrolizumab given for one year.	Weak
Do not offer ICI mono- or combination therapy in patients with recurrence during or within six months after adjuvant pembrolizumab.	Weak

7.4 Advanced/metastatic RCC

7.4.1 Local therapy of advanced/metastatic RCC

7.4.1.a Cytoreductive nephrectomy

Tumour resection is potentially curative only if all tumour deposits are excised. This includes patients with the primary tumour in place and single or oligometastatic resectable disease. For most patients with metastatic disease, cytoreductive nephrectomy (CN) is palliative and systemic treatments are necessary.

Two RCTs [501, 566] and a narrative SR were identified [567]. The narrative SR included both RCTs and ten non-RCTs. CARMENA, a phase III noninferiority RCT investigating immediate CN followed by sunitinib versus sunitinib alone, showed that sunitinib alone was not inferior to CN followed by sunitinib with regard to OS [566]. The trial included 450 patients with metastatic ccRCC of intermediate and MSKCC poor risk, of whom 226 were randomised to immediate CN followed by sunitinib and 224 to sunitinib alone. Patients in both arms had a median of two metastatic sites. Patients in both arms had a tumour burden of a median/mean of 140mL of measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, of which 80mL accounted for the primary tumour. The study did not reach the full accrual of 576 patients, and the Independent Data Monitoring Commission (IDMC) advised the trial steering committee to close the study. In an ITT analysis after a median follow-up of 50.9 months, median OS with CN was 13.9 months versus 18.4 months with sunitinib alone (HR: 0.89, 95% CI: 0.71-1.10). This was found in both risk groups. For MSKCC intermediate-risk patients (n = 256), median OS was 19.0 months with CN and 23.4 months with sunitinib alone (HR: 0.92, 95% CI: 0.60-1.24), and for MSKCC poor risk (n = 193), 10.2 months and 13.3 months, respectively (HR: 0.86, 95% CI: 0.62-1.17). Noninferiority was also found in two per-protocol analyses accounting for patients in the CN arm who either did not undergo surgery (n = 16) or did not receive sunitinib (n = 40), and patients in the sunitinib-only arm who did not receive the study drug (n = 11). Median PFS in the ITT population was 7.2 months with CN and 8.3 months with sunitinib alone (HR: 0.82, 95% CI: 0.67-1.00). The clinical benefit rate, defined as disease control beyond twelve weeks, was 36.6% with CN and 47.9% with sunitinib alone (p = 0.022). Of note, 38 patients in the sunitinib-only arm required secondary CN due to acute symptoms or for complete or near-complete response. The median time from randomisation to secondary CN was 11.1 months.

The randomised EORTC SURTIME study revealed that the sequence of CN and sunitinib did not affect PFS (HR: 0.88, 95% CI: 0.59-1.37, p = 0.569). The trial accrued poorly and therefore results are mainly exploratory. However, in secondary endpoint analysis, a strong OS benefit was observed in favour of the deferred CN approach in the ITT population with a median OS of 32.4 (range 14.5-65.3) months in the deferred CN arm versus 15.0 (9.3-29.5) months in the immediate CN arm (HR: 0.57, 95% CI: 0.34-0.95, p = 0.032). The deferred

CN approach appears to select patients with inherent resistance to systemic therapy [568]. This confirms previous findings from single-arm phase II studies [567, 569]. Moreover, deferred CN and surgery appear safe after sunitinib, which supports the findings, with some caution, of the only available RCT. In patients with poor PS or IMDC poor risk, small primaries, and high metastatic volume and/or a sarcomatoid tumour, CN is not recommended [570]. These data are confirmed by CARMENA [448] and upfront pre-surgical VEGFR-targeted therapy followed by CN seems to be beneficial [562].

Meanwhile first-line therapy recommendations for patients with their primary tumour in place have changed to ICI combination therapy (see Section 7.4.2.4) with sunitinib and other VEGFR-TKI monotherapies reserved for those who cannot tolerate ICI combination or have no access to these drugs. High-level evidence regarding CN is not available for ICI combinations but up to 30% of patients with primary metastatic disease, treated with their tumour in place, were included in the pivotal ICI combination trials (Table 7.2). The subgroup HRs, where available, suggest better outcomes for the ICI combination compared to sunitinib monotherapy. In mRCC patients without a need for immediate drug treatment, an SR evaluating effects of CN demonstrated an OS advantage of CN [567]. These data were supported by a nation-wide registry study showing that patients selected for primary CN had a significant OS advantage across all age groups [571].

Table 7.2: Key trials on immune checkpoint inhibitor combinations for primary metastatic disease

Trial	Drug combination	Number and % of patients treated with primary tumour in place	Number of patients treated with the primary tumour in place (ICI combination vs. sunitinib)		Subgroup analyses (HR with 95% CIs)	
			ICI combination	sunitinib	PFS	OS
CheckMate 214 [572]	ipilimumab + nivolumab	187/847 (22%)	84	103	NA	0.63 (0.42-0.94)
CheckMate 9ER [573]	cabozantinib + nivolumab	196/651 (30.1%)	101	95	0.63 (0.43-0.92)	0.79 (0.48-1.29)
Javelin 101 [574]	axitinib + avelumab	179/886 (20.2%)	90	89	0.75 (0.48-1.65)	NA
KEYNOTE-426 [575]	axitinib + pembrolizumab	143/861 (16.6%)	73	70	0.68 (0.45-1.03)	0.57 (0.36-0.89)
CLEAR [576]	lenvatinib + pembrolizumab	179/714 (25.1%)	97	82	0.38 (0.31-0.48)	0.52 (0.31-0.86)

CI = confidence interval; HR = hazard ratio; ICI = immune checkpoint inhibitor; NA = not available; PFS = progression-free survival; OS = overall survival.

The results of CARMENA and SURTIME demonstrated that patients who require systemic therapy benefit from immediate drug treatment. While randomised trials to investigate deferred versus no cytoreductive nephrectomy with ICI and ICI combinations are ongoing, the exploratory results from the ICI combination trials demonstrate that the respective Immune-Oncology (IO) + IO or TKI + IO combinations have a superior effect on the primary tumour and metastatic sites when compared to sunitinib alone (Table 7.2). In accordance with the CARMENA and SURTIME data, this suggests that mRCC patients and IMDC intermediate- and poor-risk groups with their primary tumour in place should be treated with upfront IO-based combinations. In patients with a clinical response to IO-based combinations, a subsequent CN may be considered. Real-world data have demonstrated durable response and surgical safety with this strategy. However, long-term surveillance is lacking [577-579]. Randomised controlled trials in this setting are ongoing but are unlikely to report soon [580].

7.4.1.a.1 Embolisation of the primary tumour

In patients unfit for surgery or with un-resectable disease, embolisation can control symptoms including visible haematuria or flank pain [347, 530] (see the recommendations in Section 7.2.2.b.4).

7.4.1.a.2 Summary of evidence and recommendations for local therapy of advanced/metastatic renal cell carcinoma

Summary of evidence	LE
Deferred CN with presurgical sunitinib in intermediate-risk patients with clear cell metastatic RCC (ccm-RCC) shows a survival benefit in secondary endpoint analyses and selects outpatients with inherent resistance to systemic therapy.	2b
Sunitinib alone is noninferior compared to immediate CN followed by sunitinib in patients with MSKCC intermediate and poor risk who require systemic therapy with VEGFR-TKI.	1a
Cytoreductive nephrectomy in patients with simultaneous complete resection of a single metastasis or oligometastases may improve survival and delay systemic therapy.	3
Patients with MSKCC or IMDC poor risk do not benefit from CN.	1a
Patients with their primary tumour in place treated with IO-based combination therapy have better PFS and OS in exploratory subgroup analyses compared to treatment with sunitinib.	2b

Recommendations	Strength rating
Do not perform cytoreductive nephrectomy (CN) in IMDC/MSKCC poor-risk patients.	Strong
Do not perform immediate CN in intermediate-risk patients who have an asymptomatic synchronous primary tumour and require systemic therapy.	Weak
Start systemic therapy without CN in intermediate-risk patients who have an asymptomatic synchronous primary tumour and require systemic therapy.	Weak
Discuss delayed CN with patients who derive clinical benefit from systemic therapy.	Weak
Perform immediate CN in patients with a good performance status who do not require systemic therapy.	Weak
Perform immediate CN in patients with oligometastases when complete local treatment of the metastases can be achieved.	Weak

IMDC = International Metastatic Renal Cell Carcinoma Database Consortium, MSKCC = Memorial Sloan Kettering Cancer Centre.

7.4.2 Therapy of oligometastatic disease

Therapy of oligometastatic disease (General considerations)

In patient with low metastatic tumour burden, there is no generally accepted definition of oligometastatic disease and its various forms of clinical presentation with regard to dynamics, size, numbers and site of metastasis.

However, two Delphi consensus approaches defined oligometastatic disease as one to five lesions at one side [581, 582]. Metastatic disease is defined as synchronous or metachronous presentation. A metachronous interval of < 1 year for recurrences following surgery with curative intent is a poor prognostic factor by IMDC classification [302, 583]. In addition, local treatment may lead to poorer outcomes compared to systemic therapy approaches as a relapse within the first 12 months and presentation with synchronous oligometastatic disease is attributed to the IMDC intermediate risk-group.

Data from the TKI era suggest that patients with oligometastatic disease recurrence can be observed for up to a median of 16 months before systemic therapy is required and that this practice is common in real-world settings (30%) [584, 585]. However, the general challenge is that a period of surveillance has never been investigated versus active local treatment or systemic therapy. Despite this, various modalities for local treatment of oligometastatic disease have evolved over time.

Two SRs of the local treatment of metastases from RCC [586-588], including metastasectomy, various radiotherapy modalities, local ablation [589] and no local treatment, did not change the level of evidence due to the heterogeneity and risk of bias to recommend one over the other. In symptomatic patients, radiotherapy to brain and bone metastases relieved local symptoms. In non-symptomatic patients, different strategies include:

7.4.2.a Complete versus no/incomplete metastasectomy

An SR of eight studies reported a significantly longer median OS or CSS following complete metastasectomy [590-597].

7.4.2.b Local therapies for RCC metastases

Various retrospective studies using metastasectomy, SBRT or local ablative therapy reported that local tumour control can be achieved. Due to the retrospective nature, cohort size and missing comparator, no definitive conclusion can be made if compared to active surveillance or immediate systemic therapy and with regard to OS.

Prospectively, single arm phase II evaluation of metastasis-directed radiotherapy prolonged the time to start systemic therapy [598] by 34 months in oligometastatic disease. Several other RCTs with SBRT in oligometastatic setting are ongoing.

7.4.2.c Adjuvant treatment in cM0 patients after metastasectomy

Patients after metastasectomy and no evidence of disease (cM0) have a high risk of relapse. The results of nine comparative studies of post-metastasectomy adjuvant treatment requirement, summarised in a recent SR, concluded that there is no benefit in terms of OS and DFS [599].

Recent attempts to reduce RFS in randomised prospective phase II trials of sorafenib and pazopanib after metastasectomy did not demonstrate an improvement in RFS [201, 202].

KEYNOTE-564 included a small percentage of patients who were treated by nephrectomy and complete metastasectomy within one year after primary diagnosis (6% in the experimental arm and 6% in the placebo arm) [552, 553]. Patients with brain and bone metastases were not included [302, 583]. Systemic therapy based on immune combinations has higher levels of evidence than surgery in this intermediate/advanced disease setting [600]. In addition, TKI-driven adjuvant trials after metastasectomy have shown no DFS or OS benefit [201, 202].

Results for single-agent pembrolizumab post-surgery for metastatic disease are therefore difficult to interpret due to the small subgroup. The DFS HR of 0.40 (95% CI: 0.20-0.81) and OS HR was 0.51 (95% CI: 0.15-1.75) in favour of resection of M1 to NED plus pembrolizumab shows that patients with subclinical, but progressive, disease who were subjected to metastasectomy had a benefit of adjuvant systemic therapy with pembrolizumab. Based on the current data, it cannot be concluded that for patients with oligo-progressive disease, metastasectomy within the first year of initial diagnosis of the primary and subsequent adjuvant pembrolizumab is superior to a period of observation and dual IO-based combination first-line therapy upon progression.

The Panel therefore does not encourage metastasectomy and adjuvant pembrolizumab in this population with recurrent disease within one year after primary surgery. A careful reassessment of disease status to rule out rapid progressive disease should be performed. Data from another adjuvant ICI study with the PD-L1 inhibitor atezolizumab (IMmotion010) also included an M1 NED subgroup which showed no DFS advantage [556]. This result underscores the need for caution in the treatment of the M1 NED subgroup. No prospective data is available for adjuvant therapy after local treatment with radiotherapy or ablation.

7.4.2.d Summary of evidence and recommendations for local therapy of metastases in metastatic RCC

Summary of evidence	LE
Retrospective comparative studies point towards a benefit of complete metastasectomy in mRCC patients in terms of OS, CSS and delay of systemic therapy.	3
A single-arm prospective and retrospective study support that oligometastases can be observed for up to 16 months before systemic therapy is required due to progression.	2a
Radiotherapy to bone and brain metastases from RCC can induce significant relief from local symptoms (e.g. pain).	3
Tyrosine kinase inhibitors treatment after metastasectomy in patients with no evidence of disease did not improve RFS when compared to placebo or observation.	1b

Recommendations	Strength rating
To control local symptoms, offer ablative therapy, including metastasectomy, to patients with metastatic disease and favourable disease factors and in whom complete resection is achievable.	Weak

Offer stereotactic radiotherapy for clinically relevant bone- or brain metastases for local control and symptom relief.	Weak
Do not offer tyrosine kinase inhibitor treatment to metastatic RCC patients after metastasectomy and no evidence of disease.	Strong
Perform a confirmatory axial scan of disease status prior to metastasectomy to rule out rapid progressive metastatic disease which requires systemic treatment.	Weak
Before initiating systemic therapy for oligometastases that cannot be resected, discuss with your patient a period of observation until progression is confirmed.	Weak

7.5 Systemic therapy for advanced/metastatic RCC

7.5.1 Chemotherapy

Chemotherapy has proven to be generally ineffective in the treatment of RCC, but can be offered to patients with collecting duct or medullary carcinoma [203].

7.5.1.a Recommendation for systemic therapy in advanced/metastatic RCC

Recommendation	Strength rating
Do not offer chemotherapy to patients with metastatic RCC.	Strong

7.5.2 Targeted therapies

In sporadic ccRCC, HIF accumulation due to VHL inactivation results in overexpression of VEGF and platelet-derived growth factor (PDGF), which promote neoangiogenesis [601-603]. This process substantially contributes to the development and progression of RCC. Several targeting drugs for the treatment of mRCC are approved in both the USA and Europe.

Most published trials have selected for clear-cell carcinoma subtypes, therefore, no robust evidence-based recommendations can be given for non-ccRCC subtypes.

In major trials leading to registration of the approved targeted agents, patients were stratified according to the IMDC risk model (see Section 6.6 on prognostic models) [304].

7.5.2.a Tyrosine kinase inhibitors

7.5.2.a.1 Sunitinib

Sunitinib is an oral TKI inhibitor and has antitumour and antiangiogenic activity. First-line monotherapy with sunitinib demonstrated significantly longer PFS compared with Interferon-alpha (IFN- α). Overall survival was greater in patients treated with sunitinib (26.4 months) versus IFN- α (21.8 months), despite crossover [604].

In the EFFECT trial, sunitinib 50mg/day (four weeks on, two weeks off) was compared with continuous uninterrupted sunitinib 37.5mg/day in patients with clear cell metastatic renal cell carcinoma (cc-mRCC) [605]. No significant differences in OS were seen (23.1 vs. 23.5 months, $p = 0.615$). Toxicity was comparable in both arms. Because of the nonsignificant, but numerically longer time to progression with the standard 50mg dosage, the authors recommended using this regimen. Alternate scheduling of sunitinib (two weeks on, one week off) is being used to manage toxicity, but robust data to support its use is lacking [606, 607].

7.5.2.a.2 Pazopanib

Pazopanib is an oral angiogenesis inhibitor. In a trial of pazopanib versus placebo in treatment-naive mRCC patients and cytokine-treated patients, a significant improvement in PFS and tumour response was observed [608].

A noninferiority trial comparing pazopanib with sunitinib (COMPARZ) established pazopanib as an alternative to sunitinib. The results of the trial showed that pazopanib was not associated with significantly worse PFS or OS compared to sunitinib. The two drugs had different toxicity profiles, and QoL was better with pazopanib [609]. In another patient-preference study (PISCES), patients preferred pazopanib to sunitinib (70% vs. 22%, $p < 0.05$) due to symptomatic toxicity [610]. Both studies were limited in that intermittent therapy (sunitinib) was compared with continuous therapy (pazopanib).

7.5.2.a.3 **Axitinib**

Axitinib is an oral selective second-generation inhibitor of VEGFR-1, -2 and -3. Axitinib was first evaluated as second-line treatment. In the AXIS trial, axitinib was compared to sorafenib in patients who had previously failed cytokine treatment or targeted agents (mainly sunitinib) [611].

The overall median PFS was greater for axitinib than sorafenib. Axitinib was associated with a greater PFS than sorafenib (4.8 vs. 3.4 months) after progression on sunitinib. Axitinib showed grade III diarrhoea in 11%, hypertension in 16% and fatigue in 11% of patients. Final analysis of OS showed no significant differences between axitinib or sorafenib [612]. In a randomised phase III trial of axitinib versus sorafenib in first-line treatment-naïve cc-mRCC, a significant difference in median PFS between the treatment groups was not demonstrated, although the study was underpowered, raising the possibility of a type II error [613]. As a result of this study, axitinib is not approved for first-line therapy.

7.5.2.a.4 **Cabozantinib**

Cabozantinib is an oral inhibitor of tyrosine kinase, including MET, VEGF and AXL. Cabozantinib was investigated in a phase I study in patients resistant to VEGFR and mTOR inhibitors demonstrating objective responses and disease control [260]. Based on these results an RCT investigated cabozantinib versus everolimus in patients with ccRCC failing one or more VEGF-targeted therapies (METEOR) [614, 615]. Cabozantinib delayed PFS compared to everolimus in VEGF-targeted therapy refractory disease (HR: 0.58, 95% CI: 0.45-0.75) [614] (LE: 1b). The median OS was 21.4 months (95% CI: 18.7 to not estimable) with cabozantinib and 16.5 months (95% CI: 14.7-18.8) with everolimus in VEGF-resistant RCC. The HR for death was 0.66 (95% CI: 0.53-0.83, $p = 0.0003$) [500]. Grade III or IV adverse events were reported in 74% with cabozantinib and 65% with everolimus. Adverse events were managed with dose reductions; doses were reduced in 60% of the patients who received cabozantinib.

The Alliance A031203 CABOSUN randomised phase II trial comparing cabozantinib and sunitinib in first line in 157 intermediate- and poor-risk patients favoured cabozantinib for RR and PFS, but not OS [616, 617]. Cabozantinib significantly increased median PFS (8.2 vs. 5.6 months, adjusted HR: 0.66, 95% CI: 0.46-0.95; one-sided $p = 0.012$). Objective response rate was 46% (95% CI: 34-57) for cabozantinib versus 18% (95% CI: 10-28) for sunitinib. All-causality grade III or IV adverse events were similar for cabozantinib and sunitinib. No difference in OS was seen. Due to limitations of the statistical analyses within this trial, the evidence is inferior to existing choices.

7.5.2.a.5 **Lenvatinib**

Lenvatinib is an oral multitarget TKI of VEGFR1, VEGFR2 and VEGFR3, with inhibitory activity against fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3 and FGFR4), platelet growth factor receptor (PDGFR α), rearranged during transfection (RET) and receptor for stem cell factor (KIT). It has been investigated in a randomised phase II study in combination with everolimus versus lenvatinib or everolimus alone (see Section 7.5.4.a.1 for a discussion of the results) [618].

7.5.2.a.6 **Tivozanib**

Tivozanib is a potent and selective TKI of VEGFR1, VEGFR2 and VEGFR3 and was compared in two phase III trials with sorafenib in patients with mRCC [619, 620]. The EMA approved Tivozanib in front-line mRCC. While Tivozanib was associated with a PFS advantage in both studies, no OS advantage was observed. In view of the choice of sorafenib as the control arm in the front-line trial, the Panel believes that there is too much uncertainty, and too many attractive alternatives, to support the use of Tivozanib in this front-line setting.

7.5.2.b **Monoclonal VEGF antibody**

Bevacizumab is a humanised monoclonal antibody. Initial first-line treatment in combination with IFN- α has been superseded by more effective therapies [621-623]. Bevacizumab in combination with atezolizumab has not been approved for treatment of mRCC (see Section 7.5.3.b) [624].

7.5.2.c **mTOR inhibitors**

7.5.2.c.1 **Temsirolimus**

Temsirolimus is a specific inhibitor of mTOR [625]. Its use has been superseded as front-line treatment option.

7.5.2.c.2 **Everolimus**

Everolimus is an oral mTOR inhibitor, which is established in the treatment of VEGF-refractory disease. The RECORD-1 study compared everolimus plus best supportive care (BSC) versus placebo plus BSC in patients with previously failed anti-VEGFR treatment (or previously intolerant of VEGF-targeted therapy) [626]. The data showed a median PFS of 4 versus 1.9 months for everolimus and placebo, respectively [626].

The Panel believes, even in the absence of conclusive data, that everolimus may present a therapeutic option in patients who were intolerant to, or previously failed, immune- and VEGFR-targeted therapies (LE: 4). Recent phase II data suggest adding lenvatinib is attractive.

7.5.2.d Small molecule inhibitor.

7.5.2.d.1 Belzutifan

Belzutifan is an inhibitor of the HIF2a transcription factor with single agent activity ccRCC. Initial Phase I/II trials in 55 patients confirmed objective response rate was 25% (all partial responses), and the median progression-free survival was 14.5 months. The most common grade ≥ 3 adverse events were anaemia (27%) and hypoxia (16%) [627]. In the randomised phase III LITESPARK 005, belzutifan shows a PFS advantage over everolimus in heavily pretreated ccRCC. Belzutifan also has a favourable adverse event profile and should be considered an attractive alternative to everolimus in this setting. There was no significant difference in OS. Results of a number of combination studies are awaited [628]. Belzutifan has also been investigated in combination with cabozantinib in a single arm phase II trial with two cohorts (treatment-naive and after immunotherapy with up to two lines) [629]. In second and third line, this combination yielded an objective response rate of 30.8% with one complete response (2%).

7.5.2.d.2 Vascular endothelial growth factor (VEGF) targeted therapy

Intermittent VEGF-targeted therapy is attractive for patients on long-term therapy, due to the chronic toxicity associated with long-term therapy such as fatigue. Intermittent VEGF-targeted therapy has been tested with sunitinib or pazopanib in a phase III study and found to be safe [630]. Patients in the study had stable disease (or better) for at least six months after starting therapy. The patients were closely followed for progression with cross-sectional imaging. Cessation of therapy was associated with higher rates of progression, but no detrimental effect was seen on OS [630]. Intermittent therapy has not been tested with VEGF/PD-1 combinations, therefore its application in the modern first line setting is unknown, but extrapolation suggests it should be safe.

7.5.2.e Summary of evidence and recommendations for single-agent targeted therapy in metastatic clear-cell RCC

Summary of evidence	LE
Single-agent VEGF-targeted therapy has been superseded by immune checkpoint-based combination therapy.	1b
Intermittent VEGF therapy can be considered in patients on long-term VEGF-targeted therapy.	2
Immuno-oncology VEGFR TKI combination established an RR and PFS benefit over single agent VEGFR TKI but no OS benefit in subgroup analysis.	2b
Pazopanib is noninferior to sunitinib as first-line management option in mRCC.	1b
Cabozantinib in intermediate- and poor-risk treatment-naive ccRCC leads to better response rates and PFS, but not OS when compared to sunitinib.	2b
Tivozanib has been approved by the EMA in the first-line setting; however, it was randomised against sorafenib, which is no longer a standard of care in the first-line setting.	1b
Single-agent VEGF-targeted therapies are preferentially recommended after first-line PD-L1-based combinations. Rechallenge with treatments already used should be avoided.	3
Single-agent cabozantinib or nivolumab are superior to everolimus after one or more lines of VEGF-targeted therapy.	1b
Everolimus prolongs PFS after VEGF-targeted therapy when compared to placebo. This is no longer widely recommended before third-line therapy.	1b
Belzutifan has a PFS advantage and no OS benefit over everolimus in second and more lines pretreated ccRCC.	1b
Lenvatinib in combination with everolimus improved PFS over everolimus alone in VEGF-refractory disease in a phase II trial. Its role after ICIs is uncertain. There is a lack of robust data on this combination, making its recommendation challenging.	2a

7.5.3 Immunotherapy

7.5.3.a Immune checkpoint inhibitors

7.5.3.a.1 Immuno-oncology monotherapy

Immune checkpoint inhibitor with monoclonal antibodies targets and blocks the inhibitory T-cell receptor PD-1 or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)-signalling to restore tumour-specific T-cell immunity [631]. Immune checkpoint inhibitor monotherapy has been investigated as second- and third-line therapy. A phase III trial of nivolumab versus everolimus after one or two lines of VEGF-targeted therapy for mRCC with a clear cell component (CheckMate 025, NCT01668784) reported a longer OS, better QoL and fewer grade III or IV adverse events with nivolumab than with everolimus [632]. Nivolumab has superior OS to everolimus (HR: 0.73, 95% CI: 0.57-0.93, $p < 0.002$) in VEGF-refractory RCC with a median OS of 25 months for nivolumab and 19.6 months for everolimus with a five-year OS probability of 26% versus 18% [633] (LE: 1b). Patients who had failed multiple lines of VEGF-targeted therapy were included in this trial, making the results broadly applicable. The trial included 15% MSKCC poor-risk patients. There was no PFS advantage with nivolumab despite the OS advantage. Progression-free survival does not appear to be a reliable surrogate of outcome for PD-1 therapy in RCC. Currently PD-L1 biomarkers are not used to select patients for this therapy.

There are no RCTs supporting the use of single-agent ICI in treatment-naïve patients. Randomised phase II data for atezolizumab versus sunitinib showed an HR of 1.19 (95% CI: 0.82-1.71), which did not justify further assessment of atezolizumab as single agent as first-line treatment option in this group of patients, despite high complete response rates in the biomarker-positive population [634]. Single-arm phase II data for pembrolizumab from the KEYNOTE-427 trial show high response rates of 38% (up to 50% in PD-L1+ patients), but a PFS of 8.7 months (95% CI: 6.7-12.2) [634]. Based on these results and in the absence of randomised phase III data, single-agent checkpoint inhibitor therapy is not recommended as an alternative in a first-line therapy setting.

In addition, several trials explored the strategy of nivolumab monotherapy in first-line ccRCC, followed by a salvage strategy with nivolumab plus ipilimumab upon progression or if stable disease was the best response. Trial results do not support such a strategy, which was frequently infeasible and of limited benefit [635, 636]. This was confirmed in a pooled analysis of three of these trials [637]. However, recent data suggest that nivolumab monotherapy may yield extensive treatment-free survival in the IMDC favourable risk patient population [638].

7.5.3.b Immunotherapy/combination therapy

The phase III trial CheckMate 214 (NCT 02231749) showed a superiority of nivolumab and ipilimumab over sunitinib. The primary endpoint population focused on the IMDC intermediate- and poor-risk population, where the combination demonstrated an OS benefit (HR: 0.63, 95% CI: 0.44-0.89), which led to regulatory approval [572] and a paradigm shift in the treatment of mRCC [639]. Results from CheckMate 214 further established that the combination of ipilimumab and nivolumab was associated with higher RR (39% in the ITT population), complete RR (8% in the ITT population [central radiology review]) and duration of response compared to sunitinib. Progression-free survival did not achieve the predefined endpoint. The exploratory analysis of OS data in the PD-L1-positive population was 0.45 (95% CI: 0.29-0.41).

An update with median follow-up of more than nine years (111 months) shows ongoing benefits for the immune combination with independently assessed complete response rates of 12% and an HR for OS in the IMDC intermediate- and poor-risk group of 0.69 (0.59-0.81) [640, 641]. However, this complete response rate has not been consistent across trials for this combination (the Cosmic313 study showed complete response rates of 4% [642, 643]).

In CheckMate 214, the 111-month OS probability was 31% for ipilimumab plus nivolumab versus 20% for sunitinib, respectively [641, 644]. In this update, the IMDC good-risk group continues to perform better with sunitinib (HR for OS: 0.80 [95% CI: 0.59-1.09]) [641, 644]. Nivolumab plus ipilimumab was associated with 46% grade III-IV toxicity and 1.5% treatment-related deaths. Nivolumab plus ipilimumab should therefore be administered in centres with experience with immune combination therapy and appropriate supportive care within the context of a multidisciplinary team (LE: 4). The PD-L1 biomarker is currently not used to select patients for therapy.

Subset analysis of the favourable-risk group was not a primary endpoint of the trial. Initial results favoured sunitinib over nivolumab plus ipilimumab for this population, leading to a recommendation restricted to intermediate- and poor-risk disease. In updated results, after a median follow-up of 111 months, ipilimumab-nivolumab was associated with an OS HR: of (HR: for OS: 0.80 [95% CI: 0.59-1.09]) while ORR (30% vs. 52%) and PFS still favoured sunitinib (HR: 1.78, 95% CI: 1.27-2.50), and improved CR rates (13% vs. 6%) and duration

of response (49% vs. 50% with ongoing response at five years) were observed with ipilimumab plus nivolumab. These longer-term results led the Guidelines Panel to change the recommendation towards nivolumab plus ipilimumab in the IMDC favourable risk patient population [641].

The frequency of steroid use has generated controversy, and further analysis, as well as real-world data, are required. For these reasons the Panel continues to recommend ipilimumab and nivolumab in the intermediate- and poor-risk population and as an alternative in the favourable risk population.

The KEYNOTE-426 trial (NCT02853331) reported results for the combination of axitinib plus pembrolizumab versus sunitinib in 861 treatment-naive cc-mRCC patients [645]. The OS and PFS was assessed by central independent review in the ITT population and were the co-primary endpoints. Response rates and assessment in the PD-L1-positive patient population were secondary endpoints. With a minimum follow-up of 35.6 months (median 42.8 months), this trial demonstrated an ongoing OS benefit for axitinib plus pembrolizumab in the ITT population (HR: 0.73, 95% CI: 0.60-0.88, $p < 0.001$). Median OS for axitinib plus pembrolizumab was 45.7 months (95% CI: 43.6 - NR) versus 40.1 month (95% CI: 34.3-44.2) for sunitinib with a PFS benefit (HR: 0.68, 95% CI: 0.58-0.80, $p < 0.0001$), which was shown across all IMDC subgroups for PFS, while OS was similar between axitinib plus pembrolizumab versus sunitinib in the favourable subgroup with an OS benefit in the IMDC intermediate- and poor-risk groups. The complete response rate by independent review was 10% in the pembrolizumab plus axitinib arm and 4% in the sunitinib arm [646]. With an extended median follow-up of 67 months median OS was 47.2 months (43.6-54.8) versus 40.8 months (34.3-47.5; HR: 0.84 95% CI: 0.71-0.99) for sunitinib, median PFS was 15.7 (13.6-20.2) versus 11.1 (8.9-12.5) HR: 0.69 (95% CI: 0.59-0.81) and ORR was 60.6% (CR 11.6%) versus 39.6% (CR 4.0%) [647]. Treatment-related adverse events (\geq grade III) occurred in 63% of patients receiving axitinib and pembrolizumab versus 58% of patients receiving sunitinib. Treatment-related deaths occurred in approximately 1% in both arms [647].

The phase III CheckMate 9ER trial randomised 651 patients to nivolumab plus cabozantinib ($n = 323$) or versus sunitinib ($n = 328$) in treatment-naive cc-mRCC patients [456]. The primary endpoint of PFS assessed by central independent review in the ITT population was significantly prolonged for nivolumab plus cabozantinib (16.6 months) versus sunitinib (8.3 months, HR: 0.51, 95% CI: 0.41-0.64, $p < 0.0001$). The nivolumab/cabozantinib combination also demonstrated a significant OS benefit in the secondary endpoint compared with sunitinib (HR: 0.60, CI: 0.40-0.89, $p = 0.0010$) after a median follow-up of 18.1 months in the initial report [573]. The independently assessed ORR was 55.7% versus 27.1% with a complete response rate of 8% for nivolumab plus cabozantinib versus 4.6% with sunitinib. The efficacy was observed independent of IMDC group and PD-L1 status. Treatment-related adverse events ($>$ grade III) occurred in 61% of patients receiving cabozantinib and nivolumab versus 51% of patients receiving sunitinib. Treatment-related deaths occurred in one patient in the nivolumab/cabozantinib arm and in two patients in the sunitinib arm. At 67.6 months - considered to be the final follow-up - the median OS was 46.5 months (40.5-53.8) in the nivolumab plus cabozantinib patients versus 35.5 months (29.2-42.9) in the sunitinib-treated patients (HR: 0.79 [95% CI: 0.65-0.96]). The updated median PFS was 16.6 months (12.5-19.3) versus 8.3 months (7.0-9.7; HR: 0.58 [95% CI: 0.49-0.70], $p < 0.0001$) [648].

The randomised phase III trial CLEAR (Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab vs. Sunitinib Alone as Treatment of Advanced RCC) was published [576, 649]. CLEAR randomised a total of 1,069 patients (in a 1:1:1 ratio) to lenvatinib plus pembrolizumab ($n = 355$) versus lenvatinib plus everolimus ($n = 357$) versus sunitinib ($n = 357$). The trial reached its primary endpoint of independently assessed PFS at a median of 23.9 versus 9.2 months for lenvatinib plus pembrolizumab versus sunitinib, respectively (HR: 0.39, 95% CI: 0.32-0.49, $p < 0.001$). Overall survival significantly improved with lenvatinib plus pembrolizumab versus sunitinib (HR: 0.66, 95% CI: 0.49-0.88, $p = 0.005$). Objective response for lenvatinib plus pembrolizumab was 71%, with 16% of the patients having a complete remission. In the final analysis with a median follow-up of 49.8 months, median OS was 53.7 months (48.7 - not estimable) for lenvatinib plus pembrolizumab versus 54.3 (40.9 - not estimable; HR: 0.79 95% CI: 0.63-0.99) for sunitinib [649]. Efficacy was observed across all IMDC risk groups independently of PD-L1 status. Treatment-related adverse events ($>$ grade III) with lenvatinib plus pembrolizumab were 72%. Treatment-related death occurred in four patients in the lenvatinib plus pembrolizumab arm and in one patient in the sunitinib arm.

The JAVELIN trial investigated 886 patients in a phase III RCT of avelumab plus axitinib versus sunitinib [574]. The trial met one of its coprimary endpoints (PFS in the PD-L1-positive population at first interim analysis [median follow up 11.5 months]). At first analysis, hazard ratios for PFS and OS in the ITT population were 0.66 (95% CI: 0.566-0.769) and 0.88 (95% CI: 0.749-1.039), respectively, demonstrating no statistically significant OS improvement at final analysis after a minimum follow-up of 68 months (median OS 44.8 vs. 38.9 months; $P = 0.0669$) [650]. The same applies to the atezolizumab/bevacizumab combination (IMmotion151), which also

achieved a PFS advantage over sunitinib in the PD-L1-positive population at interim analysis and ITT (HR: 0.74, 95% CI: 0.57-0.96), but has not shown a significant OS advantage at final analysis (HR: 0.91 [95% CI: 0.76-1.08], $p = 0.27$) [624, 651]. Therefore, these combinations cannot currently be recommended [650].

A similar combination of a PD-1 inhibitor (toripalimab) with axitinib was investigated in the RENOTORCH trial in cc-mRCC patients with intermediate and poor IMDC risk. A total of 421 patients were randomised, $n = 210$ received toripalimab plus axitinib and $n = 211$ received sunitinib. After a median follow-up of 14.6 months, toripalimab plus axitinib significantly improved PFS compared with sunitinib (HR: 0.65, 95% CI: 0.49-0.86; $p = 0.0028$). Median PFS was 18.0 months in the toripalimab plus axitinib arm, and 9.8 months in the sunitinib arm. Objective response rate was significantly higher in the toripalimab plus axitinib arm compared with the sunitinib arm (56.7% vs. 30.8%; $P < 0.0001$). Overall survival trend favoured toripalimab plus axitinib (HR: 0.61, 95% CI: 0.40-0.92). This combination is available in China [652].

In the ETER100 trial, the combination of the PD-L1 inhibitor benmelstobart plus the TKI anlotinib was investigated in cc-mRCC patient of all IMDC risk groups. The phase III trial randomised 531 cc-mRCC patients to benmelstobart plus anlotinib ($n = 266$) and sunitinib ($n = 265$). After a median follow-up of 18.7 months, the primary endpoint of PFS by BICR was significantly prolonged, with benmelstobart plus anlotinib compared to sunitinib (18.9m vs. 9.8m; HR: 0.53, CI: 0.42-0.67). Objective response rate was significantly higher with benmelstobart plus anlotinib (71.6% vs. 25.1%, $p < 0.001$). The OS is still immature, with a trend favouring benmelstobart plus anlotinib (HR: 0.66, CI: 0.48-0.92). This combination is not available in Europe [653].

In IMDC-favourable patients, the treatment with axitinib+pembrolizumab (Keynote-426), cabozantinib+nivolumab (CheckMate-9ER) and lenvatinib+pembrolizumab (CLEAR) improved PFS and ORR, but not OS [646-649, 654, 655]. Given the long-term follow-up with no OS improvement by the respective TKI+IO combination versus sunitinib, TKI monotherapy becomes a standard of care as an additional choice in IMDC-favourable patients. Although sunitinib was the TKI monotherapy used in these trials, pazopanib is a valid alternative based on the noninferiority data of the phase III trial COMPARZ [609].

The COSMIC-313 trial is the first RCT to evaluate a triple combination of cabozantinib (40mg) plus nivolumab plus ipilimumab versus nivolumab plus ipilimumab, a current standard of care, in 855 patients with IMDC intermediate- and poor-risk [642]. The primary endpoint of PFS improvement, measured in a PFS ITT of 550 patient was met after 249 events occurred with a HR: 0.73 (95% CI: 0.57-0.94, $p = 0.013$) favouring the triplet therapy. Median PFS was not reached (14.0-NE) versus 11.3 months (7.7-18.2) in the control arm with a median follow-up of 20.2 months. Overall survival advantage has not been demonstrated yet. the ORR was 43% versus 36% in the triplet versus the control arm with a complete response rate of 3% in both arms.

With an extended median follow-up of 45 months, an improvement in PFS was maintained 16.6 months (14.0-22.6) for the triplet and 11.2 (9.3-14.0) (HR:0.82, 95% CI: 0.69-0.98), although OS was not significantly different between the two groups, 41.9 versus 42 months (HR: 1.02, 95% CI: 0.85-1.23, $p = 0.84$) and ORR was 46% (CR 4%) versus 37% (CR 3%) [643].

Treatment-related adverse events (> grade III) with cabozantinib plus nivolumab plus ipilimumab were 73% versus 41% in the nivolumab plus ipilimumab control arm. The use of high-dose steroids (> = 40mg prednisolone or equivalent) was 58% (triplet) versus 35% (control). Treatment discontinuation rate of any agent was high in the triplet arm (45%) compared to the doublet (24%), whilst discontinuation of all treatments due to the same adverse events was 12% versus 5% in the control arm.

Although the primary endpoint of PFS was met, objective response rates of the triplet combination are modest as known for TKI + IO doublets. Treatment-related adverse events are high with a high rate of treatment discontinuation. As the OS rate is currently unknown, the additional benefit of this triplet therapy compared to standard immune-based doublet therapy is still uncertain.

Table 7.4: First line immune checkpoint inhibitor combination trials for clear-cell RCC

Cross trial comparison is not recommended and should occur with caution

Study	N	Experimental arm	Primary endpoint	Risk groups	PFS (mo) Median (95% CI) HR	OS (mo) Median (95% CI) HR
KEYNOTE-426 NCT02853331 Median follow-up 67 months [575, 645-647]	861	PEMBRO 200 mg. IV Q3W plus AXI 5mg. PO BID vs. SUN 50mg PO QD 4/2 wks.	PFS and OS in the ITT by BICR	IMDC FAV 31% IMD 56% POOR 13% MSKCC Not determined	(ITT) PEMBRO + AXI: 15.7 (13.6-20.2) SUN: 11.1 (8.9-12.5) HR: 0.69 (95% CI: 0.59-0.81) p < 0.0001	(ITT) PEMBRO + AXI: 47.2. (43.6-54.8) SUN: 40.8 (34.3-47.5) HR: 0.84 (95% CI: 0.71-0.99) p = 0.001
JAVELIN Renal 101 NCT02684006 Median follow-up 68 months [574, 650, 656, 657]	886	AVE 10mg/kg IV Q2W plus AXI, 5mg PO BID vs. SUN 50mg PO QD 4/2 wks.	PFS in the PD-L1+ population and OS in the ITT by BICR	IMDC FAV 22% IMD 62% POOR 16% MSKCC FAV 23% IMD 66% POOR 12%	(PD-L1+) AVE + AXI: 13.9 (11.0-17.8) SUN: 8.2 (6.9-9.4) HR: 0.57 (95% CI: 0.47-0.7) p < 0.0001	(PD-L1+) AVE+AXI: 43.2 (36.5-51.7) SUN: 36.2 (29.8-44.2) HR: 0.86 (95% CI: 0.70-1.06) p = 0.0755
IMmotion151 NCT02420821 Median follow-up 24 months [624, 651]	915	ATEZO 1200mg fixed-dose IV plus BEV 15mg/kg IV on days 1 and 22 of each 42-day cycle vs. SUN 50mg PO QD 4/2 wks.	PFS in the PD-L1+ population and OS in the ITT by IR	IMDC Not determined MSKCC FAV 20% IMD 69% POOR 12%	(PD-L1+) ATEZO + BEV: 11.2 (8.9-15.0) SUN: 7.7 (6.8-9.7) HR: 0.74 (95% CI: 0.57-0.96) p = 0.0217	(ITT) ATEZO + BEV: 36.1 (31.5-42.3) SUN: 35.3 (28.6-42.1 NE) HR: 0.91 (95% CI: 0.76-1.08) p = 0.27
CheckMate214 NCT02231749 Median follow-up of 111 months [572, 644]	1096	NIVO 3mg/kg plus ipilimumab 1mg/kg IV Q3W for 4 doses then nivolumab 3mg/kg IV Q2W vs. SUN 50mg	PFS and OS in the IMDC intermediate and poor risk population by BICR	IMDC FAV 23% IMD 61% POOR 17% MSKCC Not determined	(IMDC IMD/poor) NIVO + IPI: 12.4 (8.7-16.8) SUN: 8.5 (7-11.1) HR: 0.73 (0.61-0.87)	(IMDC IMD/poor) NIVO + IPI: 46.7 (35-55.1) SUN: 26 (21.8-32.6) HR: 0.69 (0.59-0.81)
CheckMate9ER NCT03141177 Median follow-up of 44 months [573, 654]	651	NIVO 240mg. fixed dose IV every 2 wks. plus CABO 40mg PO daily vs. SUN 50mg PO QD 4/2 wks.	PFS in the ITT by BICR	IMDC FAV 22% IMD 58% POOR 20% MSKCC Not determined	(ITT) NIVO+CABO: 16.6 (12.5-19.3) SUN: 8.3 (7.0-9.7) HR: 0.58 (95% CI: 0.49-0.70) p < 0.0001	(ITT) NIVO+CABO: 46.5 (40.5-53.8) SUN: 35.5 (29.2-42.9) HR: 0.79 (98.9% CI: 0.65-0.96)

CLEAR NCT02811861 Median follow-up of 49.8 months [576, 649, 658]	712	PEMBRO 200mg IV Q3W plus LEN 20mg PO QD vs. SUN 50mg PO QD 4/2 wks.	PFS in the ITT by BIRC	IMDC FAV 31% IMD 59% POOR 9% NE 1% MSKCC FAV 27% IMD 64% POOR 9%	(ITT) PEMBRO+LEN: 23.9 (20.8-27.7) SUN: 9.2 (6.0-11.0) HR: 0.47 (95% CI: 0.38-0.57) p > 0.001	(ITT) PEMBRO+LEN: 23.9 (20.8-27.7) SUN: 9.2 (6.0-11.0) HR: 0.47 (95% CI: 0.38-0.57) p < 0.001
RENOTORCH NCT04394975 Median follow-up of 14.6 months [652, 653]	421	TORI 240mg IV Q3W plus AXI 5mg. PO BID vs. SUN 50mg PO QD 4/2 wks. or QD 2/1wks.	PFS in the ITT by BIRC	IMDC IMD 81% POOR 19%	(ITT) TORI+AXI: 18.0 (15.0-N.E.) SUN: 9.8 (8.3-13.8) HR: 0.65 (95% CI: 0.49-0.86) p = 0.0028	(ITT) TORI+AXI: N.E. (N.E.-N.E.) SUN: 26.8 (24.5-N.E.) HR: 0.61 (95% CI: 0.40-0.92)
ETER100 NCT04523272 Median follow-up of 18.7 months [653]	531	BENMEL 1200mg IV Q3W plus ANLO 12mg PO QD 2/1 wks. vs. SUN 50mg PO QD 4/2 wks.	PFS in the ITT by BIRC	IMDC FAV 14% IMD 71% POOR 15%	(ITT) BENMEL+ANLO: 19.0 (15.3-22.8) SUN: 9.8 (8.4-12.4) HR: 0.53 (95% CI: 0.42-0.67) p < 0.001	(ITT) BENMEL+ANLO: N.E. (38.2-N.E.) SUN: N.E. (30.5-N.E.) HR: 0.66 (95% CI: 0.48-0.92) p = 0.0673
COSMIC-313 Median follow-up of 20.2 months [642]	855	NIVO 3mg/kg plus IPI 1mg/kg IV Q3W for 4 doses then NIVO 3mg/kg IV Q2W + CABO 40mg PO QD vs. NIVO 3mg/kg plus IPI 1mg/kg IV Q3W for 4 doses then NIVO 3mg/kg IV Q2W	PFS in the PITT population (first 550 pts. randomised)	IMDC IMD 75% POOR 25%	(PITT) NIVO+IPI+CABO: NR (14.0-NE) NIVO+IPI: 11.3 (7.7-18.2) HR: 0.73 (95% CI: 0.57-0.94) p = 0.013	NR

ANLO = anlotininib; ATEZO = atezolizumab; AVE = avelumab; AXI = axitinib; BENMEL = benmelstobart; BEV = bevacizumab; BICR = blinded independent central review; BID = twice a day; CABO = cabozantinib; CI = confidence interval; FAV = favourable; HR = hazard ratio; IMD = intermediate; IMDC = Metastatic Renal Cancer Database Consortium; IPI = ipilimumab; IR = investigator review; ITT = intention-to-treat; IV = intravenous; LEN = lenvatinib; mos. = months; MSKCC = Memorial Sloan Kettering Cancer Center; NE = non-estimable; NIVO = nivolumab; NR = not reached; OS = overall survival; PEMBRO = pembrolizumab; PFS = progression-free survival; PITT = PFS intention-to-treat; PO = by mouth; Pts = patients; QD = once a day; Q2W = every 2 weeks; Q3W = every 3 weeks; SUN = sunitinib; TORI = toripalimab; wks. = weeks.

Patients who stop nivolumab plus ipilimumab because of toxicity require expert guidance and support from a multidisciplinary team before rechallenge can occur (LE: 1). Patients who do not receive the full four doses of ipilimumab due to toxicity should continue on single-agent nivolumab, where safe and feasible (LE: 4). Treatment past progression with nivolumab plus ipilimumab can be justified but requires close scrutiny and the support of an expert multidisciplinary team [572, 659] (LE: 1).

Patients who stop TKI and IO due to immune-related toxicity can receive single-agent TKI once the adverse events has resolved (LE: 1). Adverse event management, including transaminitis and diarrhoea, require particular attention as both agents may be causative. Expert advice should be sought on rechallenge of ICI after significant toxicity (LE: 4). Treatment past progression on axitinib plus pembrolizumab or nivolumab plus cabozantinib requires careful consideration as it is biologically distinct from treatment past progression on ipilimumab and nivolumab.

Based on panel consensus, nivolumab plus ipilimumab, pembrolizumab plus axitinib and nivolumab plus cabozantinib and lenvatinib plus pembrolizumab should be administered in centres with experience of immune combination therapy and appropriate supportive care within the context of a multidisciplinary team (LE: 4).

7.5.4 Therapeutic strategies

7.5.4.a Treatment-naïve patients with clear-cell metastatic RCC

The combination of pembrolizumab plus axitinib as well as nivolumab plus cabozantinib and lenvatinib plus pembrolizumab is the standard of care in all IMDC-risk patients and ipilimumab plus nivolumab in IMDC intermediate- and poor-risk patients (see Figure 7.1). Therefore, the role of VEGFR-TKIs alone in front-line mRCC has been superseded in IMDC intermediate and poor risk. In the IMDC favourable group, in the absence of OS benefit, both options are acceptable. Sunitinib, pazopanib, tivozanib and cabozantinib (IMDC intermediate- and poor-risk disease) remain alternative treatment options for patients who cannot receive or tolerate immune checkpoint inhibition in this setting (see Figure 7.1).

7.5.4.a.1 Sequencing systemic therapy in clear-cell metastatic RCC

The sequencing of targeted therapies is established in mRCC and maximises outcomes [618, 632]. Pembrolizumab plus axitinib, nivolumab plus cabozantinib, lenvatinib plus pembrolizumab and nivolumab plus ipilimumab are the new standard of care in front-line therapy in IMDC intermediate/poor. The impact of front-line immune checkpoint inhibition on subsequent therapies is unclear. Randomised data on patients with disease refractory to either nivolumab plus ipilimumab or TKI plus IO in a first-line setting are limited. Sequencing immune checkpoint inhibition with atezolizumab did not demonstrate objective response rate, PFS or OS benefit over single agent TKI in the CONTACT 03 [564, 660]. In addition, in the TiNivo trial, the combination of tivozanib plus nivolumab did not improve PFS, OS and objective response rate over single-agent tivozanib [565]. Moreover, prospective data on cabozantinib, tivozanib [661] and axitinib are available for patients progressing on immunotherapy, but these studies do not focus solely on the front-line setting, involve subset analyses and are too small for definitive conclusions [632, 662].

The use of mTOR inhibitors can be considered in VEGF-targeted therapy refractory disease but has been outperformed by other VEGF-targeted therapies in mRCC and belzutifan [628, 663]. Drug choice in the third-line setting, after immune checkpoint inhibitor combinations and subsequent VEGF-targeted therapy, is unknown. The Panel recommends a subsequent agent that is approved in VEGF-refractory disease, with the exception of rechallenge with immune checkpoint blockade. Cabozantinib is the only agent in VEGF-refractory disease with RCT data showing a survival advantage and should be used preferentially [664]. Axitinib has positive PFS data in VEGF-refractory disease. Other agents have outperformed both sorafenib and everolimus in VEGF-refractory disease and are therefore less attractive [663]. The lenvatinib plus everolimus combination appears superior to everolimus alone and has been granted EMA regulatory approval based on randomised phase II data. This is an alternative despite the availability of phase II data only [618]. As shown in a study which also included patients on ICIs, tivozanib provides PFS superiority over sorafenib in VEGF-refractory disease [665].

7.5.4.a.2 Summary of evidence and recommendations for immunotherapy in cc-mRCC

Summary of evidence	LE
Treatment-naïve patients	
PD-L1 expression is not currently used for patient selection.	2b
The combination of nivolumab and ipilimumab in treatment-naïve patients with cc-mRCC of IMDC, intermediate and poor risk demonstrated OS and objective response rate benefits compared to sunitinib alone.	1b
The updated OS data for IPI/NIVO in IMDC favourable-risk patients demonstrates the long-term benefit for this subgroup of patients.	2b
The combination of pembrolizumab plus axitinib, lenvatinib plus pembrolizumab and nivolumab plus cabozantinib in treatment-naïve patients with cc-mRCC demonstrated PFS, OS and objective response rate benefits compared to sunitinib in the ITT population.	1b
The combination of pembrolizumab plus axitinib, lenvatinib plus pembrolizumab and nivolumab plus cabozantinib in treatment-naïve patients with cc-mRCC in IMDC-favourable subgroups demonstrated PFS and objective response rate benefits compared to sunitinib, without OS improvement.	2b
The combination of axitinib plus avelumab did not demonstrate significant OS benefit and axitinib plus toripalimab did not demonstrate significant OS benefit yet, as did benmelstobart plus anlotinib.	1b

Triplet CABO-NIVO-IPI demonstrated a PFS benefit over NIVO-IPI.	1b
Sequencing systemic therapy	
Nivolumab leads to superior OS compared to everolimus in disease progression after one or two lines of VEGF-targeted therapy.	1b
Axitinib, cabozantinib or lenvatinib can be continued if immune-related adverse events result in cessation of axitinib plus pembrolizumab, cabozantinib plus nivolumab or lenvatinib plus pembrolizumab. Rechallenge with immunotherapy requires expert support.	4
Patients who do not receive the full four doses of ipilimumab due to toxicity should continue on single-agent nivolumab, where safe and feasible. Rechallenge with combination therapy requires expert support.	4
Treatment past progression can be justified but requires close scrutiny and the support of an expert multidisciplinary team.	1b
Nivolumab plus ipilimumab was associated with 46% grade III-IV toxicity and 1.5% treatment-related deaths. Tyrosine kinase inhibitor-based IO combination therapies were associated with grade III-V toxicity ranging between 61-72% and 1% of treatment-related deaths.	1b
In the CONTACT 3 study atezolizumab plus cabozantinib offered no benefit compared to cabozantinib alone in patients whose cancers have previously progressed on ICI therapy.	1b
Cabozantinib as a single agent has the most robust data after first line PD1 based combination therapy.	3

Recommendations	Strength rating
First line Treatment for metastatic clear cell RCC patients	
Offer nivolumab plus ipilimumab, pembrolizumab plus axitinib, lenvatinib plus pembrolizumab or nivolumab and cabozantinib to patients with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate- or poor-risk disease.	Strong
Offer pembrolizumab plus axitinib, lenvatinib plus pembrolizumab or nivolumab and cabozantinib or nivolumab plus ipilimumab or sunitinib or pazopanib for IMDC favourable risk disease.	Weak
Offer sunitinib or pazopanib to patients with any IMDC risk who cannot receive or tolerate immune checkpoint inhibition (ICI).	Strong
Offer cabozantinib to patients with IMDC intermediate- and poor-risk clear cell metastatic renal carcinoma (cc-mRCC) who cannot receive or tolerate ICI.	Stronga
Patients who do not receive the full four doses of ipilimumab due to toxicity should continue on single-agent nivolumab, where safe and feasible. Re-challenge with combination therapy requires expert support after discontinuation for toxicity.	Weak
Offer ICI combination therapy for advanced cc-mRCC with sarcomatoid features.	Strong
Intermittent single agent vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitors (TKI) can be offered in case of partial response or stable disease for more than six months.	Weak
Sequencing systemic therapy for metastatic clear cell RCC	
Do not offer ICI monotherapy or combination therapy to patients with recurrence during or within six months after adjuvant pembrolizumab.	Weak
Sequence systemic therapy in treating metastatic RCC.	Strong
Offer carbozantinib or other VEGF-TKI as second-line therapy to patients' refractory to nivolumab plus ipilimumab or axitinib plus pembrolizumab or cabozantinib plus nivolumab or lenvatinib plus pembrolizumab.	Strong
Sequencing the agent not used as second-line therapy (nivolumab or cabozantinib) for third-line therapy is recommended.	Weak
Offer nivolumab or cabozantinib for those patients who received first line VEGF targeted therapy alone.	Strong
Treatment past progression can be justified but requires close scrutiny and the support of an expert multidisciplinary team.	Weak
Do not re-challenge patients who stopped ICI due to toxicity without expert guidance and support from a multidisciplinary team.	Strong

Do not offer programmed death-ligand 1 (PD-L1) combination therapy after progression after ICI combination.	Weak
Offer belzutifan as an alternative to everolimus in patients previously treated with second- to fourth-line therapy for clear cell metastatic RCC.	Weak

^a While this is based on a randomised phase II trial, cabozantinib (weak) looks at least as good as sunitinib in this population. This justified the same recommendation under exceptional circumstances.

Figure 7.2: Updated EAU Guidelines recommendations for the first-line treatment of cc-mRCC

	Standard of Care	Alternative in patients who can not receive or tolerate immune checkpoint inhibitors
IMDC favourable risk	Nivolumab/Cabozantinib [1b] Pembrolizumab/Axitinib [1b] Pembrolizumab/Lenvatinib [1b] Nivolumab/Ipilimumab [2b] Sunitinib [2b] Pazopanib [2b]	
IMDC intermediate and poor risk	Nivolumab/Cabozantinib [1b] Pembrolizumab/Axitinib [1b] Pembrolizumab/Lenvatinib [1b] Nivolumab/Ipilimumab [1b]	Cabozantinib [2a] Sunitinib [1b] Pazopanib* [1b]

■ Diagnosis
 ■ Treatment
 ■ Follow-up

IMDC = The International Metastatic Renal Cell Carcinoma Database Consortium.

*pazopanib for intermediate-risk disease only.

[1b] = based on one randomised controlled phase III trial.

[2a] = based on a well-designed study without randomisation, or a subgroup analysis of a randomised controlled trial.

Figure 7.3: EAU Guidelines recommendations for later-line therapy

	Standard of Care	Alternative
Prior TKI+IO Prior IO+IO	Cabozantinib [3] Any VEGF-targeted therapy that has not been used previously in combination with IO [4]	
Prior TKI	Nivolumab [1b] Cabozantinib [1b]	Axitinib [2b]
Several prior lines including IO and TKI	Belzutifan [1b]	

■ Diagnosis
 ■ Treatment
 ■ Follow-up

IO = immunotherapy; TKI = tyrosine kinase inhibitors; VEGF = vascular endothelial growth factor.

[1b] = based on one randomised controlled phase III trial.

[2b] = subgroup analysis of a randomised controlled phase III trial.

[4] = expert opinion.

7.5.4.a.3 Renal tumours with sarcomatoid features

Subset analyses have shown improved results for PD-L1 inhibitors combined with CTLA4 or VEGF-targeted therapy in renal tumours with sarcomatoid features. Ipilimumab/nivolumab, axitinib/pembrolizumab and lenvatinib/pembrolizumab, avelumab/axitinib can all be recommended instead of VEGF-targeted therapy alone. These options have OS advantages over sunitinib, sunitinib plus gemcitabine and superseded VEGF-targeted therapy. Nivolumab/ipilimumab provided *post hoc* analysis demonstrating ORR of 61%, including 23% CR rate, PFS and OS benefit over sunitinib (HR 0.50 and OS HR 0.46 respectively with median OS 48.6 vs. 14.2 month) [666, 667].

Table 7.5: Subgroup analysis of first-line immune checkpoint inhibitor combinations in RCC patients with sarcomatoid histology

Cross trial comparison is not recommended and should be done with caution.

Study	N (ITT)	Therapy	N (sRCC)	PFS (mo.) Median (95% CI) HR	OS (mo.) Median (95% CI) HR	ORR (%) (95% CI)
KEYNOTE-426 NCT02853331 Median follow-up 12.8 months [645]	861	PEMBRO + AXI SUN	51	NR	NR	58.8
			54	8.4 HR: 0.54 (0.29-1.00)	NR HR: 0.58 (0.21-1.59)	31.5
JAVELIN 101 NCT02684006 [650, 668, 669]	886	AVE + AXI SUN	47	7.0 (5.3-13.8)	NA	46.8 (32.1-61.9)
			61	4.0 (2.7-5.7) HR: 0.57 (0.33-1.00)		21.3 (11.9-33.7)
IMmotion151 NCT02420821 Median follow-up 13 to 17 months [670]	915	ATEZO + BEV SUN	68	8.3 (5.4, 12.9)	21.7 (15.3, NE)	49 (36-1)
			74	5.3 (3.3, 6.7) HR: 0.52 (0.34-0.79)	15.4 (10.4, 19.5) HR: 0.64 (0.41, 1.01)	14 (7-23)
CheckMate214 NCT02231749 minimum follow-up of 60 months [666]	1096	NIVO + IPI SUN	IMDC Intermediate and poor risk	26.5 (7.2-NE) 5.5 (4.1-6.9) HR: 0.50 (0.32-0.80)	48.6 (25.2-NE) 14.2 (9.3-22.9) HR: 0.46 (0.29-0.71)	60.8 (48.8-72.0) 23.1 (13.5-35.2)
			74			
			75			
CheckMate 9ER NCT03141177 Median follow-up 16 months [671]	651	NIVO + CABO SUN	34	10.3 (5.6-19.4)	NR (22.8-NE)	55.9 (37.9-72.8)
			41	4.2 (2.6-8.3) HR: 0.42 (0.23-0.74)	19.7 (8.9-29.5) HR: 0.36 (0.17-0.79)	22.0 (10.6-37.6)
CLEAR NCT02811861 Median follow-up 27 months [576, 672]	712	PEMBRO + LEN SUN	28	11.1	NE	60.7
			21	5.5 HR: 0.39 (0.18-0.84)	NE HR: 0.91 (0.32-2.58)	23.8

ATEZO = atezolizumab; AVE = avelumab; AXI = axitinib; BEV = bevacizumab; CABO = cabozantinib; CI = confidence interval; HR = hazard ratio; IPI = ipilimumab; ITT = intention-to-treat; mo. = months; NA = not available; NE = non-estimable; NR = not reached; NIVO = nivolumab; OS = overall survival; PEMBRO = pembrolizumab; PFS = progression-free survival; sRCC = sarcomatoid RCC; SUN = sunitinib.

7.5.4.a.4 Summary of evidence and recommendation for targeted therapy in RCC with sarcomatoid features

Summary of evidence	LE
Immune checkpoint inhibitor combination therapy is superior to sunitinib in terms of PFS and OS in trial subset analysis of clear-cell RCC with sarcomatoid features.	2a

Recommendation	Strength rating
Offer immune checkpoint inhibitor combination therapy for advanced clear cell metastatic RCC with sarcomatoid features.	Weak

7.5.4.b Treatment of patients with non-clear-cell metastatic RCC (general considerations)

For the sake of historical purposes, the panel recognises the use of non-cc-mRCC but will, where possible, refer to the distinct subtype. This is a heterogenous group including papillary, chromophobe and other rare tumours with a widely differing tumour biology. Patients with non-cc-mRCC should therefore be referred to a clinical trial, where appropriate. While no phase III trials of patients with non-cc-mRCC have been reported, it is increasingly recognised to study specific subtypes which have a higher incidence than other non-ccRCC. As pRCC comprise the majority of tumours defined as non-ccRCC, most of the evidence is available for this subtype, either from trials specifically selecting pRCC or having included a high percentage.

7.5.4.b.1 Treatment of patients with papillary metastatic RCC

Small single-arm trials have been carried out for sunitinib and everolimus [673-677]. Both these agents have been widely prescribed in pRCC, but more recent data suggests cabozantinib and other combinations may be preferable [678-680]. For pRCC, new evidence is available from the SWOG PAMMET randomised phase II trial, which compared sunitinib to cabozantinib, crizotinib and savolitinib in 152 patients with papillary mRCC [678, 680]. Progression-free survival was longer in patients in the cabozantinib group (median 9.0 months, 95% CI: 6-12) than in the sunitinib group (5.6 months, CI: 3-7; HR for progression or death 0.60 [0.37-0.97, one-sided $p = 0.019$]). Response rate for cabozantinib was 23% versus 4% for sunitinib (two-sided $p = 0.010$). Savolitinib and crizotinib did not improve PFS compared with sunitinib. Grade III or IV adverse events occurred in 69% (31/45) of patients receiving sunitinib, 74% (32/43) of patients receiving cabozantinib, 37% (10/27) receiving crizotinib, and 39% (11/28) receiving savolitinib; one grade V thromboembolic event was recorded in the cabozantinib group. These results support adding cabozantinib as an option for patients with papillary mRCC based on superior PFS results compared to sunitinib.

In addition, savolitinib was investigated in the SAVOIR trial [679] as first-line treatment for MET-driven tumours defined as chromosome seven gain, MET amplification, MET kinase domain variations or hepatocyte growth factor amplification by DNA alteration analysis ($\pm 30\%$ of screened patients were MET-positive). In a limited patient group, savolitinib ($n = 27$) was compared with sunitinib ($n = 33$). The trial was stopped early, largely due to poor accrual. The efficacy data appeared to favour savolitinib (median PFS 7.0 months, 95% CI: 2.8 months-NR vs. 5.6 months, 95% CI: 4.1-6.9 months, PFS HR: 0.71, 95% CI: 0.37-1.36, OS HR: 0.51, 94% CI: 0.21-1.17, RR: 27% vs. 7%, for savolitinib and sunitinib, respectively). The median OS for savolitinib was not reported, Savolitinib was better tolerated compared with sunitinib with 42% grade > 3 adverse events compared to 81% with sunitinib. Trials are ongoing to confirm these findings. The results on these trials are required before recommendations can be made.

Evidence for TKI + IO based combination is derived from three phase II studies of lenvatinib plus pembrolizumab and cabozantinib and nivolumab. The Keynote-B61 phase II trial investigated lenvatinib plus pembrolizumab administered to non-ccRCC patients, of whom 93 patients (59%) with pRCC [681, 682]. The primary endpoint of objective response was 54% in pRCC patients, with a median follow-up of 14.9 months, providing some evidence of good efficacy for TKI + IO based combinations. With an extended follow-up of 22.8 months, the ORR was 50% with 8% patients showing complete response.

The cabozantinib and nivolumab study enrolled 40 patients with papillary and unclassified RCC with a response rate of 47% and a PFS of 13 (7-16) months [683]. In this trial, chromophobe RCC was excluded and the percentage of pRCC was 68%.

The CALYPSO trial investigated savolitinib and durvalumab in 41 patients with metastatic papillary carcinoma in first or second line plus. The confirmed RR was 29% and the primary endpoint of confirmed RR > 50% was missed. In MET-driven tumours confirmed RR was 53% with a PFS of 12 months while PFS was 4.9 months in the treated population [684]. Indirect comparisons suggest these data compare to an increased efficacy with those of VEGFR-TKI monotherapy alone.

Efficacy for pembrolizumab in the pRCC subset (118/165) was RR: 29%, PFS: 5.5 months (95% CI: 3.9-6.1 months) and OS: 31.5 months (95% CI: 25.5 months-NR), but these results are based on a single-arm phase II study [685]. Pembrolizumab can be considered in this setting due to the high unmet need, although the VEGFR TKI + IO combination may be preferable.

7.5.4.b.2 Summary of evidence and recommendations for systemic therapy in papillary metastatic RCC

Summary of evidence	LE
Cabozantinib improved PFS over sunitinib in patients with advanced pRCC without additional molecular testing.	2a
Lenvatinib plus pembrolizumab and cabozantinib plus nivolumab demonstrated response rates of 47-54% with median PFS rates > 12 months.	2a
Pembrolizumab resulted in long-term median OS in a single-arm study in the pRCC subgroup.	2a

Recommendations	Strength rating
Offer cabozantinib to patients with papillary RCC (pRCC) based on a positive randomised controlled trial.	Weak
Offer lenvatinib plus pembrolizumab or nivolumab plus cabozantinib to patients with pRCC based on small single-arm trials.	Weak

7.5.4.b.3 Treatment of patients with metastatic non-ccRCC other than papillary RCC

The evidence surrounding systemic therapy for non-ccRCC tumours other than pRCC is especially weak and has relied on subset analysis of randomised phase II trials as well as expanded access programmes. Results consistently demonstrate that the outcome of these patients with targeted therapy is poorer than for ccRCC. Treatment in non-cc-mRCC has focused on temsirolimus, everolimus, sorafenib, sunitinib, cabozantinib and pembrolizumab in the past [673, 683, 686-688]. Data from single-arm phase II trials of lenvatinib plus pembrolizumab demonstrated clinical efficacy of this IO+TKI combinations in different non-ccRCC subgroups [681, 682, 689]. Median ORR across the non-ccRCC subgroups of 158 patients was 49%, and twelve months PFS and OS rates were 63% and 82%.

The academic prospective randomised European trial SUNNIFORECAST in therapy-naïve patients with advanced non-ccRCC entities randomized nivolumab plus ipilimumab (157 pts) or SOC (152 pts.; 124 x TKI, 17 x TKI/IO, 2x others). The study included 178 patients (57.6%) with papillary RCC, 60 patients (19.4%) with chromophobe RCC, 12 patients (3.9%) with MIT RCC, nine (2.9%) patients with collecting duct carcinoma and 50 had other subtypes. Primary endpoint was 12 months OS rate. The trial demonstrated a 12-month OS rate for nivolumab/ipilimumab (Nivo/Ipi) of 86.9% (95% CI: 80.2%-91.5%) statistically significant superior to the SOC 76.8% (95% CI: 68.6%-83.1%) (p = 0.014). Median OS was 42.4 months for the Ipi/Nivo arm and 33.9 months for the SOC arm (HR:0.83, CI: 0.59-1.17); median PFS was 5.5m for Ipi/Nivo versus 5.7 months for SOC (HR: 0.99, 95% CI: 0.76-1.18). The ORR was respectively 32.8% versus 19.6%. [690].

7.5.4.b.4 Summary of evidence and recommendation for systemic therapy in chromophobe and unclassified RCC

Summary of evidence	LE
Both mTOR inhibitors and VEGF-targeted therapies have limited activity in non-cc-mRCC. There is a nonsignificant trend for improved oncological outcomes for sunitinib over everolimus and for cabozantinib over sunitinib.	2a

In non-cc-mRCC, sunitinib improved PFS over everolimus in an SR of phase II trials and subgroups of patients.	1a
In non-cc-mRCC lenvatinib plus pembrolizumab demonstrated clinical efficacy in various non-ccRCC subgroups.	2a
In non-cc-mRCC cabozantinib plus nivolumab demonstrated clinical efficacy in various non-ccRCC subgroups except for chromophobe RCC, which were excluded from the study.	2a
OS rate at 12 months was significantly higher with nivolumab plus ipilimumab than with SOC in non-ccRCC patients.	1b

Recommendations	Strength rating
Offer sunitinib to patients with other non-clear cell renal cell carcinoma (cc-RCC) subtypes than papillary RCC.	Weak
Offer lenvatinib plus pembrolizumab to patients with non-ccRCC subtypes.	Weak
Offer cabozantinib and nivolumab to patients with non-ccRCC subtypes other than chromophobe RCC.	weak
Offer nivolumab plus ipilimumab in patients with non-ccRCC.	Weak

7.5.4.c Treatment of patients with rare tumours

7.5.4.c.1 *SMARCB1*-deficient renal medullary carcinoma

SMARCB1-deficient renal medullary carcinoma (RMC) is one of the most aggressive RCCs [50, 691] and most patients ($\pm 67\%$) will present with metastatic disease [45, 50] and three-year CSM-free survival of 35.8 % [692]. Even patients who present with seemingly localised disease may develop macro metastases shortly thereafter, often within a few weeks.

Despite treatment, median OS is thirteen months in the most recent series [57]. Due to the infiltrative nature and medullary epicentre of RMC, RN is favoured over PN even in very early-stage disease. Retrospective data indicate that nephrectomy in localised disease results in superior OS (16.4 vs. 7 months) compared with systemic chemotherapy alone, but longer survival was noted in patients who achieved an objective response to first-line chemotherapy [57, 693]. There is currently no established role for distant metastasectomy or nephrectomy in the presence of metastases.

Palliative radiation therapy is an option and may achieve regression in the targeted areas but will not prevent progression outside the radiation field [694, 695]. Renal medullary carcinoma is refractory to monotherapies with targeted anti-angiogenic regimens including TKIs and mTOR inhibitors [57, 198]. The mainstay systemic treatments for RMC are cytotoxic combination regimens that produce partial or complete responses in $\pm 29\%$ of patients [198]. There are no prospective comparisons between different chemotherapy regimens, but most published series used various combinations of platinum agents, taxanes, gemcitabine and/or anthracyclines [57, 58]. High-dose-intensity combination of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) has also shown efficacy against RMC [696], although a retrospective comparison did not show superiority of MVAC over cisplatin, paclitaxel and gemcitabine [58]. Single-agent anti-PD-1 immune checkpoint therapy has produced responses in a few case reports, although, as yet, insufficient data are available to determine the response rate to this approach [694, 695]. Whenever possible, patients should be enrolled in clinical trials of novel therapeutic approaches, particularly after failing first-line cytotoxic chemotherapy.

In a phase II basket trial, no evidence of clinical activity was showed for pembrolizumab in patients with RMC, irrespective of PD-L1 or TIL (tumour-infiltrating lymphocyte) levels [697].

7.5.4.c.2 *Other rare tumours*

Knowledge about the systemic treatment of rare tumours is very limited, mostly based on a set of case reports. For some facts about therapy of renal tumours see Section 3.5 and Table 3.2.

Metastatic collecting duct carcinoma (CDC) has the lowest mortality in concomitant use of cytoreductive nephrectomy and systemic therapy [698]. Systemic therapy was investigated in BONSAI phase II trial. Nivolumab showed clinical benefit in 60 % as a second-line therapy after cabozantinib failure [699].

With Anaplastic lymphoma kinase (ALK)-rearranged RCC, there are some reports of the efficacy of ALK inhibitors, e.g. alectinib, crizotinib and entrectinib [700, 701]. ELOC (formerly TCEB1)-mutated RCC does not exhibit clinically aggressive behaviour [700].

No data is available that indicates a recommendation for one treatment over another.

7.6 Locally recurrent RCC after treatment of localised disease

Most studies reporting on local recurrent disease after removal of the kidney have not considered the true definition of local recurrence after RN, PN and thermal ablation, which are: local recurrence in the tumour-bearing kidney, tumour growth exclusively confined to the true renal fossa, recurrences within the renal vein, the ipsilateral adrenal gland or the regional LNs. In the existing literature the topic is weakly investigated and often regarded as local recurrent disease.

RECUR is a protocol-based multicentre European registry capturing patient and tumour characteristics, risk of recurrence (RoR), recurrence patterns and survival of those curatively treated for nonmetastatic RCC from 2006 to 2011. Per-protocol resectable disease (RD) recurrence was defined as: (1) solitary metastases, (2) oligometastases, or (3) renal fossa or renal recurrence after radical or partial nephrectomy, respectively. Within the RECUR consortium, the authors assessed the effectiveness of local treatment of resectable recurrent RCC after surgical treatment of the primary kidney tumour [702]. Of 3,039 patients with localised RCC treated with curative intent, 505 presented with recurrence, including 176 with RD. Of these patients, 97 underwent local treatment of recurrence (LTR) and 79 no LTR. The median OS was 70.3 mos. versus 27.4 in the LTR versus no-LTR group ($p < 0.001$). The LTR effect on survival was consistent across risk groups. OS HR for high, intermediate and low risks were 0.36 (0.2-0.64), 0.27 (0.11-0.65) and 0.26 (0.08-0.8), respectively. Local treatment of recurrence was associated with longer survival across groups with a risk of recurrence [702]

7.6.1 Locally recurrent RCC after nephron-sparing approaches

Locally recurrent disease can affect the tumour-bearing kidney after PN or focal ablative therapy such as RFA and cryotherapy. Local relapse may be due to the incomplete resection of the primary tumour, in a minority of the cases to the local spread of the tumour by microvascular embolisation, or true multifocality [230, 703].

The prognosis of recurrent disease not due to multifocality is poor, despite salvage nephrectomy [703]. Recurrent tumour growth in the regional LNs or ipsilateral adrenal gland may reflect metachronous metastatic spread (see Section 7.3). After treatment solely for localised disease, systemic progression is common [704, 705].

There are reports that minimally invasive approaches (laparoscopic and robotic) show atypical reoccurrence (e.g. peritoneal, port site, etc.) [706, 707]. Therefore, specific manoeuvres to prevent tumour-cell contamination should be implemented. Those include the use of extraction bags, minimising trocar CO₂ leakage, avoiding tumour morcellation, cleansing of instruments before reuse, changing of gloves after tumour extraction, avoiding violation of the tumour's natural capsule, and cleansing of port sites [706, 707].

A retrospective study relying on inverse probability of treatment weighting (IPTW) and comparing percutaneous ablation and surgical resection for an isolated local recurrence (LR) following PN [708]. A total of 81 patients with an isolated LR were included and treated with either ablation (30 RFA and 12 cryoablation) or surgical resection (8 PN and 31 RN). Percutaneous ablation was associated with a significantly lower risk of postoperative complications (5% with PCA vs. 41% with PN; OR: 0.22; $p = 0.006$) and a smaller change in estimated GFR. There were no significant differences in the risk of disease recurrence (HR: 0.72; $p = 0.61$), new LR (HR: 1.51; $p = 0.59$) and distant metastasis (HR: 0.19; $p = 0.09$) [708].

Following thermal ablation or cryotherapy generally intrarenal, but also perirenal, recurrences have been reported in up to 14% of cases [709]. Whereas repeat ablation is still recommended as the preferred therapeutic option after treatment failure, the most effective salvage procedure as an alternative to complete nephrectomy has not yet been defined.

7.6.2 Locally recurrent RCC after radical nephrectomy

Isolated local fossa recurrence is rare and occurs in about 1-3% after radical nephrectomy. Recurrence is more common in pT3-4 than pT1-2 and grade III-IV disease. Most patients with local recurrence of RCC are diagnosed by either CT/MRI scans as part of the postoperative follow-up [710]. The median time to recurrence after RN was 19-36 months in isolated local recurrence or 14.5 months in the group, including metastatic cases as well [710-712].

Isolated local recurrence is associated with worse survival [230, 713]. Based on retrospective and noncomparative data only, several approaches, such as surgical excision, radiotherapy, systemic treatment and observation, have been suggested for the treatment of isolated local recurrence [714-716]. Among these alternatives, surgical resection with negative margins remains the only therapeutic option shown to be associated with improved survival [713]. Open surgery has been successfully reported in studies [717, 718]. One of the largest series including 2,945 patients treated with RN reported on 54 patients with recurrent disease localised in the renal fossa, the ipsilateral adrenal gland or the regional LNs as sole metastatic sites [714]. Another series identified 33 patients with isolated local recurrences and 30 local recurrences with synchronous metastases within a cohort of 2,502 surgically treated patients, confirming the efficacy of locally directed treatment versus conservative approaches (observation, systemic therapy) [719].

The five-year OS with isolated local recurrence was 60% (95% CI: 0.44-0.73) and ten-year OS was 32% (95% CI: 0.15-0.51). Overall survival differed significantly by the time period between primary surgery and occurrence of recurrence (< 2 years vs. > 2 years: ten-year OS rate 31% (95% CI: 10.2-55.0) versus 45% (95% CI: 21.5-65.8; HR: 0.26; $p = 0.0034$) [710]. Metastatic progression was observed in 60 patients (58.8%) after surgery [711]. Patient survival can be linked to the type of treatment received, as shown in a cohort of 96 patients, 45.8% were metastatic at the time of recurrence; three-year CSS rates after local recurrence were $92.3\% \pm 7.4\%$ for those who were treated with surgery and systemic therapy, $63.2\% \pm 13.2\%$ for those who only underwent surgery, $22.7\% \pm 0.9\%$ for those who only received systemic therapy and $20.5\% \pm 10.4\%$ for those who received no treatment ($p < 0.001$) [712]. A retrospective multicentre study of patients with local retroperitoneal recurrence after RN with or without surgical treatment from 2008 to 2020. Retroperitoneal recurrence of RCC was defined as an ipsilateral recurrence confined to the renal fossa, adrenal gland or retroperitoneal lymph nodes after prior nephrectomy, which was diagnosed by cross-sectional imaging. Treatment with retroperitoneal recurrence surgery resulted in significantly longer CSS than targeted therapy alone ($P < 0.001$). In multivariable analysis, high Fuhrman grade, size of retroperitoneal recurrence tumour, mixed type of retroperitoneal recurrence, multiple recurrence lesions and the absence of retroperitoneal recurrence surgery were associated with a significantly increased risk of death from RCC, suggesting that an aggressive surgical resection of retroperitoneal recurrence after RN represents a potentially curative treatment for selected RCC patients without synchronous metastases, resulting in significantly longer CSS than targeted therapy alone [720].

Minimally invasive approaches, including standard and hand-assisted laparoscopic and robotic approaches for the resection of isolated RCC recurrences, have been reported. A large surgical cohort published of robotic surgery in this setting ($n = 35$) providing a standardisation of the nomenclature, describing the surgical technique for each scenario and reporting on complications, renal function and oncologic outcomes [721]. Ablative therapies, including cryoablation, radiofrequency and microwave ablation, may also have a role in managing recurrent RCC patients, but further validation will be needed [722, 723].

In summary, the limited available evidence suggests that, in selected patients, surgical removal of locally recurrent disease with negative margins can induce durable tumour control, although with expected high risk of complications. A retrospective review on 51 planned repeat PNs in 47 patients with locally recurrent disease, reporting a total of 40 peri-operative complications, with temporary urinary extravasation being the most prevalent [724]. Since local recurrences develop early, with a median time interval of 10-20 months after treatment of the primary tumour [725], a guideline-adapted follow-up scheme for early detection is recommended (see Chapter 9, 'Follow-up'), even though benefit in terms of cancer control has not yet been demonstrated [726].

Adverse prognostic parameters are a short time interval since treatment of the primary tumour (< 3-12 months) [727], sarcomatoid differentiation of the recurrent lesion and incomplete surgical resection [714]. If complete surgical removal is unlikely to be performed or when significant comorbidities are present (especially when combined with poor prognostic tumour features), palliative therapeutic approaches including radiation therapy aimed at symptom control and prevention of local complications should be considered (see Sections 7.3 and 7.4). Following metastasectomy of local recurrence after nephrectomy, adjuvant therapy can be considered (see Section 7.3.5, 'Neoadjuvant and adjuvant therapy'). Local recurrence combined with other metastases is treated as a metastatic RCC.

7.6.3 **Summary of evidence and recommendation on locally recurrent RCC after treatment of localised disease**

Summary of evidence	LE
Isolated recurrence after nephron-sparing procedures or nephrectomy is a rare entity (< 2%).	3
Surgical or percutaneous treatment of local recurrences in absence of systemic progression should be considered, especially in the absence of adverse prognostic parameters and favourable performance status.	3
The most optimal modality of local treatment for locally recurrent RCC after nephron sparing procedures or nephrectomy is not defined.	3

Recommendation	Strength rating
Offer local treatment of locally-recurrent disease when technically possible and after balancing adverse prognostic features, comorbidities and life expectancy.	Weak

8. HEREDITARY AND SYNDROME SPECIFIC RCC

Five to eight percent of RCCs are hereditary, although this proportion could be underestimated due to the limitations of available studies. To date, there are more than ten hereditary RCC syndromes associated with specific germline mutations, RCC histology and comorbidities. Hereditary RCC syndromes are often suggested by family history, age of onset and presence of other lesions typical for the respective syndromes. Median age for hereditary RCC is 37 years; 70% of hereditary RCC tumours are found in the lowest decile (age 46 years or younger) of all RCC tumours [197].

Hereditary kidney tumours are found in the following entities: VHL syndrome; hereditary papillary RCC (HPRCC); Birt-Hogg-Dubé syndrome; Fumarate hydratase-deficient RCC (FHD-RCC), previously referred to as hereditary leiomyomatosis and RCC (HLRCC); tuberous sclerosis complex; Hereditary SDH deficient paraganglioma/pheochromocytoma (HPP) syndrome; Phosphatase and tensin homolog (PTEN) hamartoma syndrome (PHTS); and BRCA-1 associated protein 1 (BAP1) tumour predisposition syndrome).

RCC can also be associated with the following syndromes: Hyperparathyroidism-jaw tumour (HJT) syndrome, Chromosome 3 translocation (Cr3T) syndrome, and MITF-related melanoma and renal cell carcinoma predisposition syndrome. Renal medullary carcinoma can be included because of its association with hereditary haemoglobinopathies [74, 728-731].

8.1 Microphthalmia-associated transcription factors (MiTF) associated translocation tumours

Although not hereditary, somatic fusion translocations of *TFE3* and *TFEB* may affect 15% of patients with RCC younger than 45 years and 20-45% of children and young adults diagnosed with RCC [732].

Table 8.1: Syndrome-specific RCC histotypes and extrarenal organ involvement patterns [206, 733, 734]

Syndrome (Inheritance, estimated prevalence)	Gene	Lifetime RCC risk	Histology	Selected associated extrarenal clinical features
Hereditary RCC				
VHL syndrome (autosomal dominant; estimated prevalence: 1-9 / 100,000)	VHL (3p25.3)	30-40%	ccRCC	Retinal/CNS haemangioblastomas Pancreatic cysts and neuroendocrine tumours Endolymphatic sac tumour Pheochromocytoma Epididymal cystoadenomas Others

Hereditary papillary RCC (HPRCC) (autosomal dominant; prevalence is unknown; estimated at 1/500,000)	MET (7q31)	100%	pRCC	None
Birt-Hogg-Dubé (BHD) syndrome (autosomal dominant; estimated prevalence: 1-9 / 1,000,000)	FLCN (17p11.2)	30%	Hybrid oncocytic; chRCC; oncocytoma	Fibrofolliculomas and other skin findings Renal and lung cysts Parotid gland oncocytomas Pneumothorax
Fumarate hydratase (FH)-deficient RCC (FH-RCC) (autosomal dominant; prevalence is unknown)	FH (1p42.1)	15-32%	FH-deficient RCC	Cutaneous leiomyomas Uterine leiomyomas Leiomyosarcomas Adrenal nodules
Tuberous sclerosis complex (TSC) (autosomal dominant; estimated prevalence: 1-9 / 100,000)	TSC1/TSC2 (9q34/16p13)	<5%	ccRCC; pRCC, chRCC	Renal AMLs Angiomyofibromas and other dermatological lesions Cortical dysplasia Subependymal giant cell astrocytoma Lymphangioliomyomatosis Seizures Others
Hereditary SDH deficient paraganglioma/pheochromocytoma (HPP) syndrome (autosomal dominant; estimated prevalence: 1-9 / 1,000,000)	SDHB/C/D (1p36/1q23/11q23)	<10%	ccRCC, unclassified	Pheocromocytoma Paraganglioma GI stromal tumour
Phosphatase and tensin homolog (PTEN) hamartoma syndrome (PHTS) (autosomal dominant; prevalence is unknown)	PTEN (10q23)	10-15%	ccRCC, pRCC, chRCC	Macrocephaly Breast cancer and fibrocystic change Thyroid cancer Endometrial cancer Prostate cancer Colonic polyps Facial trichilemmomas
BRCA-1 associated protein 1 (BAP1) tumour predisposition syndrome (autosomal dominant; prevalence is unknown)	BAP-1 (3p21)	<15%	ccRCC	Uveal and cutaneous melanoma Malignant pleural mesothelioma Other cancers (cholangiocarcinoma, basal cell carcinoma, meningioma)
Syndrome-related RCC				
Hyperparathyroidism-jaw tumour (HJT) syndrome (estimated prevalence <1/1,000,000)	CDC73 (1q31.2)	<10%	RCC and Wilms	Hyperparathyroidism Parathyroid cancer Jaw fibroma Uterine cancer
Chromosome 3 translocation (Cr3T) syndrome (estimated prevalence <1/1000 000)	- Trans-locations 3:6; 3:8; 3:11	30%	ccRCC	None

Renal medullary carcinoma (prevalence is unknown)	-	-	SMARCB1-deficient renal medullary carcinoma	Hereditary haemoglobinopathies
MITF-related melanoma and renal cell carcinoma predisposition syndrome (estimated prevalence <1/1000 000)	MITF (3p14)	<10%	MitF family translocation RCC	Pheocromocitoma Melanoma Pancreatic cancer

Data on estimated prevalence/incidence are based on <https://www.orpha.net>.

Published recommendations for the selection of germline genetic testing panels in patients with cancer, including RCC [735] stated that germline genetic testing should be distinguished from biomarker testing (i.e. tumour genomic profiling). To establish whether gene variants identified in a tumour are germline, germline genetic testing must be performed. With advancements in next-generation sequencing technology, genetic panels now encompass an expanding list of available genes. Specific recommendations have been set for the following domains: a) family history collection; b) germline multigene panel testing; c) genes to be included in multigene panels; and d) germline testing in association with somatic genetic tumour testing [735]. For RCC, the genes recommended for testing and inclusion in multigene panels are: BAP1, FH, FLCN, MET, SDHA, SDHAF2, SDHB, SDHC, SDHD PTEN, VHL (more strongly recommended) and TSC1/TSC2 (less strongly recommended).

8.2 Management of hereditary and syndrome-specific RCC

Hereditary RCC often presents with multifocal, *de-novo* recurring and bilateral tumours, which requires individualised management.

Patients with hereditary kidney cancer syndromes may require repeated surgical intervention [736, 737]. In most hereditary RCCs, nephron-sparing approaches are recommended due to risk of CKD [738]. To avoid multiple repetitive partial nephrectomies, thermal ablation can be considered in the treatment paradigm. A registry based retrospective analysis of 53 patients with inherited RCC syndromes evaluated percutaneous cryoablation for primary mean 2.46cm tumours, demonstrating within mean follow-up of 30.4 months, estimated five-year local recurrence-free survival of 96% (95% CI: 75-99), metastases free survival 96.4% (95% CI: 77-99%), CSS 90.9% (95% CI: 51-99%) and OS 90.9% (95% CI: 51-99%). Complication rate was 1.7% and 7.4% had more than 25% reduction in kidney function [739].

The exceptions to nephron-sparing approaches are FHD-RCC and high-grade SDH syndromes for which immediate surgical intervention is recommended due to the aggressive nature of these tumours. For other hereditary syndromes such as VHL, surveillance is recommended until the largest tumour reaches 3cm in diameter - this to limit the number of repeat interventions [740, 741]. Active surveillance for VHL and other nonaggressive hereditary tumours, should, in individual patients, follow the size, growth rate and location of the tumours, rather than applying a standardised follow-up interval. Regular screening for both renal and extrarenal lesions should follow international guidelines for these syndromes [741]. Multidisciplinary and co-ordinated care should be offered, where appropriate [742]. In FHD-RCC, renal screening in relatives has shown benefit in detecting early-stage RCCs [54], with HLRCCs appearing to have unique molecular profiles.

In the metastatic setting, systemic therapeutic options for fumarate hydratase-deficient RCC with high metastatic potential include ICI monotherapies, which offer a better disease control rate than TKI monotherapies. In a phase II trial, ORR of 51 % of combination of erlotinib and bevacizumab was achieved [700]. Another trial expressed a favourable response to ICI/TKI combinational therapy compared to bevacizumab plus erlotinib [100].

Succinate dehydrogenase (SDH)-deficient RCC has a low risk of metastasis (12 %) with exception of high-grade with risk 70 %. Due to rarity of disease, no evidence for systemic therapy [700].

8.2.1 Von Hippel-Lindau-disease-associated RCC

Patients with VHL disease often develop RCC and tumours and cysts in other organs, including adrenal glands, CNS, retinal haemangioblastomas and pancreas, and commonly undergo several surgical resections in their lifetime. In VHL disease, belzutifan, a HIF-2 α inhibitor, has been approved by the United States Food and Drug Administration [743] for the treatment of ccRCC and other neoplasms associated with VHL for the treatment of tumours that do not require immediate surgery. Approval was based on the results from a phase II, open-label,

single-arm trial in 61 patients with tumours not larger than 3cm [744]. Belzutifan induced partial responses with an RCC ORR of 67%, and complete response rate of 11% after 41.3 months' treatment. In total, 18% of patients reported > grade III adverse events, and eight patients (13.5%) discontinued the treatment. In the treatment with pazopanib for VHL only, 52% continued with the treatment after 24 weeks [745]. A longer follow-up at 37.8 months, ORR for RCC was increased to 64%, with a median time to response of 11.1 months (range, 2.7 to 30.5). Median duration of response per Kaplan-Meier estimate was not reached (range 5.4+ to 35.8+ months). Thirty-four of 39 patients with a confirmed response (87%) remain in response as of the data cut-off date (September 2022) [744].

With favourable efficacy results and with relatively low-grade side effects, belzutifan seems to be a valuable contribution to the treatment of patients with the VHL disease. Recent data from the largest retrospective VHL cohort under active surveillance showed that 63% experienced disease progression (without systemic treatment) and surgical intervention was common: 76% required one renal surgery, and 44% multiple procedures, resulting in chronic kidney disease in 41% of them [738]. The EMA has conditional approval for belzutifan for VHL disease.

8.2.2 **TFE3-rearranged RCC**

TFE3-rearranged RCC showed objective response rate 25% with ICI and 0 % with TKI and more prolonged OS (62.4 months with ICI vs. 10.3 with TKI). Cabozantinib may be an exception with 16.6% objective response. A future role of ICI-TKI combination (such as nivolumab plus cabozantinib) and cabozantinib plus belzutifan has been discussed [700].

8.2.3 **TFEB-altered RCC**

TFEB-rearranged RCC: There is a general lack of information regarding the response to modern systemic therapy. A combination of ICI and mTOR inhibitors has been discussed. TFEB-amplified RCC (which occurs in elderly patients and displays more aggressive behaviour compared to TFEB-rearranged RCC) can be treated with VEGFR targeting agents or with a VEGFR-TKI combination [700].

8.2.4 **Combined therapy for TFE3- and TFEB-altered RCCs**

Some studies combine therapy TFE3- and TFEB-altered RCCs (due to the former grouping of both tumours to MiT family translocation RCCs). Two retrospective studies exhibit efficacy of ICI or ICI-TKI combination [746, 747]. Other studies provided evidence of the activity of cabozantinib in MiT TRCC, with more durable responses than those observed historically with other VEGFR-TKIs or ICIs [748].

8.2.5 **Summary of evidence and recommendation for hereditary and syndrome-specific RCC**

Summary of evidence	LE
Hereditary RCC syndromes are often suggested by family history, age of onset and presence of other lesions typical for the respective syndromes.	3
Hereditary RCC tumours are predominantly found in the lowest decile, with 70% occurring in individuals aged 46 years or younger.	3
To establish whether gene variants identified in a tumour are germline, germline genetic testing must be performed.	3
In VHL and non-FHD-RCC, tumours can be observed with a diameter of up to 3cm.	3
Belzutifan leads to an ORR of VHL lesions of 67% at 41.3 months.	2
There is currently no approved standard first-line treatment for non-VHL hereditary or syndrome-specific RCC.	3

Recommendation	Strength rating
Suspect hereditary or syndrome-specific RCC in patients with positive family history, young onset and bilateral or multiple tumours.	Strong
Offer germline testing to patients < 46 years.	Weak
Offer surveillance in von Hippel-Lindau (VHL) until the largest tumour reaches 3cm in diameter.	Strong
Offer belzutifan to patients with VHL-related renal and other tumours who are not surgical candidates.	Weak

9. FOLLOW-UP IN RCC

9.1 Introduction

Surveillance after treatment for RCC allows the urologist to monitor or identify the following:

- postoperative complications;
- renal function;
- local recurrence;
- recurrence in the contralateral kidney;
- distant metastases; and
- cardiovascular events.

There is no consensus on follow-up strategies after RCC treatment, with limited evidence suggesting that more frequent postoperative imaging intervals do not provide any improvement for early detection of recurrence that would lead to improved survival [726]. As such, intensive radiological surveillance may not be necessary for all patients. Follow-up is also important to assess functional outcomes and to limit long-term sequelae, such as renal function impairment, ESRD and cardiovascular events [749]. Referral of patients at risk of CKD/renal function deterioration after treatment (surgery/ablation) to a nephrologist may minimise the risk of worsening of renal function; support oncologists in managing treatment-related renal adverse events; assist in the choice of optimal follow-up radiological procedures (mainly deciding if, when, and how to use CT contrast media); and deal with oncological patients on dialysis or with kidney transplant (including if and when to start dialysis, or whether to allow a kidney transplant) (expert opinion) [252]. Patients with pre-existing or treatment-induced CKD (e.g. patients with new baseline estimated GFR equal to or less than 45ml/min. [750]), and/or known comorbidities potentially affecting renal function could benefit the most from specialist nephrological assessment during follow-up (expert opinion).

Currently, the key question is whether any recurrence detection during follow-up and subsequent treatment will lead to any meaningful change in survival outcome for these patients.

In contrast to high-grade and/or locally advanced disease, the outcome after surgery for T1a low-grade tumours is almost always excellent. It is therefore reasonable to stratify follow-up, taking into account the risk of each different RCC to develop a local or distant recurrence. Although there is no randomised evidence, large studies have examined prognostic factors with long follow-up [220, 751, 752] (LE: 4). One study has shown a survival benefit in patients who were followed within a structured surveillance protocol versus patients who were not [753]; patients undergoing follow-up appear to have a longer OS when compared to patients not undergoing routine follow-up [753].

Moreover, an individualised and risk-based approach to RCC follow-up has recently been proposed [754]. The authors used competing risk models, incorporating patient age, pathologic stage, relapse location and comorbidities, to calculate when the risk of non-RCC death exceeds the risk of RCC recurrence [755]. For patients with low-stage disease but with a Charlson comorbidity index > 2, the risk of non-RCC death exceeded that of abdominal recurrence risk already one month after surgery, regardless of patient age. As for psychological factors, an SR including fifteen studies revealed that psychological distress (defined as anxiety, depression or psychological distress at any time during treatment or follow-up) is also prevalent among RCC patients, reaching up to 77% in non-metastatic cases [756].

The RECUR consortium, initiated by this Panel, collects similar data with the aim to provide comparators for guideline recommendations. Published RECUR data support a risk-based approach; more specifically, a competing-risk analysis showed that, for low-risk patients, the risk of non-RCC-related death exceeded the risk of RCC recurrence shortly after the initial surgery. For intermediate-risk patients, the corresponding time point was reached approximately four to five years after surgery. In high-risk patients, the risk of RCC recurrence continuously exceeded the risk of non-RCC-related death [757]. In the near future, genetic profiling may refine the existing prognostic scores and external validation in datasets from adjuvant trials have been promising in improving stratification of patient's risk of recurrence [757, 758].

Recurrence after PN is rare, but early diagnosis is relevant, as the most effective treatment is surgery [717, 759]. Recurrence in the contralateral kidney is rare (1-2%) and can occur late (median 5-6 years) [760] (LE: 3). Follow-up can identify local recurrences or metastases at an early stage. At recurrence, extensive metastatic tumour growth can hinder the opportunity for surgical resection. In addition, early diagnosis of tumour recurrence may enhance the efficacy of systemic treatment if the tumour burden is low.

9.2 Which imaging investigations for which patients, and when?

- The sensitivity of chest radiography and US for detection of small RCC metastases is poor. The sensitivity of chest radiography is significantly lower than CT-scans, as proven in comparative studies including histological evaluation [761-763]. Therefore, follow-up for recurrence detection with chest radiography and US are less sensitive [764].
- Positron-emission tomography and PET-CT as well as bone scintigraphy should not be used routinely in RCC follow-up, due to their limited specificity and sensitivity [128, 144].
- Surveillance should also include evaluation of renal function and cardiovascular risk factors [749].
- Outside the scope of regular follow-up imaging of the chest and abdomen, targeted imaging should be considered in patients with organ-specific symptoms, e.g. CT or MRI imaging of the brain in patients experiencing neurological symptoms [765].

Controversy exists on the optimal duration of follow-up. Some authors argue that follow-up with imaging is not cost-effective after five years. However, late metastases are more likely to be solitary and justify more aggressive therapy with curative intent. In addition, patients with tumours that develop in the contralateral kidney can be treated with NSS if the tumours are detected early. Several authors have designed scoring systems and nomograms to quantify the likelihood of patients to develop tumour recurrences, metastases and subsequent death [282, 284, 766, 767]. These models, the most utilised of which are summarised in Chapter 6, 'Prognosis', have been compared and validated [768] (LE: 2). Using prognostic variables, several stage-based follow-up regimens have been proposed, although, none propose follow-up strategies after ablative therapies [769, 770]. A postoperative nomogram is available to estimate the likelihood of freedom from recurrence at five years [279]. A preoperative prognostic model based on age, symptoms and TNM staging has been published and validated [771] (LE: 3).

A follow-up algorithm for monitoring patients after treatment for RCC is needed, recognising not only the patient's risk of recurrence profile, but also the efficacy of the treatment given (Table 8.1). These prognostic systems can be used to adapt the follow-up schedule according to predicted risk of recurrence. Ancillary to the above, life-expectancy calculations based on comorbidity and age at diagnosis may be useful in counselling patients on duration of follow-up [772].

An SR evaluated frequency and duration of follow-up. Most studies employ a higher imaging frequency during FU after treatment for non-metastatic RCC than recommended by the 2022 EAU Guidelines. Survival and recurrence rates suggest that more frequent imaging than recommended by the EAU may not be advantageous, although high-quality evidence is needed to further improve guidelines [773].

Referral of patients at risk of CKD or with renal function deterioration after treatment to a nephrologist may minimise the risk of worsening of renal function, support oncologists in managing treatment-related renal adverse events, and assist in the choice of optimal follow-up radiological procedures (expert opinion) [252].

Patients with pre-existing or treatment-induced CKD (e.g. patients with new baseline estimated GFR < 45ml/min. [252]) and/or those with known comorbidities potentially affecting renal function could benefit the most from specialist nephrological assessment during follow-up (expert opinion).

Table 9.1: Proposed follow-up schedule following treatment for localised RCC, taking into account patient risk of recurrence profile and treatment efficacy (based on expert opinion [LE: 4])

Risk profile (*)	Oncological follow-up after date of surgery								
	3 mos.	6 mos.	12 mos.	18 mos.	24 mos.	30 mos.	36 mos.	> 3 yr (**) (***)	> 5 yr (**) (***)
Low risk of recurrence For ccRCC: Leibovich Score 0-2 For non-ccRCC: pT1a-T1b pNx-0 M0 and histological grade 1 or 2.	-	CT	-	CT	-	CT	-	CT once every two yrs	-

Intermediate risk of recurrence For ccRCC: Leibovich Score 3-5 For non-ccRCC: pT1b pNx-0 and/or histological grade 3 or 4	-	CT	CT	-	CT	-	CT	CT once yr	CT once every two yrs
High risk of recurrence For ccRCC: Leibovich Score ≥ 6 For non-ccRCC: pT2-pT4 with any histological grade or pT any, pN1 cM0 with any histological grade	CT	CT	CT	CT	CT	-	CT	CT once yr	CT once every two yrs

ccRCC = clear cell renal cell carcinoma; CT = computed tomography; mos. = months; non-ccRCC = non clear cell renal cell carcinoma; yrs. = years.

The table above provides recommendations on follow-up strategies for low, intermediate and high risk of recurrence in patients curatively treated for localised RCC either with NSS or RN. Computed tomography in the table refers to imaging of both chest and abdomen. Alternatively, MRI of the abdomen can be performed instead of a CT-scan.

- * Risk of recurrence profiles should be based on validated prognostic models. The EAU RCC Guidelines Panel recommends the 2003 Leibovich model for ccRCC [282]. However, physicians can use other validated models, based on their own national/regional recommendations. In a similar fashion, for curatively treated localised non-ccRCC, the Panel recommends the use of the University of California Los Angeles integrated staging system (UISS) to determine risk of recurrence [283].
- ** For all risk of recurrence profiles, functional follow-up - mainly monitoring renal and cardiovascular function - may continue according to specific clinical needs irrespective of the length of the oncological follow-up.
- *** For low-risk profiles at > 3 years and intermediate-risk at > 5 years of follow-up, respectively, consider counselling patients about terminating oncological follow-up imaging based on assessment of comorbidities, age, life expectancy and/or patient wishes.

9.3 Summary of evidence and recommendations for surveillance following RN or PN or ablative therapies in RCC

Summary of evidence	LE
Functional follow-up after curative treatment for RCC is useful to prevent renal and cardiovascular deterioration.	3
Oncological follow-up can detect local recurrence or metastatic disease while the patient may still be surgically curable.	4
After NSS, there is an increased risk of recurrence for larger (> 7cm) tumours, or when there is a PSM.	3
Patients undergoing follow-up have a better OS than patients not undergoing follow-up.	3
Prognostic models provide stratification of RCC risk of recurrence based on TNM and histological features.	3
In competing-risk models, risk of non-RCC-related death exceeds that of RCC recurrence or related death in low-risk patients.	3
Life expectancy estimation is feasible and may support counselling of patients on duration of follow-up.	4
Overall survival is reduced in metastatic RCC patients with symptoms of depression and distress.	2a
Referral to nephrological evaluation of patients with baseline or treatment-induced CKD and/or with known risk factors for renal function deterioration may minimise the risk of worsening of renal function, support management decisions, and tailor follow-up schedules.	4

Recommendations	Strength rating
Base follow-up after treatment of localised RCC on the risk of recurrence.	Strong
Base risk of recurrence stratification on validated subtype-specific models such as the Leibovich Score for clear cell renal cell carcinoma (ccRCC), or the University of California Los Angeles integrated staging system for non-ccRCC.	Weak
Intensify follow-up in patients after nephron-sparing surgery with a positive surgical margin.	Weak
Consider curtailing follow-up when the risk of dying from other causes is double that of the RCC recurrence risk.	Weak
Offer psychological evaluation for all patients diagnosed with RCC to provide timely support for distress, depression, or anxiety.	Weak
Seek nephrological consultation during follow-up in patients treated for RCC with one or more of the following conditions: - pre-existing chronic kidney disease (CKD) - treatment-induced CKD (e.g. new baseline eGFR < 45ml/min.) - known comorbidities potentially affecting renal function.	Weak

10. REFERENCES

- Phillips, B. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.
<https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009>
- Guyatt, G.H., et al. Going from evidence to recommendations. *BMJ*, 2008. 336: 1049.
<https://www.ncbi.nlm.nih.gov/pubmed/18467413>
- Pecoraro, A., et al. Quality Indicators for Renal Cancer Care: A Systematic Review. *Eur Urol Oncol*, 2025.
<https://www.ncbi.nlm.nih.gov/pubmed/40483206>
- Sordelli, F., et al. A Systematic Review and Meta-analysis of Oncological Outcomes of Treated and Untreated Complex Cystic Renal Masses. *Eur Urol Focus*, 2025.
<https://www.ncbi.nlm.nih.gov/pubmed/41309407>
- Ferlay, J., et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. *Eur J Cancer*, 2018. 103: 356.
<https://www.ncbi.nlm.nih.gov/pubmed/30100160>
- Capitanio, U., et al. Epidemiology of Renal Cell Carcinoma. *Eur Urol*, 2019. 75: 74.
<https://www.ncbi.nlm.nih.gov/pubmed/30243799>
- Bray, F., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*, 2024. 74: 229.
<https://www.ncbi.nlm.nih.gov/pubmed/38572751>
- Larcher, A., et al. Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors. *Eur Urol*, 2025. 88: 341.
<https://www.ncbi.nlm.nih.gov/pubmed/40750496>
- Ferlay J, et al. Global Cancer Observatory: Cancer Today (version 1.1). 2024.
<https://gco.iarc.who.int/today>
- World Health Organization. Cancer Today. 2024.
<https://gco.iarc.who.int/today/en/>
- Bukavina, L., et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. *Eur Urol*, 2022. 82: 529.
<https://www.ncbi.nlm.nih.gov/pubmed/36100483>
- World Health Organization. Global Cancer Observatory - Kidney. 2022.
<https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf>
- Commission, E. ECIS - European Cancer Information System. 2020. 2024.
<https://ecis.jrc.ec.europa.eu/>
- Cirillo, L., et al. Global epidemiology of kidney cancer. *Nephrol Dial Transplant*, 2024. 39: 920.
<https://www.ncbi.nlm.nih.gov/pubmed/38341277>

15. Tahbaz, R., *et al.* Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. *Curr Opin Urol*, 2018. 28: 62.
<https://www.ncbi.nlm.nih.gov/pubmed/29059103>
16. Huang, J., *et al.* A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking, Alcohol Consumption, and Metabolic Syndrome. *Eur Urol Focus*, 2022. 8: 200.
<https://www.ncbi.nlm.nih.gov/pubmed/33495133>
17. Du, W., *et al.* Association Between Metabolic Syndrome and Risk of Renal Cell Cancer: A Meta-Analysis. *Front Oncol*, 2022. 12: 928619.
<https://www.ncbi.nlm.nih.gov/pubmed/35832547>
18. Alcalá, K., *et al.* The relationship between blood pressure and risk of renal cell carcinoma. *Int J Epidemiol*, 2022. 51: 1317.
<https://www.ncbi.nlm.nih.gov/pubmed/35312764>
19. Graff, R.E., *et al.* Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. *Eur Urol*, 2022. 82: 247.
<https://www.ncbi.nlm.nih.gov/pubmed/35715363>
20. Gansler, T., *et al.* Prevalence of Cigarette Smoking among Patients with Different Histologic Types of Kidney Cancer. *Cancer Epidemiol Biomarkers Prev*, 2020. 29: 1406.
<https://www.ncbi.nlm.nih.gov/pubmed/32357956>
21. Al-Bayati, O., *et al.* Systematic review of modifiable risk factors for kidney cancer. *Urol Oncol*, 2019. 37: 359.
<https://www.ncbi.nlm.nih.gov/pubmed/30685335>
22. Lee, S.W., *et al.* Familial Risk of Renal Cell Cancer and Interaction with Obesity and Hyperglycemia: A Population-Based Study. *J Urol*, 2022. 208: 251.
<https://www.ncbi.nlm.nih.gov/pubmed/35298291>
23. Jakobsson, R.G., *et al.* Family History and Risk of Renal Cell Carcinoma: A National Multiregister Case-Control Study. *J Urol*, 2024. 211: 71.
<https://www.ncbi.nlm.nih.gov/pubmed/37862613>
24. Bellocco, R., *et al.* Alcohol drinking and risk of renal cell carcinoma: results of a meta-analysis. *Ann Oncol*, 2012. 23: 2235.
<https://www.ncbi.nlm.nih.gov/pubmed/22398178>
25. Wozniak, M.B., *et al.* Alcohol consumption and the risk of renal cancers in the European prospective investigation into cancer and nutrition (EPIC). *Int J Cancer*, 2015. 137: 1953.
<https://www.ncbi.nlm.nih.gov/pubmed/25866035>
26. Antwi, S.O., *et al.* Alcohol consumption, variability in alcohol dehydrogenase genes and risk of renal cell carcinoma. *Int J Cancer*, 2018. 142: 747.
<https://www.ncbi.nlm.nih.gov/pubmed/29023769>
27. Taj, T., *et al.* Anti-Inflammatory Diet Index and risk of renal cell carcinoma. *Br J Cancer*, 2025. 132: 1027.
<https://www.ncbi.nlm.nih.gov/pubmed/40188289>
28. Li, Y.D., *et al.* Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort. *BMC Med*, 2024. 22: 459.
<https://www.ncbi.nlm.nih.gov/pubmed/39396995>
29. Liao, Z., *et al.* The role of diet in renal cell carcinoma incidence: an umbrella review of meta-analyses of observational studies. *BMC Med*, 2022. 20: 39.
<https://www.ncbi.nlm.nih.gov/pubmed/35109847>
30. Rai, B.P., *et al.* Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. *Eur Urol*, 2022. 82: 182.
<https://www.ncbi.nlm.nih.gov/pubmed/35393159>
31. Stewart, G.D., *et al.* Abdominal Noncontrast Computed Tomography Scanning to Screen for Kidney Cancer and Other Abdominal Pathology Within Community-based Computed Tomography Screening for Lung Cancer: Results of the Yorkshire Kidney Screening Trial. *Eur Urol*, 2025. 87: 561.
<https://www.ncbi.nlm.nih.gov/pubmed/39271419>
32. Diana, P., *et al.* Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group. *World J Urol*, 2023. 41: 929.
<https://www.ncbi.nlm.nih.gov/pubmed/35362747>
33. Rossi, S.H., *et al.* Epidemiology and screening for renal cancer. *World J Urol*, 2018. 36: 1341.
<https://www.ncbi.nlm.nih.gov/pubmed/29610964>

34. Usher-Smith, J.A., *et al.* The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer. *BMJ Open*, 2022. 12: e063018.
<https://www.ncbi.nlm.nih.gov/pubmed/36127097>
35. Usher-Smith, J.A., *et al.* Short-term psychosocial outcomes of adding a non-contrast abdominal computed tomography (CT) scan to the thoracic CT within lung cancer screening. *BJU Int*, 2024. 133: 539.
<https://www.ncbi.nlm.nih.gov/pubmed/38097529>
36. Akerlund, J., *et al.* Increased risk for renal cell carcinoma in end stage renal disease - a population-based case-control study. *Scand J Urol*, 2021. 55: 209.
<https://www.ncbi.nlm.nih.gov/pubmed/33769206>
37. Organization., W.H., *Urinary and Male Genital Tumours WHO Classification of 5th, ed.* WHO. Vol. 8. 2022.
<https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Urinary-And-Male-Genital-Tumours-2022>
38. Moch, H., *et al.* The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. *Eur Urol*, 2022. 82: 458.
<https://www.ncbi.nlm.nih.gov/pubmed/35853783>
39. Hora, M., *et al.* European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of View. *Eur Urol*, 2023. 83: 97.
<https://www.ncbi.nlm.nih.gov/pubmed/36435661>
40. Moch, H., *et al.* The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. *Eur Urol*, 2016. 70: 93.
<https://www.ncbi.nlm.nih.gov/pubmed/26935559>
41. Organization., W.H., *WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed.* WHO. Vol. 8. 2016, Lyon.
<https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016>
42. An, J., *et al.* Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma. *Front Oncol*, 2021. 11: 786307.
<https://www.ncbi.nlm.nih.gov/pubmed/35083144>
43. Ullah, A., *et al.* Demographic Patterns and Clinicopathological Analysis of Sarcomatoid Renal Cell Carcinoma in US Population. *Clin Genitourin Cancer*, 2024. 22: 38.
<https://www.ncbi.nlm.nih.gov/pubmed/37550179>
44. Trpkov, K., *et al.* New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. *Mod Pathol*, 2021. 34: 1392.
<https://www.ncbi.nlm.nih.gov/pubmed/33664427>
45. Hora, M. Re: Philip S. Macklin, Mark E. Sullivan, Charles R. Tapping, *et al.* Tumour Seeding in the Tract of Percutaneous Renal Tumour Biopsy: A Report on Seven Cases from a UK Tertiary Referral Centre. *Eur Urol* 2019;75:861-7. *Eur Urol*, 2019. 76: e96.
<https://www.ncbi.nlm.nih.gov/pubmed/31255420>
46. Shen, L., *et al.* World Health Organization 2022 Classification Update: Radiologic and Pathologic Features of Papillary Renal Cell Carcinomas. *Acad Radiol*, 2024. 31: 3257.
<https://www.ncbi.nlm.nih.gov/pubmed/38365492>
47. Liu, S., *et al.* External validation of a four-tiered grading system for chromophobe renal cell carcinoma. *Clin Exp Med*, 2024. 24: 61.
<https://www.ncbi.nlm.nih.gov/pubmed/38554222>
48. Neves, J.B., *et al.* Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. *World J Urol*, 2021. 39: 3823.
<https://www.ncbi.nlm.nih.gov/pubmed/33851271>
49. Frank, I., *et al.* Solid renal tumors: an analysis of pathological features related to tumor size. *J Urol*, 2003. 170: 2217.
<https://www.ncbi.nlm.nih.gov/pubmed/14634382>
50. Keegan, K.A., *et al.* Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. *J Urol*, 2012. 188: 391.
<https://www.ncbi.nlm.nih.gov/pubmed/22698625>

51. Abern, M.R., *et al.* Characteristics and outcomes of tumors arising from the distal nephron. *Urology*, 2012. 80: 140.
<https://www.ncbi.nlm.nih.gov/pubmed/22626576>
52. Qian, X., *et al.* Impact of Treatment Modalities on Prognosis in Patients With Renal Collecting Duct Carcinoma: A Population-Based Study. *Front Oncol*, 2022. 12: 810096.
<https://www.ncbi.nlm.nih.gov/pubmed/35530344>
53. Kanakaraj, J., *et al.* The New WHO Category of "Molecularly Defined Renal Carcinomas": Clinical and Diagnostic Features and Management Implications. *Urol Oncol*, 2024. 42: 211.
<https://www.ncbi.nlm.nih.gov/pubmed/38519377>
54. Forde, C., *et al.* Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals. *Eur Urol Oncol*, 2020. 3: 764.
<https://www.ncbi.nlm.nih.gov/pubmed/31831373>
55. Cimadamore, A., *et al.* Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. *Transl Androl Urol*, 2021. 10: 1506.
<https://www.ncbi.nlm.nih.gov/pubmed/33850785>
56. Amin, M.B., *et al.* Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. *Am J Surg Pathol*, 2014. 38: 871.
<https://www.ncbi.nlm.nih.gov/pubmed/24805860>
57. Shah, A.Y., *et al.* Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. *BJU Int*, 2017. 120: 782.
<https://www.ncbi.nlm.nih.gov/pubmed/27860149>
58. Iacovelli, R., *et al.* Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. *Can Urol Assoc J*, 2015. 9: E172.
<https://www.ncbi.nlm.nih.gov/pubmed/26085875>
59. Alvarez, O., *et al.* Renal medullary carcinoma and sickle cell trait: A systematic review. *Pediatr Blood Cancer*, 2015. 62: 1694.
<https://www.ncbi.nlm.nih.gov/pubmed/26053587>
60. Breda, A., *et al.* Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. *World J Urol*, 2015. 33: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/24504760>
61. Neves, J.B., *et al.* Growth and renal function dynamics of renal oncocytomas in patients on active surveillance. *BJU Int*, 2021. 128: 722.
<https://www.ncbi.nlm.nih.gov/pubmed/34046981>
62. Vijay, V., *et al.* Incidence of Benign Renal Masses in a Contemporary Cohort of Patients Receiving Partial Nephrectomy for Presumed Renal Cell Carcinoma. *Clin Genitourin Cancer*, 2023. 21: e114.
<https://www.ncbi.nlm.nih.gov/pubmed/36535809>
63. Wilson, M.P., *et al.* Diagnostic accuracy of 99mTc-sestamibi SPECT/CT for detecting renal oncocytomas and other benign renal lesions: a systematic review and meta-analysis. *Abdom Radiol (NY)*, 2020. 45: 2532.
<https://www.ncbi.nlm.nih.gov/pubmed/32193593>
64. Basile, G., *et al.* The Role of (99m)Tc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. *Eur Urol*, 2024. 85: 63.
<https://www.ncbi.nlm.nih.gov/pubmed/37673752>
65. Schober, J.P., *et al.* Clinical Performance of Technetium-99m-Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice. *J Urol*, 2023. 210: 438.
<https://www.ncbi.nlm.nih.gov/pubmed/37378576>
66. Tzortzakakis, A., *et al.* (99m)Tc-Sestamibi SPECT/CT and histopathological features of oncocytic renal neoplasia. *Scand J Urol*, 2022. 56: 375.
<https://www.ncbi.nlm.nih.gov/pubmed/36065481>
67. Patel, H.D., *et al.* Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. *BJU Int*, 2017. 119: 661.
<https://www.ncbi.nlm.nih.gov/pubmed/28058773>
68. Branger, N., *et al.* Oncocytoma on renal mass biopsy: is it still the same histology when surgery is performed? Results from UroCCR-104 study. *World J Urol*, 2023. 41: 483.
<https://www.ncbi.nlm.nih.gov/pubmed/36633650>

69. Edwards, F., *et al.* Natural history of treated and untreated renal oncocytoma: a systematic review and meta-analysis. *BJU Int*, 2025. 136: 590.
<https://www.ncbi.nlm.nih.gov/pubmed/40623958>
70. Abdessater, M., *et al.* Renal Oncocytoma: An Algorithm for Diagnosis and Management. *Urology*, 2020. 143: 173.
<https://www.ncbi.nlm.nih.gov/pubmed/32512107>
71. Meagher, M.F., *et al.* Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma. *World J Urol*, 2021. 39: 1195.
<https://www.ncbi.nlm.nih.gov/pubmed/32556559>
72. Bhatt, J.R., *et al.* Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm Can Be Offered Active Surveillance as an Initial Management Strategy. *Eur Urol*, 2016. 70: 85.
<https://www.ncbi.nlm.nih.gov/pubmed/26873836>
73. Fittschen, A., *et al.* Prevalence of sporadic renal angiomyolipoma: a retrospective analysis of 61,389 in- and out-patients. *Abdom Imaging*, 2014. 39: 1009.
<https://www.ncbi.nlm.nih.gov/pubmed/24705668>
74. Organization., W.h., Pathology and genetics of tumours of the urinary system and male genital organs . World Health Organization Classification of Tumours. 3rd, ed. J.N. Eble, *et al.* Vol. 7. 2004, Lyon.
<https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Pathology-And-Genetics-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2004>
75. Nese, N., *et al.* Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. *Am J Surg Pathol*, 2011. 35: 161.
<https://www.ncbi.nlm.nih.gov/pubmed/21263237>
76. Tsai, H.Y., *et al.* Clinicopathologic analysis of renal epithelioid angiomyolipoma: Consecutively excised 23 cases. *Kaohsiung J Med Sci*, 2019. 35: 33.
<https://www.ncbi.nlm.nih.gov/pubmed/30844148>
77. Fernandez-Pello, S., *et al.* Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. *Eur Urol Oncol*, 2020. 3: 57.
<https://www.ncbi.nlm.nih.gov/pubmed/31171501>
78. Bissler, J.J., *et al.* Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis: extension of a randomized controlled trial. *Nephrol Dial Transplant*, 2016. 31: 111.
<https://www.ncbi.nlm.nih.gov/pubmed/26156073>
79. Bissler, J.J., *et al.* Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. *PLoS One*, 2017. 12: e0180939.
<https://www.ncbi.nlm.nih.gov/pubmed/28792952>
80. Geynisman, D.M., *et al.* Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial. *J Urol*, 2020. 204: 531.
<https://www.ncbi.nlm.nih.gov/pubmed/32250730>
81. Schoots, I.G., *et al.* Bosniak Classification for Complex Renal Cysts Reevaluated: A Systematic Review. *J Urol*, 2017. 198: 12.
<https://www.ncbi.nlm.nih.gov/pubmed/28286071>
82. Tse, J.R., *et al.* Prevalence of Malignancy and Histopathological Association of Bosniak Classification, Version 2019 Class III and IV Cystic Renal Masses. *J Urol*, 2021. 205: 1031.
<https://www.ncbi.nlm.nih.gov/pubmed/33085925>
83. Defortescu, G., *et al.* Diagnostic performance of contrast-enhanced ultrasonography and magnetic resonance imaging for the assessment of complex renal cysts: A prospective study. *Int J Urol*, 2017. 24: 184.
<https://www.ncbi.nlm.nih.gov/pubmed/28147450>
84. Silverman, S.G., *et al.* Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. *Radiology*, 2019. 292: 475.
<https://www.ncbi.nlm.nih.gov/pubmed/31210616>
85. Cantisani, V., *et al.* EFSUMB 2020 Proposal for a Contrast-Enhanced Ultrasound-Adapted Bosniak Cyst Categorization - Position Statement. *Ultraschall Med*, 2021. 42: 154.
<https://www.ncbi.nlm.nih.gov/pubmed/33307594>
86. Donin, N.M., *et al.* Clinicopathologic outcomes of cystic renal cell carcinoma. *Clin Genitourin Cancer*, 2015. 13: 67.
<https://www.ncbi.nlm.nih.gov/pubmed/25088469>

87. Park, J.J., *et al.* Postoperative Outcome of Cystic Renal Cell Carcinoma Defined on Preoperative Imaging: A Retrospective Study. *J Urol*, 2017. 197: 991.
<https://www.ncbi.nlm.nih.gov/pubmed/27765694>
88. Chandrasekar, T., *et al.* Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance. *J Urol*, 2018. 199: 633.
<https://www.ncbi.nlm.nih.gov/pubmed/28941915>
89. Nouhaud, F.X., *et al.* Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study). *World J Urol*, 2018. 36: 1643.
<https://www.ncbi.nlm.nih.gov/pubmed/29730837>
90. Bierley, J.D., *et al.* UICC TNM classification of malignant tumours. 2017.
<https://www.uicc.org/resources/tnm-classification-malignant-tumours-8th-edition>
91. Capitanio, U., *et al.* A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. *Eur Urol*, 2023. 83: 3.
<https://www.ncbi.nlm.nih.gov/pubmed/36253306>
92. Waalkes, S., *et al.* Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? *Eur Urol*, 2011. 59: 258.
<https://www.ncbi.nlm.nih.gov/pubmed/21030143>
93. Bertini, R., *et al.* Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases. *J Urol*, 2009. 181: 2027.
<https://www.ncbi.nlm.nih.gov/pubmed/19286201>
94. Poon, S.A., *et al.* Invasion of renal sinus fat is not an independent predictor of survival in pT3a renal cell carcinoma. *BJU Int*, 2009. 103: 1622.
<https://www.ncbi.nlm.nih.gov/pubmed/19154464>
95. Bedke, J., *et al.* Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. *BJU Int*, 2009. 103: 1349.
<https://www.ncbi.nlm.nih.gov/pubmed/19076147>
96. Izumi, K., *et al.* Contact with renal sinus is associated with poor prognosis in surgically treated pT1 clear cell renal cell carcinoma. *Int J Urol*, 2020. 27: 657.
<https://www.ncbi.nlm.nih.gov/pubmed/32458519>
97. Novara, G., *et al.* Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? *Eur Urol*, 2010. 58: 588.
<https://www.ncbi.nlm.nih.gov/pubmed/20674150>
98. Heidenreich, A., *et al.* Preoperative imaging in renal cell cancer. *World J Urol*, 2004. 22: 307.
<https://www.ncbi.nlm.nih.gov/pubmed/15290202>
99. Sheth, S., *et al.* Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. *Radiographics*, 2001. 21 Spec No: S237.
<https://www.ncbi.nlm.nih.gov/pubmed/11598260>
100. Xu, P., *et al.* Predictive value of renal tumor contour irregularity score in pathological T3a upstaging of clinical T1 renal cell carcinoma: A multi-institutional study. *Urol Oncol*, 2022. 40: 199 e1.
<https://www.ncbi.nlm.nih.gov/pubmed/35365414>
101. Sobin LH., G.M., Wittekind C. (eds). TNM classification of malignant tumors. 2009. 7th edn.
<https://www.ncbi.nlm.nih.gov/nlmcatalog/101511218>
102. Amin, M.B., *et al.* The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA Cancer J Clin*, 2017. 67: 93.
<https://www.ncbi.nlm.nih.gov/pubmed/28094848>
103. Ficarra, V., *et al.* The Simplified PADUA REnal (SPARE) nephrometry system: a novel classification of parenchymal renal tumours suitable for partial nephrectomy. *BJU Int*, 2019. 124: 621.
<https://www.ncbi.nlm.nih.gov/pubmed/30963680>
104. Simmons, M.N., *et al.* Diameter-axial-polar nephrometry: integration and optimization of R.E.N.A.L. and centrality index scoring systems. *J Urol*, 2012. 188: 384.
<https://www.ncbi.nlm.nih.gov/pubmed/22698624>
105. Klatte, T., *et al.* A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. *Eur Urol*, 2015. 68: 980.
<https://www.ncbi.nlm.nih.gov/pubmed/25911061>
106. Spaliviero, M., *et al.* An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy. *Eur Urol*, 2016. 69: 72.
<https://www.ncbi.nlm.nih.gov/pubmed/26298208>

107. Hakky, T.S., *et al.* Zonal NePhRO scoring system: a superior renal tumor complexity classification model. *Clin Genitourin Cancer*, 2014. 12: e13.
<https://www.ncbi.nlm.nih.gov/pubmed/24120084>
108. Davidiuk, A.J., *et al.* Mayo adhesive probability score: an accurate image-based scoring system to predict adherent perinephric fat in partial nephrectomy. *Eur Urol*, 2014. 66: 1165.
<https://www.ncbi.nlm.nih.gov/pubmed/25192968>
109. Tanaka, H., *et al.* Defining Tumour Shape Irregularity for Preoperative Risk Stratification of Clinically Localised Renal Cell Carcinoma. *Eur Urol Open Sci*, 2023. 48: 36.
<https://www.ncbi.nlm.nih.gov/pubmed/36743398>
110. Longoni, M., *et al.* Head-to-head comparison of nephrometry scores for partial nephrectomy: implications for clinical guidelines. *Eur J Surg Oncol*, 2025. 51: 110283.
<https://www.ncbi.nlm.nih.gov/pubmed/40592281>
111. Jayson, M., *et al.* Increased incidence of serendipitously discovered renal cell carcinoma. *Urology*, 1998. 51: 203.
<https://www.ncbi.nlm.nih.gov/pubmed/9495698>
112. Campbell, S.C. Commentary RE: Increased Incidence of Serendipitously Discovered Renal Cell Carcinoma. *Urology*, 2020. 145: 333.
<https://www.ncbi.nlm.nih.gov/pubmed/32304679>
113. Vasudev, N.S., *et al.* Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. *BMJ Open*, 2020. 10: e035938.
<https://www.ncbi.nlm.nih.gov/pubmed/32398335>
114. Patard, J.J., *et al.* Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. *Eur Urol*, 2003. 44: 226.
<https://www.ncbi.nlm.nih.gov/pubmed/12875943>
115. Lee, C.T., *et al.* Mode of presentation of renal cell carcinoma provides prognostic information. *Urol Oncol*, 2002. 7: 135.
<https://www.ncbi.nlm.nih.gov/pubmed/12474528>
116. Sacco, E., *et al.* Paraneoplastic syndromes in patients with urological malignancies. *Urol Int*, 2009. 83: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/19641351>
117. Moldovan, T., *et al.* Incidence and clinical relevance of paraneoplastic syndromes in patients with renal cell carcinoma. *Urol Oncol*, 2023. 41: 392 e11.
<https://www.ncbi.nlm.nih.gov/pubmed/37537025>
118. Kim, H.L., *et al.* Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. *J Urol*, 2003. 170: 1742.
<https://www.ncbi.nlm.nih.gov/pubmed/14532767>
119. Magera, J.S., Jr., *et al.* Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. *Urology*, 2008. 71: 278.
<https://www.ncbi.nlm.nih.gov/pubmed/18308103>
120. Uzzo, R.G., *et al.* Nephron sparing surgery for renal tumors: indications, techniques and outcomes. *J Urol*, 2001. 166: 6.
<https://www.ncbi.nlm.nih.gov/pubmed/11435813>
121. Huang, W.C., *et al.* Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. *Lancet Oncol*, 2006. 7: 735.
<https://www.ncbi.nlm.nih.gov/pubmed/16945768>
122. Israel, G.M., *et al.* How I do it: evaluating renal masses. *Radiology*, 2005. 236: 441.
<https://www.ncbi.nlm.nih.gov/pubmed/16040900>
123. Israel, G.M., *et al.* Pitfalls in renal mass evaluation and how to avoid them. *Radiographics*, 2008. 28: 1325.
<https://www.ncbi.nlm.nih.gov/pubmed/18794310>
124. Shi, X., *et al.* The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis. *Front Oncol*, 2021. 11: 790381.
<https://www.ncbi.nlm.nih.gov/pubmed/35096589>
125. Gong, I.H., *et al.* Relationship among total kidney volume, renal function and age. *J Urol*, 2012. 187: 344.
<https://www.ncbi.nlm.nih.gov/pubmed/22099987>
126. Ferda, J., *et al.* Assessment of the kidney tumor vascular supply by two-phase MDCT-angiography. *Eur J Radiol*, 2007. 62: 295.
<https://www.ncbi.nlm.nih.gov/pubmed/17324548>

127. Shao, P., *et al.* Precise segmental renal artery clamping under the guidance of dual-source computed tomography angiography during laparoscopic partial nephrectomy. *Eur Urol*, 2012. 62: 1001.
<https://www.ncbi.nlm.nih.gov/pubmed/22695243>
128. Vogel, C., *et al.* Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. *Clin Genitourin Cancer*, 2019. 17: e345.
<https://www.ncbi.nlm.nih.gov/pubmed/30528378>
129. Correas, J.M., *et al.* [Guidelines for contrast enhanced ultrasound (CEUS)--update 2008]. *J Radiol*, 2009. 90: 123.
<https://www.ncbi.nlm.nih.gov/pubmed/19212280>
130. Mitterberger, M., *et al.* Contrast-enhanced ultrasound for diagnosis of prostate cancer and kidney lesions. *Eur J Radiol*, 2007. 64: 231.
<https://www.ncbi.nlm.nih.gov/pubmed/17881175>
131. Fan, X., *et al.* Associations between contrast-enhanced ultrasound features and WHO/ISUP grade of clear cell renal cell carcinoma: a retrospective study. *Int Urol Nephrol*, 2024. 56: 1157.
<https://www.ncbi.nlm.nih.gov/pubmed/37670195>
132. Mueller-Lisse, U.G., *et al.* Imaging of advanced renal cell carcinoma. *World J Urol*, 2010. 28: 253.
<https://www.ncbi.nlm.nih.gov/pubmed/20458484>
133. Hallscheidt, P.J., *et al.* Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. *J Comput Assist Tomogr*, 2005. 29: 64.
<https://www.ncbi.nlm.nih.gov/pubmed/15665685>
134. Putra, L.G., *et al.* Improved assessment of renal lesions in pregnancy with magnetic resonance imaging. *Urology*, 2009. 74: 535.
<https://www.ncbi.nlm.nih.gov/pubmed/19604560>
135. Giannarini, G., *et al.* Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. *Eur Urol*, 2012. 61: 326.
<https://www.ncbi.nlm.nih.gov/pubmed/22000497>
136. Johnson, B.A., *et al.* Diagnostic performance of prospectively assigned clear cell Likelihood scores (ccLS) in small renal masses at multiparametric magnetic resonance imaging. *Urol Oncol*, 2019. 37: 941.
<https://www.ncbi.nlm.nih.gov/pubmed/31540830>
137. Steinberg, R.L., *et al.* Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging. *Eur Radiol*, 2021. 31: 314.
<https://www.ncbi.nlm.nih.gov/pubmed/32770377>
138. Capogrosso, P., *et al.* Follow-up After Treatment for Renal Cell Carcinoma: The Evidence Beyond the Guidelines. *Eur Urol Focus*, 2016. 1: 272.
<https://www.ncbi.nlm.nih.gov/pubmed/28723399>
139. Furrer, M.A., *et al.* Comparison of the Diagnostic Performance of Contrast-enhanced Ultrasound with That of Contrast-enhanced Computed Tomography and Contrast-enhanced Magnetic Resonance Imaging in the Evaluation of Renal Masses: A Systematic Review and Meta-analysis. *Eur Urol Oncol*, 2020. 3: 464.
<https://www.ncbi.nlm.nih.gov/pubmed/31570270>
140. Choudhary, S., *et al.* Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. *Clin Radiol*, 2009. 64: 517.
<https://www.ncbi.nlm.nih.gov/pubmed/19348848>
141. Rosenkrantz, A.B., *et al.* MRI features of renal oncocytoma and chromophobe renal cell carcinoma. *AJR Am J Roentgenol*, 2010. 195: W421.
<https://www.ncbi.nlm.nih.gov/pubmed/21098174>
142. Hindman, N., *et al.* Angiomyolipoma with minimal fat: can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? *Radiology*, 2012. 265: 468.
<https://www.ncbi.nlm.nih.gov/pubmed/23012463>
143. Pedrosa, I., *et al.* MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. *Radiographics*, 2008. 28: 985.
<https://www.ncbi.nlm.nih.gov/pubmed/18635625>
144. Park, J.W., *et al.* Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. *BJU Int*, 2009. 103: 615.
<https://www.ncbi.nlm.nih.gov/pubmed/19007371>

145. Rizzo, A., *et al.* The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. *Cancers (Basel)*, 2023. 15.
<https://www.ncbi.nlm.nih.gov/pubmed/36672305>
146. Wang, G., *et al.* Head-to-head comparison of [(68)Ga]Ga-P16-093 and 2-[(18)F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study. *Eur J Nucl Med Mol Imaging*, 2023. 50: 1499.
<https://www.ncbi.nlm.nih.gov/pubmed/36600099>
147. Singhal, T., *et al.* Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis. *Ann Nucl Med*, 2024. 38: 176.
<https://www.ncbi.nlm.nih.gov/pubmed/38340144>
148. Sadaghiani, M.S., *et al.* Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis. *J Nucl Med*, 2024. 65: 1007.
<https://www.ncbi.nlm.nih.gov/pubmed/38782453>
149. Parihar, A.S., *et al.* Diagnostic Accuracy of (99m)Tc-Sestamibi SPECT/CT for Characterization of Solid Renal Masses. *J Nucl Med*, 2023. 64: 90.
<https://www.ncbi.nlm.nih.gov/pubmed/35772963>
150. Shuch, B., *et al.* [(89)Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. *Lancet Oncol*, 2024. 25: 1277.
<https://www.ncbi.nlm.nih.gov/pubmed/39270701>
151. Gouravani, M., *et al.* Diagnostic performance of artificial intelligence in detection of renal cell carcinoma: a systematic review and meta-analysis. *BMC Cancer*, 2025. 25: 155.
<https://www.ncbi.nlm.nih.gov/pubmed/39871201>
152. Xiong, Y., *et al.* Artificial intelligence links CT images to pathologic features and survival outcomes of renal masses. *Nat Commun*, 2025. 16: 1425.
<https://www.ncbi.nlm.nih.gov/pubmed/39915478>
153. Bechtold, R.E., *et al.* Imaging approach to staging of renal cell carcinoma. *Urol Clin North Am*, 1997. 24: 507.
<https://www.ncbi.nlm.nih.gov/pubmed/9275976>
154. Miles, K.A., *et al.* CT staging of renal carcinoma: a prospective comparison of three dynamic computed tomography techniques. *Eur J Radiol*, 1991. 13: 37.
<https://www.ncbi.nlm.nih.gov/pubmed/1889427>
155. Lim, D.J., *et al.* Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. *J Urol*, 1993. 150: 1112.
<https://www.ncbi.nlm.nih.gov/pubmed/8371366>
156. Larcher, A., *et al.* When to perform preoperative chest computed tomography for renal cancer staging. *BJU Int*, 2017. 120: 490.
<https://www.ncbi.nlm.nih.gov/pubmed/27684653>
157. Voss, J., *et al.* Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort. *BJU Int*, 2020. 125: 561.
<https://www.ncbi.nlm.nih.gov/pubmed/31955483>
158. Ilangovan, S., *et al.* Staging CT chest for cT1a renal masses: Does it change management? *BJUJ Compass*, 2025. 6: e70068.
<https://www.ncbi.nlm.nih.gov/pubmed/40995187>
159. Marshall, M.E., *et al.* Low incidence of asymptomatic brain metastases in patients with renal cell carcinoma. *Urology*, 1990. 36: 300.
<https://www.ncbi.nlm.nih.gov/pubmed/2219605>
160. Koga, S., *et al.* The diagnostic value of bone scan in patients with renal cell carcinoma. *J Urol*, 2001. 166: 2126.
<https://www.ncbi.nlm.nih.gov/pubmed/11696720>
161. Henriksson, C., *et al.* Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. *Scand J Urol Nephrol*, 1992. 26: 363.
<https://www.ncbi.nlm.nih.gov/pubmed/1292074>
162. Seaman, E., *et al.* Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. *Urology*, 1996. 48: 692.
<https://www.ncbi.nlm.nih.gov/pubmed/8911510>
163. Beuselink, B., *et al.* Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors. *Acta Oncol*, 2020. 59: 818.
<https://www.ncbi.nlm.nih.gov/pubmed/32297532>

164. Kotecha, R.R., *et al.* Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. *J Natl Compr Canc Netw*, 2021. 19: 432.
<https://www.ncbi.nlm.nih.gov/pubmed/33578374>
165. Warren, K.S., *et al.* The Bosniak classification of renal cystic masses. *BJU Int*, 2005. 95: 939.
<https://www.ncbi.nlm.nih.gov/pubmed/15839908>
166. Bosniak, M.A. The use of the Bosniak classification system for renal cysts and cystic tumors. *J Urol*, 1997. 157: 1852.
<https://www.ncbi.nlm.nih.gov/pubmed/9112545>
167. McGrath, T.A., *et al.* Proportion of malignancy in Bosniak classification of cystic renal masses version 2019 (v2019) classes: systematic review and meta-analysis. *Eur Radiol*, 2023. 33: 1307.
<https://www.ncbi.nlm.nih.gov/pubmed/35999371>
168. McGrath, T.A., *et al.* Bosniak Classification of Cystic Renal Masses Version 2019: Proportion of Malignancy by Class and Subclass-Systematic Review and Meta-Analysis. *AJR Am J Roentgenol*, 2025. 224: e2432342.
<https://www.ncbi.nlm.nih.gov/pubmed/39772585>
169. Richard, P.O., *et al.* Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience. *Eur Urol*, 2015. 68: 1007.
<https://www.ncbi.nlm.nih.gov/pubmed/25900781>
170. Shannon, B.A., *et al.* The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. *J Urol*, 2008. 180: 1257.
<https://www.ncbi.nlm.nih.gov/pubmed/18707712>
171. Maturen, K.E., *et al.* Renal mass core biopsy: accuracy and impact on clinical management. *AJR Am J Roentgenol*, 2007. 188: 563.
<https://www.ncbi.nlm.nih.gov/pubmed/17242269>
172. Volpe, A., *et al.* Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. *J Urol*, 2008. 180: 2333.
<https://www.ncbi.nlm.nih.gov/pubmed/18930274>
173. Veltri, A., *et al.* Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. *Eur Radiol*, 2011. 21: 393.
<https://www.ncbi.nlm.nih.gov/pubmed/20809129>
174. Abel, E.J., *et al.* Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. *J Urol*, 2010. 184: 1877.
<https://www.ncbi.nlm.nih.gov/pubmed/20850148>
175. Richard, P.O., *et al.* Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses? *J Urol*, 2018. 200: 731.
<https://www.ncbi.nlm.nih.gov/pubmed/29653161>
176. Amaral, B.S., *et al.* Renal Tumor Biopsy: Rationale to Avoid Surgery in Small Renal Masses. *Curr Urol Rep*, 2021. 22: 46.
<https://www.ncbi.nlm.nih.gov/pubmed/34487255>
177. Marconi, L., *et al.* Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. *Eur Urol*, 2016. 69: 660.
<https://www.ncbi.nlm.nih.gov/pubmed/26323946>
178. Ranieri, V., *et al.* Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses. *BJU Int*, 2024. 134: 796.
<https://www.ncbi.nlm.nih.gov/pubmed/39041496>
179. Bernstein, D.E., *et al.* A modified Delphi consensus statement on the role of biopsy in small renal masses. *BJUI Compass*, 2025. 6: e70018.
<https://www.ncbi.nlm.nih.gov/pubmed/40264828>
180. Leveridge, M.J., *et al.* Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. *Eur Urol*, 2011. 60: 578.
<https://www.ncbi.nlm.nih.gov/pubmed/21704449>
181. Breda, A., *et al.* Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study. *BJU Int*, 2010. 105: 940.
<https://www.ncbi.nlm.nih.gov/pubmed/19888984>
182. Cate, F., *et al.* Core Needle Biopsy and Fine Needle Aspiration Alone or in Combination: Diagnostic Accuracy and Impact on Management of Renal Masses. *J Urol*, 2017. 197: 1396.
<https://www.ncbi.nlm.nih.gov/pubmed/28093293>
183. Yang, C.S., *et al.* Percutaneous biopsy of the renal mass: FNA or core needle biopsy? *Cancer Cytopathol*, 2017. 125: 407.
<https://www.ncbi.nlm.nih.gov/pubmed/28334518>

184. Motzer, R.J., *et al.* Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2014. 32: 2765.
<https://www.ncbi.nlm.nih.gov/pubmed/25049330>
185. Wood, B.J., *et al.* Imaging guided biopsy of renal masses: indications, accuracy and impact on clinical management. *J Urol*, 1999. 161: 1470.
<https://www.ncbi.nlm.nih.gov/pubmed/10210375>
186. Somani, B.K., *et al.* Image-guided biopsy-diagnosed renal cell carcinoma: critical appraisal of technique and long-term follow-up. *Eur Urol*, 2007. 51: 1289.
<https://www.ncbi.nlm.nih.gov/pubmed/17081679>
187. Vasudevan, A., *et al.* Incidental renal tumours: the frequency of benign lesions and the role of preoperative core biopsy. *BJU Int*, 2006. 97: 946.
<https://www.ncbi.nlm.nih.gov/pubmed/16643475>
188. Kinnear, N., *et al.* Concordance between renal tumour biopsy and robotic-assisted partial and radical nephrectomy histology: a 10-year experience. *J Robot Surg*, 2024. 18: 45.
<https://www.ncbi.nlm.nih.gov/pubmed/38240940>
189. Neuzillet, Y., *et al.* Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. *J Urol*, 2004. 171: 1802.
<https://www.ncbi.nlm.nih.gov/pubmed/15076280>
190. Schmidbauer, J., *et al.* Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. *Eur Urol*, 2008. 53: 1003.
<https://www.ncbi.nlm.nih.gov/pubmed/18061339>
191. Wunderlich, H., *et al.* The accuracy of 250 fine needle biopsies of renal tumors. *J Urol*, 2005. 174: 44.
<https://www.ncbi.nlm.nih.gov/pubmed/15947574>
192. Abel, E.J., *et al.* Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses. *J Urol*, 2015. 194: 886.
<https://www.ncbi.nlm.nih.gov/pubmed/25837535>
193. Macklin, P.S., *et al.* Tumour Seeding in the Tract of Percutaneous Renal Tumour Biopsy: A Report on Seven Cases from a UK Tertiary Referral Centre. *Eur Urol*, 2019. 75: 861.
<https://www.ncbi.nlm.nih.gov/pubmed/30591353>
194. Cooper, S., *et al.* Diagnostic Yield and Complication Rate in Percutaneous Needle Biopsy of Renal Hilar Masses With Comparison With Renal Cortical Mass Biopsies in a Cohort of 195 Patients. *AJR Am J Roentgenol*, 2019. 212: 570.
<https://www.ncbi.nlm.nih.gov/pubmed/30645159>
195. Bratslavsky, G., *et al.* Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. *Cancer*, 2021. 127: 3957.
<https://www.ncbi.nlm.nih.gov/pubmed/34343338>
196. Mucci, L.A., *et al.* Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. *JAMA*, 2016. 315: 68.
<https://www.ncbi.nlm.nih.gov/pubmed/26746459>
197. Shuch, B., *et al.* Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. *J Clin Oncol*, 2014. 32: 431.
<https://www.ncbi.nlm.nih.gov/pubmed/24378414>
198. Beckermann, K.E., *et al.* Renal Medullary Carcinoma: Establishing Standards in Practice. *J Oncol Pract*, 2017. 13: 414.
<https://www.ncbi.nlm.nih.gov/pubmed/28697319>
199. Kickuth, R., *et al.* Interventional management of hypervascular osseous metastasis: role of embolotherapy before orthopedic tumor resection and bone stabilization. *AJR Am J Roentgenol*, 2008. 191: W240.
<https://www.ncbi.nlm.nih.gov/pubmed/19020210>
200. Forauer, A.R., *et al.* Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma. *Acta Oncol*, 2007. 46: 1012.
<https://www.ncbi.nlm.nih.gov/pubmed/17851849>
201. Appleman, L.J., *et al.* Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. *J Clin Oncol*, 2024. 42: 2061.
<https://www.ncbi.nlm.nih.gov/pubmed/38531002>

202. Procopio, G., *et al.* Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. *Eur Urol Oncol*, 2019. 2: 699.
<https://www.ncbi.nlm.nih.gov/pubmed/31542243>
203. Amato, R.J. Chemotherapy for renal cell carcinoma. *Semin Oncol*, 2000. 27: 177.
<https://www.ncbi.nlm.nih.gov/pubmed/10768596>
204. Negrier, S., *et al.* Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. *Cancer*, 2007. 110: 2468.
<https://www.ncbi.nlm.nih.gov/pubmed/17932908>
205. Motzer, R.J., *et al.* Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*, 2007. 356: 115.
<https://www.ncbi.nlm.nih.gov/pubmed/17215529>
206. Carlo, M.I., *et al.* Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. *Eur Urol*, 2019. 76: 754.
<https://www.ncbi.nlm.nih.gov/pubmed/31326218>
207. Sun, M., *et al.* Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. *Eur Urol*, 2011. 60: 644.
<https://www.ncbi.nlm.nih.gov/pubmed/21741163>
208. Zhang, L., *et al.* Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis. *BMC Cancer*, 2018. 18: 870.
<https://www.ncbi.nlm.nih.gov/pubmed/30176824>
209. Fuhrman, S.A., *et al.* Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol*, 1982. 6: 655.
<https://www.ncbi.nlm.nih.gov/pubmed/7180965>
210. Delahunt, B., *et al.* The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. *Am J Surg Pathol*, 2013. 37: 1490.
<https://www.ncbi.nlm.nih.gov/pubmed/24025520>
211. Paner, G.P., *et al.* Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. *Eur Urol*, 2018. 73: 560.
<https://www.ncbi.nlm.nih.gov/pubmed/29325693>
212. Dagher, J., *et al.* Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. *Histopathology*, 2017. 71: 918.
<https://www.ncbi.nlm.nih.gov/pubmed/28718911>
213. Leibovich, B.C., *et al.* Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. *J Urol*, 2010. 183: 1309.
<https://www.ncbi.nlm.nih.gov/pubmed/20171681>
214. Adibi, M., *et al.* Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. *Urol Oncol*, 2015. 33: 427 e17.
<https://www.ncbi.nlm.nih.gov/pubmed/26004164>
215. Kim, T., *et al.* Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. *Clin Genitourin Cancer*, 2015. 13: 225.
<https://www.ncbi.nlm.nih.gov/pubmed/25544725>
216. Patel, H.D., *et al.* Percentage of sarcomatoid histology is associated with survival in renal cell carcinoma: Stratification and implications by clinical metastatic stage. *Urol Oncol*, 2022. 40: 347 e1.
<https://www.ncbi.nlm.nih.gov/pubmed/35551862>
217. Ohashi, R., *et al.* Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. *Virchows Arch*, 2020. 476: 409.
<https://www.ncbi.nlm.nih.gov/pubmed/31760491>
218. Cheville, J.C., *et al.* Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. *Am J Surg Pathol*, 2003. 27: 612.
<https://www.ncbi.nlm.nih.gov/pubmed/12717246>
219. Patard, J.J., *et al.* Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. *J Clin Oncol*, 2005. 23: 2763.
<https://www.ncbi.nlm.nih.gov/pubmed/15837991>
220. Capitanio, U., *et al.* A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. *BJU Int*, 2009. 103: 1496.
<https://www.ncbi.nlm.nih.gov/pubmed/19076149>

221. Klatte, T., *et al.* Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. *Am J Clin Pathol*, 2012. 137: 761.
<https://www.ncbi.nlm.nih.gov/pubmed/22523215>
222. Linehan, W.M., *et al.* Genetic basis of cancer of the kidney: disease-specific approaches to therapy. *Clin Cancer Res*, 2004. 10: 6282S.
<https://www.ncbi.nlm.nih.gov/pubmed/15448018>
223. Yang, X.J., *et al.* A molecular classification of papillary renal cell carcinoma. *Cancer Res*, 2005. 65: 5628.
<https://www.ncbi.nlm.nih.gov/pubmed/15994935>
224. Furge, K.A., *et al.* Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. *Oncogene*, 2007. 26: 1346.
<https://www.ncbi.nlm.nih.gov/pubmed/17322920>
225. Boissier, R., *et al.* Long-term oncological outcomes of cystic renal cell carcinoma according to the Bosniak classification. *Int Urol Nephrol*, 2019. 51: 951.
<https://www.ncbi.nlm.nih.gov/pubmed/30977021>
226. Wahlgren, T., *et al.* Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). *Br J Cancer*, 2013. 108: 1541.
<https://www.ncbi.nlm.nih.gov/pubmed/23531701>
227. Li, P., *et al.* Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. *Cancer Med*, 2016. 5: 169.
<https://www.ncbi.nlm.nih.gov/pubmed/26645975>
228. Golijanin, B., *et al.* The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. *Urol Oncol*, 2019. 37: 932.
<https://www.ncbi.nlm.nih.gov/pubmed/31570248>
229. Fukuda, S., *et al.* Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. *J Immunother Cancer*, 2021. 9.
<https://www.ncbi.nlm.nih.gov/pubmed/33602695>
230. Lee, Z., *et al.* Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. *J Urol*, 2020. 203: 684.
<https://www.ncbi.nlm.nih.gov/pubmed/31596672>
231. Bensalah, K., *et al.* Prognostic value of thrombocytosis in renal cell carcinoma. *J Urol*, 2006. 175: 859.
<https://www.ncbi.nlm.nih.gov/pubmed/16469566>
232. Kim, H.L., *et al.* Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. *J Urol*, 2004. 171: 1810.
<https://www.ncbi.nlm.nih.gov/pubmed/15076282>
233. Patard, J.J., *et al.* Multi-institutional validation of a symptom based classification for renal cell carcinoma. *J Urol*, 2004. 172: 858.
<https://www.ncbi.nlm.nih.gov/pubmed/15310983>
234. Cho, D.S., *et al.* Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma. *Scand J Urol*, 2016. 50: 186.
<https://www.ncbi.nlm.nih.gov/pubmed/26878156>
235. Patel, A., *et al.* Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. *Clin Cancer Res*, 2020. 26: 4863.
<https://www.ncbi.nlm.nih.gov/pubmed/32546645>
236. Kapur, P., *et al.* Determinants of late metastases in renal cell carcinoma. *J Natl Cancer Inst*, 2025. 117: 1387.
<https://www.ncbi.nlm.nih.gov/pubmed/40065697>
237. Shao, Y., *et al.* Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. *BMC Urol*, 2020. 20: 90.
<https://www.ncbi.nlm.nih.gov/pubmed/32631294>
238. Albiges, L., *et al.* Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. *J Clin Oncol*, 2016. 34: 3655.
<https://www.ncbi.nlm.nih.gov/pubmed/27601543>
239. Donin, N.M., *et al.* Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma. *Cancer Epidemiol Biomarkers Prev*, 2016. 25: 1326.
<https://www.ncbi.nlm.nih.gov/pubmed/27418270>

240. Ji, J., *et al.* Impact of BMI on the Survival of Renal Cell Carcinoma Patients Treated with Targeted Therapy: A Systematic Review and Meta-Analysis. *Nutr Cancer*, 2023. 75: 1768.
<https://www.ncbi.nlm.nih.gov/pubmed/37462083>
241. Bagheri, M., *et al.* Renal cell carcinoma survival and body mass index: a dose-response meta-analysis reveals another potential paradox within a paradox. *Int J Obes (Lond)*, 2016. 40: 1817.
<https://www.ncbi.nlm.nih.gov/pubmed/27686524>
242. Dai, J., *et al.* The Prognostic Value of Body Fat Components in Metastasis Renal Cell Carcinoma Patients Treated with TKIs. *Cancer Manag Res*, 2020. 12: 891.
<https://www.ncbi.nlm.nih.gov/pubmed/32104071>
243. Tsutsumi, T., *et al.* Distinct effect of body mass index by sex as a prognostic factor in localized renal cell carcinoma treated with nephrectomy ~ data from a multi-institutional study in Japan ~. *BMC Cancer*, 2021. 21: 201.
<https://www.ncbi.nlm.nih.gov/pubmed/33639880>
244. Cella, D., *et al.* The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214. *Oncologist*, 2024. 29: 511.
<https://www.ncbi.nlm.nih.gov/pubmed/38280218>
245. Xu, J., *et al.* Impact of perioperative blood transfusion on prognosis after nephrectomy in patients with renal cell carcinoma: A meta-analysis and systematic review. *Medicine (Baltimore)*, 2024. 103: e37646.
<https://www.ncbi.nlm.nih.gov/pubmed/38579099>
246. Campi, R., *et al.* Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic review. *Minerva Urol Nephrol*, 2022. 74: 146.
<https://www.ncbi.nlm.nih.gov/pubmed/34714036>
247. Pecoraro, A., *et al.* Frailty and Renal Cell Carcinoma: Integration of Comprehensive Geriatric Assessment into Shared Decision-making. *Eur Urol Oncol*, 2025. 8: 190.
<https://www.ncbi.nlm.nih.gov/pubmed/39306584>
248. Alfred Witjes, J., *et al.* European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. *Eur Urol*, 2024. 85: 17.
<https://www.ncbi.nlm.nih.gov/pubmed/37858453>
249. Tilki, D., *et al.* EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. *Eur Urol*, 2024. 86: 164.
<https://www.ncbi.nlm.nih.gov/pubmed/38688773>
250. Cornford, P., *et al.* EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol*, 2024. 86: 148.
<https://www.ncbi.nlm.nih.gov/pubmed/38614820>
251. Ellis, G., *et al.* Comprehensive geriatric assessment for older adults admitted to hospital. *Cochrane Database Syst Rev*, 2017. 9: CD006211.
<https://www.ncbi.nlm.nih.gov/pubmed/28898390>
252. Stewart, G.D., *et al.* The multispeciality approach to the management of localised kidney cancer. *Lancet*, 2022. 400: 523.
<https://www.ncbi.nlm.nih.gov/pubmed/35868329>
253. Pecoraro, A., *et al.* Estimating Postoperative Renal Function After Surgery for Nonmetastatic Renal Masses: A Systematic Review of Available Prediction Models. *Eur Urol Oncol*, 2023. 6: 137.
<https://www.ncbi.nlm.nih.gov/pubmed/36631353>
254. Tillquist, K., *et al.* The Nephrologist's Perspective in Evaluation and Management of Localized Renal Masses: Core Curriculum 2025. *Am J Kidney Dis*, 2025. 86: 690.
<https://www.ncbi.nlm.nih.gov/pubmed/40910966>
255. Hammers, H.J., *et al.* CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. *J Clin Oncol*, 2015. 33: TPS4578.
https://doi.org/10.1200/jco.2015.33.15_suppl.tps4578
256. Fan, D., *et al.* Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma. *PeerJ*, 2020. 8: e9261.
<https://www.ncbi.nlm.nih.gov/pubmed/32547875>
257. Sim, S.H., *et al.* Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. *Br J Cancer*, 2012. 107: 1131.
<https://www.ncbi.nlm.nih.gov/pubmed/22918393>
258. Sabatino, M., *et al.* Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. *J Clin Oncol*, 2009. 27: 2645.
<https://www.ncbi.nlm.nih.gov/pubmed/19364969>

259. Li, G., *et al.* Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. *J Urol*, 2008. 180: 510.
<https://www.ncbi.nlm.nih.gov/pubmed/18550116>
260. Choueiri, T.K., *et al.* A phase I study of cabozantinib (XL184) in patients with renal cell cancer. *Ann Oncol*, 2014. 25: 1603.
<https://www.ncbi.nlm.nih.gov/pubmed/24827131>
261. Raimondi, A., *et al.* Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. *Front Oncol*, 2020. 10: 1644.
<https://www.ncbi.nlm.nih.gov/pubmed/32903369>
262. Klatte, T., *et al.* Prognostic factors and prognostic models for renal cell carcinoma: a literature review. *World J Urol*, 2018. 36: 1943.
<https://www.ncbi.nlm.nih.gov/pubmed/29713755>
263. Ueda, K., *et al.* The Prognostic Value of Systemic Inflammatory Markers in Advanced Renal Cell Carcinoma Patients Treated With Molecular Targeted Therapies. *Anticancer Res*, 2020. 40: 1739.
<https://www.ncbi.nlm.nih.gov/pubmed/32132082>
264. Motzer, R.J., *et al.* Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. *Nat Med*, 2020. 26: 1733.
<https://www.ncbi.nlm.nih.gov/pubmed/32895571>
265. Rini, B.I., *et al.* Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). *Ann Oncol*, 2018. 29: viii724.
<https://doi.org/10.1093/annonc/mdy424.037>
266. Scelo, G., *et al.* KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study. *Clin Cancer Res*, 2018. 24: 5594.
<https://www.ncbi.nlm.nih.gov/pubmed/30037816>
267. Zhang, K.J., *et al.* Diagnostic role of kidney injury molecule-1 in renal cell carcinoma. *Int Urol Nephrol*, 2019. 51: 1893.
<https://www.ncbi.nlm.nih.gov/pubmed/31385177>
268. Xu, W., *et al.* Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214. *J Clin Oncol*, 2025. 43: 437.
https://doi.org/10.1200/JCO.2025.43.5_suppl.437
269. Rini, B.I., *et al.* Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma. *Ann Oncol*, 2025.
<https://www.ncbi.nlm.nih.gov/pubmed/40885527>
270. Dabestani, S., *et al.* Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort Study. *Eur Urol Oncol*, 2025.
<https://www.ncbi.nlm.nih.gov/pubmed/40866172>
271. Minardi, D., *et al.* Loss of nuclear BAP1 protein expression is a marker of poor prognosis in patients with clear cell renal cell carcinoma. *Urol Oncol*, 2016. 34: 338 e11.
<https://www.ncbi.nlm.nih.gov/pubmed/27085487>
272. Kapur, P., *et al.* Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. *Lancet Oncol*, 2013. 14: 159.
<https://www.ncbi.nlm.nih.gov/pubmed/23333114>
273. Joseph, R.W., *et al.* Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. *J Urol*, 2016. 195: 180.
<https://www.ncbi.nlm.nih.gov/pubmed/26300218>
274. Kapur, P., *et al.* Predicting Oncologic Outcomes in Small Renal Tumors. *Eur Urol Oncol*, 2022. 5: 687.
<https://www.ncbi.nlm.nih.gov/pubmed/36115820>
275. Klatte, T., *et al.* Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. *J Clin Oncol*, 2009. 27: 746.
<https://www.ncbi.nlm.nih.gov/pubmed/19124809>
276. Turajlic, S., *et al.* Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. *Cell*, 2018. 173: 581.
<https://www.ncbi.nlm.nih.gov/pubmed/29656895>
277. Kroeger, N., *et al.* Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. *Cancer*, 2013. 119: 1547.
<https://www.ncbi.nlm.nih.gov/pubmed/23335244>

278. Rini, B., *et al.* A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. *Lancet Oncol*, 2015. 16: 676.
<https://www.ncbi.nlm.nih.gov/pubmed/25979595>
279. Sorbellini, M., *et al.* A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. *J Urol*, 2005. 173: 48.
<https://www.ncbi.nlm.nih.gov/pubmed/15592023>
280. Zisman, A., *et al.* Improved prognostication of renal cell carcinoma using an integrated staging system. *J Clin Oncol*, 2001. 19: 1649.
<https://www.ncbi.nlm.nih.gov/pubmed/11250993>
281. Frank, I., *et al.* An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. *J Urol*, 2002. 168: 2395.
<https://www.ncbi.nlm.nih.gov/pubmed/12441925>
282. Leibovich, B.C., *et al.* Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. *Cancer*, 2003. 97: 1663.
<https://www.ncbi.nlm.nih.gov/pubmed/12655523>
283. Patard, J.J., *et al.* Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. *J Clin Oncol*, 2004. 22: 3316.
<https://www.ncbi.nlm.nih.gov/pubmed/15310775>
284. Karakiewicz, P.I., *et al.* Multi-institutional validation of a new renal cancer-specific survival nomogram. *J Clin Oncol*, 2007. 25: 1316.
<https://www.ncbi.nlm.nih.gov/pubmed/17416852>
285. Zigeuner, R., *et al.* External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. *Eur Urol*, 2010. 57: 102.
<https://www.ncbi.nlm.nih.gov/pubmed/19062157>
286. Rosiello, G., *et al.* Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma. *Urol Oncol*, 2022. 40: 271 e19.
<https://www.ncbi.nlm.nih.gov/pubmed/35140049>
287. Correa, A.F., *et al.* Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. *J Clin Oncol*, 2019. 37: 2062.
<https://www.ncbi.nlm.nih.gov/pubmed/31216227>
288. Klatte, T., *et al.* The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. *BMC Med*, 2019. 17: 182.
<https://www.ncbi.nlm.nih.gov/pubmed/31578141>
289. Erdem, S., *et al.* External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis. *Urol Oncol*, 2022. 40: 198 e9.
<https://www.ncbi.nlm.nih.gov/pubmed/35172939>
290. Juul, S., *et al.* GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study. *Int J Urol*, 2022. 29: 641.
<https://www.ncbi.nlm.nih.gov/pubmed/35362146>
291. Piccinelli, M.L., *et al.* Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma. *Eur Urol Open Sci*, 2023. 53: 109.
<https://www.ncbi.nlm.nih.gov/pubmed/37441347>
292. Bedke, J., *et al.* TNM-based risk eligibility for adjuvant trials in renal cell carcinoma. *Lancet*, 2023. 402: 1018.
<https://www.ncbi.nlm.nih.gov/pubmed/37524097>
293. Okita, K., *et al.* Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma. *Clin Genitourin Cancer*, 2019. 17: e440.
<https://www.ncbi.nlm.nih.gov/pubmed/30772204>
294. Ernst, M.S., *et al.* Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. *Eur Urol*, 2023. 84: 109.
<https://www.ncbi.nlm.nih.gov/pubmed/36707357>

295. Massari, F., *et al.* Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. *Clin Genitourin Cancer*, 2021. 19: 32.
<https://www.ncbi.nlm.nih.gov/pubmed/32694008>
296. Kang, M., *et al.* Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis. *J Cancer*, 2020. 11: 7202.
<https://www.ncbi.nlm.nih.gov/pubmed/33193883>
297. Guida, A., *et al.* Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. *Oncotarget*, 2020. 11: 4582.
<https://www.ncbi.nlm.nih.gov/pubmed/33346231>
298. Rebuzzi, S.E., *et al.* Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. *ESMO Open*, 2022. 7: 100634.
<https://www.ncbi.nlm.nih.gov/pubmed/36493602>
299. Zisman, A., *et al.* Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. *J Clin Oncol*, 2002. 20: 4559.
<https://www.ncbi.nlm.nih.gov/pubmed/12454113>
300. Leibovich, B.C., *et al.* Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. *Eur Urol*, 2018. 73: 772.
<https://www.ncbi.nlm.nih.gov/pubmed/29398265>
301. Buti, S., *et al.* Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. *Ann Oncol*, 2017. 28: 2747.
<https://www.ncbi.nlm.nih.gov/pubmed/28945839>
302. Motzer, R.J., *et al.* Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. *J Clin Oncol*, 2002. 20: 289.
<https://www.ncbi.nlm.nih.gov/pubmed/11773181>
303. Karnofsky, D.A., *et al.* The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. *Cancer*, 1948. 1: 634.
[https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142\(194811\)1:4%3C634::AID-CNCR2820010410%3E3.0.CO;2-L](https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142(194811)1:4%3C634::AID-CNCR2820010410%3E3.0.CO;2-L)
304. Heng, D.Y., *et al.* External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. *Lancet Oncol*, 2013. 14: 141.
<https://www.ncbi.nlm.nih.gov/pubmed/23312463>
305. Giles, R., *et al.* Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries. *Eur Urol Open Sci*, 2022. 37: 3.
<https://www.ncbi.nlm.nih.gov/pubmed/35243386>
306. Charles, C., *et al.* Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). *Soc Sci Med*, 1997. 44: 681.
<https://www.ncbi.nlm.nih.gov/pubmed/9032835>
307. Angel, S., *et al.* Challenges in achieving patient participation: A review of how patient participation is addressed in empirical studies. *Int J Nurs Stud*, 2015. 52: 1525.
<https://www.ncbi.nlm.nih.gov/pubmed/25980558>
308. Bonetti, L., *et al.* Nursing interventions to promote patient engagement in cancer care: A systematic review. *Int J Nurs Stud*, 2022. 133: 104289.
<https://www.ncbi.nlm.nih.gov/pubmed/35751947>
309. Kelly, D., *et al.* The role of nursing in the management of patients with renal and hepatic cancers: A systematic literature review. *Eur J Oncol Nurs*, 2021. 55: 102043.
<https://www.ncbi.nlm.nih.gov/pubmed/34655916>
310. Basch, E., *et al.* Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. *JAMA*, 2017. 318: 197.
<https://www.ncbi.nlm.nih.gov/pubmed/28586821>
311. Sheikh, M., *et al.* Smoking Cessation After Diagnosis of Kidney Cancer Is Associated With Reduced Risk of Mortality and Cancer Progression: A Prospective Cohort Study. *J Clin Oncol*, 2023. 41: 2747.
<https://www.ncbi.nlm.nih.gov/pubmed/36989465>
312. Organization, W.H. *European Code Against Cancer*, 5th Edition. 2025.
<https://cancer-code-europe.iarc.who.int/>

313. Beyer, K., *et al.* A Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer. *Eur Urol Open Sci*, 2023. 48: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/36578462>
314. MacLennan, S., *et al.* Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. *Eur Urol*, 2012. 62: 1097.
<https://www.ncbi.nlm.nih.gov/pubmed/22841673>
315. Kunath, F., *et al.* Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. *Cochrane Database Syst Rev*, 2017. 5: CD012045.
<https://www.ncbi.nlm.nih.gov/pubmed/28485814>
316. Van Poppel, H., *et al.* A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol*, 2011. 59: 543.
<https://www.ncbi.nlm.nih.gov/pubmed/21186077>
317. Capitanio, U., *et al.* Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. *Eur Urol*, 2015. 67: 683.
<https://www.ncbi.nlm.nih.gov/pubmed/25282367>
318. Scosyrev, E., *et al.* Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. *Eur Urol*, 2014. 65: 372.
<https://www.ncbi.nlm.nih.gov/pubmed/23850254>
319. Lane, B.R., *et al.* Survival and Functional Stability in Chronic Kidney Disease Due to Surgical Removal of Nephrons: Importance of the New Baseline Glomerular Filtration Rate. *Eur Urol*, 2015. 68: 996.
<https://www.ncbi.nlm.nih.gov/pubmed/26012710>
320. Van Poppel, H., *et al.* A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol*, 2007. 51: 1606.
<https://www.ncbi.nlm.nih.gov/pubmed/17140723>
321. Poulakis, V., *et al.* Quality of life after surgery for localized renal cell carcinoma: comparison between radical nephrectomy and nephron-sparing surgery. *Urology*, 2003. 62: 814.
<https://www.ncbi.nlm.nih.gov/pubmed/14624900>
322. Mir, M.C., *et al.* Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. *Eur Urol*, 2017. 71: 606.
<https://www.ncbi.nlm.nih.gov/pubmed/27614693>
323. Janssen, M.W.W., *et al.* Survival outcomes in patients with large (≥ 7 cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up. *PLoS One*, 2018. 13: e0196427.
<https://www.ncbi.nlm.nih.gov/pubmed/29723225>
324. Patel, S.H., *et al.* Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. *Clin Genitourin Cancer*, 2020. 18: e723.
<https://www.ncbi.nlm.nih.gov/pubmed/32600941>
325. Shah, P.H., *et al.* Partial Nephrectomy is Associated with Higher Risk of Relapse Compared with Radical Nephrectomy for Clinical Stage T1 Renal Cell Carcinoma Pathologically Up Staged to T3a. *J Urol*, 2017. 198: 289.
<https://www.ncbi.nlm.nih.gov/pubmed/28274620>
326. Veccia, A., *et al.* Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors. *Eur Urol Focus*, 2021. 7: 574.
<https://www.ncbi.nlm.nih.gov/pubmed/32571744>
327. Liu, H., *et al.* A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma. *Transl Androl Urol*, 2021. 10: 1170.
<https://www.ncbi.nlm.nih.gov/pubmed/33850752>
328. Lane, B.R., *et al.* Management of the adrenal gland during partial nephrectomy. *J Urol*, 2009. 181: 2430.
<https://www.ncbi.nlm.nih.gov/pubmed/19371896>
329. Bekema, H.J., *et al.* Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. *Eur Urol*, 2013. 64: 799.
<https://www.ncbi.nlm.nih.gov/pubmed/23643550>

330. Blom, J.H., *et al.* Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. *Eur Urol*, 2009. 55: 28.
<https://www.ncbi.nlm.nih.gov/pubmed/18848382>
331. Capitanio, U., *et al.* Lymph node dissection in renal cell carcinoma. *Eur Urol*, 2011. 60: 1212.
<https://www.ncbi.nlm.nih.gov/pubmed/21940096>
332. Myers, A.A., *et al.* Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? *Eur Urol Oncol*, 2024. 7: 412.
<https://www.ncbi.nlm.nih.gov/pubmed/37980250>
333. Gershman, B., *et al.* Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. *J Urol*, 2018. 199: 1143.
<https://www.ncbi.nlm.nih.gov/pubmed/29225056>
334. Kim, S., *et al.* The Relationship of Lymph Node Dissection with Recurrence and Survival for Patients Treated with Nephrectomy for High-Risk Renal Cell Carcinoma. *J Urol*, 2012. 187: e233.
<https://doi.org/10.1016/j.juro.2012.02.649>
335. Dimashkieh, H.H., *et al.* Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. *J Urol*, 2006. 176: 1978.
<https://www.ncbi.nlm.nih.gov/pubmed/17070225>
336. Terrone, C., *et al.* Reassessing the current TNM lymph node staging for renal cell carcinoma. *Eur Urol*, 2006. 49: 324.
<https://www.ncbi.nlm.nih.gov/pubmed/16386352>
337. Whitson, J.M., *et al.* Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. *J Urol*, 2011. 185: 1615.
<https://www.ncbi.nlm.nih.gov/pubmed/21419453>
338. Capitanio, U., *et al.* Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). *BJU Int*, 2014. 114: 210.
<https://www.ncbi.nlm.nih.gov/pubmed/24854206>
339. Gershman, B., *et al.* Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score-based Analysis. *Eur Urol*, 2018. 73: 469.
<https://www.ncbi.nlm.nih.gov/pubmed/29132713>
340. Herrlinger, A., *et al.* What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. *J Urol*, 1991. 146: 1224.
<https://www.ncbi.nlm.nih.gov/pubmed/1942267>
341. Chapin, B.F., *et al.* The role of lymph node dissection in renal cell carcinoma. *Int J Clin Oncol*, 2011. 16: 186.
<https://www.ncbi.nlm.nih.gov/pubmed/21523561>
342. Kwon, T., *et al.* Reassessment of renal cell carcinoma lymph node staging: analysis of patterns of progression. *Urology*, 2011. 77: 373.
<https://www.ncbi.nlm.nih.gov/pubmed/20817274>
343. Bex, A., *et al.* Intraoperative sentinel node identification and sampling in clinically node-negative renal cell carcinoma: initial experience in 20 patients. *World J Urol*, 2011. 29: 793.
<https://www.ncbi.nlm.nih.gov/pubmed/21107845>
344. Sherif, A.M., *et al.* Sentinel node detection in renal cell carcinoma. A feasibility study for detection of tumour-draining lymph nodes. *BJU Int*, 2012. 109: 1134.
<https://www.ncbi.nlm.nih.gov/pubmed/21883833>
345. May, M., *et al.* Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma. *Br J Radiol*, 2009. 82: 724.
<https://www.ncbi.nlm.nih.gov/pubmed/19255117>
346. Subramanian, V.S., *et al.* Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. *Urology*, 2009. 74: 154.
<https://www.ncbi.nlm.nih.gov/pubmed/19428069>
347. Maxwell, N.J., *et al.* Renal artery embolisation in the palliative treatment of renal carcinoma. *Br J Radiol*, 2007. 80: 96.
<https://www.ncbi.nlm.nih.gov/pubmed/17495058>
348. Wang, L., *et al.* Oncologic and perioperative outcomes of laparoscopic versus open radical nephrectomy for the treatment of renal tumor (> 7 cm): a systematic review and pooled analysis of comparative outcomes. *World J Surg Oncol*, 2023. 21: 35.
<https://www.ncbi.nlm.nih.gov/pubmed/36747217>

349. Gratzke, C., *et al.* Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. *BJU Int*, 2009. 104: 470.
<https://www.ncbi.nlm.nih.gov/pubmed/19239445>
350. Hemal, A.K., *et al.* Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. *J Urol*, 2007. 177: 862.
<https://www.ncbi.nlm.nih.gov/pubmed/17296361>
351. Jeong, I.G., *et al.* Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy With Perioperative Outcomes and Health Care Costs, 2003 to 2015. *JAMA*, 2017. 318: 1561.
<https://www.ncbi.nlm.nih.gov/pubmed/29067427>
352. Crocerossa, F., *et al.* Robot-assisted Radical Nephrectomy: A Systematic Review and Meta-analysis of Comparative Studies. *Eur Urol*, 2021. 80: 428.
<https://www.ncbi.nlm.nih.gov/pubmed/33218826>
353. Soga, N., *et al.* Comparison of radical nephrectomy techniques in one center: minimal incision portless endoscopic surgery versus laparoscopic surgery. *Int J Urol*, 2008. 15: 1018.
<https://www.ncbi.nlm.nih.gov/pubmed/19138194>
354. Park, Y.H., *et al.* Comparison of laparoendoscopic single-site radical nephrectomy with conventional laparoscopic radical nephrectomy for localized renal-cell carcinoma. *J Endourol*, 2010. 24: 997.
<https://www.ncbi.nlm.nih.gov/pubmed/20370595>
355. Wang, L., *et al.* Perioperative and oncologic outcomes of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy for large-volume renal carcinoma (> 7 cm): a systematic review and pooled analysis of comparative outcomes. *World J Surg Oncol*, 2023. 21: 86.
<https://www.ncbi.nlm.nih.gov/pubmed/36894912>
356. Guglielmetti, G.B., *et al.* A Prospective, Randomized Trial Comparing the Outcomes of Open vs Laparoscopic Partial Nephrectomy. *J Urol*, 2022. 208: 259.
<https://www.ncbi.nlm.nih.gov/pubmed/35404109>
357. Gill, I.S., *et al.* Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. *J Urol*, 2007. 178: 41.
<https://www.ncbi.nlm.nih.gov/pubmed/17574056>
358. Lane, B.R., *et al.* 7-year oncological outcomes after laparoscopic and open partial nephrectomy. *J Urol*, 2010. 183: 473.
<https://www.ncbi.nlm.nih.gov/pubmed/20006866>
359. Gong, E.M., *et al.* Comparison of laparoscopic and open partial nephrectomy in clinical T1a renal tumors. *J Endourol*, 2008. 22: 953.
<https://www.ncbi.nlm.nih.gov/pubmed/18363510>
360. Marszalek, M., *et al.* Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients. *Eur Urol*, 2009. 55: 1171.
<https://www.ncbi.nlm.nih.gov/pubmed/19232819>
361. Muramaki, M., *et al.* Prognostic Factors Influencing Postoperative Development of Chronic Kidney Disease in Patients with Small Renal Tumors who Underwent Partial Nephrectomy. *Curr Urol*, 2013. 6: 129.
<https://www.ncbi.nlm.nih.gov/pubmed/24917730>
362. Tugcu, V., *et al.* Transperitoneal versus retroperitoneal laparoscopic partial nephrectomy: initial experience. *Arch Ital Urol Androl*, 2011. 83: 175.
<https://www.ncbi.nlm.nih.gov/pubmed/22670314>
363. Bazzi, W.M., *et al.* Comparison of laparoendoscopic single-site and multiport laparoscopic radical and partial nephrectomy: a prospective, nonrandomized study. *Urology*, 2012. 80: 1039.
<https://www.ncbi.nlm.nih.gov/pubmed/22990064>
364. Grimm, M.O., *et al.* Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa. *Ann Oncol*, 2025. 36: 988.
<https://www.ncbi.nlm.nih.gov/pubmed/40250528>
365. Kowalewski, K.F., *et al.* Randomized Controlled Feasibility Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy: The ROBOCOP II Study. *Eur Urol Oncol*, 2024. 7: 91.
<https://www.ncbi.nlm.nih.gov/pubmed/37316398>
366. Bravi, C.A., *et al.* The IRON Study: Investigation of Robot-assisted Versus Open Nephron-sparing Surgery. *Eur Urol Open Sci*, 2023. 49: 71.
<https://www.ncbi.nlm.nih.gov/pubmed/36874602>

367. Calpin, G.G., *et al.* Comparing the outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a network meta-analysis. *BJU Int*, 2023. 132: 353.
<https://www.ncbi.nlm.nih.gov/pubmed/37259476>
368. Masson-Lecomte, A., *et al.* A prospective comparison of the pathologic and surgical outcomes obtained after elective treatment of renal cell carcinoma by open or robot-assisted partial nephrectomy. *Urol Oncol*, 2013. 31: 924.
<https://www.ncbi.nlm.nih.gov/pubmed/21906969>
369. Peyronnet, B., *et al.* Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors. *Ann Surg Oncol*, 2016. 23: 4277.
<https://www.ncbi.nlm.nih.gov/pubmed/27411552>
370. Ni, Y., *et al.* A Systematic Review and Meta-Analysis of Comparison of Outcomes of Robot-Assisted versus Open Partial Nephrectomy in Clinical T1 Renal Cell Carcinoma Patients. *Urol Int*, 2022. 106: 757.
<https://www.ncbi.nlm.nih.gov/pubmed/35193139>
371. Nisen, H., *et al.* Hand-assisted laparoscopic versus open partial nephrectomy in patients with T1 renal tumor: Comparative perioperative, functional and oncological outcome. *Scand J Urol*, 2015. 49: 446.
<https://www.ncbi.nlm.nih.gov/pubmed/26317448>
372. Chang, K.D., *et al.* Functional and oncological outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a multicentre comparative matched-pair analyses with a median of 5 years' follow-up. *BJU Int*, 2018. 122: 618.
<https://www.ncbi.nlm.nih.gov/pubmed/29645344>
373. Choi, J.E., *et al.* Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. *Eur Urol*, 2015. 67: 891.
<https://www.ncbi.nlm.nih.gov/pubmed/25572825>
374. Rich, J.M., *et al.* Transperitoneal Versus Retroperitoneal Single-port Robotic-assisted Partial Nephrectomy: An Analysis from the Single Port Advanced Research Consortium. *Eur Urol Focus*, 2023. 9: 1059.
<https://www.ncbi.nlm.nih.gov/pubmed/37394396>
375. Raver, M., *et al.* Adoption of Single-Port Robotic Partial Nephrectomy Increases Utilization of the Retroperitoneal Approach: A Report from the Single-Port Advanced Research Consortium. *J Laparoendosc Adv Surg Tech A*, 2025. 35: 131.
<https://www.ncbi.nlm.nih.gov/pubmed/39909473>
376. Biasatti, A., *et al.* The current landscape of single-port robotic surgery in urology. *Nat Rev Urol*, 2025.
<https://www.ncbi.nlm.nih.gov/pubmed/40897917>
377. Okhawere, K.E., *et al.* Comparison of outcomes between single-port and multiport retroperitoneal robotic partial nephrectomy. *Urol Oncol*, 2025. 43: 63 e1.
<https://www.ncbi.nlm.nih.gov/pubmed/39379208>
378. Hu, A., *et al.* Comparison of single-port versus multi-port robotic assisted partial nephrectomy: a systematic review and meta-analysis of perioperative and oncological outcomes. *J Robot Surg*, 2024. 18: 321.
<https://www.ncbi.nlm.nih.gov/pubmed/39136882>
379. Ficarra, V., *et al.* Comparison of Single- and Multiport Robot-assisted Approaches in Prostate and Renal Surgery: A Systematic Review and Meta-analysis. *Eur Urol*, 2025. 88: 589.
<https://www.ncbi.nlm.nih.gov/pubmed/41016915>
380. Carbonara, U., *et al.* Retroperitoneal Robot-assisted Partial Nephrectomy: A Systematic Review and Pooled Analysis of Comparative Outcomes. *Eur Urol Open Sci*, 2022. 40: 27.
<https://www.ncbi.nlm.nih.gov/pubmed/35515269>
381. Kalble, S., *et al.* Randomised controlled feasibility trial of retroperitoneal vs transperitoneal robot-assisted partial nephrectomy: the ROPARN study. *BJU Int*, 2025. 135: 977.
<https://www.ncbi.nlm.nih.gov/pubmed/39840817>
382. Ficarra, V., *et al.* Evaluation of Clinical Research on Novel Multiport Robotic Platforms for Urological Surgery According to the IDEAL Framework: A Systematic Review of the Literature. *Eur Urol Open Sci*, 2024. 67: 7.
<https://www.ncbi.nlm.nih.gov/pubmed/39100226>
383. Minervini, A., *et al.* Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study. *J Urol*, 2011. 185: 1604.
<https://www.ncbi.nlm.nih.gov/pubmed/21419454>

384. Minervini, A., *et al.* Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. *J Urol*, 2020. 203: 496.
<https://www.ncbi.nlm.nih.gov/pubmed/31609167>
385. Bertolo, R., *et al.* Resection Techniques During Robotic Partial Nephrectomy: A Systematic Review. *Eur Urol Open Sci*, 2023. 52: 7.
<https://www.ncbi.nlm.nih.gov/pubmed/37182118>
386. Lu, Q., *et al.* Robot-assisted Simple Enucleation Versus Standard Robot-assisted Partial Nephrectomy for Low- or Intermediate-complexity, Clinical T1 Renal Tumors: A Randomized Controlled Noninferiority Trial. *Eur Urol Oncol*, 2024. 7: 275.
<https://www.ncbi.nlm.nih.gov/pubmed/37598032>
387. Antonelli, A., *et al.* On-clamp versus off-clamp robotic partial nephrectomy: A systematic review and meta-analysis. *Urologia*, 2019. 86: 52.
<https://www.ncbi.nlm.nih.gov/pubmed/31179885>
388. Antonelli, A., *et al.* Is off-clamp robot-assisted partial nephrectomy beneficial for renal function? Data from the CLOCK trial. *BJU Int*, 2022. 129: 217.
<https://www.ncbi.nlm.nih.gov/pubmed/34086393>
389. Cignoli, D., *et al.* Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time. *BJU Int*, 2023. 132: 283.
<https://www.ncbi.nlm.nih.gov/pubmed/36932928>
390. Sharma, G., *et al.* Off-clamp Versus On-clamp Robot-assisted Partial Nephrectomy: A Propensity-matched Analysis. *Eur Urol Oncol*, 2023. 6: 525.
<https://www.ncbi.nlm.nih.gov/pubmed/37193626>
391. Mellouki, A., *et al.* Evaluation of oncological outcomes of robotic partial nephrectomy according to the type of hilar control approach (On-clamp vs Off-clamp), a multicentric study of the French network of research on kidney cancer-UROCCR 58-NCT03293563. *World J Urol*, 2023. 41: 287.
<https://www.ncbi.nlm.nih.gov/pubmed/33606044>
392. Piramide, F., *et al.* Three-dimensional Model-assisted Minimally Invasive Partial Nephrectomy: A Systematic Review with Meta-analysis of Comparative Studies. *Eur Urol Oncol*, 2022. 5: 640.
<https://www.ncbi.nlm.nih.gov/pubmed/36216739>
393. Pattou, M., *et al.* Effects of a personalized or generic three-dimensional tumoral kidney model on patient experience and caregiver-patient interactions, before and after partial nephrectomy, a randomized trial (Rein 3D Print Personalize-UroCCR 114). *PLoS One*, 2025. 20: e0323515.
<https://www.ncbi.nlm.nih.gov/pubmed/40824885>
394. Margue, G., *et al.* Clinical Trial Protocol for ACCURATE: A CCafU-UroCCR Randomized Trial: Three-dimensional Image-guided Robot-assisted Partial Nephrectomy for Renal Complex Tumor (UroCCR 99). *Eur Urol Oncol*, 2025. 8: 914.
<https://www.ncbi.nlm.nih.gov/pubmed/40199643>
395. Stolzenburg, J.U., *et al.* Use of Interactive Three-dimensional Modeling for Partial Nephrectomy in the 3DPN Study. *Eur Urol Focus*, 2025. 11: 8.
<https://www.ncbi.nlm.nih.gov/pubmed/40011129>
396. Henderickx, M., *et al.* Surgical margins after partial nephrectomy as prognostic factor for the risk of local recurrence in pT1 RCC: a systematic review and narrative synthesis. *World J Urol*, 2022. 40: 2169.
<https://www.ncbi.nlm.nih.gov/pubmed/35503118>
397. Tabayoyong, W., *et al.* Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal Masses. *J Urol*, 2015. 194: 1548.
<https://www.ncbi.nlm.nih.gov/pubmed/26094808>
398. Porpiglia, F., *et al.* Partial Nephrectomy in Clinical T1b Renal Tumors: Multicenter Comparative Study of Open, Laparoscopic and Robot-assisted Approach (the RECORd Project). *Urology*, 2016. 89: 45.
<https://www.ncbi.nlm.nih.gov/pubmed/26743388>
399. Morrone, A., *et al.* Positive surgical margin's impact on short-term oncological prognosis after robot-assisted partial nephrectomy (MARGINS study: UroCCR no 96). *Sci Rep*, 2022. 12: 18342.
<https://www.ncbi.nlm.nih.gov/pubmed/36316438>
400. Steinestel, J., *et al.* Positive surgical margins in nephron-sparing surgery: risk factors and therapeutic consequences. *World J Surg Oncol*, 2014. 12: 252.
<https://www.ncbi.nlm.nih.gov/pubmed/25103683>
401. Wood, E.L., *et al.* Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. *J Urol*, 2018. 199: 393.
<https://www.ncbi.nlm.nih.gov/pubmed/28941919>

402. Bensalah, K., *et al.* Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. *Eur Urol*, 2010. 57: 466.
<https://www.ncbi.nlm.nih.gov/pubmed/19359089>
403. Lopez-Coste, M.A., *et al.* Oncological outcomes and prognostic factors after nephron-sparing surgery in renal cell carcinoma. *Int Urol Nephrol*, 2016. 48: 681.
<https://www.ncbi.nlm.nih.gov/pubmed/26861062>
404. Shah, P.H., *et al.* Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors. *J Urol*, 2016. 196: 327.
<https://www.ncbi.nlm.nih.gov/pubmed/26907508>
405. Tellini, R., *et al.* Positive Surgical Margins Predict Progression-free Survival After Nephron-sparing Surgery for Renal Cell Carcinoma: Results From a Single Center Cohort of 459 Cases With a Minimum Follow-up of 5 Years. *Clin Genitourin Cancer*, 2019. 17: e26.
<https://www.ncbi.nlm.nih.gov/pubmed/30266249>
406. Ryan, S.T., *et al.* Impact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database. *Minerva Urol Nephrol*, 2021. 73: 233.
<https://www.ncbi.nlm.nih.gov/pubmed/32748614>
407. Kim, S.P., *et al.* Treatment of Patients with Positive Margins after Partial Nephrectomy. *J Urol*, 2016. 196: 301.
<https://www.ncbi.nlm.nih.gov/pubmed/27188474>
408. Antic, T., *et al.* Partial nephrectomy for renal tumors: lack of correlation between margin status and local recurrence. *Am J Clin Pathol*, 2015. 143: 645.
<https://www.ncbi.nlm.nih.gov/pubmed/25873497>
409. Marconi, L., *et al.* Hospital Volume as a Determinant of Outcomes After Partial Nephrectomy: A Systematic Review by the European Association of Urology Renal Cell Carcinoma Guidelines Panel. *Eur Urol Oncol*, 2025. 8: 616.
<https://www.ncbi.nlm.nih.gov/pubmed/40210551>
410. Yildirim, H., *et al.* Variation in the management of cT1 renal cancer by surgical hospital volume: A nationwide study. *BJUI Compass*, 2023. 4: 455.
<https://www.ncbi.nlm.nih.gov/pubmed/37334025>
411. Tran, M.G.B., *et al.* Guideline adherence for the surgical treatment of T1 renal tumours correlates with hospital volume: an analysis from the British Association of Urological Surgeons Nephrectomy Audit. *BJU Int*, 2020. 125: 73.
<https://www.ncbi.nlm.nih.gov/pubmed/31293036>
412. Couapel, J.P., *et al.* Is there a volume-outcome relationship for partial nephrectomy? *World J Urol*, 2014. 32: 1323.
<https://www.ncbi.nlm.nih.gov/pubmed/24270969>
413. Stencil, M.G., *et al.* Partial Nephrectomy Drives the Association Between High-volume Centers and Decreased Mortality: A Surveillance, Epidemiology, and End Results-Medicare Analysis. *Urology*, 2023. 181: 55.
<https://www.ncbi.nlm.nih.gov/pubmed/37544519>
414. Pfail, J., *et al.* Omission of intraoperative drain placement during robotic partial nephrectomy and robotic radical prostatectomy is safe: an analysis of 18,000 patients. *World J Urol*, 2024. 42: 601.
<https://www.ncbi.nlm.nih.gov/pubmed/39470850>
415. Territo, A., *et al.* To drain or not to drain in uro-oncological robotic surgery? A systematic review and meta-analysis. *Minerva Urol Nephrol*, 2023. 75: 144.
<https://www.ncbi.nlm.nih.gov/pubmed/36722161>
416. Kowalewski, K.F., *et al.* Prophylactic abdominal or retroperitoneal drain placement in major uro-oncological surgery: a systematic review and meta-analysis of comparative studies on radical prostatectomy, cystectomy and partial nephrectomy. *World J Urol*, 2020. 38: 1905.
<https://www.ncbi.nlm.nih.gov/pubmed/31664510>
417. Wangjian, W., *et al.* Application of enhanced recovery after surgery in partial nephrectomy for renal tumors: A systematic review and meta-analysis. *Front Oncol*, 2023. 13: 1049294.
<https://www.ncbi.nlm.nih.gov/pubmed/36845687>
418. Lane, B.R., *et al.* Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. *Cancer*, 2010. 116: 3119.
<https://www.ncbi.nlm.nih.gov/pubmed/20564627>
419. Hollingsworth, J.M., *et al.* Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. *Cancer*, 2007. 109: 1763.
<https://www.ncbi.nlm.nih.gov/pubmed/17351954>

420. Volpe, A., *et al.* The natural history of incidentally detected small renal masses. *Cancer*, 2004. 100: 738.
<https://www.ncbi.nlm.nih.gov/pubmed/14770429>
421. Sun, M., *et al.* Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥ 75 years with multiple comorbidities. *BJU Int*, 2013. 111: 67.
<https://www.ncbi.nlm.nih.gov/pubmed/22612472>
422. Zini, L., *et al.* A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. *BJU Int*, 2009. 103: 899.
<https://www.ncbi.nlm.nih.gov/pubmed/19154499>
423. Xing, M., *et al.* Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study. *Radiology*, 2018. 288: 81.
<https://www.ncbi.nlm.nih.gov/pubmed/29737950>
424. Sun, M., *et al.* Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. *Eur Urol*, 2014. 65: 235.
<https://www.ncbi.nlm.nih.gov/pubmed/23567066>
425. Huang, W.C., *et al.* Surveillance for the management of small renal masses: Utilization and outcomes in a population-based cohort. *J Clin Oncol*, 2013. 31: 343.
https://doi.org/10.1200/jco.2013.31.6_suppl.343
426. Hyams, E.S., *et al.* 1679 Partial Nephrectomy Vs. Non-Surgical Management for Small Renal Masses: A Population-Based Comparison of Disease-Specific and Overall Survival. *J Urol*, 2012. 187: E678.
<https://doi.org/10.1016/j.juro.2012.02.1552>
427. Jewett, M.A., *et al.* Active surveillance of small renal masses: progression patterns of early stage kidney cancer. *Eur Urol*, 2011. 60: 39.
<https://www.ncbi.nlm.nih.gov/pubmed/21477920>
428. Smaldone, M.C., *et al.* Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. *Cancer*, 2012. 118: 997.
<https://www.ncbi.nlm.nih.gov/pubmed/21766302>
429. Klatte, T., *et al.* Intermediate- and long-term oncological outcomes of active surveillance for localized renal masses: a systematic review and quantitative analysis. *BJU Int*, 2021. 128: 131.
<https://www.ncbi.nlm.nih.gov/pubmed/34060192>
430. Finelli, A., *et al.* Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. *Eur Urol*, 2020. 78: 460.
<https://www.ncbi.nlm.nih.gov/pubmed/32680677>
431. Patel, N., *et al.* Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. *BJU Int*, 2012. 110: 1270.
<https://www.ncbi.nlm.nih.gov/pubmed/22564495>
432. Pierorazio, P.M., *et al.* Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. *Eur Urol*, 2015. 68: 408.
<https://www.ncbi.nlm.nih.gov/pubmed/25698065>
433. Uzosike, A.C., *et al.* Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry. *J Urol*, 2018. 199: 641.
<https://www.ncbi.nlm.nih.gov/pubmed/28951284>
434. Metcalf, M.R., *et al.* Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry. *J Urol*, 2021. 205: 1286.
<https://www.ncbi.nlm.nih.gov/pubmed/33356478>
435. Abou Youssif, T., *et al.* Active surveillance for selected patients with renal masses: updated results with long-term follow-up. *Cancer*, 2007. 110: 1010.
<https://www.ncbi.nlm.nih.gov/pubmed/17628489>
436. Abouassaly, R., *et al.* Active surveillance of renal masses in elderly patients. *J Urol*, 2008. 180: 505.
<https://www.ncbi.nlm.nih.gov/pubmed/18550113>
437. Crispen, P.L., *et al.* Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. *Cancer*, 2009. 115: 2844.
<https://www.ncbi.nlm.nih.gov/pubmed/19402168>
438. Rosales, J.C., *et al.* Active surveillance for renal cortical neoplasms. *J Urol*, 2010. 183: 1698.
<https://www.ncbi.nlm.nih.gov/pubmed/20299038>

439. Pierorazio, P., *et al.* 633 Quality of Life on Active Surveillance for a Small Renal Masses Versus Immediate Intervention: Interim Analysis of the Dissrm (Delayed Intervention and Surveillance for Small Renal Masses) Registry. *J Urol*, 2013. 189: e259.
<https://doi.org/10.1016/j.juro.2013.02.185>
440. Atwell, T.D., *et al.* Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. *AJR Am J Roentgenol*, 2013. 200: 461.
<https://www.ncbi.nlm.nih.gov/pubmed/23345372>
441. Widdershoven, C.V., *et al.* Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-up. *Abdom Radiol (NY)*, 2021. 46: 373.
<https://www.ncbi.nlm.nih.gov/pubmed/32564209>
442. Chan, V.W., *et al.* The changing trends of image-guided biopsy of small renal masses before intervention-an analysis of European multinational prospective EuRECA registry. *Eur Radiol*, 2022. 32: 4667.
<https://www.ncbi.nlm.nih.gov/pubmed/35122492>
443. Lay, A.H., *et al.* Oncologic Efficacy of Radio Frequency Ablation for Small Renal Masses: Clear Cell vs Papillary Subtype. *J Urol*, 2015. 194: 653.
<https://www.ncbi.nlm.nih.gov/pubmed/25846416>
444. McClure, T., *et al.* Efficacy of percutaneous radiofrequency ablation may vary with clear cell renal cell cancer histologic subtype. *Abdom Radiol (NY)*, 2018. 43: 1472.
<https://www.ncbi.nlm.nih.gov/pubmed/28936542>
445. Liu, N., *et al.* Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype. *Urol Oncol*, 2017. 35: 530 e1.
<https://www.ncbi.nlm.nih.gov/pubmed/28408296>
446. Breen, D.J., *et al.* Image-guided Cryoablation for Sporadic Renal Cell Carcinoma: Three- and 5-year Outcomes in 220 Patients with Biopsy-proven Renal Cell Carcinoma. *Radiology*, 2018. 289: 554.
<https://www.ncbi.nlm.nih.gov/pubmed/30084744>
447. Sisul, D.M., *et al.* RENAL nephrometry score is associated with complications after renal cryoablation: a multicenter analysis. *Urology*, 2013. 81: 775.
<https://www.ncbi.nlm.nih.gov/pubmed/23434099>
448. Kim, E.H., *et al.* 1200 Outcomes of Laparoscopic and Percutaneous Cryoablation for Renal Masses. *J Urol*, 2013. 189: e492.
<https://doi.org/10.1016/j.juro.2013.02.2554>
449. Goyal, J., *et al.* Single-center comparative oncologic outcomes of surgical and percutaneous cryoablation for treatment of renal tumors. *J Endourol*, 2012. 26: 1413.
<https://www.ncbi.nlm.nih.gov/pubmed/22642574>
450. Jiang, K., *et al.* Laparoscopic cryoablation vs. percutaneous cryoablation for treatment of small renal masses: a systematic review and meta-analysis. *Oncotarget*, 2017. 8: 27635.
<https://www.ncbi.nlm.nih.gov/pubmed/28199973>
451. Zargar, H., *et al.* Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. *Eur Urol*, 2016. 69: 116.
<https://www.ncbi.nlm.nih.gov/pubmed/25819723>
452. Pickersgill, N.A., *et al.* Ten-Year Experience with Percutaneous Cryoablation of Renal Tumors: Tumor Size Predicts Disease Progression. *J Endourol*, 2020. 34: 1211.
<https://www.ncbi.nlm.nih.gov/pubmed/32292059>
453. Morkos, J., *et al.* Percutaneous Cryoablation for Stage 1 Renal Cell Carcinoma: Outcomes from a 10-year Prospective Study and Comparison with Matched Cohorts from the National Cancer Database. *Radiology*, 2020. 296: 452.
<https://www.ncbi.nlm.nih.gov/pubmed/32515677>
454. Hebbadj, S., *et al.* Safety Considerations and Local Tumor Control Following Percutaneous Image-Guided Cryoablation of T1b Renal Tumors. *Cardiovasc Intervent Radiol*, 2018. 41: 449.
<https://www.ncbi.nlm.nih.gov/pubmed/29075877>
455. Grange, R., *et al.* Computed tomography-guided percutaneous cryoablation of T1b renal tumors: safety, functional and oncological outcomes. *Int J Hyperthermia*, 2019. 36: 1065.
<https://www.ncbi.nlm.nih.gov/pubmed/31648584>
456. Pecoraro, A., *et al.* Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer. *J Urol*, 2019. 202: 1120.
<https://www.ncbi.nlm.nih.gov/pubmed/31347950>

457. Andrews, J.R., *et al.* Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. *Eur Urol*, 2019. 76: 244.
<https://www.ncbi.nlm.nih.gov/pubmed/31060824>
458. Sundelin, M.O., *et al.* Repeated Cryoablation as Treatment Modality After Failure of Primary Renal Cryoablation: A European Registry for Renal Cryoablation Multinational Analysis. *J Endourol*, 2019. 33: 909.
<https://www.ncbi.nlm.nih.gov/pubmed/31507206>
459. Lian, H., *et al.* Single-center comparison of complications in laparoscopic and percutaneous radiofrequency ablation with ultrasound guidance for renal tumors. *Urology*, 2012. 80: 119.
<https://www.ncbi.nlm.nih.gov/pubmed/22633890>
460. Young, E.E., *et al.* Comparison of safety, renal function outcomes and efficacy of laparoscopic and percutaneous radio frequency ablation of renal masses. *J Urol*, 2012. 187: 1177.
<https://www.ncbi.nlm.nih.gov/pubmed/22357170>
461. Kim, S.D., *et al.* Radiofrequency ablation of renal tumors: four-year follow-up results in 47 patients. *Korean J Radiol*, 2012. 13: 625.
<https://www.ncbi.nlm.nih.gov/pubmed/22977331>
462. Trudeau, V., *et al.* Comparison of Postoperative Complications and Mortality Between Laparoscopic and Percutaneous Local Tumor Ablation for T1a Renal Cell Carcinoma: A Population-based Study. *Urology*, 2016. 89: 63.
<https://www.ncbi.nlm.nih.gov/pubmed/26514977>
463. Psutka, S.P., *et al.* Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. *Eur Urol*, 2013. 63: 486.
<https://www.ncbi.nlm.nih.gov/pubmed/22959191>
464. Johnson, B.A., *et al.* Ten-Year Outcomes of Renal Tumor Radio Frequency Ablation. *J Urol*, 2019. 201: 251.
<https://www.ncbi.nlm.nih.gov/pubmed/30634350>
465. Sorce, G., *et al.* Cancer-specific Mortality After Cryoablation vs Heat-based Thermal Ablation in T1a Renal Cell Carcinoma. *J Urol*, 2023. 209: 81.
<https://www.ncbi.nlm.nih.gov/pubmed/36440817>
466. Chang, X., *et al.* Radio frequency ablation versus partial nephrectomy for clinical T1b renal cell carcinoma: long-term clinical and oncologic outcomes. *J Urol*, 2015. 193: 430.
<https://www.ncbi.nlm.nih.gov/pubmed/25106899>
467. Yu, J., *et al.* Percutaneous Microwave Ablation versus Laparoscopic Partial Nephrectomy for cT1a Renal Cell Carcinoma: A Propensity-matched Cohort Study of 1955 Patients. *Radiology*, 2020. 294: 698.
<https://www.ncbi.nlm.nih.gov/pubmed/31961239>
468. Shapiro, D.D., *et al.* Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery. *Urology*, 2020. 135: 88.
<https://www.ncbi.nlm.nih.gov/pubmed/31585198>
469. Zhou, W., *et al.* Radiofrequency Ablation, Cryoablation, and Microwave Ablation for T1a Renal Cell Carcinoma: A Comparative Evaluation of Therapeutic and Renal Function Outcomes. *J Vasc Interv Radiol*, 2019. 30: 1035.
<https://www.ncbi.nlm.nih.gov/pubmed/30956075>
470. Aarts, B.M., *et al.* Safety and efficacy of RFA versus MWA for T1a renal cell carcinoma: a propensity score analysis. *Eur Radiol*, 2023. 33: 1040.
<https://www.ncbi.nlm.nih.gov/pubmed/36066733>
471. Abu-Ghanem, Y., *et al.* Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. *Eur Urol Oncol*, 2020. 3: 433.
<https://www.ncbi.nlm.nih.gov/pubmed/32245655>
472. Huang, R.S., *et al.* Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis. *Lancet Oncol*, 2025. 26: 387.
<https://www.ncbi.nlm.nih.gov/pubmed/39922208>
473. Chan, V.W., *et al.* Meta-analysis on SBRT and ablation for localised RCC. *Lancet Oncol*, 2025. 26: e235.
<https://www.ncbi.nlm.nih.gov/pubmed/40318650>

474. Guazzoni, G., *et al.* Oncologic results of laparoscopic renal cryoablation for clinical T1a tumors: 8 years of experience in a single institution. *Urology*, 2010. 76: 624.
<https://www.ncbi.nlm.nih.gov/pubmed/20579705>
475. Larcher, A., *et al.* Long-term oncologic outcomes of laparoscopic renal cryoablation as primary treatment for small renal masses. *Urol Oncol*, 2015. 33: 22 e1.
<https://www.ncbi.nlm.nih.gov/pubmed/25301741>
476. Thompson, R.H., *et al.* Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. *Eur Urol*, 2015. 67: 252.
<https://www.ncbi.nlm.nih.gov/pubmed/25108580>
477. Haber, G.P., *et al.* Tumour in solitary kidney: laparoscopic partial nephrectomy vs laparoscopic cryoablation. *BJU Int*, 2012. 109: 118.
<https://www.ncbi.nlm.nih.gov/pubmed/21895929>
478. Turna, B., *et al.* Minimally invasive nephron sparing management for renal tumors in solitary kidneys. *J Urol*, 2009. 182: 2150.
<https://www.ncbi.nlm.nih.gov/pubmed/19758655>
479. Cazalas, G., *et al.* A multicenter comparative matched-pair analysis of percutaneous tumor ablation and robotic-assisted partial nephrectomy of T1b renal cell carcinoma (AblatT1b study-UroCCR 80). *Eur Radiol*, 2023. 33: 6513.
<https://www.ncbi.nlm.nih.gov/pubmed/37004570>
480. Attawettayanon, W., *et al.* Thermal Ablation Versus Partial Nephrectomy for cT1 Renal Mass in a Solitary Kidney: A Matched Cohort Comparative Analysis. *Ann Surg Oncol*, 2024. 31: 2133.
<https://www.ncbi.nlm.nih.gov/pubmed/38071719>
481. Junker, T., *et al.* Partial Nephrectomy versus Percutaneous Cryoablation of Small Renal Cell Carcinomas: A Comparison of Adverse Events in a Prospective Multicenter Cohort Study. *J Vasc Interv Radiol*, 2022. 33: 1375.
<https://www.ncbi.nlm.nih.gov/pubmed/35842025>
482. Neves, J.B., *et al.* Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy. *Eur Urol*, 2024. 85: 333.
<https://www.ncbi.nlm.nih.gov/pubmed/37684178>
483. Correa, R.J.M., *et al.* The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. *Eur Urol Focus*, 2019. 5: 958.
<https://www.ncbi.nlm.nih.gov/pubmed/31248849>
484. Ali, M., *et al.* The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. *Eur Urol*, 2022. 82: 613.
<https://www.ncbi.nlm.nih.gov/pubmed/35843777>
485. Suleja, A., *et al.* Stereotactic Body Radiotherapy (SBRT) for the Treatment of Primary Localized Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. *Cancers (Basel)*, 2024. 16: 3276.
<https://www.ncbi.nlm.nih.gov/pubmed/39409897>
486. Sundahl, N., *et al.* Stereotactic Body Radiation Therapy Alone or in Combination with Immunotherapy in Kidney Cancer: A Systematic Review. *Eur Urol*, 2025. 88: 142.
<https://www.ncbi.nlm.nih.gov/pubmed/40221282>
487. Siva, S., *et al.* Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). *Lancet Oncol*, 2024. 25: e18.
<https://www.ncbi.nlm.nih.gov/pubmed/38181809>
488. Siva, S., *et al.* Stereotactic Ablative Radiotherapy for \geq T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK). *Int J Radiat Oncol Biol Phys*, 2020. 108: 941.
<https://www.ncbi.nlm.nih.gov/pubmed/32562838>
489. Tetar, S.U., *et al.* The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer. *Cancers (Basel)*, 2020. 12.
<https://www.ncbi.nlm.nih.gov/pubmed/32992844>
490. Grubb, W.R., *et al.* Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma. *Radiother Oncol*, 2021. 155: 138.
<https://www.ncbi.nlm.nih.gov/pubmed/33214131>
491. Margulis, V., *et al.* Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus-Safety Lead-in Results of a Phase 2 Trial. *Int J Radiat Oncol Biol Phys*, 2021. 110: 1135.
<https://www.ncbi.nlm.nih.gov/pubmed/33549705>

492. Swaminath, A., *et al.* Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer - Results from a Prospective Cohort Study. *Clin Oncol (R Coll Radiol)*, 2021. 33: 468.
<https://www.ncbi.nlm.nih.gov/pubmed/33775496>
493. Grelier, L., *et al.* Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience. *Cancers (Basel)*, 2021. 13.
<https://www.ncbi.nlm.nih.gov/pubmed/34201451>
494. Glicksman, R.M., *et al.* Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function Outcomes. *Clin Oncol (R Coll Radiol)*, 2023. 35: 20.
<https://www.ncbi.nlm.nih.gov/pubmed/35948465>
495. Hannan, R., *et al.* Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer. *Eur Urol*, 2023. 84: 275.
<https://www.ncbi.nlm.nih.gov/pubmed/36898872>
496. Siva, S., *et al.* Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. *Lancet Oncol*, 2024. 25: 308.
<https://www.ncbi.nlm.nih.gov/pubmed/38423047>
497. Gaudreault, M., *et al.* Dose-Effect Relationship of Kidney Function After SABR for Primary Renal Cell Carcinoma: TROG 15.03 FASTRACK II. *Int J Radiat Oncol Biol Phys*, 2024. 120: 648.
<https://www.ncbi.nlm.nih.gov/pubmed/38679212>
498. Bhandi, B., *et al.* The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. *BJU Int*, 2018. 121: 684.
<https://www.ncbi.nlm.nih.gov/pubmed/29319926>
499. Luo, X., *et al.* Influence of lymph node dissection in patients undergoing radical nephrectomy for non-metastatic renal cell carcinoma: a systematic review and meta-analysis. *Eur Rev Med Pharmacol Sci*, 2019. 23: 6079.
<https://www.ncbi.nlm.nih.gov/pubmed/31364109>
500. Capitanio, U., *et al.* When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during follow-up. *BJU Int*, 2013. 112: E59.
<https://www.ncbi.nlm.nih.gov/pubmed/23795799>
501. Tsui, K.H., *et al.* Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. *J Urol*, 2000. 163: 1090.
<https://www.ncbi.nlm.nih.gov/pubmed/10737472>
502. Gershman, B., *et al.* Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. *Eur Urol*, 2017. 72: 300.
<https://www.ncbi.nlm.nih.gov/pubmed/28094055>
503. Haferkamp, A., *et al.* Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. *J Urol*, 2007. 177: 1703.
<https://www.ncbi.nlm.nih.gov/pubmed/17437789>
504. Skinner, D.G., *et al.* Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. *Ann Surg*, 1989. 210: 387.
<https://www.ncbi.nlm.nih.gov/pubmed/2774709>
505. Klatte, T., *et al.* Prognostic factors for renal cell carcinoma with tumor thrombus extension. *J Urol*, 2007. 178: 1189.
<https://www.ncbi.nlm.nih.gov/pubmed/17698087>
506. Ciancio, G., *et al.* Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience. *Eur Urol*, 2010. 57: 667.
<https://www.ncbi.nlm.nih.gov/pubmed/19560258>
507. Chen, Z., *et al.* Outcomes of renal cell carcinoma with associated venous tumor thrombus: experience from a large cohort and short time span in a single center. *BMC Cancer*, 2021. 21: 766.
<https://www.ncbi.nlm.nih.gov/pubmed/34215223>
508. Al-Rusan, O.M., *et al.* A Contemporary Clinicopathologic Analysis of Patients With Renal Cell Carcinoma and Vena Cava Involvement. *Int J Surg Pathol*, 2024. 32: 279.
<https://www.ncbi.nlm.nih.gov/pubmed/37306114>
509. Neves, R.J., *et al.* Surgical treatment of renal cancer with vena cava extension. *Br J Urol*, 1987. 59: 390.
<https://www.ncbi.nlm.nih.gov/pubmed/3594097>
510. Kirkali, Z., *et al.* A critical analysis of surgery for kidney cancer with vena cava invasion. *Eur Urol*, 2007. 52: 658.
<https://www.ncbi.nlm.nih.gov/pubmed/17548146>

511. Moinzadeh, A., *et al.* Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? *J Urol*, 2004. 171: 598.
<https://www.ncbi.nlm.nih.gov/pubmed/14713768>
512. Bissada, N.K., *et al.* Long-term experience with management of renal cell carcinoma involving the inferior vena cava. *Urology*, 2003. 61: 89.
<https://www.ncbi.nlm.nih.gov/pubmed/12559273>
513. Woodruff, D.Y., *et al.* The perioperative management of an inferior vena caval tumor thrombus in patients with renal cell carcinoma. *Urol Oncol*, 2013. 31: 517.
<https://www.ncbi.nlm.nih.gov/pubmed/21514183>
514. Hao, X., *et al.* Development and validation of a comprehensive predictive model for surgical planning in patients with renal cell carcinoma and inferior vena cava tumor thrombus. *Eur J Surg Oncol*, 2025. 51: 109381.
<https://www.ncbi.nlm.nih.gov/pubmed/39581156>
515. Psutka, S.P., *et al.* Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma. *Ther Adv Urol*, 2015. 7: 216.
<https://www.ncbi.nlm.nih.gov/pubmed/26445601>
516. Abel, E.J., *et al.* Positive vascular wall margins have minimal impact on cancer outcomes in patients with non-metastatic renal cell carcinoma (RCC) with tumour thrombus. *BJU Int*, 2014. 114: 667.
<https://www.ncbi.nlm.nih.gov/pubmed/24128265>
517. Tabbara, M.M., *et al.* Current Approaches in Surgical and Immunotherapy-Based Management of Renal Cell Carcinoma with Tumor Thrombus. *Biomedicines*, 2023. 11.
<https://www.ncbi.nlm.nih.gov/pubmed/36672712>
518. Klatte, T., *et al.* Tyrosine kinase inhibitor treatment for renal cell carcinoma with inferior vena cava tumour thrombus: a quantitative summary. *BJU Int*, 2023. 131: 566.
<https://www.ncbi.nlm.nih.gov/pubmed/36638048>
519. Wang, K., *et al.* T.H.R.O.B.V.S. Score - A Comprehensive Model to Predict the Surgical Complexity of Renal Cell Carcinoma With Tumor Thrombus. *Front Oncol*, 2022. 12: 900550.
<https://www.ncbi.nlm.nih.gov/pubmed/35814463>
520. Liu, Z., *et al.* Renal cell carcinoma with tumor thrombus growing against the direction of venous return: an indicator of complicated surgery and poor prognosis. *BMC Surg*, 2021. 21: 443.
<https://www.ncbi.nlm.nih.gov/pubmed/34963464>
521. Wagner, B., *et al.* Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. *Eur Urol*, 2009. 55: 452.
<https://www.ncbi.nlm.nih.gov/pubmed/18692951>
522. Scilipoti, P., *et al.* Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus. *World J Urol*, 2024. 42: 264.
<https://www.ncbi.nlm.nih.gov/pubmed/38676733>
523. Lardas, M., *et al.* Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. *Eur Urol*, 2016. 70: 265.
<https://www.ncbi.nlm.nih.gov/pubmed/26707869>
524. Shi, T., *et al.* Robot-assisted Cavectomy Versus Thrombectomy for Level II Inferior Vena Cava Thrombus: Decision-making Scheme and Multi-institutional Analysis. *Eur Urol*, 2020. 78: 592.
<https://www.ncbi.nlm.nih.gov/pubmed/32305170>
525. Baboudjian, M., *et al.* Predictive factors of recurrence after surgery in patients with non-metastatic renal cell carcinoma with venous tumor thrombus (UroCCR-56 Study). *World J Urol*, 2023. 41: 295.
<https://www.ncbi.nlm.nih.gov/pubmed/33765164>
526. Garg, H., *et al.* A Decade of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy: A Systematic Review and Meta-Analysis of Perioperative Outcomes. *J Urol*, 2022. 208: 542.
<https://www.ncbi.nlm.nih.gov/pubmed/35762219>
527. Zhang, Y., *et al.* Comparative analysis of surgical and oncologic outcomes of robotic, laparoscopic and open radical nephrectomy with venous thrombectomy: a propensity-matched cohort study. *Int J Clin Oncol*, 2023. 28: 145.
<https://www.ncbi.nlm.nih.gov/pubmed/36380158>
528. Ljungberg, B., *et al.* European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*, 2022. 82: 399.
<https://www.ncbi.nlm.nih.gov/pubmed/35346519>
529. Lamb, G.W., *et al.* Management of renal masses in patients medically unsuitable for nephrectomy—natural history, complications, and outcome. *Urology*, 2004. 64: 909.
<https://www.ncbi.nlm.nih.gov/pubmed/15533476>

530. Hallscheidt, P., *et al.* [Preoperative and palliative embolization of renal cell carcinomas: follow-up of 49 patients]. *Rofo*, 2006. 178: 391.
<https://www.ncbi.nlm.nih.gov/pubmed/16612730>
531. Wright, B., *et al.* Trans-arterial embolization of renal cell carcinoma: a systematic review and meta-analysis. *Abdom Radiol (NY)*, 2022. 47: 2238.
<https://www.ncbi.nlm.nih.gov/pubmed/35380246>
532. Stewart, G.D., *et al.* A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). *Br J Cancer*, 2022. 127: 1051.
<https://www.ncbi.nlm.nih.gov/pubmed/35739300>
533. Bex, A., *et al.* A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). *Future Oncol*, 2019. 15: 2203.
<https://www.ncbi.nlm.nih.gov/pubmed/31023100>
534. Hakimi, K., *et al.* PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy. *BJU Int*, 2024. 133: 425.
<https://www.ncbi.nlm.nih.gov/pubmed/37916303>
535. Gorin, M.A., *et al.* Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. *Eur Urol Oncol*, 2022. 5: 113.
<https://www.ncbi.nlm.nih.gov/pubmed/34049847>
536. Rodriguez-Fernandez, I.A., *et al.* Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. *Eur Urol Oncol*, 2019. 2: 448.
<https://www.ncbi.nlm.nih.gov/pubmed/31277782>
537. Galligioni, E., *et al.* Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. *Cancer*, 1996. 77: 2560.
<https://www.ncbi.nlm.nih.gov/pubmed/8640706>
538. Figlin, R.A., *et al.* Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. *J Clin Oncol*, 1999. 17: 2521.
<https://www.ncbi.nlm.nih.gov/pubmed/10561318>
539. Clark, J.I., *et al.* Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. *J Clin Oncol*, 2003. 21: 3133.
<https://www.ncbi.nlm.nih.gov/pubmed/12810695>
540. Atzpodiën, J., *et al.* Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). *Br J Cancer*, 2005. 92: 843.
<https://www.ncbi.nlm.nih.gov/pubmed/15756254>
541. Jocham, D., *et al.* Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. *Lancet*, 2004. 363: 594.
<https://www.ncbi.nlm.nih.gov/pubmed/14987883>
542. Chamie, K., *et al.* Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. *JAMA Oncol*, 2017. 3: 913.
<https://www.ncbi.nlm.nih.gov/pubmed/27787547>
543. Haas, N.B., *et al.* Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. *JAMA Oncol*, 2017. 3: 1249.
<https://www.ncbi.nlm.nih.gov/pubmed/28278333>
544. Motzer, R.J., *et al.* Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. *J Clin Oncol*, 2017. 35: 3916.
<https://www.ncbi.nlm.nih.gov/pubmed/28902533>
545. Motzer, R.J., *et al.* Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. *Eur Urol*, 2021. 79: 334.
<https://www.ncbi.nlm.nih.gov/pubmed/33461782>
546. Harshman, L.C., *et al.* Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. *Cancer*, 2018. 124: 925.
<https://www.ncbi.nlm.nih.gov/pubmed/29266178>

547. Lenis, A.T., *et al.* Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. *J Urol*, 2018. 199: 43.
<https://www.ncbi.nlm.nih.gov/pubmed/28479237>
548. Gross-Goupil, M., *et al.* Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. *Ann Oncol*, 2018. 29: 2371.
<https://www.ncbi.nlm.nih.gov/pubmed/30346481>
549. Motzer, R.J., *et al.* Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. *Eur Urol*, 2018. 73: 62.
<https://www.ncbi.nlm.nih.gov/pubmed/28967554>
550. Ryan, C.W., *et al.* Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet*, 2023. 402: 1043.
<https://www.ncbi.nlm.nih.gov/pubmed/37524096>
551. Gulati, S., *et al.* Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Netw Open*, 2024. 7: e2425288.
<https://www.ncbi.nlm.nih.gov/pubmed/39106067>
552. Powles, T., *et al.* Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*, 2022. 23: 1133.
<https://www.ncbi.nlm.nih.gov/pubmed/36055304>
553. Choueiri, T.K., *et al.* Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. *N Engl J Med*, 2021. 385: 683.
<https://www.ncbi.nlm.nih.gov/pubmed/34407342>
554. Choueiri, T.K., *et al.* Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. *N Engl J Med*, 2024. 390: 1359.
<https://www.ncbi.nlm.nih.gov/pubmed/38631003>
555. Haas, N.B., *et al.* Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). *J Clin Oncol*, 2025. 43: 4514.
https://doi.org/10.1200/JCO.2025.43.16_suppl.4514
556. Pal, S.K., *et al.* Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. *Lancet*, 2022. 400: 1103.
<https://www.ncbi.nlm.nih.gov/pubmed/36099926>
557. Motzer, R.J., *et al.* Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. *Lancet*, 2023. 401: 821.
<https://www.ncbi.nlm.nih.gov/pubmed/36774933>
558. Motzer, R.J., *et al.* Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial. *J Clin Oncol*, 2024. 42: LBA358.
<https://pubmed.ncbi.nlm.nih.gov/39303200/>
559. Motzer, R.J., *et al.* Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial. *J Clin Oncol*, 2025. 43: 189.
<https://www.ncbi.nlm.nih.gov/pubmed/39303200>
560. Allaf, M.E., *et al.* Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. *Lancet Oncol*, 2024. 25: 1038.
<https://www.ncbi.nlm.nih.gov/pubmed/38942046>
561. Bedke, J., *et al.* 2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. *Eur Urol*, 2022. 81: 134.
<https://www.ncbi.nlm.nih.gov/pubmed/34920897>
562. de Bruijn, R., *et al.* Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. *Eur Urol Oncol*, 2020. 3: 168.
<https://www.ncbi.nlm.nih.gov/pubmed/31956080>
563. Bedke, J., *et al.* The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma. *Eur Urol*, 2023. 83: 10.
<https://www.ncbi.nlm.nih.gov/pubmed/36511268>

564. Pal, S.K., *et al.* Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. *Lancet*, 2023. 402: 185.
<https://www.ncbi.nlm.nih.gov/pubmed/37290461>
565. Choueiri, T.K., *et al.* Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. *Lancet*, 2024. 404: 1309.
<https://www.ncbi.nlm.nih.gov/pubmed/39284329>
566. Mejean, A., *et al.* Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. *N Engl J Med*, 2018. 379: 417.
<https://www.ncbi.nlm.nih.gov/pubmed/29860937>
567. Bhandi, B., *et al.* Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. *Eur Urol*, 2019. 75: 111.
<https://www.ncbi.nlm.nih.gov/pubmed/30467042>
568. Bex, A., *et al.* Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. *JAMA Oncol*, 2019. 5: 164.
<https://www.ncbi.nlm.nih.gov/pubmed/30543350>
569. Powles, T., *et al.* The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. *Eur Urol*, 2011. 60: 448.
<https://www.ncbi.nlm.nih.gov/pubmed/21612860>
570. Heng, D.Y., *et al.* Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur Urol*, 2014. 66: 704.
<https://www.ncbi.nlm.nih.gov/pubmed/24931622>
571. Ljungberg, B., *et al.* Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. *Scand J Urol*, 2020. 54: 487.
<https://www.ncbi.nlm.nih.gov/pubmed/32897123>
572. Motzer, R.J., *et al.* Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med*, 2018. 378: 1277.
<https://www.ncbi.nlm.nih.gov/pubmed/29562145>
573. Choueiri, T.K., *et al.* Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*, 2021. 384: 829.
<https://www.ncbi.nlm.nih.gov/pubmed/33657295>
574. Motzer, R.J., *et al.* Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*, 2019. 380: 1103.
<https://www.ncbi.nlm.nih.gov/pubmed/30779531>
575. Powles, T., *et al.* Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2020. 21: 1563.
<https://www.ncbi.nlm.nih.gov/pubmed/33284113>
576. Motzer, R., *et al.* Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med*, 2021. 384: 1289.
<https://www.ncbi.nlm.nih.gov/pubmed/33616314>
577. Pignot, G., *et al.* Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. *Eur Urol Oncol*, 2022. 5: 577.
<https://www.ncbi.nlm.nih.gov/pubmed/35853818>
578. Yip, W., *et al.* Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. *Eur Urol Oncol*, 2023. 6: 604.
<https://www.ncbi.nlm.nih.gov/pubmed/37005212>
579. Dragomir, A., *et al.* Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. *Eur Urol Focus*, 2022. 8: 1703.
<https://www.ncbi.nlm.nih.gov/pubmed/34736870>
580. Iisager, L., *et al.* Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial. *BMC Cancer*, 2024. 24: 260.
<https://www.ncbi.nlm.nih.gov/pubmed/38402173>

581. Albiges, L., *et al.* Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study. *Eur Urol Oncol*, 2025. <https://www.ncbi.nlm.nih.gov/pubmed/39924391>
582. Marvaso, G., *et al.* Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology. *Lancet Oncol*, 2024. 25: e193. <https://www.ncbi.nlm.nih.gov/pubmed/38697165>
583. Heng, D.Y., *et al.* Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol*, 2009. 27: 5794. <https://www.ncbi.nlm.nih.gov/pubmed/19826129>
584. Harrison, M.R., *et al.* Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). *Cancer*, 2021. 127: 2204. <https://www.ncbi.nlm.nih.gov/pubmed/33765337>
585. Rini, B.I., *et al.* Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. *Lancet Oncol*, 2016. 17: 1317. <https://www.ncbi.nlm.nih.gov/pubmed/27498080>
586. Dabestani, S., *et al.* Local treatments for metastases of renal cell carcinoma: a systematic review. *Lancet Oncol*, 2014. 15: e549. <https://www.ncbi.nlm.nih.gov/pubmed/25439697>
587. Ljungberg, B., *et al.* EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol*, 2015. 67: 913. <https://www.ncbi.nlm.nih.gov/pubmed/25616710>
588. Ouzaid, I., *et al.* Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. *Eur Urol Oncol*, 2019. 2: 141. <https://www.ncbi.nlm.nih.gov/pubmed/31017089>
589. Fung, K.F.K., *et al.* Beyond the Scalpel: the Role of Image-Guided Thermal Ablation in Management of Metastatic Renal Cell Carcinoma in the Era of Immunotherapy. *Cardiovasc Intervent Radiol*, 2025. 48: 1104. <https://www.ncbi.nlm.nih.gov/pubmed/40555768>
590. Brinkmann, O.A., *et al.* The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy. *Eur Urol Suppl*, 2007. 6: 641. <https://www.sciencedirect.com/science/article/pii/S1569905607000978>
591. Alt, A.L., *et al.* Survival after complete surgical resection of multiple metastases from renal cell carcinoma. *Cancer*, 2011. 117: 2873. <https://www.ncbi.nlm.nih.gov/pubmed/21692048>
592. Kwak, C., *et al.* Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment. *Urol Int*, 2007. 79: 145. <https://www.ncbi.nlm.nih.gov/pubmed/17851285>
593. Petralia, G., *et al.* 450 Complete Metastasectomy Is an Independent Predictor of Cancer-Specific Survival in Patients with Clinically Metastatic Renal Cell Carcinoma. *Eur Urol Suppl*, 2010. 9: 162. [https://doi.org/10.1016/S1569-9056\(10\)60446-0](https://doi.org/10.1016/S1569-9056(10)60446-0)
594. Russo, P., *et al.* Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. *ScientificWorldJournal*, 2007. 7: 768. <https://www.ncbi.nlm.nih.gov/pubmed/17619759>
595. Staehler, M.D., *et al.* Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. *World J Urol*, 2010. 28: 543. <https://www.ncbi.nlm.nih.gov/pubmed/20440505>
596. Eggener, S.E., *et al.* Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. *J Urol*, 2008. 180: 873. <https://www.ncbi.nlm.nih.gov/pubmed/18635225>
597. Lee, S.E., *et al.* Metastatectomy prior to immunochemotherapy for metastatic renal cell carcinoma. *Urol Int*, 2006. 76: 256. <https://www.ncbi.nlm.nih.gov/pubmed/16601390>
598. Tang, C., *et al.* Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial. *Lancet Oncol*, 2025. 26: 1289. <https://www.ncbi.nlm.nih.gov/pubmed/40915303>
599. Monda, S., *et al.* Post-Metastasectomy Adjuvant Therapy in Patients with Renal Cell Carcinoma: A Systematic Review. *Kidney Cancer*, 2024. 8: 115. <https://www.ncbi.nlm.nih.gov/pubmed/39263257>

600. Bedke, J., *et al.* The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. *Eur Urol*, 2021. 80: 393.
<https://www.ncbi.nlm.nih.gov/pubmed/34074559>
601. Patel, P.H., *et al.* Targeting von Hippel-Lindau pathway in renal cell carcinoma. *Clin Cancer Res*, 2006. 12: 7215.
<https://www.ncbi.nlm.nih.gov/pubmed/17189392>
602. Yang, J.C., *et al.* A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med*, 2003. 349: 427.
<https://www.ncbi.nlm.nih.gov/pubmed/12890841>
603. Patard, J.J., *et al.* Understanding the importance of smart drugs in renal cell carcinoma. *Eur Urol*, 2006. 49: 633.
<https://www.ncbi.nlm.nih.gov/pubmed/16481093>
604. Motzer, R.J., *et al.* Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2009. 27: 3584.
<https://www.ncbi.nlm.nih.gov/pubmed/19487381>
605. Motzer, R.J., *et al.* Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. *J Clin Oncol*, 2012. 30: 1371.
<https://www.ncbi.nlm.nih.gov/pubmed/22430274>
606. Bracarda, S., *et al.* Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. *Ann Oncol*, 2016. 27: 366.
<https://www.ncbi.nlm.nih.gov/pubmed/26685011>
607. Jonasch, E., *et al.* A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. *Ann Oncol*, 2017. 28: 804.
<https://www.ncbi.nlm.nih.gov/pubmed/28049139>
608. Sternberg, C.N., *et al.* Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol*, 2010. 28: 1061.
<https://www.ncbi.nlm.nih.gov/pubmed/20100962>
609. Motzer, R.J., *et al.* Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *N Engl J Med*, 2013. 369: 722.
<https://www.ncbi.nlm.nih.gov/pubmed/23964934>
610. Escudier, B., *et al.* Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. *J Clin Oncol*, 2014. 32: 1412.
<https://www.ncbi.nlm.nih.gov/pubmed/24687826>
611. Rini, B.I., *et al.* Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet*, 2011. 378: 1931.
<https://www.ncbi.nlm.nih.gov/pubmed/22056247>
612. Motzer, R.J., *et al.* Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. *Lancet Oncol*, 2013. 14: 552.
<https://www.ncbi.nlm.nih.gov/pubmed/23598172>
613. Hutson, T.E., *et al.* Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. *Lancet Oncol*, 2013. 14: 1287.
<https://www.ncbi.nlm.nih.gov/pubmed/24206640>
614. Choueiri, T.K., *et al.* Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*, 2015. 373: 1814.
<https://www.ncbi.nlm.nih.gov/pubmed/26406150>
615. Choueiri, T.K., *et al.* Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2016. 17: 917.
<https://www.ncbi.nlm.nih.gov/pubmed/27279544>
616. Choueiri, T.K., *et al.* Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. *J Clin Oncol*, 2017. 35: 591.
<https://www.ncbi.nlm.nih.gov/pubmed/28199818>
617. Choueiri, T.K., *et al.* Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. *Eur J Cancer*, 2018. 94: 115.
<https://www.ncbi.nlm.nih.gov/pubmed/29550566>

618. Motzer, R.J., *et al.* Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol*, 2015. 16: 1473.
<https://www.ncbi.nlm.nih.gov/pubmed/26482279>
619. Motzer, R.J., *et al.* Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. *J Clin Oncol*, 2013. 31: 3791.
<https://www.ncbi.nlm.nih.gov/pubmed/24019545>
620. Molina, A.M., *et al.* Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. *Eur J Cancer*, 2018. 94: 87.
<https://www.ncbi.nlm.nih.gov/pubmed/29547835>
621. Escudier, B., *et al.* Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. *J Clin Oncol*, 2010. 28: 2144.
<https://www.ncbi.nlm.nih.gov/pubmed/20368553>
622. Rini, B.I., *et al.* Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. *J Clin Oncol*, 2008. 26: 5422.
<https://www.ncbi.nlm.nih.gov/pubmed/18936475>
623. Rini, B.I., *et al.* Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. *J Clin Oncol*, 2010. 28: 2137.
<https://www.ncbi.nlm.nih.gov/pubmed/20368558>
624. Rini, B.I., *et al.* Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *Lancet*, 2019. 393: 2404.
<https://www.ncbi.nlm.nih.gov/pubmed/31079938>
625. Larkin, J.M., *et al.* Kinase inhibitors in the treatment of renal cell carcinoma. *Crit Rev Oncol Hematol*, 2006. 60: 216.
<https://www.ncbi.nlm.nih.gov/pubmed/16860997>
626. Motzer, R.J., *et al.* Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*, 2008. 372: 449.
<https://www.ncbi.nlm.nih.gov/pubmed/18653228>
627. Jonasch, E., *et al.* Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. *N Engl J Med*, 2021. 385: 2036.
<https://www.ncbi.nlm.nih.gov/pubmed/34818478>
628. Choueiri, T.K., *et al.* Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. *N Engl J Med*, 2024. 391: 710.
<https://www.ncbi.nlm.nih.gov/pubmed/39167807>
629. Choueiri, T.K., *et al.* Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. *Lancet Oncol*, 2023. 24: 553.
<https://www.ncbi.nlm.nih.gov/pubmed/37011650>
630. Brown, J.E., *et al.* Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. *Lancet Oncol*, 2023. 24: 213.
<https://www.ncbi.nlm.nih.gov/pubmed/36796394>
631. Ribas, A. Tumor immunotherapy directed at PD-1. *N Engl J Med*, 2012. 366: 2517.
<https://www.ncbi.nlm.nih.gov/pubmed/22658126>
632. Motzer, R.J., *et al.* Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*, 2015. 373: 1803.
<https://www.ncbi.nlm.nih.gov/pubmed/26406148>
633. Motzer, R.J., *et al.* Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. *Cancer*, 2020. 126: 4156.
<https://www.ncbi.nlm.nih.gov/pubmed/32673417>
634. McDermott, D.F., *et al.* Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. *J Clin Oncol*, 2021. 39: 1020.
<https://www.ncbi.nlm.nih.gov/pubmed/33529051>
635. Atkins, M.B., *et al.* Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). *J Clin Oncol*, 2022. 40: 2913.
<https://www.ncbi.nlm.nih.gov/pubmed/35442713>

636. Choueiri, T.K., *et al.* FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. *J Immunother Cancer*, 2022. 10.
<https://www.ncbi.nlm.nih.gov/pubmed/36328377>
637. McKay, R.R., *et al.* A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. *Oncologist*, 2024. 29: 324.
<https://www.ncbi.nlm.nih.gov/pubmed/37950901>
638. Atkins, M.B., *et al.* Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). *J Immunother Cancer*, 2024. 12.
<https://www.ncbi.nlm.nih.gov/pubmed/38604810>
639. Ljungberg, B., *et al.* European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. *Eur Urol*, 2019. 75: 799.
<https://www.ncbi.nlm.nih.gov/pubmed/30803729>
640. Tannir, N.M., *et al.* Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. *Ann Oncol*, 2024. 35: 1026.
<https://www.ncbi.nlm.nih.gov/pubmed/39098455>
641. Choueiri, T.K., *et al.* Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial. *J Clin Oncol*, 2025. 43: 4505.
https://doi.org/10.1200/JCO.2025.43.16_suppl.4505
642. Choueiri, T.K., *et al.* Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. *N Engl J Med*, 2023. 388: 1767.
<https://www.ncbi.nlm.nih.gov/pubmed/37163623>
643. Albiges, L., *et al.* Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. *J Clin Oncol*, 2025. 43: 438.
https://doi.org/10.1200/JCO.2025.43.5_suppl.438
644. Motzer, R.J., *et al.* Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. *Cancer*, 2022. 128: 2085.
<https://www.ncbi.nlm.nih.gov/pubmed/35383908>
645. Rini, B.I., *et al.* Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*, 2019. 380: 1116.
<https://www.ncbi.nlm.nih.gov/pubmed/30779529>
646. Plimack, E.R., *et al.* Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study. *Eur Urol*, 2023. 84: 449.
<https://www.ncbi.nlm.nih.gov/pubmed/37500340>
647. Rini, B.I., *et al.* Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. *Nat Med*, 2025. 31: 3475.
<https://www.ncbi.nlm.nih.gov/pubmed/40750932>
648. Motzer, R.J., *et al.* Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial. *J Clin Oncol*, 2025. 43: 439.
https://doi.org/10.1200/JCO.2025.43.5_suppl.439
649. Motzer, R.J., *et al.* Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. *J Clin Oncol*, 2024. 42: 1222.
<https://www.ncbi.nlm.nih.gov/pubmed/38227898>
650. Choueiri, T.K., *et al.* Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. *Ann Oncol*, 2025. 36: 387.
<https://www.ncbi.nlm.nih.gov/pubmed/39706335>
651. Motzer, R.J., *et al.* Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. *JAMA Oncol*, 2022. 8: 275.
<https://www.ncbi.nlm.nih.gov/pubmed/34940781>
652. Yan, X.Q., *et al.* Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. *Ann Oncol*, 2024. 35: 190.
<https://www.ncbi.nlm.nih.gov/pubmed/37872020>

653. Zhou, A., *et al.* First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*, 2025. 26: 1145.
<https://www.ncbi.nlm.nih.gov/pubmed/40907513>
654. Powles, T., *et al.* Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. *ESMO Open*, 2024. 9: 102994.
<https://www.ncbi.nlm.nih.gov/pubmed/38642472>
655. Motzer, R.J., *et al.* Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. *Eur Urol*, 2024. 86: 4.
<https://www.ncbi.nlm.nih.gov/pubmed/38582713>
656. Choueiri, T.K., *et al.* Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. *Ann Oncol*, 2020. 31: 1030.
<https://www.ncbi.nlm.nih.gov/pubmed/32339648>
657. Haanen, J., *et al.* Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. *ESMO Open*, 2023. 8: 101210.
<https://www.ncbi.nlm.nih.gov/pubmed/37104931>
658. Choueiri, T.K., *et al.* Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. *Lancet Oncol*, 2023. 24: 228.
<https://www.ncbi.nlm.nih.gov/pubmed/36858721>
659. Albiges, L., *et al.* Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. *ESMO Open*, 2020. 5: e001079.
<https://www.ncbi.nlm.nih.gov/pubmed/33246931>
660. Auvray, M., *et al.* Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. *Eur J Cancer*, 2019. 108: 33.
<https://www.ncbi.nlm.nih.gov/pubmed/30616146>
661. Beckermann, K.E., *et al.* Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. *Oncologist*, 2024. 29: 254.
<https://www.ncbi.nlm.nih.gov/pubmed/38262444>
662. Ornstein, M.C., *et al.* Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. *Lancet Oncol*, 2019. 20: 1386.
<https://www.ncbi.nlm.nih.gov/pubmed/31427205>
663. Coppin, C., *et al.* Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. *BJU Int*, 2011. 108: 1556.
<https://www.ncbi.nlm.nih.gov/pubmed/21952069>
664. Zelefsky, M.J., *et al.* Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. *Int J Radiat Oncol Biol Phys*, 2012. 82: 1744.
<https://www.ncbi.nlm.nih.gov/pubmed/21596489>
665. Rini, B.I., *et al.* Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. *Lancet Oncol*, 2020. 21: 95.
<https://www.ncbi.nlm.nih.gov/pubmed/31810797>
666. Rini, B.I., *et al.* Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. *J Immunother Cancer*, 2022. 10.
<https://www.ncbi.nlm.nih.gov/pubmed/36549781>
667. Carthon, B.C., *et al.* Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808. *Clin Genitourin Cancer*, 2023. 21: 546.
<https://www.ncbi.nlm.nih.gov/pubmed/37455214>

668. Choueiri, T.K., *et al.* Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S). *Ann Oncol*, 2019. 30: v361. <https://www.sciencedirect.com/science/article/pii/S0923753419591268>
669. Choueiri, T.K., *et al.* Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: *post hoc* analysis of a randomized clinical trial. *ESMO Open*, 2021. 6: 100101. <https://www.ncbi.nlm.nih.gov/pubmed/33901870>
670. Rini, B.I., *et al.* Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. *Eur Urol*, 2021. 79: 659. <https://www.ncbi.nlm.nih.gov/pubmed/32654802>
671. Motzer, R.J., *et al.* Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. *J Clin Oncol*, 2021. 39: 308. https://doi.org/10.1200/JCO.2021.39.6_suppl.308
672. Grunwald, V., *et al.* Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. *Front Oncol*, 2023. 13: 1223282. <https://www.ncbi.nlm.nih.gov/pubmed/37664025>
673. Koh, Y., *et al.* Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. *Ann Oncol*, 2013. 24: 1026. <https://www.ncbi.nlm.nih.gov/pubmed/23180114>
674. Fernandez-Pello, S., *et al.* A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. *Eur Urol*, 2017. 71: 426. <https://www.ncbi.nlm.nih.gov/pubmed/27939075>
675. Tannir, N.M., *et al.* A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. *Eur Urol*, 2012. 62: 1013. <https://www.ncbi.nlm.nih.gov/pubmed/22771265>
676. Ravaud, A., *et al.* First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)dagger. *Ann Oncol*, 2015. 26: 1123. <https://www.ncbi.nlm.nih.gov/pubmed/25802238>
677. Escudier, B., *et al.* Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. *Eur J Cancer*, 2016. 69: 226. <https://www.ncbi.nlm.nih.gov/pubmed/27680407>
678. Pal, S.K., *et al.* A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. *Lancet*, 2021. 397: 695. <https://www.ncbi.nlm.nih.gov/pubmed/33592176>
679. Choueiri, T.K., *et al.* Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. *JAMA Oncol*, 2020. 6: 1247. <https://www.ncbi.nlm.nih.gov/pubmed/32469384>
680. Barata, P., *et al.* Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. *J Clin Oncol*, 2024. 42: 3911. <https://www.ncbi.nlm.nih.gov/pubmed/39255440>
681. Albiges, L., *et al.* Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. *Lancet Oncol*, 2023. 24: 881. <https://www.ncbi.nlm.nih.gov/pubmed/37451291>
682. Voss, M.H., *et al.* First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. *Eur Urol*, 2025. 41: 4518. <https://www.ncbi.nlm.nih.gov/pubmed/40707309>
683. Fitzgerald, K.N., *et al.* Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. *Eur Urol*, 2024. 86: 90. <https://www.ncbi.nlm.nih.gov/pubmed/38782695>
684. Suarez, C., *et al.* Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). *J Clin Oncol*, 2023. 41: 2493. <https://www.ncbi.nlm.nih.gov/pubmed/36809050>

685. McDermott, D.F., *et al.* Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. *J Clin Oncol*, 2021. 39: 1029.
<https://www.ncbi.nlm.nih.gov/pubmed/33529058>
686. Hudes, G., *et al.* Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med*, 2007. 356: 2271.
<https://www.ncbi.nlm.nih.gov/pubmed/17538086>
687. Gore, M.E., *et al.* Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. *Lancet Oncol*, 2009. 10: 757.
<https://www.ncbi.nlm.nih.gov/pubmed/19615940>
688. Sanchez, P., *et al.* Non-clear cell advanced kidney cancer: is there a gold standard? *Anticancer Drugs*, 2011. 22 Suppl 1: S9.
<https://www.ncbi.nlm.nih.gov/pubmed/21173605>
689. Lee, C.H., *et al.* Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. *J Clin Oncol*, 2022. 40: 2333.
<https://www.ncbi.nlm.nih.gov/pubmed/35298296>
690. Bergmann, L., *et al.* Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. *Ann Oncol*, 2025. 36: 796.
<https://www.ncbi.nlm.nih.gov/pubmed/40180121>
691. Cancer Genome Atlas Research, N., *et al.* Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*, 2016. 374: 135.
<https://www.ncbi.nlm.nih.gov/pubmed/26536169>
692. Panunzio, A., *et al.* Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma. *Cancer Epidemiol*, 2023. 82: 102297.
<https://www.ncbi.nlm.nih.gov/pubmed/36401949>
693. Msaouel, P., *et al.* Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. *Clin Genitourin Cancer*, 2019. 17: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/30287223>
694. Beckermann, K.E., *et al.* Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. *J Immunother Cancer*, 2017. 5: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/28105368>
695. Sodji, Q., *et al.* Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition. *J Immunother Cancer*, 2017. 5: 62.
<https://www.ncbi.nlm.nih.gov/pubmed/28807004>
696. Rathmell, W.K., *et al.* High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. *Urology*, 2008. 72: 659.
<https://www.ncbi.nlm.nih.gov/pubmed/18649931>
697. Nze, C., *et al.* A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. *Cancers (Basel)*, 2023. 15: 3806.
<https://www.ncbi.nlm.nih.gov/pubmed/37568622>
698. Panunzio, A., *et al.* Collecting duct carcinoma: Epidemiology, clinical characteristics and survival. *Urol Oncol*, 2023. 41: 110 e7.
<https://www.ncbi.nlm.nih.gov/pubmed/36456452>
699. Buti, S., *et al.* BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients. *Tumori*, 2023. 109: 418.
<https://www.ncbi.nlm.nih.gov/pubmed/36474412>
700. Rizzo, M., *et al.* Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification. *Cancer Treat Rev*, 2023. 116: 102558.
<https://www.ncbi.nlm.nih.gov/pubmed/37060647>
701. Iannantuono, G.M., *et al.* Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review. *Int J Mol Sci*, 2022. 23.
<https://www.ncbi.nlm.nih.gov/pubmed/35409355>
702. Marconi, L., *et al.* Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups. *Eur Urol Open Sci*, 2023. 47: 65.
<https://www.ncbi.nlm.nih.gov/pubmed/36601038>
703. Antonelli, A., *et al.* Features of Ipsilateral Renal Recurrences After Partial Nephrectomy: A Proposal of a Pathogenetic Classification. *Clin Genitourin Cancer*, 2017. 15: 540.
<https://www.ncbi.nlm.nih.gov/pubmed/28533051>

704. Bertolo, R., *et al.* Low Rate of Cancer Events After Partial Nephrectomy for Renal Cell Carcinoma: Clinicopathologic Analysis of 1994 Cases with Emphasis on Definition of "Recurrence". *Clin Genitourin Cancer*, 2019. 17: 209.
<https://www.ncbi.nlm.nih.gov/pubmed/31000486>
705. Kreshover, J.E., *et al.* Renal cell recurrence for T1 tumors after laparoscopic partial nephrectomy. *J Endourol*, 2013. 27: 1468.
<https://www.ncbi.nlm.nih.gov/pubmed/24074156>
706. Russo, P., *et al.* Outcomes for Atypical Tumor Recurrences Following Minimally Invasive Kidney Cancer Operations. *Eur Urol Open Sci*, 2022. 40: 125.
<https://www.ncbi.nlm.nih.gov/pubmed/35638088>
707. Fallara, G., *et al.* Recurrence pattern in localized RCC: results from a European multicenter database (RECUR). *Urol Oncol*, 2022. 40: 494 e11.
<https://www.ncbi.nlm.nih.gov/pubmed/36127233>
708. Brassier, M., *et al.* Percutaneous Ablation Versus Surgical Resection for Local Recurrence Following Partial Nephrectomy for Renal Cell Cancer: A Propensity Score Analysis (REPART Study-UroCCR 71). *Eur Urol Focus*, 2022. 8: 210.
<https://www.ncbi.nlm.nih.gov/pubmed/33622625>
709. Wah, T.M., *et al.* Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. *BJU Int*, 2014. 113: 416.
<https://www.ncbi.nlm.nih.gov/pubmed/24053769>
710. Herout, R., *et al.* Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. *Urol Oncol*, 2018. 36: 11 e1.
<https://www.ncbi.nlm.nih.gov/pubmed/28927783>
711. Thomas, A.Z., *et al.* Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. *J Urol*, 2015. 194: 316.
<https://www.ncbi.nlm.nih.gov/pubmed/25758610>
712. Marchioni, M., *et al.* Management of local recurrence after radical nephrectomy: surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. *Int Urol Nephrol*, 2021. 53: 2273.
<https://www.ncbi.nlm.nih.gov/pubmed/34417970>
713. Itano, N.B., *et al.* Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. *J Urol*, 2000. 164: 322.
<https://www.ncbi.nlm.nih.gov/pubmed/10893575>
714. Margulis, V., *et al.* Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. *J Urol*, 2009. 181: 2044.
<https://www.ncbi.nlm.nih.gov/pubmed/19286220>
715. Russell, C.M., *et al.* Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. *Urology*, 2018. 117: 95.
<https://www.ncbi.nlm.nih.gov/pubmed/29678662>
716. Srivastava, A., *et al.* Incidence of T3a up-staging and survival after partial nephrectomy: Size-stratified rates and implications for prognosis. *Urol Oncol*, 2018. 36: 12 e7.
<https://www.ncbi.nlm.nih.gov/pubmed/28970053>
717. Sandhu, S.S., *et al.* Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. *BJU Int*, 2005. 95: 522.
<https://www.ncbi.nlm.nih.gov/pubmed/15705072>
718. Master, V.A., *et al.* Management of isolated renal fossa recurrence following radical nephrectomy. *J Urol*, 2005. 174: 473.
<https://www.ncbi.nlm.nih.gov/pubmed/16006867>
719. Psutka, S.P., *et al.* Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. *BJU Int*, 2017. 119: 116.
<https://www.ncbi.nlm.nih.gov/pubmed/27489013>
720. Huang, J., *et al.* Surgical Management and Oncologic Outcomes for Local Retroperitoneal Recurrence of Renal Cell Carcinoma After Radical Nephrectomy. *Clin Genitourin Cancer*, 2023. 21: 315 e1.
<https://www.ncbi.nlm.nih.gov/pubmed/36396584>
721. Martini, A., *et al.* Salvage Robot-assisted Renal Surgery for Local Recurrence After Surgical Resection or Renal Mass Ablation: Classification, Techniques, and Clinical Outcomes. *Eur Urol*, 2021. 80: 730.
<https://www.ncbi.nlm.nih.gov/pubmed/34088520>
722. Ierardi, A.M., *et al.* Percutaneous microwave ablation therapy of renal cancer local relapse after radical nephrectomy: a feasibility and efficacy study. *Med Oncol*, 2020. 37: 27.
<https://www.ncbi.nlm.nih.gov/pubmed/32166412>

723. Ushijima, Y., *et al.* Cryoablation for Secondary Renal Cell Carcinoma After Surgical Nephrectomy. *Cardiovasc Intervent Radiol*, 2021. 44: 414.
<https://www.ncbi.nlm.nih.gov/pubmed/33205290>
724. Johnson, A., *et al.* Feasibility and outcomes of repeat partial nephrectomy. *J Urol*, 2008. 180: 89.
<https://www.ncbi.nlm.nih.gov/pubmed/18485404>
725. Mouracade, P., *et al.* Imaging strategy and outcome following partial nephrectomy. *Urol Oncol*, 2017. 35: 660 e1.
<https://www.ncbi.nlm.nih.gov/pubmed/28863862>
726. Dabestani, S., *et al.* Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). *Scand J Urol*, 2019. 53: 14.
<https://www.ncbi.nlm.nih.gov/pubmed/30907214>
727. Rieken, M., *et al.* Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. *Clin Genitourin Cancer*, 2018. 16: e903.
<https://www.ncbi.nlm.nih.gov/pubmed/29653814>
728. Srigley, J.R., *et al.* The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. *Am J Surg Pathol*, 2013. 37: 1469.
<https://www.ncbi.nlm.nih.gov/pubmed/24025519>
729. Pignot, G., *et al.* Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. *Urology*, 2007. 69: 230.
<https://www.ncbi.nlm.nih.gov/pubmed/17275070>
730. Przybycin, C.G., *et al.* Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens. *Adv Anat Pathol*, 2013. 20: 245.
<https://www.ncbi.nlm.nih.gov/pubmed/23752087>
731. Moch, H., *et al.* Morphological clues to the appropriate recognition of hereditary renal neoplasms. *Semin Diagn Pathol*, 2018. 35: 184.
<https://www.ncbi.nlm.nih.gov/pubmed/29454577>
732. Kauffman, E.C., *et al.* Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. *Nat Rev Urol*, 2014. 11: 465.
<https://www.ncbi.nlm.nih.gov/pubmed/25048860>
733. Shuch, B., *et al.* Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management. *J Clin Oncol*, 2018: JCO2018792523.
<https://www.ncbi.nlm.nih.gov/pubmed/30372385>
734. Maher, E.R. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. *World J Urol*, 2018. 36: 1891.
<https://www.ncbi.nlm.nih.gov/pubmed/29680948>
735. Tung, N., *et al.* Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. *J Clin Oncol*, 2024. 42: 2599.
<https://www.ncbi.nlm.nih.gov/pubmed/38759122>
736. Shuch, B., *et al.* The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. *Urol Clin North Am*, 2012. 39: 133.
<https://www.ncbi.nlm.nih.gov/pubmed/22487757>
737. Bratslavsky, G., *et al.* Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. *J Urol*, 2008. 179: 67.
<https://www.ncbi.nlm.nih.gov/pubmed/17997447>
738. Linehan, W.M., *et al.* Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease. *Eur Urol*, 2025. 88: 56.
<https://www.ncbi.nlm.nih.gov/pubmed/40274483>
739. Osman, F.H., *et al.* Oncological and Peri-Operative Outcomes of Percutaneous Cryoablation of Renal Cell Carcinoma for Patients with Hereditary RCC Diseases-An Analysis of European Multi-Centre Prospective EuRECA Registry. *Cancers (Basel)*, 2023. 15: 3322.
<https://www.ncbi.nlm.nih.gov/pubmed/37444432>
740. Chahoud, J., *et al.* Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. *World J Urol*, 2021. 39: 2409.
<https://www.ncbi.nlm.nih.gov/pubmed/32936333>
741. Alliance, V. VHLA Suggested Active Surveillance Guidelines. 2020. 2022.
<https://www.vhl.org/wp-content/uploads/forms/vhla-active-surveillance-guidelines.pdf>
742. Nielsen, S.M., *et al.* Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. *J Clin Oncol*, 2016. 34: 2172.
<https://www.ncbi.nlm.nih.gov/pubmed/27114602>

743. FDA. FDA D.I.S.C.O. Burst Edition: FDA approval of Welireg (belzutifan) for adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery. 2021.
<https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-welireg-belzutifan-adult-patients-von-hippel-lindau-disease-who>
744. Srinivasan, R., *et al.* Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. *Lancet Oncol*, 2025. 26: 571.
<https://www.ncbi.nlm.nih.gov/pubmed/40228516>
745. Jonasch, E., *et al.* Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. *Lancet Oncol*, 2018. 19: 1351.
<https://www.ncbi.nlm.nih.gov/pubmed/30236511>
746. Alhalabi, O., *et al.* Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. *Oncologist*, 2023. 28: 433.
<https://www.ncbi.nlm.nih.gov/pubmed/36640141>
747. Hong, J., *et al.* Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study. *J Urol Oncol*, 2024. 22: 59.
<https://e-juo.org/journal/view.php?number=571>
748. Thouvenin, J., *et al.* Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. *Oncologist*, 2022. 27: 1041.
<https://www.ncbi.nlm.nih.gov/pubmed/35979929>
749. Capitano, U., *et al.* Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. *Eur Urol Oncol*, 2020. 3: 209.
<https://www.ncbi.nlm.nih.gov/pubmed/31411993>
750. Campbell, S.C., *et al.* Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. *J Urol*, 2021. 206: 199.
<https://www.ncbi.nlm.nih.gov/pubmed/34115547>
751. Lam, J.S., *et al.* Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. *J Urol*, 2005. 173: 1853.
<https://www.ncbi.nlm.nih.gov/pubmed/15879764>
752. Scoll, B.J., *et al.* Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. *J Urol*, 2009. 181: 506.
<https://www.ncbi.nlm.nih.gov/pubmed/19084868>
753. Beisland, C., *et al.* A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. *World J Urol*, 2016. 34: 1087.
<https://www.ncbi.nlm.nih.gov/pubmed/26922650>
754. Merrill, S.B., *et al.* Utilization of Patient-Specific Characteristics and Competing Risks to Tailor the Duration of Surveillance Imaging After Surgery for Renal Cell Carcinoma. *JU Open Plus*, 2024. 2.
https://journals.lww.com/juop/fulltext/2024/03000/utilization_of_patient_specific_characteristics.6.aspx
755. Stewart-Merrill, S.B., *et al.* Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. *J Clin Oncol*, 2015. 33: 4151.
<https://www.ncbi.nlm.nih.gov/pubmed/26351352>
756. Vartolomei, L., *et al.* Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review. *J Clin Med*, 2022. 11.
<https://www.ncbi.nlm.nih.gov/pubmed/36362610>
757. Dabestani, S., *et al.* Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. *Eur Urol Focus*, 2019. 5: 857.
<https://www.ncbi.nlm.nih.gov/pubmed/29525381>
758. Rini, B.I., *et al.* Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. *Clin Cancer Res*, 2018. 24: 4407.
<https://www.ncbi.nlm.nih.gov/pubmed/29773662>
759. Bruno, J.J., 2nd, *et al.* Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. *BJU Int*, 2006. 97: 933.
<https://www.ncbi.nlm.nih.gov/pubmed/16643473>
760. Bani-Hani, A.H., *et al.* Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. *J Urol*, 2005. 173: 391.
<https://www.ncbi.nlm.nih.gov/pubmed/15643178>

761. Schaner, E.G., *et al.* Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study. *AJR Am J Roentgenol*, 1978. 131: 51. <https://www.ncbi.nlm.nih.gov/pubmed/97985>
762. Patel, T., *et al.* Lung Metastases Imaging. 2022. 2017. <https://emedicine.medscape.com/article/358090-overview>
763. Chang, A.E., *et al.* Evaluation of computed tomography in the detection of pulmonary metastases: a prospective study. *Cancer*, 1979. 43: 913. <https://www.ncbi.nlm.nih.gov/pubmed/284842>
764. Doornweerd, B.H., *et al.* Chest X-ray in the follow-up of renal cell carcinoma. *World J Urol*, 2014. 32: 1015. <https://www.ncbi.nlm.nih.gov/pubmed/24096433>
765. Sountoulides, P., *et al.* Atypical presentations and rare metastatic sites of renal cell carcinoma: a review of case reports. *J Med Case Rep*, 2011. 5: 429. <https://www.ncbi.nlm.nih.gov/pubmed/21888643>
766. Kattan, M.W., *et al.* A postoperative prognostic nomogram for renal cell carcinoma. *J Urol*, 2001. 166: 63. <https://www.ncbi.nlm.nih.gov/pubmed/11435824>
767. Lam, J.S., *et al.* Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. *J Urol*, 2005. 174: 466. <https://www.ncbi.nlm.nih.gov/pubmed/16006866>
768. Cindolo, L., *et al.* Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. *Cancer*, 2005. 104: 1362. <https://www.ncbi.nlm.nih.gov/pubmed/16116599>
769. Skolarikos, A., *et al.* A review on follow-up strategies for renal cell carcinoma after nephrectomy. *Eur Urol*, 2007. 51: 1490. <https://www.ncbi.nlm.nih.gov/pubmed/17229521>
770. Chin, A.I., *et al.* Surveillance strategies for renal cell carcinoma patients following nephrectomy. *Rev Urol*, 2006. 8: 1. <https://www.ncbi.nlm.nih.gov/pubmed/16985554>
771. Karakiewicz, P.I., *et al.* A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. *Eur Urol*, 2009. 55: 287. <https://www.ncbi.nlm.nih.gov/pubmed/18715700>
772. Cho, H., *et al.* Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. *Ann Intern Med*, 2013. 159: 667. <https://www.ncbi.nlm.nih.gov/pubmed/24247672>
773. van den Brink, L., *et al.* Is Frequent Imaging Necessary? Impact of Computed Tomography During Follow-up After Surgical Treatment for Nonmetastatic Renal Cell Carcinoma: A Systematic Review. *Eur Urol Oncol*, 2025. 8: 829. <https://www.ncbi.nlm.nih.gov/pubmed/39665918>

11. CONFLICT OF INTEREST

All members of the Renal Cell Cancer Guidelines Panel have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is published below and also publicly accessible through the European Association of Urology website: <https://uroweb.org/guideline/renalcellcarcinoma/panel>.

This Guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative and travel and meeting expenses. No honoraria or other reimbursements have been provided.

Disclosures: The EAU Guidelines Office certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: A. Bex reported receiving research support and grants from Pfizer; a trial participant for Roche/Genentech and BMS and a company consultant for Ipsen. J. Bedke reported serving as a company consultant for Astella, AstraZeneca, BMS, Eisai, Ipsen, Janssen, Merck Sorono, MSD, Pfizer and Roche; receiving company speaker honoraria from Ipsen Pharma GmbH, BMS, MSD, Pfizer and Seagen; declares trial participation with Astella, AstraZeneca, BMS, Eisai, Ipsen, MSD, Nektar, Novartis, Pfizer, Roche and Seagen and receiving honoraria from Ipsen. U. Capitanio reported receiving consultation fees from MSD Italia srl and serving as company speaker and receiving fellowship and travel grants from Merck Sharp & Dohme S.p.A. S. Dabestani reported serving as a company consultant for Elypta AB. M. Hora reported serving as a company consultant for MSD, receiving company speaker honorarium from MSD and consultation fees from Merck Spol. S.R.O. G. Pignot reported receiving company speaker honoraria from Merck, AstraZeneca, Bouchara Recordati, Pfizer, Ipsen, J&J, Bayer, Bristol Myers Squibb and Astellas; receiving honoraria or consultation fees from AstraZeneca, Bayer, J&J and Intuitive Surgical; and participating in clinical trials with J&J and Vitadx International. M. Tran received research support from Boston Scientific and honoraria, consultation fees from Boston Scientific, Eisai Europe Ltd, Telix Pharmaceuticals and Merck Sharp & Dohme. R. Campi received consultation fees from Telix pharmaceuticals and Nucleix; fellowship, travel grants from MSD Italia srl. T. Powles reported receiving honoraria or consultation fees from AstraZeneca, Astellas Pharma, Bristol Myers Squibb, Eisai Europe Ltd, Exelixis, Inc, F. Hoffmann-La Roche Ltd, Incyte Biosciences, Ipsen, Merck & Co Inc, Merck KGaA, Merck Sharp & Dohme, Merck Sharp & Dohme LLC, MSD Sharp & Dohme GmbH, Novartis Pharma AG, Pfizer, and Seattle Genetics; receiving grants or research support from AstraZeneca, Astellas Pharma, Astellas Pharma US, Bristol Myers Squibb, Eisai Europe Ltd, Exelixis, Inc., F. Hoffmann-La Roche Ltd, Ipsen, Johnson & Johnson, Merck & Co. Inc., Merck KGaA, Merck Sharp & Dohme, Merck Sharp & Dohme LLC, Merck Sharp & Dohme International Services, Novartis Pharma AG, Pfizer and Seattle Genetics; and reporting other relationships with AstraZeneca, F. Hoffmann-La Roche Ltd, Ipsen, MSD Sharp & Dohme GmbH, Merck Sharp & Dohme LLC and Pfizer. T. Klatte reported receiving fellowship or travel grants from Bristol Myers Squibb and serving as company consultant for Bristol-Myers Squibb Germany, Medac GmbH and Merck Healthcare Germany GmbH. C. Suarez reported serving as a company consultant to Vall Hebron Institute of Oncology (VHIO). Riccardo Campi has had advisory roles and has received travel grants from Telix Pharmaceuticals and MSD. Patricia Zondervan reported serving as company consultant for Telix pharma and receiving travel grants from IPSEN, BMS and Pfizer. T. Kuusk reported receiving company speaker honoraria from Telix and served as an advisory role for Telix. S. Bonn, D. Breen, Y. Abu Ghanem, R. Woodward, C. Palumbo, L. Lund and L. Marconi all have nothing to declare.

12. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

EAU Guidelines. Edn. presented at the EAU Annual Congress London 2026. ISBN 978-94-92671-32-5.

If a publisher and/or location is required, include:

EAU Guidelines Office, Arnhem, The Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>

References to individual guidelines should be structured in the following way:

Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.

13. COPYRIGHT AND TERMS OF USE

The content of the EAU Guidelines and all products derived from them is made available for personal and educational use only. No commercial usage is authorised. No part of the EAU Guidelines or any related products may be translated or reproduced in any form without written permission from the EAU. Furthermore, the EAU prohibits the usage or upload of its Guidelines, and any material derived from these texts (whether in full or in part) on external websites, bots, pages, portals, servers, software or external applications, including those employing artificial intelligence technologies and infrastructure, such as large language models and generative AI, deep learning and machine learning, unless written permission has been granted for such by the EAU.

The EAU accepts no responsibility for the content, quality or performance of materials, applications and products derived from the EAU Guidelines and does not endorse or warrant their use. In the event of any discrepancies, the original language version shall be considered authoritative.